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Abstract 
IL-33 and IL-17 family cytokines (IL-17A – IL-17F) have been shown to play roles 
in the pathogenesis of chronic inflammatory diseases such as rheumatoid 
arthritis and inflammatory bowel disease. However knowledge of their role in 
periodontal disease pathogenesis is limited. The aim of this study was therefore 
to determine clinical associations between IL-33 and IL-17 family cytokines and 
chronic periodontitis. In addition, to begin to investigate the biological 
significance of these associations using in vitro model systems. 
97 patients with chronic periodontitis and 77 healthy volunteers were recruited 
in Glasgow and Newcastle. Serum, gingival crevicular fluid (GCF) and saliva were 
analysed for levels of IL-33 and IL-17 family cytokines by ELISA. Periodontal 
tissues from 17 chronic periodontitis patients and 10 healthy subjects from 
Glasgow were also investigated for IL-33 and IL-17 family cytokines mRNA 
expression by real time PCR. Immunohistochemical analysis was also performed 
on tissue to investigate expression of IL-33 and IL-17E at the protein level. In 
vitro experiments were performed using the OKF6/TERT-2 oral keratinocyte cell 
line and primary human gingival epithelial (PHGE) cells. The cells were 
stimulated with either a live Porphyromonas gingivalis monospecies biofilm or 
recombinant cytokines and changes in expression of cytokines, chemokines and 
their receptors evaluated by real-time PCR, immunocytochemical analysis or 
ELISA. In addition, transcriptional activity was monitored by analysis of changes 
in the phosphorylation (activation) of the NF-κB p65 subunit transcription factor 
using serum, GCF and saliva. IL-17A and IL-17A/F levels were higher in chronic 
periodontitis patients, but serum IL-17E was lower.  IL-17A, IL-17A/F and the 
serum IL-17A:IL-17E ratio correlated positively with clinical parameters. IL-33, 
and IL-17 family cytokine (except IL-17B) gene transcripts were higher in tissue 
of chronic periodontitis patients. In addition, IL-33, ST2, IL-17E and IL-17RB 
proteins are expressed in periodontal tissues. Furthermore, IL-33 protein 
expression is upregulated in tissue of chronic periodontitis patients. In vitro 
models showed that IL-33 and its receptors (ST2 and ST2L) are expressed by oral 
keratinocytes (OKF6/TERT-2 cells and PHGE cells) and IL-33 expression up-
regulated in response to P. gingivalis. However, IL-33 failed to induce expression 
of a range of inflammatory mediators and receptors in OKF6/TERT-2 cells.  In 
vitro, IL-17E inhibited P. gingivalis monospecies biofilm and IL-17A induced 
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expression of chemokines (IL-8 and/or CXCL5) by OKF6/TERT-2 cells at the 
transcriptional level by blocking the phosphorylation (activation) of the NF-κB 
p65 subunit. 
This study demonstrates clinical associations between IL-33 and IL-17 family 
cytokines and chronic periodontitis. The expression of IL-33 by oral keratinocytes 
and its up regulation upon exposure to P. gingivalis suggest it plays a role in the 
innate immune response to pathogens within the periodontium. However, the 
role of IL-33 in the periodontal inflammatory response remains to be elucidated. 
The negative correlations between serum levels of IL-17A and IL-17E and 
correlations with disease parameters, combined with their differing effects on 
the induction of expression of key neutrophil chemoattractants (CXCL5 and 
CXCL8), suggest opposing roles in periodontal immunity. Indeed, it can be 
hypothesised that the differential regulation of chemokine expression is due to 
IL-17A having pro- and IL-17E having anti-inflammatory properties. Indeed, as 
neutrophils play a key role in the early events associated with periodontal 
disease progression, the data suggests IL-17E is a rational target for therapeutic 
intervention. 
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1.1 Periodontal disease 
The periodontium is a term that refers to the specialised periodontal tissues that 
support the teeth in their positions in the upper and lower jaws. The 
periodontium consists of four major tissues: alveolar bone, cementum, 
periodontal ligament and gingiva. Since the main function of periodontium is to 
support the teeth, maintaining a healthy periodontium is very important in 
ensuring masticatory function. However, there are many diseases and conditions 
the pathogenesis of which are known to precipitate damage to the periodontium 
and may eventually lead to tooth loss (Armitage, 1999). 
Plaque induced gingivitis is the most common form of periodontal disease 
(Ababneh et al., 2012; Albandar & Kingman, 1999; Page, 1985). It is 
characterised by inflammation of the gingiva and is associated with the presence 
of bacterial plaque at the gingival margin. However, this results in no observable 
loss of bone and no loss of tooth attachment. Indeed, the inflammation that is 
characteristic of gingivitis is reversible upon removal of gingival plaque 
(Mariotti, 1999).  
Without proper oral health care, plaque induced gingivitis can progress to 
chronic periodontitis. Chronic periodontitis is characterised by destruction of the 
alveolar bone, cementum, periodontal ligament and gingiva, which results 
clinically in the formation of a periodontal pocket and/or gingival recession. 
Periodontal disease affects 60 - 90 % of the population (Bartold et al., 2010). In 
addition, The World Health Organisation (WHO) reported severe chronic 
periodontitis in 5 – 20 % of the adult population worldwide (Jin et al., 2011). In 
the UK, advanced chronic periodontal disease was found to affect 8 – 15 % of the 
population (Kelly et al., 1998). Furthermore, periodontal disease represents a 
significant cost burden to the National Health Service; with treatment and its 
sequelae costing the National Health Service in Scotland alone at least £20 
million annually ("Scottish dental practice board: annual report," 2009). In 
addition, evidence suggests that bi-directional links occur between periodontal 
disease and other chronic inflammatory conditions such as rheumatoid arthritis, 
diabetes and cardiovascular disease (Kaur et al., 2013; Pizzo et al., 2010). 
Therefore, it can be hypothesised that treatment of periodontal disease and 
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associated conditions places an even larger cost burden on limited National 
Health Service resources than previously described. 
Although gingivitis and chronic periodontitis are initiated and sustained by 
bacterial plaque, the host defence mechanisms are believed to play an 
important role in their pathogenesis (Lindhe et al., 1999). In an attempt to 
remove the plaque microflora the periodontium mounts an immune response. In 
susceptible individuals this can result in dysregulated production of immuno-
modulatory mediators (cytokines, chemokines, prostanoids, and enzymes); which 
actually fail to clear the pathogens and cause bystander damage (Graves, 2008). 
In addition, evidence is now emerging that suggests elevated levels of these 
immune system mediators migrate into the peripheral circulation and influence 
the aetiology of other diseases or conditions such as rheumatoid arthritis, 
diabetes and cardiovascular disease (Kaur, et al., 2013; Pihlstrom et al., 2005; 
Williams et al., 2008). The prominent role of the inflammatory response in the 
pathogenesis of periodontal disease and associated conditions therefore suggests 
that host response modulation may provide novel therapeutic interventions 
(Preshaw, 2008). 
 
1.2 Dental biofilm 
Dental biofilm (also known as dental plaque) has similar properties with biofilms 
found in other parts of body and the environment. Dental biofilm is a complex 
multi-species biofilm with over 800 bacterial species being isolated by culture 
methods (Aas et al., 2005; Becker et al., 2002; Paster et al., 2001; Preza et al., 
2008). However, this figure is now known to be a gross underestimate as 
advancements in microbial sequencing technologies have identified numerous 
un-culturable species in dental biofilm (Dethlefsen et al., 2007; Keijser et al., 
2008). The constituent species of dental biofilm varies between individuals and 
is determined by the oral environment. The oral environment, in turn, is 
determined by factors such as genetics, age, diet, smoking, alcohol intake and 
individual oral hygiene practices (Marsh, 1991). These factors have profound 
effects on the microbial composition of dental biofilm and therefore the onset of 
oral pathologies such as dental caries and periodontal disease (Baehni & 
Takeuchi, 2003). 
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Dental biofilm accumulation on tooth surfaces has long been known to associate 
with inflammation and destruction of the periodontium (Lovdal et al., 1958; 
Ramfjord et al., 1968; Waerhaug, 1956, 1967). Initially, the biofilm bacteria 
themselves were thought to play the major role in the pathogenesis of 
periodontal disease. Loe and colleagues (1965) were amongst the earliest groups 
to describe the involvement of specific bacteria in periodontal disease 
progression. Their studies demonstrated that the composition of dental biofilm 
associated with a healthy gingiva tissue consists predominantly of Gram-positive 
bacteria with very few Gram-negative species. In contrast, there was up to a 40 
% increase in the number of Gram-negative bacteria in dental biofilm associated 
with an inflamed gingiva. Therefore, these authors introduced the specific 
plaque hypothesis (Loesche, 1976). The introduction of this hypothesis led to the 
quest to find specific pathogenic organisms that may be responsible for the 
aetiology of periodontal disease. This led in the coming years to the 
identification of around 20 culturable bacterial species which had associations 
with periodontal disease (Paster, et al., 2001). Of these species, only a few are 
well-studied; for example Porphyromonas (P.) gingivalis, Tannerella (T.) 
forsythus, Aggregatibacter (A.) actinomycetemcomitans, Campylobacter (C.) 
rectus, Streptococcus (S.) constellatus, Fusobacterium (F.) nucleatum, and 
Treponema (T.) denticola (Estrela et al., 2010; Komiya Ito et al., 2010; Paster, 
et al., 2001; Slots & Ting, 1999; Socransky et al., 1998; Socransky et al., 1988). 
However, sequence-based mapping of the oral microbiota has identified the 
presence of around 1179 taxa in dental biofilm and showed that 68 % of the 
phylotypes present were known un-culturables (Dewhirst et al., 2010). This 
therefore raises the possibility that some of those bacterial species we are yet to 
culture have important roles in the pathogenesis of periodontal disease. 
The formation of dental biofilm starts with the establishment of the salivary 
pellicle on enamel surfaces immediately after tooth brushing. The early 
colonisers attach to this salivary pellicle. Early colonising species are 
predominantly (60 – 90 %) Streptococci, with the remainder made up of a variety 
of other species including Capnocytophaga, Actinomyces, Eikenella, 
Haemophilus, Prevotella, Propionibacterium and Veillonella (Kolenbrander et 
al., 2010; Nyvad & Kilian, 1987). The early colonising species grow laterally and 
co-aggregate to form a niche environment which propagates their growth and 
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survival. This leads to an increase in the thickness of the biofilm (vertical 
growing) (Filoche et al., 2010; Socransky & Haffajee, 2005). Co-aggregation 
between bacterial species has been demonstrated to be important for bacterial 
colonisation, metabolic communication, genetic exchange (Hojo et al., 2009) 
and therefore survival during early biofilm formation (Bradshaw et al., 1998). 
Without mechanical disruption of early dental biofilm, the colonising species 
continue to grow and proliferate causing changes in biofilm physiology. The 
metabolic activity of the aerobic species reduces the oxygen concentration and 
pH within the biofilm promoting colonisation of the intermediate and subsequent 
late species (Hojo, et al., 2009). F. nucleatum is a prominent intermediate 
species and has been isolated from dental biofilm associated with periodontal 
health and disease. Importantly, F. nucleatum was demonstrated to co-
aggregate with both early and late colonising species in dental biofilm and 
therefore this species is an important bridging organism that promotes 
pathogenic biofilm formation (Kolenbrander et al., 2002). The presence of F. 
nucleatum, as well as physiological changes in the biofilm micro-environment, 
thus provide the perfect conditions for the late colonising pathogenic Gram-
negative anaerobes, such as the Actinobacillus, Prevotella, Porphyromonas and 
Treponema species (Kolenbrander, et al., 2002). 
P. gingivalis is a Gram-negative oral anaerobe and is one of the most studied 
bacterial species in relation to the pathogenesis of periodontal disease (Estrela, 
et al., 2010). P. gingivalis is present in 85.7 % of biofilm samples from patients 
with periodontal disease, compared to only 23.1 % of samples from healthy 
subjects (Yang et al., 2004). The presence of P. gingivalis has also been shown 
to positively correlate with clinical parameters such as the clinical probing depth 
of the periodontal pocket (Kawada et al., 2004). Furthermore, treatment and 
healing outcomes have also been shown to associate with decreasing presence of 
P. gingivalis within the subgingival biofilm (Haffajee et al., 1997; Kawada, et 
al., 2004). Indeed, the importance of this organism in disease pathogenesis has 
been eloquently demonstrated in vivo as oral inoculation of P. gingivalis in mice 
caused significant inflammation, induced bone loss and periodontal tissue 
destruction (Hajishengallis et al., 2011; Wang et al., 2007a). 
Although the presence of P. gingivalis in subgingival biofilm has long been 
associated with periodontal diseases (Curtis et al., 2001; Lamont & Jenkinson, 
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1998; Van Dyke, 2007); studies have shown that P. gingivalis can also present in 
the biofilm of healthy subjects; and in fact in patients with periodontal disease 
P. gingivalis is actually present at low levels (Kumar et al., 2006) compared to 
many other species. Therefore in recent years questions have been raised as to 
whether P. gingivalis alone is the sole aetiological agent for periodontal disease. 
In fact, oral inoculation of P. gingivalis into specific pathogen free mice, but not 
the germ free mice, was shown to induce periodontal bone loss (Hajishengallis, 
et al., 2011). This therefore demonstrated the contributing role of commensal 
bacteria in P. gingivalis-induced bone loss. In addition, P. gingivalis inoculation 
into specific pathogen free mice led to the increase in bacterial load compared 
to the sham control. Therefore P. gingivalis was found to be important in 
promoting biofilm formation which was in agreement with previous findings in a 
rabbit periodontitis model (Hasturk et al., 2007). These studies led to a change 
in researcher’s attitude toward the role of P. gingivalis in periodontal disease 
pathogenesis. Previously, it was thought periodontal diseases were associated 
with an increased dental biofilm biomass (Loe, et al., 1965; Loesche & Syed, 
1978; Moore et al., 1982; Theilade et al., 1966; Zee et al., 1996). However, 
studies on subgingival biofilm stability showed that a healthy periodontium was 
associated with 75.5 % conservation of biofilm microbiota whilst diseased or 
deteriorating periodontal conditions were often associated with < 50 % 
conservation (Kumar, et al., 2006). In addition, health-associated dental biofilm 
was shown to be inhabited by a rich diversity of bacterial flora and this diversity 
was reduced in biofilm associated with periodontal diseases; with putative 
periodontal pathogens becoming the prominent species (Kistler et al., 2013). 
Therefore, it is now apparent that the constituent species of dental biofilms is a 
more important factor than bacterial load. In addition, P. gingivalis, even at low 
levels, can alter the composition of biofilm flora therefore  the current concept 
implicates P. gingivalis as being a keystone pathogen shaping the dental biofilm 
community and disease pathogenesis (Darveau et al., 2012). 
Despite P. gingivalis having been shown to be associated with the onset and 
progression of periodontal diseases (Curtis, et al., 2001; Lamont & Jenkinson, 
1998; Van Dyke, 2007), the fact still remains that P. gingivalis has been reported 
to be present in biofilm of periodontally healthy individuals (Bik et al., 2010; 
Ximenez-Fyvie et al., 2000) and subjects are not equally susceptible to P. 
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gingivalis exposure (Johnson et al., 1988; Savitt & Socransky, 1984). This 
therefore points to a far more complex pathogenesis for periodontal diseases 
involving not just oral pathogens but other factors such as the host immune 
response.  
 
1.3 Host immune response and periodontal disease 
The host immune response is important in maintaining the health of periodontal 
tissues. This is particularly highlighted in patients with immunodeficiencies. 
Patients with functional leukocyte disorders such as Chediak-Higashi syndrome 
and chronic granulomatous disease, which manifest as compromised neutrophil 
responses, have been demonstrated to be at greater risk of periodontal disease 
(Deas et al., 2003; Kinane, 1999; Tempel et al., 1972). In addition, patients with 
neutropenias (chronic neutropenia, chronic benign neutropenia and cyclic 
neutropenia), which are granulocyte disorders characterized by an abnormally 
low number of neutrophils have also been shown to have increased periodontal 
inflammation and bone loss (Baehni et al., 1983; Deas, et al., 2003; Deasy et al., 
1980; Stabholz et al., 1990). Furthermore, patients with human 
immunodeficiency virus (HIV) infection, which is characterised by decreased 
numbers of peripheral  CD4+ T cells, were found to be susceptible to periodontal 
disease (Lucht et al., 1991). 
The presence of pathogens in periodontal pockets will activate innate and 
adaptive immune responses in an attempt to clear the pathogenic threat as well 
as promote tissue homeostasis. However, the persistent presence of pathogens 
can cause the continuous activation of innate and adaptive immune responses; 
which in turn causes inappropriate inflammatory mediator (cytokine, chemokine, 
antimicrobial proteins and enzymes) synthesis and secretion that directly or 
indirectly lead to periodontal tissue destruction (Monack et al., 2004; Preshaw & 
Taylor, 2011). These inflammatory mediators, which can be produced by 
periodontal host cells in response to pathogen, are known to cause degradation 
of extracellular matrix of periodontal tissue (Liu et al., 2010). In addition, they 
can play important roles in driving  osteoclast activity and therefore promoting 
loss of alveolar bone (Bartold, et al., 2010).  
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1.3.1 Innate immunity and periodontal disease 
The formation of a dental biofilm usually occurs on tooth surfaces at the occlusal 
area and gingival margin. Without mechanical disruption, the biofilm will grow 
into a thick mature biofilm extending into the subgingival area (subgingival 
biofilm). The subgingival biofilms are comprised of mostly Gram-negative, 
anaerobic bacteria which lead to the deposition of virulence factors into the 
gingival crevicular fluid (GCF). These substances can cause injury to host cells 
directly. However, the host is equipped with an innate defence system which is 
designed to recognise these substances and protect the tissue from microbial 
attack. 
Cytokines and chemokines play important roles in initiating immune responses 
through activation of innate immunity (Medzhitov, 2010). In the periodontium, 
host cells such as epithelial cells, fibroblasts, macrophages and dendritic cells 
play a key role in the initial sensing of microbial presence through an array of 
pattern recognition receptors (PRRs) expressed on their surfaces (Andrukhov et 
al., 2013; Beklen et al., 2008; Jotwani et al., 2010; Mahanonda et al., 2009; 
Shimada et al., 2012). In health the presence of commensal bacteria in a dental 
biofilm activate a low level innate immune response. This low level response is 
important in priming host tissue cells and promoting tissue homeostasis. A shift 
in the composition of the dental biofilm and the presence of pathogenic 
organisms however cause an amplification of this immune response by localised 
cells (Handfield et al., 2008; Taylor, 2010). The greater presence of pathogenic 
organisms leads to an increase in the number of microbe associated molecular 
patterns (MAMPs) derived from pathogens which drive tissue inflammation 
(Hajishengallis, 2009). Activation of PRRs (e.g., Toll-like receptor-2 (TLR-2), 
TLR-3, TLR-4 and TLR-5) by respective MAMPs induce increased expression of 
cytokines and chemokines such as interleukin-8 (IL-8), IL-6, IL-1β, interferon 
gamma (IFN-γ), IL-4, IL-12, tumor necrosis factor alpha (TNF-α), granulocyte-
macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating 
factor (G-CSF), macrophage colony-stimulating factor (M-CSF), C-X-C motif 
chemokine-10 (CXCL10), macrophage inflammatory protein-1α (MIP-1α), MIP-1β, 
chemokine (C-C motif) ligand-20 (CCL20), eotaxin and eotaxin-2 (Andrukhov, et 
al., 2013; Beklen, et al., 2008; Eskan et al., 2007; Hosokawa et al., 2013; 
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Jotwani, et al., 2010; Kocgozlu et al., 2009; Luo et al., 2012; Mahanonda, et al., 
2009; Milward et al., 2013; Shimada, et al., 2012). 
Many of the pathogenic organisms found in dental biofilm possess a host of 
virulence factors. Many of these virulence factors are termed MAMPs. MAMPs are 
highly conserved structures of microorganisms such as lipopolysaccharide (LPS), 
peptidoglycan, lipoprotein, bacterial DNA and double stranded RNA (Mahanonda 
& Pichyangkul, 2007). MAMPs interact with PRRs, such as TLRs, and initiate 
innate immune responses. Numerous resident and recruited host cells of 
periodontal tissues express surface TLRs. These include neutrophils, langerhans 
cells, monocytes/macrophages, osteoblasts, periodontal ligament fibroblasts, 
gingival fibroblasts and gingival epithelial cells (Mahanonda & Pichyangkul, 
2007). Interactions between MAMPs and TLRs leads to information transmission 
through intracellular signalling pathways that in turn leads to the expression of 
inflammatory mediators and antimicrobial agents as well as the promotion of 
immune cell differentiation and activation. Therefore TLRs play a major role in 
initiating defence mechanisms aimed to eradicate pathogenic threats. 
P. gingivalis possesses several inherent MAMPs such as LPS, fimbriae and 
bacterial DNA, which are capable of invoking innate immune responses (Bostanci 
& Belibasakis, 2012). LPS is a major component of the outer membrane of Gram-
negative bacteria. The main function of LPS is to provide structural integrity and 
protection to the bacteria. P. gingivalis LPS is recognised by TLR-2 and -4 
(Darveau et al., 2004). P. gingivalis LPS activation of TLR-2 and TLR-4 has been 
shown to induce monocytes and macrophages to produce pro-inflammatory 
cytokines and chemokines such as TNF-α, IL-12, IL-1β, IL-7, IL-8, IL-17A, CXCL2, 
CXCL10, CCL5 and IFN-γ, as well as vascular factors such as vascular cell 
adhesion molecule 1 (VCAM-1) and vascular endothelial growth factor (Bostanci 
et al., 2007; Hirschfeld et al., 2001; Zhou et al., 2005). In oral epithelial cells, 
LPS of P. gingivalis, via TLR-2, was also shown to induce increased expression of 
IL-6, IL-8, IL-1β, IL-1α, TNF-α, GM-CSF, eotaxin, eotaxin 2, CXCL10, MIP-1α and 
MIP-1β (Kocgozlu, et al., 2009; Luo, et al., 2012; Milward, et al., 2013). 
Therefore the evidence suggests that TLR-2 plays a key role in driving the oral 
innate immune response against P. gingivalis. Indeed, the persistent activation 
of TLR-2 by P. gingivalis may therefore play a role in periodontal disease 
pathogenesis. This was elucidated further in vivo as TLR-2-deficient mice were 
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shown resistant to bone loss following oral infection with P. gingivalis (Burns et 
al., 2006). 
The fimbriae of P. gingivalis is a thin, filamentous, cell surface appendage that 
is involved in facilitating cellular adherence, and also contributes to host 
virulence. Through these fimbriae, P. gingivalis can adhere to early colonizing 
bacteria and therefore play a prominent role in the formation of dental biofilms 
(Bostanci, et al., 2007). Fimbriae of P. gingivalis has also been shown to induce 
production of pro-inflammatory cytokines and chemokines, such as IL-1β, IL-8, 
IL-6 and TNF-α, from host cells like dendritic cells, macrophages and endothelial 
cells via TLR-2 and TLR-4 (Aoki et al., 2010; Davey et al., 2008; Jotwani & 
Cutler, 2004; Pollreisz et al., 2010; Takahashi et al., 2006; Zhou, et al., 2005). 
In addition, the fimbriae of P. gingivalis has also shown to induce production of 
IL-1β, IL-6 and IL-8 by gingival epithelial cells; again via TLR-2 (Asai et al., 2001; 
Gao et al., 2012). 
The deoxyribonucleic acid (DNA) of bacteria is known to be involved in 
activation of immune responses. The un-methylated CpG (-C-phosphate-G-) 
dinucleotide component of bacterial DNA is known to be recognised by host cells 
via TLR-9 (Dalpke et al., 2006). In monocytes, DNA of P. gingivalis was shown to 
induce increased expression of IL-1β, IL-6, IL-8 and TNF-α via TLR-9 (Sahingur et 
al., 2010; Sahingur et al., 2012). In addition, P. gingivalis and A. 
actinomycetemcomitans DNA induced increased expression of TNF-α and IL-6 in 
macrophages, gingival fibroblasts and HEK293 cells (human embryonic kidney 
293 cell line) which had been transfected with TLR-9 (Nonnenmacher et al., 
2003). However, study also showed immunosuppression effect of bacterial DNA. 
For example, DNA of P. gingivalis was shown to upregulate the expression of the 
suppressor of cytokine signalling (SOCS), including SOCS1 and SOCS5 and 
downregulate the expression of IL-10 by cultured splenocytes (Taubman et al., 
2007). 
As well as inducing the release of cytokines and chemokines, activation of TLRs 
can also induce the increased expression and release of host antimicrobial 
agents. Once such family of molecules are the antimicrobial peptides (AMPs); 
which includes the α-defensins, -defensins, cathelicidins (LL-37) and 
calprotectin. AMPs are also defined as host defense peptides because of their 
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essential role in innate immunity. AMPs are generally comprised of less than 50 
amino acids and characterized by their cationic and amphipathic properties. In 
general, when AMPs are folded in membrane mimetic environments, one side of 
the AMP is positively charged (mainly due to lysine and arginine residues) and 
the other side contains a considerable proportion of hydrophobic residues (Shai, 
1999). The microbiocidal activity of AMPs is related to this hydrophobic and 
cationic structure. These properties facilitate their attraction and attachment to 
the anionic membranes of bacteria, viruses and fungi. This amphipathic 
structure leads to the creation of pores in microbial membranes which increase 
membrane permeability and ultimately leads to disruptions in ion gradients and 
energy dissipation and hence cell lysis (Izadpanah & Gallo, 2005). In addition to 
their microbiocidal function many AMPs also play a role in dictating immune 
responses in a cytokine/chemokine-like fashion. For example, cathelicidin (LL-
37) is a chemoattractant of neutrophils, monocytes and T cells through the 
formyl peptide receptor-like 1 (FPRL1) (De et al., 2000). In addition, human -
defensin-2 was shown to induce mast cells to release histamine and produce 
prostaglandin D2 (Befus et al., 1999).  
The complement system consists of small protein networks which are involved in 
innate and adaptive immune responses to microorganisms (Dunkelberger & Song, 
2010). The complement system consists of three different converging pathways: 
the classical pathway, the lectin pathway and the alternative pathway. 
Activation of the classical pathway and lectin pathway require binding of 
antibody and its antigen, and binding of mannose binding lectin (MBL) to a 
pathogen’s carbohydrate moieties respectively. The activation of the alternative 
pathway depends on the spontaneous formation of C3b (from C3) which binds to 
carbohydrates, lipids and proteins on the surface of foreign objects; including  
bacteria (Sarma & Ward, 2011). Activation of the complement system leads to 
the production of anaphylatoxins C3a and C5a and vasoactive amines. Vasoactive 
amines cause an increase in vascular permeability, an important stage in the 
acute inflammatory response. In addition, C3a and C5a activate resident mast 
cells inducing the release of cytokines such as TNF-α, which increases the 
expression of adhesion molecules that further promote migration of 
polymorphonuclear leukocytes to sites of inflammation (Ohlrich et al., 2009). In 
vitro and in vivo, C3a and especially C5a are also found to be powerful 
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chemoattractants that attract neutrophils, monocytes and macrophages to the 
site of inflammation upon activation (Ohlrich, et al., 2009; Toews & Vial, 1984; 
Toews et al., 1985; van Lookeren Campagne et al., 2007). Activation of C5a 
promotes inflammation through C5a-induced vasodilation, increased vascular 
permeability and flow of inflammatory exudate that encourage migration of 
polymorphonuclear leukocytes and monocytes/macrophages to the site of 
inflammation (Krauss et al., 2010; Snyderman, 1972). The bacterial killing by the 
complement system is achieved by promotion of phagocytosis (e.g., through the 
3b opsonin), and also by direct killing of bacteria through the C5b-9 membrane 
attack complex (Ricklin et al., 2010). Levels of cleaved C3 have been shown to 
be higher in the GCF of the gingivitis patients (Attstrom et al., 1975; Niekrash & 
Patters, 1986; Patters et al., 1989). In addition, even higher levels of cleaved C3 
are found in the GCF of patients with chronic periodontitis (Monefeldt et al., 
1995; Niekrash & Patters, 1985; Niekrash et al., 1984). Similarly, GCF levels of 
C5 were shown to be higher in chronic periodontitis (Attstrom, et al., 1975) and 
C5 was highly expressed in gingival tissue explant cultures from chronic 
periodontitis patients (Lally et al., 1982). 
The resident cells of periodontal tissues include epithelial cells, gingival and 
periodontal ligament fibroblasts, endothelial cells, dendritic cells, osteoblasts, 
osteoclasts and cementoblasts (Hans & Hans, 2011). In the presence of 
pathogens, chemokines such as IL-8 and CXCL10 are released by these resident 
cells and function to induce  the migration of other immune cells such as 
polymorphonuclear leukocytes, monocytes and T lymphocytes into tissues 
(Larsen et al., 1989; Modi et al., 1990; Taub et al., 1993). The migrating 
immune cells, in conjunction with resident cells, serve to regulate periodontal 
innate immunity. GCF contains approximately 95 % polymorphonuclear 
leukocytes, 1-3 % monocytes/macrophages and 1-2 % lymphocytes (Ebersole, 
2003); and activation of these cells, especially polymorphonuclear leukocytes 
and monocytes/macrophages plays a key role in the early defence of periodontal 
tissues by recognising, engulfing and killing microorganisms. Complement 
activation by periodontal pathogens, such as P. gingivalis, induces an acute 
inflammatory response which is characterised by vasodilation, increased vascular 
permeability and increased flow of inflammatory exudate to the site of 
inflammation. Cell migration is aided by the increased expression of a number of 
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chemokines (e.g., IL-8, CXCL10 and CCL20) by oral keratinocytes in response to 
P. gingivalis (Dommisch et al., 2010; Eskan et al., 2008b; Kinane et al., 2006). 
IL-8 is a known chemoattractant for polymorphonuclear leukocytes and T 
lymphocytes (Larsen, et al., 1989; Modi, et al., 1990) and CXCL10 is known as a 
chemoattractant for monocytes and T lymphocytes (Taub, et al., 1993). At sites 
of infection/inflammation, polymorphonuclear leukocytes identify bacteria 
through opsonins (e.g., IgG and C3b); host-derived molecules that adhere to  
bacterial surfaces and target the organisms for engulfment and phagocytosis 
(Nussbaum & Shapira, 2011). Polymorphonuclear leukocytes also kill bacteria 
directly through the release of oxidative and enzymatic molecules (Nussbaum & 
Shapira, 2011; Scott & Krauss, 2012). Like polymorphonuclear leukocytes, 
macrophages also identify bacteria through opsonins (e.g., IgG and C3b) and also 
destroy them by phagocytosis (Stuart & Ezekowitz, 2005; van Lookeren 
Campagne, et al., 2007). Through surface receptors such as TLRs, cluster of 
differentiation 14 (CD14) and CD36 macrophages can recognise microbial 
pathogens by their MAMPs. Activation of macrophage TLRs then promote their 
antimicrobial action, leading to phagocytosis and the further expression of 
cytokines and chemokines, which in turn promote further migration and 
activation of phagocytes and therefore propagate the inflammatory response 
(Taylor et al., 2005).  
Dendritic cells are the most important antigen presenting cells (Steinman, 1991). 
Langerhans cells, a unique epithelial subset of dendritic cells were found in high 
number in the sulcular epithelium, and their presence was found to be positively 
associated with dental biofilm formation (Wilensky et al., 2013). Dendritic cells 
are known for their capability to phagocytose and endocytose pathogens or 
antigens. Once internally processed, dendritic cells generate a major 
histocompatibility complex (MHC)-peptide complex and migrate to secondary 
lymphoid organs to interact with and activate T lymphocytes (Thery & 
Amigorena, 2001). Although not as competent as dendritic cells, macrophages 
have also been shown to have the capacity to act as an antigen presenting cells 
(Barker et al., 2002; Unanue, 1984). Therefore dendritic cells and macrophages 
act as important cells that link innate and adaptive immunity within the 
periodontium.   
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1.3.2 Adaptive immunity and periodontal disease 
There have been numerous studies which indicate an important role for adaptive 
immunity in the pathogenesis of periodontal disease. Anti P. gingivalis 
antibodies were found in serum of patients with chronic periodontitis but not in 
healthy subjects (Kojima et al., 1997; Maeda et al., 1994; Tabeta et al., 2000; 
Whitney et al., 1992). In addition, the antibody levels were found to be 
positively associated with the levels of P. gingivalis in dental biofilm (Kojima, et 
al., 1997). The anti P. gingivalis antibody titre was also found to be elevated in 
GCF of patients with periodontal disease (Mooney & Kinane, 1997; Reinhardt et 
al., 1989; Tew et al., 1985) and the levels in GCF were found to be higher 
compared to the levels in serum (Reinhardt, et al., 1989; Tew, et al., 1985). 
These indicate the involvement of antibody producing cells and therefore 
adaptive immunity in periodontal disease. 
The number of T cells and B cells is elevated in gingival tissue of patients with 
periodontal disease. For example, immunohistochemistry and flow cytometry 
showed increased numbers of T cells and B cells were present in gingival biopsies 
from advanced chronic periodontitis patients compared to healthy subjects 
(Berglundh et al., 1998). Lappin and colleagues (1999) showed 
immunohistochemically that numbers of B cells and T cell were increased in 
periodontal tissue samples compared to healthy subjects and that there were 
more  B cells than T cells in the diseased periodontal tissue. Furthermore T 
helper type 17 (Th17) cells have been found within the periodontium in 
periodontal disease patients and are implicated to play an important 
osteoclastogenic role (Sato et al., 2006). Berglundh and Donati (2005) reviewed 
studies investigating the presence of immune cells in periodontal samples 
(biopsies, GCF and blood) and found that plasma cells are the most common 
cells (50 %), followed by B cells (about 18 %) and that total T cells combined 
contributed only 10 % of the total immune cell population. 
Animal models have shown that lymphocytes are involved either directly or 
indirectly in periodontal disease pathogenesis. For example, Baker and 
colleagues (1999) studied the severe combined immunodeficient (SCID) mice, 
which are lacking in B and T lymphocytes. SCID mice challenged with P. 
gingivalis exhibited less bone loss compared to their immune-competent wild 
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type counterparts, suggesting that the B and T lymphocytes are involved in bone 
resorption. In addition, studies using non-obese diabetic (NOD)/SCID mice, 
engrafted with human peripheral blood lymphocytes (CD4+ T cells) from a 
patient with localized juvenile periodontitis, then challenged with A. 
actinomycetemcomitans, exhibited greater bone loss than wild type control mice 
(Teng et al., 2000). Furthermore, adoptive transfer of A. 
actinomycetemcomitans-responsive B cells to athymic (without thymus) rats 
caused an increase in bone resorption when the rats were challenged with A. 
actinomycetemcomitans compared to rats immunized with non-antigen specific 
cells (Han et al., 2006). Collectively these studies demonstrate that lymphocytes 
have a contributing role in periodontal disease pathogenesis.  
In vitro, oral pathogens were shown to induce cytokine release from oral 
epithelial cells, which in turn induced human monocyte-derived dendritic cells 
(MDDCs) to mediate polarisation of T helper type 2 (Th2) cells from CD4+ T cells 
(Rimoldi et al., 2005). Conversely, oral pathogens could also directly induce 
MDDCs to mediate polarization of T helper type 1 (Th1) cells from CD4+ T cells. 
Human MDDCs in response to the periodontal pathogen P. gingivalis were shown 
to induce maturation and polarization of CD4+ T cells towards both Th1 and Th2 
cells (Jotwani et al., 2003). In addition, the importance of T cells in protecting 
periodontal tissues was shown in vivo as T cell deficient rats were found to 
suffer greater periodontal bone loss compared to control wild type rats (Yoshie 
et al., 1985). Additionally, temporarily B lymphocyte deficient rats inoculated 
with a mixture of periodontal pathogens were also shown to present with greater 
periodontal bone loss compared to controls (Klausen et al., 1989). Together, in 
vivo evidence indicates a potential role for adaptive immunity in the 
pathogenesis of periodontal disease. However, to date, our understanding of this 
role is still limited. 
 
1.3.3 The role of the host immune response in soft tissue 
destruction  
One of the major clinical hallmarks of periodontal disease is the destruction of 
the soft tissues which support the teeth. The destruction of periodontal soft 
tissues can be mediated both by bacterially derived factors as well as host 
response molecules. 
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P. gingivalis possesses several inherent virulence factors which are capable of 
invoking damaging effects on host cells (Bostanci & Belibasakis, 2012). 
Gingipains are a group of cysteine proteinases secreted by P. gingivalis. Up to 85 
% of the total proteolytic activity of P. gingivalis is mediated by gingipains 
(Potempa et al., 1997). Gingipains have various effects on the immune system. 
They have been shown to be capable of disrupting the function of T cells by 
cleaving surface receptors such as CD2, CD4 and CD8 (Kitamura et al., 2002).  
They are also capable of inactivating cytokines such as IL-4, IL-5 and IL-12 by 
their proteolytic activity (Tam et al., 2009; Yun et al., 2001) and therefore 
disrupting immune regulation. In addition, gingipains are also known to 
encourage adhesion of P. gingivalis to host epithelial cells and fibroblasts 
(Andrian et al., 2004; Chen et al., 2001) and directly degrade extracellular 
matrix components such as laminin, fibronectin, collagen type III, IV and V 
(Potempa et al., 2000). 
In addition to gingipains, P. gingivalis secrete enzymes such as chondroitinase 
and heparitinase, which are capable of degrading the proteoglycans within the 
human gingiva (Smith et al., 1997). In addition, P. gingivalis is also known to 
produce proteases such as collagenase, fibrinolysin and phospholipase A, which 
directly degrade periodontal tissues (Schenkein et al., 1999). The activity of 
these enzymes promotes the permeation of P. gingivalis into the gingival 
epithelium and can provide a gateway for other organisms to invade. In addition, 
these enzymes play a direct role in localised tissue destruction.  
Under normal physiological conditions, periodontal tissues achieve homeostasis 
by continuous remodelling of connective tissues. This is achieved by the 
degradation of the old, injured or infected extracellular matrix (ECM). The ECM 
is comprised of interstitial and basement membrane which in turn are held 
together by a variety of proteins: collagen, fibronectin, laminin and 
proteoglycans. These proteins can be degraded by endopeptidases, for example, 
the matrix metalloproteinases (MMPs); metal-dependant endopeptidases which 
play important roles in remodelling by degradation of the ECM (Birkedal-Hansen, 
1993). Fibroblasts play a very important role in restoring the degraded ECM by 
synthesising and secreting  collagen (Midwood et al., 2004). The processes of 
ECM synthesis and degradation occurs throughout life and are finely balanced in 
order to maintain tissue homeostasis. However, in diseases such as arthritis and 
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cancer  degradation of the ECM is not balanced by synthesis, which in part is due 
to inappropriate regulation of endopeptidase activity (Reynolds et al., 1994). 
There are four major groups of MMPs; collagenases (MMP-1, MMP-8 and MMP-13), 
gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10 and MMP-11) and 
membrane-type (MMP-14, MMP-15, MMP-16, MMP- 17)  (Sorsa et al., 2004). 
Collectively, members of the MMP family are able to degrade most of the ECM 
macromolecules (Birkedal-Hansen, 1993). MMPs are secreted in the form of a 
pro-enzyme by host cells such as fibroblasts, keratinocytes, endothelial cells and 
monocytes/macrophages. The release of MMPs by these cells is regulated by 
cytokines and growth factors such as IL-1, TNF-α, platelet-derived growth factor 
(PDGF), transforming growth factor alpha (TGF- α) and epidermal growth factor 
(EGF) which are mostly released by host cells after tissue injury or during 
inflammation (Birkedal-Hansen, 1993; Reynolds, et al., 1994). The activities of 
MMPs are controlled by tissue inhibitors of metalloproteinases (TIMPs) whose 
expression is also regulated by host cells such as keratinocytes, fibroblasts and 
monocytes/macrophages (Birkedal-Hansen, 1993; Reynolds, et al., 1994). The 
balanced activity between MMPs and TIMPs plays an important role in tissue 
homeostasis. Therefore, conditions which lead to increased MMP activity over 
TIMP activity are characterized by tissue destruction (Birkedal-Hansen, 1993; 
Reynolds, et al., 1994). 
Like other diseases that involve soft tissue destruction, such as arthritis and 
cancer, periodontal disease is associated with increased MPP activity (Reynolds, 
et al., 1994). Among all MMPs, MMP-8, MMP-9 and MMP13 were identified as 
potential important contributors in pathologic soft tissue destruction in 
periodontal disease (Sorsa, et al., 2004). Immunohistochemical analysis of 
periodontal tissue samples showed that MMP-1, MMP-3, MMP-8 and MMP-13 were 
highly expressed in gingival samples from periodontal disease patients; but not 
expressed in healthy subjects (Hernandez et al., 2006; Ingman et al., 1994; 
Sorsa et al., 2011; Tervahartiala et al., 2000). In addition, MMP evaluation of 
GCF samples showed elevated levels of MMP-2, MMP-8, MMP-9 and MMP-13 in 
periodontal disease patients compared to healthy subjects (Hernandez et al., 
2010; Hernandez Rios et al., 2009; Sorsa et al., 2010; Sorsa, et al., 2011). 
Additionally, periodontal treatment was also shown to reduce the GCF level of 
MMP-8 (Hernandez, et al., 2010; Mantyla et al., 2006) as well as the plasma 
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level of MMP-9, and a reduction in levels was associated with periodontal healing 
(Marcaccini et al., 2009). The pathologic soft tissue destruction in periodontal 
disease was also seen to associate with increased expression of MMPs over TIMPs 
(Bildt et al., 2008; Garlet et al., 2006; Hernandez Rios, et al., 2009; Pozo et al., 
2005).  
At the cellular level, MMPs such as MMP-1, MMP-3, MMP-8 and MMP-9 were found 
to be expressed by oral keratinocytes, fibroblasts, endothelial cells, 
macrophages and polymorphonuclear leukocytes (Birkedal-Hansen, 1993; Hannas 
et al., 2007; Ingman, et al., 1994). Periodontal pathogens and cytokines were 
shown to regulate expression and release of the MMPs. For instance, P. gingivalis 
and A. actinomycetemcomitans were shown to induce gingival epithelial cells 
and periodontal fibroblasts to express MMP-1, MMP-2, MMP-3 and MMP-9 (Andrian 
et al., 2007; Chang et al., 2002; DeCarlo et al., 1997). In addition, IL-1α, IL-1β, 
TNF-α and IL-17A were shown to induce periodontal fibroblasts to express MMP-
1, MMP-2, MMP-3, MMP-8, MMP-10, MMP-13 and MMP-14 (Ahn et al., 2013; Beklen 
et al., 2007; Chang, et al., 2002; Cox et al., 2006). Immunohistochemical 
analysis revealed immune cells in the periodontium such as neutrophils and 
macrophages, also express MMPs; such as MMP-7, MMP-8 and MMP-13 (Kiili et al., 
2002; Tervahartiala, et al., 2000). Once released, MMPs are capable of 
mediating the degradation of the extracellular matrix, including the interstitial 
and basement membranes of the periodontium (Birkedal-Hansen, 1993). In 
addition, MMPs are also capable of processing the degradation of the bioactive 
substrates such cytokines, chemokines, growth factors, and immune modulators 
thereby mediating the inflammatory response that contributes to the 
pathogenesis of periodontal disease (Kuula et al., 2009; Sorsa et al., 2006). 
 
1.3.4 The role of the host immune response in hard tissue 
destruction  
Like the soft tissues, hard tissue (bone) undergoes life-long remodelling to 
maintain homeostasis. In bone remodelling, the matured and injured bone tissue 
is removed and replaced with new bone tissue. Bone remodelling occurs in 
response to a functional demand such as mechanical loading, where the bone 
tissue is removed when not required and added to in response to an increased 
load. There are two cell types that are directly responsible for bone tissue 
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remodelling: osteoblasts and osteoclasts. Osteoblast cells are responsible for 
bone tissue deposition while osteoclast cells are responsible for resorption of old 
or injured bone tissue. The imbalance of osteoclast cell activity over osteoblast 
cell activity leads to increased osteoclastogenesis (bone destruction) over 
osteblastogenesis (bone formation) and therefore bone resorption. This 
phenomenon is seen in chronic inflammatory diseases such as arthritis and 
periodontal disease (Figure 1-1). 
 
 
 
 
 
 
 
Figure 1-1: Bone remodelling during chronic inflammation 
In health, bone resorption by osteoclasts and bone deposition by osteoblasts 
occurs in balance to maintain alveolar bone homeostasis. Homeostasis is 
controlled by balanced expression of RANKL and OPG within the extracellular 
area. However, chronic inflammation leads to an increase in RANKL production 
by host cells such as fibroblasts, osteoblasts, macrophages and lymphocytes. 
This overproduction of RANKL increases the RANKL:OPG ratio allowing increased 
RANKL to bind to RANK on pre-osteoclast cells surfaces. The RANKL/RANK 
binding complex signals osteoclast formation and leads to increased bone 
resorption. RANKL = receptor activator of nuclear factor-κB ligand; RANK = 
receptor activator of nuclear factor-κB; OPG = osteoprotegerin; and M-CSF = 
macrophage colony-stimulating factor. 
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Osteoclasts are multinucleated cells that are derived from the 
monocyte/macrophage lineage (Boyle et al., 2003; Lerner, 2000). Osteoclast 
cells require cytokines to regulate proliferation and activation. One of the 
earliest cytokines identified in mediating their activation is M-CSF, which is 
produced by many cell types including osteoblasts, fibroblasts, endothelial cells, 
macrophages and lymphocytes (Rajavashisth et al., 1990; Rambaldi et al., 1987; 
Sieff et al., 1988; Yamashita et al., 2012). The role of M-CSF is to promote the 
proliferation and survival of pre-osteoclasts as well as mature osteoclasts 
(Chambers, 2000). Binding of M-CSF to macrophage colony-stimulating factor 
receptor (M-CSFR; a member of the tyrosine kinase receptor superfamily) results 
in activation of several transcription factors including c-Fos (a part of a bigger 
Fos family of transcription factors such as c-Fos and FosB), which leads to the 
initiation of osteoclastogenesis (Bartold, et al., 2010). M-CSF is also involved in 
inducing expression of receptor activator of nuclear factor kappa-B 
ligand (RANKL), another important mediator for osteoclast formation (Ji et al., 
2009). This membrane bound protein is expressed by a variety of cells, including 
activated T cells, B cells, osteoblasts, fibroblasts and bone marrow stromal cells 
(Bartold, et al., 2010; Collin-Osdoby et al., 2001; Katagiri & Takahashi, 2002; 
Quinn & Saleh, 2009). The binding of RANKL to its receptor (RANK) on pre-
osteoclast cells results in osteoclast formation (Bartold, et al., 2010). Therefore, 
in vivo, RANKL has been demonstrated to play a crucial role in bone resorption 
(Lacey et al., 1998; Pettit et al., 2001). The activity of RANKL is however 
mediated by osteoprotegerin (OPG), a soluble tumour necrosis factor receptor-
like molecule that acts as decoy and blocks the RANKL–RANK binding and thus 
prevents osteoclastogenesis (Bartold, et al., 2010). OPG is produced by 
endothelial cells, smooth muscle cells, osteoblasts and bone marrow stromal 
cells (Venuraju et al., 2010). The expression of OPG is also regulated by 
inflammatory cytokines. For instance, an in vitro study showed that IL-1β, and 
TNF-α were capable of inducing OPG release from human umbilical vein 
endothelial cells (HUVECs) (Zannettino et al., 2005).  
The ratio of RANKL/OPG is an important and decisive factor in mediating 
inflammation induced bone destruction. The role of the host immune response in 
modulating osteoclastogenesis has been well defined. Lymphocytes, especially T 
cells, can exert both stimulatory and inhibitory effect on osteoclasts through 
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expression of mediators such as RANKL and M-CSF that are directly involved in 
osteoclastogenesis. In addition, lymphocytes produce pro-inflammatory 
cytokines such as IL-1, IL-6, TNF-α and IL-17A that induce local cells to produce 
RANKL (Quinn & Saleh, 2009). In contrast, lymphocytes also produce OPG, GM-
CSF, IFN-γ, IFN-β, IL-4, IL-10 and IL-13 that can inhibit osteoclastogenesis (Quinn 
& Saleh, 2009). 
In periodontal disease, bone tissue destruction has been associated with an 
elevated RANKL/OPG ratio. Semi quantitative real-time polymerase chain 
reaction analysis showed that gingival tissue sample of chronic periodontitis 
patients expressed high levels of RANKL but low levels of OPG compared to 
samples of healthy gingival tissue (Liu et al., 2003). Indeed, 
immunohistochemical analysis confirmed these findings at the protein level 
(Crotti et al., 2003). The serum and GCF RANKL/OPG ratios are also elevated in 
patients with chronic periodontitis compared with healthy subjects (Baltacioglu 
et al., 2014; Mogi et al., 2004). 
At the cellular level, RANKL was found to be highly expressed by lymphocytes 
and macrophages within diseased gingival tissue (Crotti, et al., 2003; Kawai et 
al., 2006; Liu, et al., 2003). In contrast, OPG was found to be equally expressed 
by endothelial cells in tissues of both chronic periodontitis patients and healthy 
subjects (Crotti, et al., 2003). In addition, in vitro analysis has showed that 
RANKL and OPG can also be expressed by cells of mesenchymal origin such as 
gingival fibroblasts and periodontal ligament cells (Kajiya et al., 2010). In vitro, 
activated T cells and B cells have also been found to express high levels of 
RANKL. However, the expression of OPG by these cells was either below the 
level of detection or at most in moderate levels (Choi et al., 2001; Kawai, et al., 
2006). The periodontal pathogen, A. actinomycetemcomitans, was shown to 
activate polarization of peripheral blood lymphocytes to become RANKL 
producing T cells and B cells (Kawai, et al., 2006). In addition, co-culture of 
RANKL-producing activated CD8+ T cells with osteoclast cells showed that 
blockage of OPG by a monoclonal antibody lead to increased osteoclastic activity 
(Choi, et al., 2001). In vitro, connective tissue cells such as gingival fibroblasts 
and periodontal ligament fibroblasts were also found to express RANKL and OPG 
upon stimulation with either cytokines or pathogens. For instance, IL-1α 
stimulation was shown to induce increased expression of OPG (Hormdee et al., 
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2005). In addition, P. gingivalis was shown to induce increased expression of 
RANKL and decreased expression of OPG from gingival fibroblasts and 
periodontal ligament fibroblasts (Belibasakis et al., 2007). Therefore, the 
evidence suggests that periodontal pathogens can modulate the RANKL/OPG 
ratio and drive the hard tissue destruction associated with periodontal disease. 
 
1.4 IL-17 family cytokines 
 
1.4.1 Introduction 
The IL-17 family cytokines is one of the most recently described. To date, the 
family consists of six members (IL-17A - IL-17F) (Iwakura et al., 2011). IL-17 
family cytokines signal through complexes of five known receptors (IL-17RA - IL-
17RE) (Zhang et al., 2011b). IL-17A, which is also known as IL-17, is the founding 
member of the IL-17 family cytokines. This cytokine was discovered in 1995 by 
Yao and colleagues as being expressed by a specific subset of CD4+ T cells, 
termed Th17 cells (Yao et al., 1995a; Yao et al., 1995b). Since its discovery, 
Th17 cells have been found to play central roles in the defence of mucosal 
surfaces against extracellular pathogens and contribute to human and 
experimental autoimmunity (Gaffen, 2009a). The discovery of IL-17A and Th17 
cells stimulated great interest among immunologists which eventually led to the 
discovery of additional members of the IL-17 family; IL-17B, IL-17C, IL-17D, IL-
17E and IL-17F by a sequence homology search of IL-17A (Iwakura, et al., 2011). 
At present our knowledge with regard to the role of the IL-17 family cytokines 
play in health and disease, how these cytokines can interact to co-ordinate 
immune responses and the exact signalling mechanisms of some family members 
is lacking. 
 
1.4.2 IL-17A, IL-17F and IL-17A/F 
The human IL-17A cytokine is a glycoprotein expressed as a 155 amino acid 
precursor protein, which is released as a mature 136 amino acid protein after 
cleavage to remove the signal peptide (Fossiez et al., 1996). Human IL-17A is 
secreted as a 35 kDa homodimer which can either be glycosylated or 
unglycosylated (Fossiez, et al., 1996; Yao, et al., 1995b). The IL-17F protein 
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consists of 163 amino acids and shares 40 % homology with IL-17A and 26 % 
homology with IL-17C (Starnes et al., 2001). Like IL-17A, IL-17F is expressed as a 
disulphide-linked homodimer glycoprotein containing a cysteine-knot motif 
(Fossiez, et al., 1996; Hymowitz et al., 2001). In addition to the formation of IL-
17A and IL-17F homodimers, in vitro a heterodimeric IL-17A/F molecule has 
been shown to be produced by HEK293 cells (a human embryonic kidney cell 
line) and activated human CD4+ T cells (Wright et al., 2007). 
IL-17A, IL-17F and IL-17A/F are known to be produced by immune (innate and 
adaptive) cells such as Th17 cells, CD8+ T cells, γδ T cells, natural killer (NK) 
cells, natural killer T (NKT) cells, macrophages, neutrophils and mast cells; as 
well as stromal cells (Table 1-1). Interestingly, studies have shown that IL-17A 
and IL-17F are not always co-expressed. For example, evaluation of colonic 
epithelial cell lines (CMT93 and Colon26) revealed expression of the messenger 
ribonucleic acid (mRNA) encoding IL-17F and not IL-17A (Ishigame et al., 2009).  
Studies have demonstrated that IL-23 is important in promoting Th17 cell 
development from memory and naïve CD4+ T cells (Aggarwal et al., 2003; 
Harrington et al., 2005; Oppmann et al., 2000). In addition, stimulation of Th17 
cells with IL-23 alone or in combination with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin has been shown to increase or augment the expression of 
IL-17A and IL-17F (Aggarwal, et al., 2003; Harrington, et al., 2005; Park et al., 
2005). Similarly, γδ T cells, IL-17A and IL-17F were found constitutively 
expressed but expression was increased in response to either IL-23, PMA, 
ionomycin or pathogens (Do et al., 2010; Haas et al., 2009; Lockhart et al., 
2006; Martin et al., 2009; Sutton et al., 2009). In addition, purified mouse γδ T 
cells stimulated with heat-killed Mycobacterium tuberculosis, heat-killed 
Escherichia (E.) coli and LPS from Salmonella minnesota showed increased 
expression of IL-17A in vitro. Furthermore, addition of IL-23 to the stimulating 
culture led to further augmented expression of IL-17A (Martin, et al., 2009). 
Table 1-1 details further the variety of stimulants which induce IL-17A, IL-17F 
and IL-17A/F expression in a variety of cell types.  
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Cell type 
 
 
Cytokine 
expressed 
 
Stimulators or conditions 
 
References 
Th17 cells 
IL-17A  
IL-17F 
IL-17A/F 
MOG peptide, IL-23, combinations of PMA & ionomycin, anti-CD3, anti-CD28 & 
rhIL-2 
(Aggarwal, et al., 2003; Chang & Dong, 
2007; Harrington, et al., 2005; Liang et al., 
2007; Park, et al., 2005; Wright, et al., 
2007) 
γδ  T cells IL-17A 
IL-17F 
Combinations of PMA & ionomycin, heat-killed Mycobacterium tuberculosis, E. 
coli (heat-killed), Candida (C.) albicans (live), IL-23 and IL-1β 
(Do, et al., 2010; Haas, et al., 2009; 
Lockhart, et al., 2006; Martin, et al., 2009; 
Sutton, et al., 2009) 
CD8+ T cells IL-17A Cells derived from lesional psoriatic skin (unstimulated) (Teunissen et al., 1998) 
NK cells IL-17A Combinations of PMA & ionomycin, and soluble toxoplasma antigen (STAg) (Luci et al., 2009; Passos et al., 2010) 
NKT cells IL-17A Combinations of IL-23 & anti-CD3 antibody (Rachitskaya et al., 2008) 
Monocytes/ 
macrophages 
IL-17A 
IL-17F 
LPS (E. coli), chitin, Bordetella pertussis toxin, macrophages isolated from 
BALF of asthmatic patients and macrophages isolated from colon of IBD 
patients 
(Andreasen et al., 2009; Bosmann et al., 
2013; Da Silva et al., 2008; Fujino et al., 
2003; Michel et al., 2007; Song et al., 2008; 
Starnes, et al., 2001) 
Mast cells 
 
IL-17A 
IL-17F 
TNF-α, IgG complexes, C5a, LPS (not specify), combinations of LTA (not 
specify) & MALP-2, IgE cross-linking and mast cells from synovial tissue of RA 
patients 
(Hueber et al., 2010; Ikeda et al., 2003; 
Mrabet-Dahbi et al., 2009) 
Neutrophils IL-17A 
Bordetella pertussis (live), Neutrophils from kidney following acute kidney 
ischaemic-reperfusion injury 
(Andreasen, et al., 2009; Li et al., 2010) 
Epithelial 
cells 
IL-17A 
IL-17F 
Citrobacter rodentium, lung epithelial cells in response to I.P ovalbumin 
injection  
(Ishigame, et al., 2009; Suzuki et al., 2007) 
Table 1-1: Cellular distribution of IL-17A, IL-17F and IL-17A/F 
MOG = myelin oligodendrocyte glycoprotein; PMA = phorbol 12-myristate 13-acetate; LTA = lipoteichoic acid; MALP-2 = macrophage-
activated lipopeptide 2 ; Ig = immunoglobulin (e.g., IgG, IgE and IgE); NK cells = natural killer cells; NKT cells = natural killer T cells; RA 
= rheumatoid arthritis; IBD = inflammatory bowel disease; BALF = bronchoalveolar lavage fluid; and I.P = intraperitoneal.  
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1.4.3 Receptors for IL-17A, IL-17F and IL-17A/F 
IL-17F and IL-17A have the highest homology among members of IL-17 family 
cytokines and they are known to bind to the same receptor. IL-17A receptor (IL-
17RA) was found to be a pivotal receptor for IL-17A signalling as stimulation of 
fibroblast cells isolated from IL-17RA deficient mice showed no expression of the 
IL-17A induced chemokine CXCL1 (Toy et al., 2006). Although IL-17RA also binds 
IL-17F and IL-17A/F, studies have shown that IL-17RA binds with high affinity to 
IL-17A, medium affinity to IL-17A/F and low affinity to IL-17F (Kuestner et al., 
2007; Wright, et al., 2007). In addition, studies have shown that IL-17RC is also 
required for IL-17A signalling. This was demonstrated using small interfering RNA 
(siRNA) knockout of IL-17RA and IL-17RC in synoviocytes isolated from 
rheumatoid arthritis patients where  deficiency of either receptor failed to 
induce IL-17A mediated expression of IL-6 and IL-8 (Zrioual et al., 2008). In 
addition, IL-17RC has been shown to have similar affinities for IL-17A, IL-17F and 
IL-17A/F (Kuestner, et al., 2007; Wright, et al., 2007). Furthermore, 
immunoprecipitation studies also showed that IL-17RA and IL-17RC are capable 
of assembling in vitro, supporting a model in which IL-17A, IL-17F and IL-17A/F 
signalling are mediated by a heterodimeric receptor complex containing at least 
one IL-17RA and IL-17RC protein (Toy, et al., 2006). Since IL-17A, IL-17F and IL-
17A/F showed different binding affinity to IL-17RA it was hypothesised that they 
induce differential intracellular signalling strength. This was confirmed in an in 
vitro study that showed IL-17A had the greatest capability of inducing mouse 
lung epithelial cells to produce CXCL1, followed by IL-17A/F and IL-17F (Liang, 
et al., 2007).     
Numerous cell types, such as T cells, B cells, macrophages, dendritic cells, and 
colonic mucosal epithelial cells have been shown to co-express IL-17RA and IL-
17RC (Ishigame, et al., 2009). In addition, human foreskin fibroblast, synovial 
fibroblasts, brain endothelial cells and bronchial epithelial cells have been 
shown to be responsive to IL-17A, IL-17F and IL-17A/F stimulation. This therefore 
suggests a variety of cell types are capable of responding to IL-17 signalling. 
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1.4.4 Effect of IL-17A, IL-17F and IL-17A/F on target cells 
IL-17A, IL-17F and IL-17A/F are known to be involved in inflammation and host 
defence against infection. Activation of signalling pathways through IL-17RA by 
IL-17A, IL-17F or IL-17A/F induces the release of pro-inflammatory and 
antimicrobial proteins, which play a major role in recruiting neutrophils, fighting 
pathogens and if expressed in an unbalanced fashion promote tissue destruction. 
IL-17A, IL-17F and IL-17A/F are known to induce expression of cytokines (e.g., 
IL-6, G-CSF and GM-CSF), chemokines (e.g., CXCL1, CXCL2 and CXCL8), matrix 
metalloproteinases (e.g., MMP1, MMP3 and MMP9), and antimicrobial peptides 
(e.g., β defensin-2, S100A7 and S100A8) from a variety of cells (Table 1-2). 
Indeed, despite being originally identified as a T cell associated cytokine the 
majority of IL-17A released during an inflammatory response is now known to be 
produced by, and act upon, innate immune cells (Cua & Tato, 2010).  
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Stimulant 
 
 
Target cells 
 
Effects 
 
References 
IL-17A Macrophages Increase expression of IL-1β, IL-3, 
IL-6, IL-9, TNF-α, CCL5, MMP-3 and 
PGE3 
(Barin et al., 2012; 
Ishigame, et al., 2009; 
Jovanovic et al., 1998) 
 
IL-17A Neutrophils Increase expression of MMP-9 and 
myeloperoxidase 
 
(Zelante et al., 2007) 
IL-17A Dendritic cells Promotes development of dendritic 
cells from bone marrow-derived 
cells and increases expression of 
CD11c, CD40, CD80, CD86, MHC 
class II 
 
(Antonysamy et al., 
1999; Schnyder-
Candrian et al., 2006) 
IL-17A  
IL-17F 
IL-17A/F 
Keratinocytes Increase expression of antimicrobial 
peptides (B-defensins, S100A7, 
S100A8 and S100A9), ICAM-1, IL-6, 
IL-8, CXCL1 and GM-CSF. 
(Albanesi et al., 1999; 
Albanesi et al., 2000; 
Kawaguchi et al., 2006; 
Liang, et al., 2007; 
Liang et al., 2006; 
Teunissen, et al., 1998; 
Wright, et al., 2007) 
 
IL-17A  
IL-17F 
IL-17A/F 
Fibroblasts Increase cells proliferation and 
migration; and Increase expression 
for IL-8, IL-6, PGE2, G-CSF, ICAM-1, 
MMP-1, MMP-3, MMP-13, CCL2, 
CCL7, CXCL1 and CXCL20 
 
(Chang & Dong, 2007; 
Fossiez, et al., 1996; Hu 
et al., 2010; Park, et 
al., 2005; Valente et 
al., 2012; Yagi et al., 
2007; Yao, et al., 
1995b) 
 
IL-17A 
IL-17F 
Endothelial 
cells 
Increase expression of  IL-6, G-CSF 
GM-CSF, TGF-B1, TGF-B2, MCP-1, 
Lymphotoxin-B and IL-2 
 
(Fossiez, et al., 1996; 
Numasaki et al., 2004a; 
Numasaki et al., 2004b) 
IL-17A 
IL-17F 
Synoviocytes Increased expression of IL-6, IL-8, 
G-CSF, GM-CSF, CXCL1, CXCL2, 
CXCL5, CCL20, VEGF and PGE2 
 
(Chabaud et al., 1998; 
Zrioual, et al., 2008) 
IL-17A Osteoblasts Increased expression of CXCL1, 
CXCL2, CXCL5, CCL2, PGE2, and 
RANKL 
(Ruddy et al., 2004; 
Shen et al., 2005) 
Table 1-2: Effect of IL-17A, IL-17F and IL-17A/F on target cells   
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1.4.5 Role of IL-17A, IL-17F and IL-17A/F in inflammation and 
infection 
IL-17A, IL-17F and IL-17A/F play a number of immuno-regulatory roles during 
inflammation and infection. In a rheumatoid arthritis model, IL-17A was found 
localised to the T cell infiltrate in rheumatoid synovium samples (Chabaud et 
al., 1999), indicating the possible role of IL-17A in the pathogenesis of 
rheumatoid arthritis. In addition, supernatants from synovial tissue of 
rheumatoid arthritis patients, cultured ex vivo, was found to contain biologically 
active IL-17A that induced in vitro synoviocyte cultures to produce IL-6 and 
leukaemia inhibitory factor (LIF) (Chabaud, et al., 1998). 
In a collagen induced arthritis (CIA) model, the contribution of IL-17A in the 
pathogenesis of arthritis was determined when the disease was found to be 
markedly suppressed in IL-17-deficient mice (Nakae et al., 2003a). The authors 
also showed that IL-17A was responsible for the priming of collagen-specific T 
cells as well as increasing production of collagen-specific IgG2a, which suggest 
that IL-17A plays role in the development of CIA by activating autoantigen 
specific cellular and humoral responses. In addition, IL-1 receptor antagonist (IL-
1RA) deficient mice showed spontaneous arthritis development; which was 
hypothesised to be due to unopposed activity of IL-1. However, the spontaneous 
development of arthritis was not observed in IL-1RA deficient mice which were 
also deficient in IL-17A (Nakae et al., 2003b); suggesting that IL-17A plays a 
pivotal role in disease pathogenesis. Furthermore, elevated IL-17A expression 
was shown in T cells isolated from the lymph nodes of IL-1RA deficient mice.  
The role of IL17F in the pathogenesis of rheumatoid arthritis is not as well 
characterised as IL-17A. Using the IL-1 receptor antagonist-deficient mice, the 
spontaneous development of arthritis was found to be only partially suppressed 
in mice that were also IL-17F deficient (Ishigame, et al., 2009). The contribution 
of the IL-17A/F heterodimer to the pathogenesis of arthritis remains to be 
determined. 
In an experimental autoimmune encephalomyelitis (EAE) study, IL-17A deficient 
mice exhibited significantly delayed onset and progression of disease compared 
to wild type mice. In addition, IL-17F deficient mice only showed a slight delay 
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in disease onset and progression compared to wild type mice (Yang et al., 2008). 
This study also showed that CD4+ T cell infiltration into the central nervous 
system tissues was greatly reduced in IL-17A deficient and IL-17F deficient mice. 
However, mRNA expression of the chemokines, CCL2 and CCL7 were reduced in 
the central nervous system of IL-17F deficient mice; but this reduction in 
expression was more profound in IL-17A deficient mice. In addition, CXCL1 
expression in the central nervous system was severely impaired in IL-17A 
deficient mice but not in IL-17F deficient. This suggested that IL-17A is playing a 
more pivotal role than IL-17F in the initiation of inflammation in EAE. Indeed 
intraperitoneal injection of an anti-IL17A antibody was shown to delay the 
development of EAE when compared to injection with control IgG (Park, et al., 
2005). Furthermore, mice administered with recombinant human IL-17A (rhIL-
17A) developed signs of EAE (Park, et al., 2005). Similarly to arthritis, the 
contribution of the IL-17A/F heterodimer to the pathogenesis of EAE remain to 
be determined. 
The roles of IL-17A and IL-17F have also been studied in inflammatory bowel 
diseases; such as ulcerative colitis and Crohn’s disease. Immunohistochemical 
analysis showed that IL-17A was expressed in colonic samples of patients with 
ulcerative colitis and Crohn’s disease, but not in healthy subjects. In addition, 
double-staining with anti-CD3 and anti-CD86 antibodies showed that those IL-
17A+ cells in the colonic samples were T cells and monocytes/macrophages 
(Fujino, et al., 2003). IL-17A mRNA expression was also found to be significantly 
increased in tissue of patients with ulcerative colitis and Crohn’s disease which 
also co-incided with increased circulating levels of IL-17A (Fujino, et al., 2003). 
As for IL-17F, mRNA expression was found to be significantly increased in 
inflamed colonic lesions (Seiderer et al., 2008). In an acute 
trinitrobenzenesulfonic acid-induced colitis mouse model, IL-17A was found to 
be increased in colonic tissue samples and accompanied with colonic 
inflammation and increased expression of IL-6 and MIP-2. However, the 
trinitrobenzenesulfonic acid-induced colitis was  found to be suppressed in IL-
17R deficient mice (Zhang et al., 2006). Furthermore, in a dextran sulphate 
sodium (DSS) acute colitis model, symptoms such as diarrhoea, bloody faeces 
and increased weight loss were found to be more severe in IL-17A deficient 
mice, whereas milder symptoms were observed in IL-17F deficient mice as 
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compared to the wild type controls (Yang, et al., 2008). Similarly to arthritis and 
EAE the contribution of the IL-17A/F heterodimer to the pathogenesis of 
inflammatory bowel diseases remain to be determined. 
IL-17A, IL-17F and IL-17A/F were found to play important roles in infection. In 
vivo, mice intraperitoneally injected with E. coli LPS were shown to have 
increased serum levels of IL-17A, IL-17F and IL-17A/F (Bosmann, et al., 2013). In 
a Pneumocystis carinii mouse infection model, IL-17A expression was found to be 
increased in the lung of the infected mice. In addition, if the mice were intra-
nasally administered with an anti-IL17A neutralising antibody, the Pneumocystis 
carinii burden was found to increase 10,000-fold at four weeks post-infection 
when compared to the control mice (Rudner et al., 2007). In the Klebsiella 
pneumonia lung infection model, the lung production of IL-17A and IL-17F was 
found to be significantly reduced in the IL-23 p19 deficient mice and these mice 
exhibited substantial mortality from a sub-lethal dose of Klebsiella pneumonia 
(103 CFU). In contrast, administration of IL-17A was shown to restore the 
bacterial control in the lung (Happel et al., 2005). IL-17R deficient mice infected 
with the Klebsiella pneumonia also showed a 100 % mortality rate after 48 h, 
compared with only a 40 % mortality rate in the controls. The IL-17R deficient 
mice also presented with delayed neutrophil migration and greater 
dissemination of Klebsiella pneumonia compared with control mice (Ye et al., 
2001). The role of IL-17A, IL-17F and IL-17A/F in the recruitment of neutrophils 
was therefore investigated in vivo. In mice which were intranasally challenged 
with IL-17A, IL-17F and IL-17A/F, the IL-17A/F challenged mice demonstrated a 
significant increase in bronchoalveolar lavage fluid neutrophils, CXCL1 and 
CXCL5 (Liang, et al., 2007). Although the induction of neutrophil recruitment 
was similar in mice challenged with IL-17A and IL-17A/F, the bronchoalveolar 
lavage fluid expression of CXCL1 and CXCL5 was significantly less in mice treated 
with IL-17A/F compared to those challenged with IL-17A. In addition, mice 
treated with IL-17F were shown to have lower levels of neutrophil recruitment 
and expression of CXCL1 and CXCL5. These data indicate that IL-17A, IL-17F and 
IL-17A/F were required in the protection against infection. However, 
overproduction of IL-17A, IL-17F and IL-17A/F could induce increased migration 
of neutrophils to the site of inflammation. 
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1.4.6 IL-17B, IL-17C and IL-17D 
IL-17B, IL-17C and IL-17D remain poorly characterized. Homology sequence 
analysis showed that IL-17A, IL-17B and IL-17C shared 26 – 28 % amino acid 
identity (Li et al., 2000a). The predicted precursor proteins of IL-17B and IL-17C 
were found to be 180 and 197 amino acids respectively (Li, et al., 2000a). IL-
17D, shares 27 %  homology with IL-17B and is 202 amino acids in length, making 
IL-17D the largest member of the IL-17 family (Starnes et al., 2002). IL-17B, but 
not IL-17C, was found to be expressed in the human spinal cord, pancreas, small 
intestine and stomach (Li, et al., 2000a; Shi et al., 2000). IL-17B was also found 
to be expressed in chondrocytes of normal bovine articular cartilage (Moseley et 
al., 2003) and in inflamed cartilage from collagen induced arthritis mice 
(Yamaguchi et al., 2007). IL-17B was also found to be expressed in the neuron 
cell body and axons (Moore et al., 2002). IL-17C was found to expressed in the 
broad range of cells such as CD4+ T cells, CD11b+ MHC class II+ macrophages, and 
CD11c+ MHC class II+ dendritic cells (Yamaguchi, et al., 2007).  
Of all the IL-17 family cytokines IL-17D is the least well studied. IL-17D has been 
found to be highly expressed in skeletal muscle, brain, adipose tissue, heart, 
lung and pancreas and lowly expressed in bone marrow, the fetal liver and 
kidney (Starnes, et al., 2002). IL-17D was also found to be lowly expressed in 
resting CD4+ T cells and resting CD19+ B cells, and even lower expression was 
found in activated CD4+ T cells, resting and activated CD8+ T cells, resting and 
activated CD14+ monocytes and activated CD19+ B cells (Starnes, et al., 2002). 
 
1.4.7 Receptors for IL-17B, IL-17C and IL-17D 
In comparison to IL-17A, IL-17F and IL-17A/F our knowledge of the receptor 
complexes for IL-17B, IL-17C and IL-17D is not as complete. Kinetic binding 
analysis showed that IL-17B binds to IL-17RB with relatively high affinity, which 
was confirmed in vitro by co-immunoprecipitation (Shi, et al., 2000). IL-17RB 
has been shown to be expressed in the brain, skeletal muscle, lung, stomach, 
pancreas, liver, colon, small intestine, kidney and testis (Lee et al., 2001; Shi, 
et al., 2000). IL-17RB has also been shown to be expressed by a number of cell 
lines such as WRL-68 human embryonic liver cells, Colo587 pancreas 
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adenocarcinoma-mesothelioma cells, PANC-1 pancreatic epithelioid carcinoma 
cells, HeLa cancer cells, K562 leukemia cells, Raji Burkitts lymphoma cells and 
colorectal adenocarcinoma cell lines (Shi, et al., 2000). Despite its affinity for 
IL-17RB, to date there is no conclusive proof that binding initiates IL-17B 
signalling and therefore the role of IL-17B in the immune system is not presently 
understood (Chang & Dong, 2011). Recently, it has been found that IL-17C is a 
ligand for the orphan receptor IL-17RE, and the IL-17C/IL-17RE signalling 
complex mediates host defence and autoimmune inflammation (Chang et al., 
2011; Ramirez-Carrozzi et al., 2011; Song et al., 2011). However, the 
receptor(s) for IL-17D at present remain unknown.  
 
1.4.8 Role of IL-17B, IL-17C and IL-17D in inflammation and 
infection 
The role of IL-17B, IL-17C and IL-17D in both health and disease remain poorly 
characterised. However, initial findings suggest that IL-17B, IL-17C and IL-17D 
have pro-inflammatory functions and play a role in the pathogenesis of chronic 
inflammatory diseases. For instance, in the collagen induced arthritis mouse 
model, levels of IL-17B and IL-17C were found to be highly elevated in the 
arthritic paws of mice (Yamaguchi, et al., 2007). In addition, IL-17B and IL-17C 
bone marrow chimeric mice, prepared by intravenous injection of bone marrow 
precursor cells that had been retrovirally transduced with IL-17B and IL-17C, 
were clearly shown to exacerbate arthritis, which was accompanied with 
increased serum level of TNF-α (Yamaguchi, et al., 2007). Intraperitoneal 
injection of rhIL-17B was also shown to cause a dose-dependent influx of 
polymorphonuclear leukocytes into the peritoneal cavity within 4 h (Shi, et al., 
2000). In addition, intranasal administration of adenovirus expressed IL-17C was 
shown to cause bronchoalveolar lavage neutrophilia (Hurst et al., 2002). 
Additionally, in vitro analysis showed that IL-17B and IL-17C were capable of 
inducing increased expression of IL-1β from a mouse fibroblast cell line (3T3), 
and both IL-17B and IL-17C were also shown to induce increased expression of IL-
1β, IL-6 and IL-23 from mouse macrophages (Yamaguchi, et al., 2007). 
Furthermore, Mycoplasma pneumoniae and a TLR-5 agonist (flagellin) were also 
shown to induce IL-17C expression in lung and gut tissues (Van Maele et al., 
2010; Wu et al., 2007).  
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IL-17D mRNA expression has been detected in rheumatoid nodules (Stamp et al., 
2008) indicating a role in joint inflammation. However, the role of IL-17D in 
disease pathogenesis is little studied in vivo.  In vitro, IL-17D has been shown to 
have an inhibitory effect on myeloid progenitor cell populations (Starnes, et al., 
2002) and also inhibits hematopoietic progenitor colony formation (Broxmeyer et 
al., 2006). In addition, IL-17D was also reported to induce endothelial cells to 
produce IL-6, IL-8 and GM-CSF via NF-kB (nuclear factor kappa-light-chain-
enhancer of activated B cells) dependent pathways (Starnes, et al., 2002).  
 
1.4.9 IL-17E 
IL-17E is a 177 amino acid protein with 16 – 20 % homology to IL-17A, IL-17B and 
IL-17C (Lee, et al., 2001). IL-17E mRNA has been detected in brain, spinal cord, 
skeletal muscle, heart, lung, salivary gland, thymus, thyroid gland, trachea, 
liver, spleen, small intestine, stomach, colon, uterus, placenta, kidney, prostate 
and testis tissue (Fort et al., 2001; Kim et al., 2002; Lee, et al., 2001; Pan et 
al., 2001). Studies have also shown that a number of cells are capable of 
expressing IL-17E including; polarized Th2 cells (Fort, et al., 2001), primary bone 
marrow-derived mast cells (Ikeda, et al., 2003), alveolar macrophages (Kang et 
al., 2005), eosinophils (Dolgachev et al., 2009), basophils (Wang et al., 2007b), 
lung epithelial cells (Angkasekwinai et al., 2007), intestinal epithelial cells (Zaph 
et al., 2008) and brain capillary endothelial cells (Sonobe et al., 2009). 
IL-17RB is the known receptor for IL-17E (Lee, et al., 2001; Shi, et al., 2000). In 
addition, although in vitro binding assays showed IL-17E does not bind to IL-17RA 
directly, IL-17RA forms a complex with IL-17RB for effective IL-17E signalling (Ely 
et al., 2009; Hymowitz, et al., 2001). In vitro, naïve T cells isolated from wild 
type mice cultured in the presence of IL-17E, TGF-β and IL-4 exhibited 
significantly enhanced IL-9 secretion. However, no similar effect was observed 
with naïve T cells isolated from IL-17RA-deficient mice (Angkasekwinai et al., 
2010). Furthermore, splenocytes isolated from either IL-17RB knockout or IL-
17RA knockout mice did not release IL-5 or IL-13 in response to IL-17E 
stimulation (Rickel et al., 2008). In addition, in vivo, both IL-17RB and IL-17RA 
knockout mice did not respond to intranasal administration of IL-17E compared 
to wild type mice which exhibited increased bronchoalveolar lavage fluid 
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cellularity, increased bronchoalveolar lavage fluid IL-5 and IL-13 levels and also 
increased expression of lung CCL2, CCL11, IL-5, IL-13, IL-9 and IL-10 mRNA 
(Rickel, et al., 2008). These studies therefore confirmed that both IL-17RA and 
IL-17RB are required for effective IL-17E signalling. 
 
1.4.10 Effect of IL-17E on target cells 
IL-17E is a unique member of the IL-17 family cytokines. It differs from other IL-
17 family members in its ability to promote a Th2-biased inflammatory response. 
In addition, IL-17E is a ‘double edged sword’ as it also has the ability to down 
regulate localised destructive inflammatory responses; including the ability to 
inactivate the function of Th17 cells. As stated above, a number of cells express 
IL-17RB such as Th2 cells, mast cells, macrophages, eosinophils, basophils, 
epithelial cells and endothelial cells thus make those cells possible targets for 
IL-17E signalling. 
IL-17E is known to regulate Th2 cell differentiation, which is associated with 
sustained expression of transcription factors JunB (Jun B proto-oncogene) and 
GATA-3 (GATA binding protein 3) (Angkasekwinai, et al., 2007; Wang, et al., 
2007b).  In vitro studies showed that IL-17E treatment of Th2 cells resulted in 
increased expression of the prototypic Th2 cytokine, IL-4 (Angkasekwinai, et al., 
2007; Wang, et al., 2007b). In addition, IL-17E regulates IL-4 expression through 
induction of the NFATc1 (nuclear factor of activated T cells, cytoplasmic 1) and 
JunB transcription factors, which in turn leads to the IL-4-dependent 
upregulation of GATA-3 expression (Angkasekwinai, et al., 2007). Interestingly, 
IL-17E can regulate Th2 memory cell differentiation and the production of IL-5 
and IL-13 in an IL-4-independent manner, by sustained expression of 
transcription factors MAF, JunB and GATA-3 (Wang, et al., 2007b). IL-17E was 
also demonstrated to promote the differentiation of the recently discovered 
innate cell populations; such as natural helper cells (NHCs), multipotent 
progenitor type2 (MMPtype2) cells, nuocytes, and innate type 2 helper (Ih2) cells 
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2010b). In 
addition, stimulation of these cells with IL-17E has been shown to induce 
expression of Th2 related cytokines such IL-4, IL-5 and IL-13 (Saenz, et al., 
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2010b). These finding suggest that IL-17E could also induce a Th2-biased 
immunity through interactions with innate immune cell populations. 
IL-17E has been found to have a key role in negatively regulating potentially 
damaging inflammatory responses. IL-17E has been demonstrated to block the 
function of Th17 cells. It is known that the differentiation of Th17 cells is 
promoted by IL-6 and TGF-β1, whereas IL-23 is required for the subsequent 
expansion or survival of Th17 cells (Weaver et al., 2007). In vitro, addition of IL-
23 to a culture of naïve CD4+ T cells and LPS-activated CD11c+ dendritic cells, in 
the presence of neutralizing antibodies against IFN-γ and IL-4, had been shown 
to induce IL-17-producing cells (Kleinschek et al., 2007). Interestingly, addition 
of IL-17E to the culture caused the population of Th17 cells induced by IL-23 to 
reduce by half, accompanied by reduced expression of IL-17A and increased 
expression of IL-13. Furthermore, this study also showed that addition of an anti-
IL-13 antibody to the co-culture caused an increase in the population of Th17 
cells accompanied by increased expression of IL-17A (Kleinschek, et al., 2007). 
IL-17E is known to be capable of inducing IL-13 release from immune cells such 
as Th2 cells, mast cells and macrophages (Angkasekwinai, et al., 2010; Ikeda, et 
al., 2003; Kang, et al., 2005). It has therefore been hypothesised that IL-17E 
induced expression of IL-13 is the mechanism by which it regulates Th17 
responses. In addition to IL-13, IL-4 has also been shown to inhibit proliferation 
and activation of Th17 cells by a mechanism which is dependent on STAT6 (signal 
transducer and activator of transcription 6) (Cooney et al., 2011; Harrington, et 
al., 2005; Park, et al., 2005). Since IL-17E was also shown to induce Th2 cells to 
produce IL-4 (Angkasekwinai, et al., 2007; Wang, et al., 2007b) it has also been 
hypothesised that IL-17E inhibits Th17 cell proliferation via IL-4. 
IL-17E can inhibit cytokine and chemokine production from cells stimulated with 
pathogenic bacteria. IL-17E, together with other cytokines such as IL-4, IL-13 
and IL-10, has been shown to inhibit production of chemokines (e.g., CCL2, 
CCL3, IL-8 and CXCL9) by naive CD4+ T cells stimulated with LPS or IFN-γ (Stolfi 
et al., 2011). In addition, IL-17E was also shown to inhibit production of IL-23 
and TNF-α by Th1 cells stimulated by bacterial LPS or PNG (Caruso et al., 2009a; 
Caruso et al., 2009b). Furthermore, IL-17E has been shown to directly inhibit 
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LPS-induced IL-23 expression by macrophages, independent of the pathway 
related to IL-4, IL-13 and STAT6 (Zaph, et al., 2008). 
Contrary to the studies demonstrating an anti-inflammatory role for IL-17E there 
are also some in vitro studies that support the role of IL-17E as a pro-
inflammatory cytokine. An in vitro study on a human renal cell line (TK-10) 
showed that stimulation with IL-17E increased expression of NF-kB-responsive 
luciferase reporter gene activity in addition to inducing release of IL-8 (Lee, et 
al., 2001). In addition, studies on an embryonic fibroblast cell line (NIH-3T3) 
(Pan, et al., 2001) and primary human lung fibroblasts (Letuve et al., 2006) 
found that IL-17E could induce the expression of CCL5, CCL11, CXCL8 (IL-8), GM-
CSF and G-CSF. 
 
1.4.11 Role of IL-17E in inflammation and infection 
IL-17E is known to play a major role in Th2 driven pathologies. Elevated 
expression of IL-17E and IL-17RB was observed in asthmatic lung tissues, atopic 
dermatitis skin lesions, as well as in the parasite infected lung and gut (Hurst, et 
al., 2002; Wang, et al., 2007b). Transgenic overexpression of IL-17E in wild type 
mice has been shown to cause a Th2 driven inflammatory response, 
characterised by a mixed infiltration of neutrophils, eosinophils, lymphocytes, 
plasma cells and macrophages, in multiple tissues such as the liver, heart, lung, 
lymph nodes, kidney, spleen, and urinary bladder (Pan, et al., 2001). In 
addition, IL-17E overexpression in lung epithelial cells was shown to associate 
with increased inflammation, mucus production and airway infiltration by 
macrophages and eosinophils (Angkasekwinai, et al., 2007).  Studies suggested 
that the IL-17E induced inflammation in vivo is caused by a Th2-biased response, 
characterised by increased expression of Th2 cytokines such as IL-4, IL-5 and IL-
13. For instance, mice injected with IL-17E show signs of splenomegaly and 
spleen eosinophilia, which is accompanied by increased level of serum 
immunoglobulin (IgE and IgG1), as well as increased mRNA expression of IL-4, IL-
5 and IL-13 in various organ tissues such as the spleen, stomach, small intestine, 
kidney, liver, lung and colon (Fort, et al., 2001; Pan, et al., 2001). Intranasal 
administration of IL-17E into naïve mice was shown to induce inflammation 
similar to that seen in asthmatic patients, which included increased levels of 
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eosinophils, increased IL-5 and IL-13 levels in BAF, goblet cell hyperplasia, and 
increased airway hyperresponsiveness. (Rickel, et al., 2008). In addition, in an 
allergen induced experimental asthma model, mice which were intranasally 
sensitized with allergen from Aspergillus (A.) oryzae and chicken ovalbumin 
protein were shown to develop a Th2-biased response with increased 
eosinophilia as well as increased bronchoalveolar lavage fluid IL-4, IL-5 and IL-13 
levels. However, blockage of IL-17E by intraperitoneal injection of an anti-IL-17E 
antibody was shown to reduce these responses (Angkasekwinai, et al., 2007). 
IL-17E is known in vitro to inhibit the Th17 cell response. Th17 cells are 
characterised by the production of IL-17A, IL-17F, IL-21 and IL-22 (Ouyang et al., 
2008). Th17 cells and their effector cytokines are involved in regulating the 
expression of various other cytokines and chemokines by keratinocytes and 
fibroblast to mediate host defence against pathogens, as well as to mediate 
pathogenesis of many autoimmune diseases such as rheumatoid arthritis and 
encephalomyelitis (Kurebayashi et al., 2013; Ouyang, et al., 2008). The ability 
of IL-17E to inhibit Th17 cells suggests it may play an important role in 
regulating potentially destructive localised inflammatory responses. Indeed, in 
vivo, IL-17E deficient mice were found to be susceptible to EAE; which was 
associated with increased peripheral expression of IL-23 as well as increased 
recruitment of Th17 cells into the central nervous system. The role of IL-17A in 
driving EAE was demonstrated by the fact that neutralisation of IL-17A with an 
anti-IL-17A monoclonal antibody prevented the development of disease. In 
addition, treatment of mice with recombinant IL-17E prevented development of 
EAE demonstrating the importance of this cytokine in regulating the IL-17A/Th17 
response (Kleinschek, et al., 2007). IL-17E deficient mice, chronically infected 
with the parasite Trichuris (T.) muris were also shown to develop severe 
intestinal inflammation characterised by lymphocyte infiltration, crypt 
elongation and an absence of goblet cells.  This observation was found to be 
associated with increased level of pro-inflammatory cytokines such as IL-17A and 
IFN-γ in the mesenteric lymph node and caecum, which is consistent with the 
hypothesis that IL-17E could act to limit localised inflammation (Owyang et al., 
2006). 
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The role of IL-17E in microbial immunity has been a subject of study over the 
last 10 years. Evaluation of the large intestine of germ free mice found 
increased expression of IL-23, as well as an increase in the population of Th17 
cells, compared to the conventionally reared mice (Zaph, et al., 2008). 
However, the presence of commensal bacteria in the gut induced increased 
expression of IL-17E by intestinal epithelial cells and intraperitoneal 
administration of IL-17E to germ free mice reduced expression of IL-23 and the 
population of Th17 cells in the large intestine (Zaph, et al., 2008). Consistent 
with a role for IL-17E in limiting IL-23 and Th17 cells in the large intestine, 
neutralization of IL-23 also resulted in a decreased Th17 cell response. In line 
with this data, IL-17E mRNA expression was found to be decreased in the ileum 
of germ free mice compared to the specific pathogen free mice, and expression 
of IL-17E mRNA in specific pathogen free mice continued to increase with age 
(Sawa et al., 2011) indicating a possible association with microbial colonisation 
of the intestine. IL-17E also repressed the RORγt+ (RAR-related orphan receptor 
gamma, thymus) innate lymphoid cell production of IL-22 which was 
demonstrated to be important for bacterial clearance in vivo (Aujla et al., 2008; 
Rubino et al., 2012; Zheng et al., 2008). In addition, mice fed by parental 
nutrition (intravenous feeding, bypassing the usual process of eating and 
digestion) showed decreased luminal levels of molecules of innate immunity; the 
Paneth cell antimicrobial molecule secretory phospholipase - A2 (sPLA2) and the 
goblet cell glycoprotein mucin – 2 (MUC-2). However, addition of exogenous IL-
17E into diet was shown to increase luminal levels of sPLA2 and MUC-2 
(Heneghan et al., 2013). Additionally, the authors showed that ex vivo 
incubation of intestinal tissue segments isolated from parental feeding mice with 
combinations of E. coli and exogenous IL-17E was shown to increase tissue levels 
of sPLA2 and decrease E. coli entero-invasion. This study suggests that IL-17E 
could induce increased expression of MUC-2 and sPLA2 by Paneth cells which is 
important in clearance of pathogenic bacteria in digestive system. 
In the endotoxemia mouse model, where mice were intraperitoneally injected 
with LPS and peptidoglycan, mice pre-treated with IL-17E (intraperitoneal 
injection) exhibit decreased serum levels of pro-inflammatory cytokines 
including IL-12/p70, TNF-α and IL-6; and this finding was found to coincide with 
decreased survival rate of LPS injected mice pre-treated with IL-17E (Caruso, et 
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al., 2009b). In addition, in the peptidoglycan-induced colitis mouse model, 
where mice were intravenously administered with peptidoglycan, mice pre-
treated with IL-17E (intraperitoneal injection) were shown to have lesser 
severity of the colitis as shown by: the absence of diarrhoea and less weight loss; 
and lesser histopathological evidence of colonic inflammation, which was found 
to associate with decreased colonic protein levels of IL-12 and INF-γ (Caruso, et 
al., 2009a).    
 
1.4.12 IL-17 family cytokines and periodontal disease 
The role of the IL-17 family cytokines in the pathogenesis of periodontal disease 
is poorly understood. In human studies, IL-17A has been shown to be associated 
with periodontal disease pathogenesis. There are Th17 cells within the 
periodontium (Adibrad et al., 2012; Cardoso et al., 2009) and IL-17A levels are 
elevated in solubilized tissue (Behfarnia et al., 2013; Honda et al., 2008; 
Ohyama et al., 2009; Takahashi et al., 2005), serum (Duarte et al., 2010; 
Schenkein et al., 2010) and GCF (Buduneli et al., 2009; Vernal et al., 2005) of 
chronic periodontitis patients.  
Serum levels of IL-17A and IL-17A/F correlate with clinical parameters of 
periodontal disease such as clinical probing depth (CPD) and clinical attachment 
loss (CAL) (Ozcaka et al., 2013; Schenkein, et al., 2010). In addition, GCF levels 
of IL-17A in patients with chronic periodontitis (Buduneli, et al., 2009) and 
serum levels of IL-17A in patients with aggressive periodontitis (Duarte, et al., 
2010) are reduced after non-surgical therapies. Additionally, in an ex vivo study, 
IL-17A levels in the bathing supernatant of gingival tissues from periodontal 
disease patients were found to be significantly higher compared to tissue from 
healthy sites (Vernal, et al., 2005). The levels of IL-17A (serum and GCF) in 
periodontal disease patients with rheumatoid arthritis were also found to be 
higher compared to systemically healthy chronic periodontitis patients and 
patients with only rheumatoid arthritis  (Gumus et al., 2013), indicating a 
possible contributing  link between periodontal disease and rheumatoid arthritis. 
Polymorphisms in the IL-17A gene have been shown to have an association with 
periodontal disease. Studies of peripheral blood showed that a single nucleotide 
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polymorphism (rs10484879) correlated with incidences of chronic periodontitis 
and peri-implantitis (Kadkhodazadeh et al., 2013). In addition, Correa and 
colleagues (2012) reported a higher distribution of a single nucleotide 
polymorphism (rs2275913) in chronic periodontitis patients compared to healthy 
subjects. Furthermore, carriers of this single nucleotide polymorphism 
(rs2275913) were shown to have higher serum levels of IL-17A, which was 
accompanied by increased myeloperoxidase activity and IL-8 expression in 
periodontal tissues (Correa, et al., 2012) 
In vivo models have suggested that IL-17A plays a protective role in periodontal 
disease. Indeed, IL-17RA deficient mice show exacerbated bone loss in a P. 
gingivalis induced model (Yu et al., 2007). In this IL-17R deficient animal model, 
IL-17 conferred protection by promoting neutrophil migration into the gingival 
tissues. The absence of IL-17R signalling significantly compromised the 
antimicrobial effects of infiltrating neutrophils, rendering the animals more 
susceptible to periodontal disease. However, IL-17A has been implicated in the 
pathogenesis of many chronic inflammatory diseases, such as rheumatoid 
arthritis, psoriasis, Crohn’s disease and multiple sclerosis (Korn et al., 2009). 
Numerous studies of models of arthritis, a diseases process with notable parallels 
to periodontal disease, demonstrated that IL-17A may contribute to initiation 
and perpetuation of chronic destructive inflammation (Miossec et al., 2009). In 
addition, neutralising IL-17A is therapeutically beneficial and a neutralising anti-
IL17A monoclonal antibody has demonstrated promise as a treatment for 
rheumatoid arthritis in human trials (Genovese et al., 2010). In this respect, 
Liang and colleagues (2010) demonstrated that old mice had significantly 
increased spontaneous periodontal bone loss compared to young mice, which 
was associated with increased expression of IL-17A. In addition, young Del-1 (an 
endogenous leukocyte-endothelial adhesion inhibitor) deficient mice were found 
to develop spontaneous periodontal disease, which was characterised by 
excessive neutrophil migration into periodontal tissues and increased expression 
of IL-17A (Eskan et al., 2012). Interestingly, the authors also demonstrated that 
Del-1 expression in periodontal tissues diminished with age. Furthermore, Eskan 
and colleagues (2012) showed periodontal disease was prevented if the Del-1 
deficient mice were crossed with IL-17A receptor deficient mice. Additionally, 
the IL-17A deficient mice which were orally infected with P. gingivalis exhibited 
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significant bone loss which was accompanied with a decrease in neutrophil 
migration into the gingivae (Yu, et al., 2007). Together these in vivo studies 
suggest IL-17A plays a potentially double-edged role in periodontal disease, with 
the ability to both protect against infection and perpetuate inflammation. 
Therefore, an effective and balanced IL-17A response is required for the 
protection of the oral mucosa against pathogens. 
The effect of IL-17A on periodontal cells has also been evaluated in vitro. The 
rhIL-17A was shown to induce human gingival fibroblast cells to produce IL-6 
(Takahashi, et al., 2005). IL-17A was also shown to inhibit the expression of Del-
1 by endothelial cells which could contribute to the continuous and excessive 
migration of neutrophils into inflamed periodontal tissues (Eskan, et al., 2012). 
Apart from IL-17A, the role of other IL-17 family members in periodontal disease 
is less well studied. Knowledge of the role of IL-17F in periodontal disease has 
not been explored in detail. Analysis of peripheral blood samples showed that 
there was no difference in IL-17F gene expression between healthy subjects and 
chronic periodontitis patients (Jain et al., 2013). Furthermore, mRNA evaluation 
of periodontal tissue samples also showed no difference in IL-17F expression 
between tissues from healthy subjects and chronic periodontitis patients 
(Honda, et al., 2008). In contrast, levels of IL-17F were found to be significantly 
increased in serum, GCF and saliva samples of patients who suffer both 
polycystic ovarian syndrome and gingivitis, as compared to systemically healthy 
individuals (Ozcaka, et al., 2013). Similarly, studies on the association between 
IL-17E and chronic periodontitis are limited. However, IL-17E was detected in 
GCF and serum of periodontal disease patients and levels negatively correlated 
with periodontal clinical probing depth (Ozcaka, et al., 2013). To date there are 
no studies investigating the role of IL-17B, IL-17C and IL-17D in the pathogenesis 
of periodontal disease. 
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1.5 IL-10 
 
1.5.1 Introduction 
Interelukin-10 (IL-10) is the founding member of the IL-10 family cytokines, 
which also includes IL-19, IL-20, IL-22, IL-24, IL-26 and also more distantly 
related members such as IL-28A, IL-28B, and IL-29 (Ouyang et al., 2011). IL-10, 
was originally found to be secreted by Th2 cells upon stimulation with mitogen 
or antigen (Fiorentino et al., 1989). In fact, IL-10 was originally  termed cytokine 
synthesis inhibitory factor (CSIF) as it was shown to inhibit production of IL-2, IL-
3, lymphotoxin, IFN-γ and granulocyte macrophage colony-stimulating factor 
(GM-CSF) by Th1 clone cells stimulated with a combination of antigen and 
antigen presenting cells (Fiorentino, et al., 1989). Since then, many studies have 
followed investigating the anti-inflammatory effect of IL-10 and it is now well 
characterised as an anti-inflammatory cytokine (Moore et al., 2001; Sabat et al., 
2010).  
IL-10 is a 178 amino acid polypeptide (Vieira et al., 1991) and formation of a 
homodimer has been shown to be required to produce the active IL-10 cytokine 
(Tan et al., 1993; Zdanov et al., 1995). IL-10 has been shown to be expressed by 
various immune cells such as Th2 cells, Th1 cells, B cells, dendritic cells, 
macrophages, mast cells, eosinophils, neutrophils, CD4+ T cells and CD8+ T cells 
(Couper et al., 2008; Sabat, et al., 2010). In vitro, the release of IL-10 by these 
cells was found to be elicited by exposure to various endogenous and exogenous 
mediators such as LPS and catecholamines (Sabat, et al., 2010). IL-10 requires 
two receptor subunits (IL-10R1 and IL-10R2) to mediate effective intracellular 
signalling. The human IL-10R1 was identified by expression cloning from a human 
Burkitt’s lymphoma cell line and was found to have 70 % genetic sequence 
homology and 60 % amino acid sequence homology  to the previously identified 
mouse IL-10R1 (Ho et al., 1993; Liu et al., 1994). The structure of human IL-
10R1 was found to be similar to those of the class II cytokine receptor family 
which includes the interferon receptor (IFNR) (Liu, et al., 1994). Indeed, IL-10 
exhibits structural similarities with IFN-γ (Zdanov, et al., 1995) and hence it has 
been demonstrated that both these cytokines share the same class II cytokine 
receptors (Zdanov, et al., 1995). IL-10R2 was previously known as CRFB4, and is 
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a transmembrane protein of unknown function belonging to the class II cytokine 
receptor family. In vitro studies have shown that IL-10 did not induce signal 
transduction in cells which only express IL-10R1. Furthermore, IL-10R1 and 
IL10R2 can be co-precipitated in the presence of IL-10 (Kotenko et al., 1997). 
Additionally macrophages and splenocytes isolated from IL-10R2 deficient mice 
did not respond to exogenous IL-10 stimulation in vivo (Spencer et al., 1998). 
These studies therefore indicate the importance of IL-10R2 for functional IL-10 
signalling. 
 
1.5.2 Effect of IL-10 on target cells 
IL-10 is known for its ability to act as an anti-inflammatory and 
immunosuppressive cytokine. It is well established that monocytes/macrophages 
are a key target for IL-10. In studies of primary human monocytes stimulated 
with IFN-γ, LPS, and combinations of IFN-γ and LPS, IL-10 was shown to strongly 
inhibit the expression of pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, 
IL-8, TNF-α, GM-CSF, and G-CSF (de Waal Malefyt et al., 1991). A similar pattern 
of inhibition was also observed in studies using a macrophage cell line 
(Fiorentino et al., 1991). In addition, IL-10 was also shown to induce increased 
IL-1RA mRNA expression by LPS-stimulated monocytes (Jenkins et al., 1994). IL-
1RA is known for its role in antagonising the pro-inflammatory effect of IL-1α 
and IL-1β (Perrier et al., 2006). Furthermore, bone marrow derived macrophages 
isolated from IL-10 deficient mice were found to secrete significantly lower 
amounts of IL-23 compared to wild type controls (Schuetze et al., 2005). Since 
most of the pro-inflammatory action of IL-23 is mediated through IL-17A, TNF-α 
and IL-6; inhibition of IL-23 by IL-10 could down regulate Th17 driven responses 
(Stetsko & Sauder, 2008). IL-10 was also found to inhibit the production of IL-12 
by LPS-activated monocytes (D'Andrea et al., 1993). As IL-12 is important for Th1 
cell proliferation it was concluded that IL-10 can also inhibit the Th1 response 
(Stetsko & Sauder, 2008). A direct effect of IL-10 on T cell responses has also 
been demonstrated. Human IL-10 was shown to inhibit the antigen and 
phytohemagglutinin (PHA) proliferative responses of Th1 and Th2 cells (Del Prete 
et al., 1993). Furthermore, IL-10 inhibits the release of IFN-γ by Th1 cells and 
the release of IL-4 and IL-5 by Th2 cells in response to antigen-specific 
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stimulation. Together these data indicate that IL-10 could directly or indirectly 
inhibit the response of Th1, Th2 and Th17 cells to various inflammatory stimuli.  
IL-10 was also shown to have an inhibitory effect on polymorphonuclear 
leukocyte function. Studies have shown that IL-10 inhibits the production of pro-
inflammatory cytokines such as TNF-α and IL-1β by polymorphonuclear 
leukocytes stimulated with LPS (Cassatella et al., 1993). In addition, IL-10 was 
also shown to inhibit LPS-stimulated polymorphonuclear leukocytes production 
of chemokines such as MIP-1α, MIP-1β and IL-8 as well as the production of PGE2 
(Kasama et al., 1994; Niiro et al., 1997). Cytokine and chemokine production by 
other immune cells in response to antigen such as eosinophils and mast cells 
were also shown to be inhibited by IL-10 (Arock et al., 1996; Takanaski et al., 
1994). 
The anti-inflammatory effect of IL-10 on epithelial cells has also been 
investigated. Denning and colleagues (2000) showed that both receptors for IL-
10, IL-10R1 and IL-10R2 were expressed by colonic epithelial cells, and IL-10 was 
shown to block the IFN-γ-induced expression of Class II MHC molecules on 
cultured intestinal epithelial cells. IL-10 was also shown to inhibit the Chlamydia 
trachomatis induced expression of IL-6, IL-8 and TNF-α from Hela cells (cervical 
cancer cell line). In addition, IL-10 was also shown to inhibit the release of TNF-
α and IL-6 from primary human keratinocytes (isolated from neonate foreskins) 
stimulated with combinations of LPS and IFN-γ (Becherel et al., 1995). 
 
1.5.3 Role of IL-10 in inflammation and infection 
Elevated expression of IL-10 has been found in tissues derived from studies of 
numerous chronic inflammatory diseases such as inflammatory bowel diseases, 
atopic dermatitis and rheumatoid arthritis (Asadullah et al., 1998; Katsikis et 
al., 1994). IL-10 levels were elevated in serum and synovial fluid samples from 
patients with rheumatoid arthritis (al-Janadi et al., 1996; Cush et al., 1995). In 
line with the above data, monocytes purified from the synovial fluid of 
rheumatoid arthritis patients were found to express higher levels of IL-10 than 
monocytes derived from healthy subjects (Alanara et al., 2010). In addition, 
  
 
66
serum IL-10 was also increased in patients with active ulcerative colitis 
(Mitsuyama et al., 2006). 
In vivo, the role of IL-10 as an anti-inflammatory cytokine has been eloquently 
demonstrated. In a collagen induced arthritis mouse model, IL-10 deficient mice 
were found to be prone to higher incidence and increased severity of arthritis 
(Finnegan et al., 2003; Johansson et al., 2001), which was found to associate 
with decreased serum levels of anti-collagen antibodies (IgG1 and IgG2a) as well 
as increased proliferation of macrophages (Finnegan, et al., 2003). In addition, 
intraperitoneal injection of recombinant IL-10 into the collagen induced arthritis 
mouse model supressed the severity of symptoms (Tanaka et al., 1996). 
Similarly, in an EAE mouse model, where encephalomyelitic mice were induced 
by flank injection of encephalitogenic peptide, IL-10 deficient mice were shown 
to develop a more severe EAE compared to sham controls (Bettelli et al., 1998). 
In addition, mice injected with IL-10 transgenic T cells, which had been 
engineered to secrete IL-10 were more resistant to EAE. IL-10 has also been 
shown to have anti-inflammatory properties in colitis disease models. Dextran 
sulphate sodium-induced colitis mice exhibited increased expression of TNF-α 
and IL-1β in colonic tissue of IL-10 deficient mice compared to sham controls 
(Tomoyose et al., 1998), In addition, IL-10 deficient mice were shown to develop 
spontaneous bowel inflammation showing an important immuno-regulatory 
function of IL-10 within the gastrointestinal tract (Kuhn et al., 1993; Murai et 
al., 2009). 
Studies have shown that IL-10 plays a role in fungal and bacterial induced 
pathologies. In a mouse model of C. albicans infection,  IL-10 deficient mice 
were shown to be resistant to renal candidiasis when compared to the wild type 
mice (Vazquez-Torres et al., 1999). This resistance was thought to be achieved 
through neutrophil activity as neutrophils isolated from the peritoneum of IL-10 
deficient mice were found to have greater ability to kill C. albicans 
blastoconidia and hyphae when compared to those isolated from wild type mice 
(Vazquez-Torres, et al., 1999). This finding is in line with other studies that 
showed IL-10 plays a role in negatively regulating neutrophil function. Similarly, 
intraperitoneal injection of E. coli into IL-10 deficient mice resulted in reduced 
recovery (CFU/ml) of E. coli from peritoneal fluid, blood and lung when 
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compared to wild type mice. This indicates endogenous IL-10 impaired bacterial 
clearance. However, although IL-10 impairs the clearance of E. coli and can 
facilitate the outgrowth and dissemination of bacteria during peritonitis, it in 
turn was shown to protect mice from lethality by attenuating the development 
of a systemic inflammatory response syndrome by a mechanism that involves 
inhibition of TNF-α (Sewnath et al., 2001). 
In summary, IL-10 was found to be elevated in tissue samples as well as in 
clinical samples of patients with chronic inflammatory diseases such as 
rheumatoid arthritis and ulcerative colitis. These findings were in agreement 
with the in vivo findings that demonstrated disease severity in animal models 
(EAE, arthritis and colitis) was greater in IL-10 deficient mice. However, in 
microbial infection models, IL-10 was found to negatively impact on microbial 
clearance from tissues/organs. However, despite hindering clearance of 
pathogenic organisms, IL-10 was found to protect mice from associated excessive 
inflammation induced pathologies. Therefore these studies clearly demonstrate 
a role for IL-10 in negatively regulating immune responses. 
 
1.5.4 IL-10 and periodontal disease 
The role of IL-10 in the pathogenesis of periodontal disease has been studied 
previously. Using quantitative real-time polymerase chain reaction (real-time 
PCR) and enzyme-linked immunosorbent assay (ELISA), IL-10 (mRNA and protein) 
expression were found to increase in gingival tissue samples of chronic 
periodontitis patients when compared to healthy subjects (Napimoga et al., 
2011). Furthermore, analysis of GCF has shown that IL-10 is only detected in 
samples of chronic periodontitis patients but not healthy subjects (Gamonal et 
al., 2000). In contrast, IL-10 levels in saliva and serum were found to be greater 
in healthy subjects compared to chronic periodontitis patients (Gumus et al., 
2014). Furthermore, Gumus and colleagues (2014) showed that IL-10 levels in 
saliva and serum negatively correlated with clinical parameters such as 
periodontal probing depth, clinical attachment loss and bleeding index. 
In vivo, IL-10 deficient mice orally inoculated with P. gingivalis were shown to 
suffer severe alveolar bone loss compared to wild type controls (Sasaki et al., 
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2004). In addition, IL-10 deficient mice also exhibited accelerated spontaneous 
bone loss compared to wild type controls (Al-Rasheed et al., 2003). In vitro, 
primary human gingival fibroblasts were found  to upregulate expression of IL-10 
in response to P. gingivalis (LPS) (Almasri et al., 2007). In addition, gingival 
mononuclear cells isolated from P. gingivalis infected mice showed increased 
spontaneous production of IL-10 compared to mononuclear cells  isolated from 
sham infected mice (Kobayashi et al., 2011). These studies therefore suggest 
that IL-10 plays an anti-inflammatory role in the oral cavity and can inhibit the 
pathogenesis of periodontal disease. 
 
1.6 IL-33 
 
1.6.1 Introduction 
The discovery of IL-33 has an interesting history. It was previously reported in 
1991 as DVS27 and its expression was found to be highly upregulated in canine 
vasospastic cerebral arteries (Onda et al., 1999). Later in 2003 it was discovered 
as a nuclear factor from high endothelial venules (NF-HEV) (Baekkevold et al., 
2003). Even though the cytokine properties of this molecule were not apparent 
at the time, these studies reported at least two important features: (a) nuclear 
localization and (b) a molecular structure that contained a structural homology 
with DNA-binding domains. Therefore it was initially thought to play a role as a 
transcription factor. In 2005, however, it was discovered as the latest IL-1 family 
member and shown to bind to the orphan IL-1 receptor, ST2 (also known as IL-
1RL1, interleukin 1 receptor-like 1), hence it was renamed IL-33 (Schmitz et al., 
2005). IL-33 is the eleventh member of the IL-1 family cytokines that also 
includes IL-1α, IL-1β, IL-1RA, IL-18, IL-1F5, IL-1F6, IL-1F7, IL-1F8, IL-1F9 and IL-
1F10 (Barksby et al., 2007; Sims et al., 2001). Like other members of the IL-1 
family, IL-33 was found to be involved in regulating inflammatory and immune 
processes. Indeed, in its role as a cytokine, IL-33 was found to induce Th2 
associated cytokine production both in vitro and in vivo.   
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1.6.2 Molecular structure 
The human IL-33 gene was found to be located on the short arm of chromosome 
9 at location 9p24.1 (Baekkevold, et al., 2003; Schmitz, et al., 2005), while its 
mouse counterpart was found located on the syntenic chromosome region 19qC1 
(Schmitz, et al., 2005). Human and mouse IL-33 share 55 % amino acid sequence 
homology. Analyses of the cDNA (complementary deoxyribonucleic acid) 
sequences of the human and mouse IL-33 gene showed they encoded a 270 and 
266 amino acids protein respectively, with reported molecular weights of 30 kDa 
for human IL-33 and 29.9 kDa for mouse IL-33 (Schmitz, et al., 2005). Schmitz 
and colleagues (2005) reported that IL-33 was produced as a 30 kDa propeptide 
that required cleavage by caspase-1 for generation of the mature form. Caspase-
1 was shown to cleave IL-33 at Ser111, transforming the propeptide into the 18 
kDa mature form (amino acids 112 – 270). This post-translational processing is 
common for other IL-1 family members such as IL-1α, IL-1β and IL-18. For 
instance, pro-IL-1 and pro-IL-18 were found to require peptide cleavage by 
caspase-1 and/or caspase-8 for maturation (Arend et al., 2008; Dinarello, 1998) 
and calpain was reported as a required factor for the processing of mature IL-1 
(Arend, et al., 2008; Dinarello, 1997). 
Despite these findings more recent data has found caspase-1 may have 
contradictory effects on the biological activity of IL-33. Cayrol and Girard (2009) 
reported that the full length IL-33 protein is itself biologically active and that 
processing by caspase-1 results in IL-33 inactivation. They further demonstrated 
that caspase-1 cleavage does not occur at the site initially proposed (Ser111), but 
after residue Asp178 (aspartic acid 178) between the fourth and fifth predicted 
beta-strands of the IL-1-like domain. In addition, they also found that caspase-3, 
the prototypic apoptotic caspase shares a similar cleavage site with caspase-1 
which is at DGVD178G, and both caspase-1 and caspase-3 activation leads to the 
production of an inactive 20 – 22 kDa fragment of IL-33. Therefore the authors 
concluded that IL-33 is inactivated by endogenous caspases during cell apoptosis. 
Alignment of IL-33 protein sequences revealed two evolutionarily conserved 
regions: the predicted homeodomain-like helix–turn–helix (HTH) motif (amino 
acids 1 – 65) within the N-terminal portion (Baekkevold, et al., 2003) and the C-
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terminal IL-1-like domain (amino acids 112 – 270) (Schmitz, et al., 2005). The 
cytokine activity is expected to reside in the carboxyl (c-) terminal of IL-33, 
which is predicted to form a -trefoil structure, similar to IL-1 and IL-18. These 
similar conserved features likely reflect common evolutionary roots (Arend, et 
al., 2008). 
 
1.6.3 Functions of IL-33 
Schmitz and colleagues (2005) were the first to report the cytokine activity of IL-
33 when they observed that the protein mediates its biological effects via the 
ST2 receptor to activate NF-B and MAP (mitogen activated protein) kinases. 
They also observed that IL-33 was able to drive the production of Th2-associated 
cytokines (i.e., IL-5 and IL-13) from in vitro polarized Th2 cells. In addition, in 
vivo, they found IL-33 was capable of inducing the expression of IL-4, IL-5, and 
IL-13 and promoting severe pathological changes in mucosal organs. Studies have 
shown positive associations between IL-33 expression and inflammatory disease 
activity in tissues such as the synovial membrane, lung and colon. This indicated 
a direct or indirect role of IL-33 as a cytokine driving disease pathogenesis. For 
example, IL-33 was abundantly expressed in the synovial membrane from 
patients with rheumatoid arthritis (Xu et al., 2008). IL-33 was also abundantly 
expressed in the lungs of mice that were exposed to pulmonary challenge with 
either LPS or house dust mite extracts (Hammad et al., 2009). In addition, IL-33 
mRNA levels were markedly increased in the colon of mice that were infected 
with the nematode parasite T. muris (Humphreys et al., 2008). 
Even though the evidence for the function of IL-33 as a cytokine is clear, 
researchers are still in debate as to how IL-33 is released from cells. Some 
studies report that cells do not release IL-33 unless they become injured or 
undergo necrosis (Cayrol & Girard, 2009; Nile et al., 2010). For example, Cayrol 
and Girard (2009) showed that mechanical endothelial cell damage induced the 
release of full-length IL-33 and high-mobility group box protein 1 (HMGB1) from 
endothelial cells. However, neither IL-33 nor HMGB1 were found in the 
supernatants of undamaged control cells. In addition Carol and Girard (2009) 
also showed both IL-33 and HMGB1 were released from cells subjected to 
necrosis by exposure to several cycles of freeze/thawing. In addition, IL-33 has 
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been detected in the culture supernatants from damaged fibroblast-like 
synoviocytes but not activated peripheral blood mononuclear cells (PBMC) and 
non-damaged fibroblast-like synoviocytes (Matsuyama et al., 2010). These 
findings demonstrated that IL-33 had similarity with the ‘alarmin’ family of 
proteins which are also only released in response to cell damage. This family 
includes HMGB1, defensins, heat shock proteins, lactoferrin, cathelicidin and IL-
1α (Cayrol & Girard, 2009; de la Rosa et al., 2008; Haraldsen et al., 2009; 
Moussion et al., 2008; Oppenheim et al., 2007). However, despite being 
characterised as an ‘alarmin’, studies have found that under certain conditions 
IL-33 is released by viable cells such as monocytes, macrophages, fibroblasts and 
glial cells (Hudson et al., 2008; Li et al., 2008; Sanada et al., 2007; Talabot-Ayer 
et al., 2009). In vitro, THP-1 cells (human monocyte cell line) forced to express 
pro-IL-33 and subjected to LPS or PMA stimulation did secrete pro-IL-33 
(Talabot-Ayer, et al., 2009). In addition, IL-33 was reported to be secreted from 
PMA-stimulated rat cardiac fibroblasts (Sanada, et al., 2007) and from adenosine 
triphosphate (ATP) stimulated mixed glial cell cultures and astrocyte-enriched 
cultures (Hudson, et al., 2008). A combination of LPS and aluminium hydroxide 
adjuvant (alum) treated human macrophages were also shown to secrete pro-IL-
33 which was found to be dependent on NLRP3 (nucleotide-binding domain and 
leucine rich repeat containing pyrin domain 3) and its adaptor molecule ASC 
(apoptosis-associated speck-like protein containing CARD) (Li, et al., 2008).  
Immunohistochemical studies revealed that IL-33 is predominantly localized to 
the nucleus in numerous cells, indicative of a role for IL-33 as a nuclear protein 
(Baekkevold, et al., 2003; Carriere et al., 2007; Kuchler et al., 2008; Moussion, 
et al., 2008; Onda, et al., 1999). Database searches revealed significant 
structural homology  between the first 65 amino N-terminal residues of IL-33 and 
the DNA-binding homeodomains of several drosophila and vertebrate 
transcription factors, indicating that IL-33 may function as a transcription factor 
(Baekkevold, et al., 2003). Furthermore, Carriere and colleagues (2007) showed 
that the evolutionarily conserved homeodomain-like helix-turn-helix motif of IL-
33 mediated nuclear localization, heterochromatin-association, and targeting of 
IL-33 to mitotic chromosomes. In addition, IL-33 was found to have 
transcriptional repressor properties which were mediated by the homeodomain-
like helix-turn-helix motif. Furthermore, Roussel and colleagues (2008) showed 
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that IL-33 binds to chromatin by docking into the acidic pocket formed by the 
histone H2A–H2B dimer at the surface of the nucleosome. Based on the current 
understanding, IL-33 has similarity to IL-1 and HMGB1 which also have been 
shown to have transcriptional regulatory properties (Lotze & Tracey, 2005; Maier 
et al., 1994; Scaffidi et al., 2002; Werman et al., 2004). Therefore, like IL-1α 
and HMGB1, IL-33 is a dual function protein acting as a pro-inflammatory 
cytokine extracellularly and as nuclear factor with transcriptional regulatory 
properties intracellularly. 
 
1.6.4 IL-33 expression in cells and tissues 
IL-33 is constitutively expressed in a variety of cells and expression increased in 
response to pro-inflammatory mediators. The following cells have been 
described to constitutively express IL-33: High endothelial venules (HEV) and 
endothelial cells (HEV ECs) from human tonsils, (Baekkevold, et al., 2003; 
Carriere, et al., 2007), endothelial cells of large and small blood vessel (Matsuda 
et al., 2009; Moussion, et al., 2008), fibroblastic reticular cells of lymphoid 
tissues (Moussion, et al., 2008), smooth muscle cells of bronchial, pulmonary and 
coronary arteries (Prefontaine et al., 2009; Schmitz, et al., 2005), epithelial 
cells of skin (keratinocytes), stomach, colonic mucosa, tonsillar crypts and 
salivary gland (Beltran et al., 2010; Moussion, et al., 2008; Schmitz, et al., 2005) 
and glial cells of the central nervous system (Hudson, et al., 2008). In addition, 
IL-33 expression studies showed that skin, gut, lung, brain and spinal cord are 
prominent sites of IL-33 expression (Hudson, et al., 2008; Moussion, et al., 2008; 
Schmitz, et al., 2005). 
IL-33 was found to be highly expressed in inflamed or diseased tissues (Beltran, 
et al., 2010; Matsuda, et al., 2009; Matsuyama, et al., 2010; Xu, et al., 2008). 
However, IL-33 expression was not detected in resting immune cells such as 
monocytes, monocyte-derived dendritic cells, natural killer (NK) cells, B cells 
and T cells (Schmitz, et al., 2005). However, Schmitz and colleagues (2005) did 
report a modest amount of IL-33 expression in monocytes and dendritic cells 
upon stimulation with LPS. In addition, a later study showed that IL-33 was 
modestly expressed in resting monocytes but this expression was significantly 
upregulated upon LPS stimulation (Nile, et al., 2010). In fact, a further study 
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showed that the IL-33 expression in murine bone marrow derived macrophages is 
increased by up to 300 fold when stimulated with LPS (Goh et al., 2009). 
Mouse primary macrophages stimulated with TLR-3 (Poly I:C) and TLR-4 (LPS) 
agonists exhibited upregulated IL-33 mRNA expression and using a LPS-
stimulated TANK-binding kinase 1 (TBK-1)-/- MEF (mouse embryonic fribroblasts) 
IL-33 expression was found to be TBK-1-dependent (Polumuri et al., 2012). In 
addition, human corneal epithelial cells required stimulation by TLR-3 (Polyl:C) 
and TLR-5 (Flagelin) agonists to express IL-33, and this IL-33 expression was 
found to be suppressed after blocking nuclear translocation of the NF-κB p65 
subunit by a IκBα (inhibitor of kappa B, alpha) inhibitor (BAY11-7082) and NF-κB 
inhibitor (quinazoline) (Zhang et al., 2011a). Cytokines such as IL-1β, TNF-α, 
IFN-γ and IL-17A were shown to induce IL-33 expression by keratinocytes, 
fibroblasts, macrophages and endothelial cells (Kamekura et al., 2012; 
Meephansan et al., 2012; Nomura et al., 2012; Palmer et al., 2009; Savinko et 
al., 2012; Xu, et al., 2008). Nomura and colleagues (2012) showed that TNF-α 
induced expression of IL-33 by nasal fibroblasts was mediated by 
phosphoinositide 3–kinase (PI3K), c–Jun N–Terminal (JNK) and NF-κB pathways. In 
addition, EGFR, ERK (extracellular-signal-regulated kinase), p38 and JAK (Janus 
kinase)/STAT1 pathway were found to mediate the IL-17A induced expression of 
IL-33 by normal human epidermal keratinocytes (Meephansan, et al., 2012). 
 
1.6.5 IL-33 receptors 
ST2 was originally discovered by Yanagisawa and colleagues (1993) as an orphan 
receptor. The specific ligand for ST2 was demonstrated to be IL-33 in 2005 
(Schmitz, et al., 2005). ST2 belongs to the IL-1 receptor family, which is a 
subfamily of the IL-1R/TLR superfamily and therefore ST2 is also known as IL-1 
receptor-like-1 (IL1RL-1). The other members of this subfamily are interleukin-1 
receptor accessory protein (IL-1RAcP), IL-18R, IL-18RAcP, IL-1Rrp2 and IL-1RAPL 
(Dunne & O'Neill, 2003; O'Neill & Dinarello, 2000; Schmitz, et al., 2005). 
Similarly to other family members, ST2 has an extracellular three-
immunoglobulin (Ig) domain (IL-33 binding domain) and also an intracellular TIR 
(toll/interleukin-1 receptor) domain that functions to activate intracellular 
signalling pathways (O'Neill & Dinarello, 2000; Schmitz, et al., 2005). There are 
  
 
74
three variants of the IL-33 receptor described by researchers: a longer 
transmembrane form of the receptor (ST2L), a shorter soluble receptor (sST2) 
and a variant soluble receptor (ST2V) (Iwahana et al., 2004; Iwahana et al., 
1999; Schmitz, et al., 2005; Turnquist et al., 2008; Yanagisawa, et al., 1993). 
Analysis of the exon-intron structure of the ST2 gene family revealed that the 
ST2L, sST2 and ST2V are generated by alternative splicing which is controlled by 
two distinct promoters, a proximal promoter and a distal promoter (Bergers et 
al., 1994; Iwahana, et al., 1999; Li et al., 2000b; Tominaga et al., 1999). 
IL-33 has been shown to specifically bind to ST2 (Palmer et al., 2008; Schmitz, 
et al., 2005). However, for active signal transduction to occur IL-1RAcP is 
required. Therefore the active IL-33 receptor (IL-33R) is a heterodimeric 
molecule consisting of ST2 and IL-1RAcP (Ali et al., 2007; Chackerian et al., 
2007). The importance of this heterodimer was demonstrated by Palmer and 
colleagues (2008) who showed that IL-1RAcP increased the affinity of murine IL-
33 for ST2 four fold. Even though sST2 has the same affinity for IL-33 as ST2, it 
does not possess the intracellular component and therefore the binding complex 
formed between sST2, IL-33 and IL-1RAcP does not lead to active signal 
transduction. Therefore, sST2 merely functions as a decoy that competes with 
ST2 for IL-33 (Hayakawa et al., 2007; O'Neill, 2008; Schmitz, et al., 2005). 
ST2 is constitutively expressed by immune cells such as mature mast cells and 
mast cell precursors, dendritic cells, macrophages, B cells and Th2 cells but not 
Th1 cells (Allakhverdi et al., 2007; Espinassous et al., 2009; Joshi et al., 2010; 
Komai-Koma et al., 2011; Lecart et al., 2002; Matsuda, et al., 2009; Moritz et 
al., 1998; Turnquist, et al., 2008; Xu et al., 1998; Yanagisawa et al., 1997). ST2 
has also found to be abundantly expressed by epithelial cells in the colonic 
mucosa, cornea and lung (Beltran, et al., 2010; Lin et al., 2013; Yagami et al., 
2010) as well as keratinocytes of skin (Hueber et al., 2011).   
 
1.6.6 Effects of IL-33 on target cells 
Mast cells were found to constitutively express ST2 (Allakhverdi, et al., 2007; 
Matsuda, et al., 2009; Moritz, et al., 1998; Schmitz, et al., 2005), which make 
them a target cell for IL-33. In vitro, mast cells directly respond to IL-33 and 
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activate protein kinase signalling cascades involving NF-κB, ERK1/2 and p38 
(Matsuda, et al., 2009; Schmitz, et al., 2005). In the case of p38, this was found 
to be inactivated by the presence of sST2 (Matsuda, et al., 2009). Activation of 
protein kinase signalling cascades have been shown in mast cells to result in the 
expression of inflammatory mediators such as IL-1, IL-5, IL-6, IL-10, IL-13, TNF- 
α, GM-CSF, CXCL8/IL-8, CCL1, monocyte chemotactic protein 1 (MCP-1) and MIP-
1 (Allakhverdi, et al., 2007; Ho et al., 2007; Palmer, et al., 2008; Xu, et al., 
2008).  
ST2 was also abundantly expressed by Th2 cells, but not any other T lymphocyte 
subsets, such as naïve CD4+ T cells, Th1 cells, Th17 cells and regulatory T cells 
(Lecart, et al., 2002; Lohning et al., 1998; Nakae et al., 2007; Xu, et al., 1998), 
Therefore IL-33 plays a role in regulating Th2 responses. Naïve CD4+ T cells 
stimulated with PHA or Staphylococcal enterotoxin B (SEB) were shown to 
differentiate into effector Th2 cells in the presence of IL-33 (Komai-Koma et al., 
2007; Kurowska-Stolarska et al., 2008). IL-33 was also shown to enhance the 
production of Th2 mediators such as IL-5 and IL-13 (Guo et al., 2009; Kurowska-
Stolarska, et al., 2008; Schmitz, et al., 2005). In fact, IL-33 was also shown to 
induce Th2 cells to express IL-33 (Guo, et al., 2009). In vitro, Komai-koma and 
colleagues (2007) showed that IL-33 acts as a chemoattractant for Th2 cells that 
have high levels of ST2 expression. In addition, the authors showed injection of 
recombinant IL-33 into the footpad of ST2-knockout mice, which had been 
adoptively transferred with polarized Th2 cells, led to the localised 
accumulation of transferred Th2 cells at the injection site. 
Macrophages have been shown to express ST2 indicating that these cells could 
respond to IL-33 signalling (Espinassous, et al., 2009; Joshi, et al., 2010). 
Indeed, Espionassous and colleagues (2009) showed that the release of TNF-α by 
murine peritoneal macrophages cells in response to LPS was increased in the 
presence of IL-33. Furthermore, the authors showed the potentiating effect of 
IL-33 was abolished when macrophages are treated with an anti-ST2 antibody. 
IL-33 also stimulated mouse bone marrow derived macrophages to express the 
Th2 cytokines: IL-5 and IL-13 (Yang et al., 2013). In addition, IL-33 also 
stimulated IL-13-primed peripheral blood derived macrophages to express CCL17 
and CCL24 (Kurowska-Stolarska et al., 2009). IL-33 stimulation also increased the 
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expression of MD-2 (myeloid differentiation protein 2) and TLR-4 in 
macrophages, therefore increasing their sensitivity to bacterial LPS (Espinassous, 
et al., 2009). IL-33 was also shown to induce naïve macrophage to express CCL3, 
a marker for classically activated macrophages (M1). However, when IL-33 was 
added to polarised M1 macrophages, an increase in expression of CCL18, a 
marker for alternatively activated macrophages (M2) was observed (Joshi, et al., 
2010). This indicates that IL-33 stimulation of naïve macrophages favours M1 
chemokine generation whilst addition to polarised macrophages promotes and 
amplifies M2 chemokine expression. Interestingly, Mun and colleagues (2010) 
observed that IL-33 also stimulates the formation of tartrate-resistance acid 
phosphate (TRAP)+ osteoclasts from human monocytes via activation of signalling 
molecules that are critical for osteoclast cell development such as Syk (spleen 
tyrosine kinase), phospholipase Cγ2, Gab2, MAP kinases, MAP3K7 (mitogen-
activated protein kinase kinase kinase 7), and NF-κB. Furthermore, using an 
osteogenic disk model, IL-33 was able to induce bone resorption by CD14+ 
monocyte-derived osteoclasts. However, in contrast, ST2 deficient mice 
presented with normal bone formation but increased bone resorption and IL-33 
abolished the generation of tartrate-resistance acid phosphate (TRAP)+ 
osteoclasts even in the presence of RANKL and M-CSF (Schulze et al., 2010). 
B cells have been demonstrated to express ST2 (Komai-Koma, et al., 2011; 
Yanagisawa, et al., 1997) and IL-33 demonstrated to activate B1 cell 
proliferation and induce production of IgM, IL-5 and IL-13 (Komai-Koma, et al., 
2011). In addition, IL-33 was shown to require IL-4 to induce B cells proliferation 
and production of IgE (Komai-Koma et al., 2012). Thus these studies indicate a 
role for IL-33 in modulating B cell function in a Th2 dependant manner. IL-33 
was also shown to augment dendritic cells expansion from mouse bone marrow 
in a time and dose dependent manner (Mayuzumi et al., 2009). This role was 
found to be dependent on GM-CSF as IL-33-induced expression of dendritic cells 
was completely blocked by an anti-GM-CSF antibody. IL-33 was also found to 
induce dendritic cells to express IL-6, IL-1β, TNF-α and CCL17 (Besnard et al., 
2011). IL-33 was also shown to activate mouse bone marrow derived dendritic 
cells to express high level of MHC class II molecules and CD86 (Rank et al., 
2009). This study also showed that IL-33-activated dendritic cells were capable 
of priming naïve CD4+ T cells to produce IL-5 and IL-13. The capability of IL-33-
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activated dendritic cells in priming naïve CD4+ T cells to produce IL-5 and IL-13 
was also confirmed by Besnard and colleagues (2011). Therefore, IL-33 can 
influence dendritic cells function and promote Th2 responses. 
In terms of granulocytes, IL-33 has been shown to induce the production of IL-
13, CCL17 and TGF-β from eosinophils (Stolarski et al., 2010). In addition, IL-33 
exacerbated eosinophil-mediated airway inflammation by increasing the 
numbers of eosinophils, macrophages, lymphocytes and levels of IL-13, TGF-β, 
CCL3, CCL17, and CCL24 in the lung. Schneider and colleagues (2009) also 
showed that basophils produce pro-inflammatory mediators, such as histamine, 
IL-4 and IL-6 upon treatment with IL-33. In addition, IL-33 activation of 
neutrophils was shown to increase expression of the surface complement 
receptor 3 (CR3) which in turn increased phagocytosis of opsonised C. albicans 
(Le et al., 2012).   
Numerous epithelial cells express ST2L and are therefore a key target for IL-33. 
Yagami and colleagues (2010) evaluated the effect of IL-33 on normal human 
bronchial epithelial cells and found that  IL-33 increased the expression of  IL-8 
in a dose and time dependant manner. The IL-33 induced expression of IL-8 was 
found to be mediated by an ST2 dependant pathway. IL-33 stimulation led to the 
increased phosphorylation of the MAPK, ERK but not p38. In addition, in the 
presence of an ERK inhibitor (PD98059), a significant reduction in IL-33 mediated 
IL-8 expression by normal human bronchial epithelial cells was observed. In 
contrast, the authors showed that IL-33 had no effect on the expression of IL-1β, 
IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TNF-α, MCP-1 and CXCL10. Furthermore, 
Fujita and colleagues (2012) demonstrated that IL-33 induced the expression of 
IL-17F by bronchial epithelial cells in a dose dependant manner.  In agreement 
with previous studies (Yagami, et al., 2010), the authors showed that IL-33 
signalling led to the increased phosphorylation of ERK but not p38 and JNK. 
However, the authors also demonstrated the induction of increased 
phosphorylation of mitogen and stress-activated protein kinase 1 (MSK1). MSK1 
has been shown to involved in the phosphorylation of NF-κB in vitro and in vivo 
(Vermeulen et al., 2003). Although IL-17A shares high homology with IL-17F, the 
authors also found that even though there is basal release of IL-17A from 
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bronchial epithelial cells, IL-33 stimulation did not induce increased expression 
(Fujita, et al., 2012).  
Kamekura and colleagues (2012) evaluated the effect of IL-33 on human nasal 
epithelial cells (HNEC). Stimulation of HNECs with IL-33 (100 ng/ml) for 6 h 
induced expression of IL-8 and GM-CSF. The expression of IL-8 and GM-CSF were 
found to be significantly decreased if the HNECs were pre-incubated with an 
anti-IL-33 or anti-ST2 antibody, indicating the direct role of IL-33 signalling. In 
analysing signalling pathways involved in the IL-33 mediated inflammatory 
response in HNECs, cells were pre-treated with inhibitors of ERK, p38, JNK, NF-
κB and EGFR prior to treatment with IL-33. The authors found that IL-33-
mediated expression of IL-8 was dose-dependently reduced by inhibitors of ERK 
(PD98059) and EGFR (AG1478), which is consistent with other studies (Fujita, et 
al., 2012; Yagami, et al., 2010). In addition, they also found that IL-33-mediated 
expression of GM-CSF was dose-dependently reduced by treatment with the 
inhibitor of JNK (SP600125), NF-κB (IMD-0354) and EGFR (AG1478). 
Meephanson and colleagues (2012) studied the effect of IL-33 on normal human 
epidermal keratinocytes. The authors found that after 48 h of stimulation with 
IL-33 (100 ng/ml) a significant increase in IL-8 expression was observed from 
normal human epidermal keratinocytes. On the other hand, Balato and 
colleagues (2012) demonstrated that IL-33 alone could not induce the expression 
of IL-6, VEGF, MCP-1 and IL-20 by normal human epidermal keratinocytes. 
However, IL-33 could increase the TNF-α induced expression of IL-6, VEGF, MCP-
1 and IL-20. Parallel results were also found using the immortalised human 
keratinocyte cell line (HaCaT). In addition, HaCaT cells require co-stimulation 
with IL-33 for IL-17A to induce expression of IL-20 and VEGF. Interestingly, 
however, intracellular IL-33 has been found to actually suppress NF-κB (Ali et 
al., 2011). Therefore, as intracellular IL-33 suppresses NF-κB function, it was 
hypothesised that IL-33 knockdown would enhance the TNF-α-induced expression 
of IL-8. Indeed, as expected, knock down of IL-33 with small interfering RNA 
(siRNA) enhanced the TNF-α-mediated expression of IL-8 (Oliveira et al., 1994).   
Studies on human and mouse fibroblasts isolated from the heart (Zhu & Carver, 
2012), skin (Wong et al., 2012) lung (Kurokawa et al., 2011) and embryo 
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(Funakoshi-Tago et al., 2008) showed that IL-33 could induce expression of 
various cytokines and chemokines such as IL-6, IL-13, MCP-1, MCP-3, CXCL1, 
CXCL10, CCL2 and CCL11, as well as TGF-β. While IL-33 could induce increased 
expression of CCL11 by mouse lung fibroblasts, co-stimulation with IL-33 and IL-
13 has been shown to synergistically augment CCL11 expression (Kurokawa, et 
al., 2011). In rat cardiac fibroblasts, IL-33 stimulation could induce translocation 
of the phosphorylated p65 subunit of NF-kB into the nucleus in a dose dependent 
manner. In addition, in murine embryonic fibroblasts of TRAF6-deficient mice, 
IL-33 failed to induce MCP-1, MCP-3 and IL-6 expression; indicating that TRAF6 is 
important for IL-33-induced signal transduction (Funakoshi-Tago, et al., 2008). 
The study also showed that IL-33-induced activation of p38 and JNK was 
completely impaired in TRAF6-deficient murine embryonic fibroblasts. In 
addition, IL-33 has also been shown to induce phosphorylation of STAT3 by 
primary human dermal fibroblasts (Wong, et al., 2012). In human fibroblasts 
isolated from rheumatoid arthritis synovial tissue, Kunisch and colleagues (2012) 
showed that stimulation with IL-33 did not significantly induce increased 
expression of IL-6, MCP-1, MMP-1 and MMP-3 and no significant increases in the 
phosphorylation of p38, ERK or JNK were observed. However, using a lentiviral 
expression system, fibroblasts that were induced to overexpress intracellular IL-
33 and stimulated with TNF-α exhibited increased expression of IL-6, IL-8, MCP-1 
and increased PGE2 secretion.   
 
1.6.7 Role of IL-33 in inflammation and infection 
IL-33 and ST2 expression was found to be elevated in the synovial tissue, 
synovial fluid and serum of rheumatoid arthritis patients (Carriere, et al., 2007; 
Matsuyama, et al., 2010; Palmer, et al., 2009; Xu, et al., 2008). This therefore 
implicated a role for IL-33 in the pathogenesis of rheumatoid arthritis. Numerous 
in vivo studies have investigated the role of IL-33 in the pathogenesis of 
rheumatoid arthritis using a collagen induced arthritis mouse model. In collagen 
induced arthritis mice, an increase in IL-33 expression was detected during the 
early phases of inflammation in the joint. Furthermore, intraperitoneal injection 
with a monoclonal anti-ST2 antibody decreased the severity of disease (Palmer, 
et al., 2009). Intraperitoneal injection with sST2-Fc (engineered fusion protein) 
into collagen induced arthritis mice was also shown to attenuate the mean 
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arthritic index and significantly lower the serum levels of IL-12, TNF- and IFN-γ  
(Leung et al., 2004). In addition, when CIA was attempted in ST2-knock out mice 
there was markedly attenuated levels of IL-17, IFN-γ, and TNF-α in the draining 
lymph nodes and lower infiltration of mononuclear and polymorphonuclear 
leukocytes cells into synovial tissues (Xu, et al., 2008). Furthermore, collagen 
induced arthritis mice intraperitoneally injected with recombinant IL-33 
exhibited increased disease severity and significantly increased levels of IL-5, IL-
17, IL-12, IFN-γ and TNF-α in the draining lymph nodes (Xu, et al., 2008). 
In inflammatory bowel diseases, IL-33 was found to be highly expressed in 
diseased tissue samples (Beltran, et al., 2010; Carriere, et al., 2007; Sponheim 
et al., 2010). Carriere and colleagues (2007) also showed that serum levels of IL-
33 were significantly increased in inflammatory bowel diseases patients 
compared to healthy subjects. This indicated a possible role for IL-33 in the 
pathogenesis of inflammatory bowel diseases. Wild type mice intraperitoneally 
injected with recombinant IL-33 presented with marked epithelial cell 
hyperplasia in the gastrointestinal tract (GIT), accompanied with GIT 
eosinophilia and mononuclear cell infiltration (Schmitz, et al., 2005). However, 
IL-33 deficient mice exhibited increased severity of symptoms, inflammation and 
myeloperoxidase activity in a dextran induce colitis mouse model (Oboki et al., 
2010). In contrast, in a trinitrobenzene sulfonic acid-induced experimental 
colitis model, induction of colitis in mice treated with recombinant IL-33 
resulted in reduced inflammatory cell migration and weight loss compared to the 
mice treatment with saline or control IgG. In addition, mice treated with 
recombinant IL-33 exhibited decreased serum levels of IFN-γ and increased 
serum level of Th2 cytokines (IL-5 and IL-13) (Duan et al., 2012). These 
therefore suggested that IL-33 had a protective role in inflammatory bowel 
diseases. 
IL-33 has been demonstrated to play a role in airway inflammation. IL-33 was 
highly expressed in smooth muscle and epithelial cells of bronchial tissue from 
asthma patients (Prefontaine, et al., 2009; Prefontaine et al., 2010). In an 
ovalbumin-induced airway inflammation mouse model, the expression of IL-33 
and ST2 in lungs was increased (Hayakawa, et al., 2007; Louten et al., 2011). In 
addition, when the ovalbumin-induced airway inflammation model was run in 
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ST2 deficient mice, decreased severity of airway inflammation was observed 
which was characterised by a reduction in inflammatory cell numbers 
(eosinophils and macrophages) and reduced levels of IL-5 in the bronchoalveolar 
lavage fluid (Kurowska-Stolarska, et al., 2008). In addition, IL-33 deficient mice 
also showed decreased pulmonary inflammation characterised by decreased cell 
migration (eosinophils and lymphocytes) as well as decreased Th2 cytokines (IL-5 
and IL-13) in the bronchoalveolar lavage fluid (Louten, et al., 2011; Oboki, et 
al., 2010). Intranasal administration of recombinant IL-33 was also shown to 
induce immediate allergic responses as evidenced by increased mucous 
production by the airway epithelium and increased levels of IL-5 and IL-13 in 
lung tissue as well as in bronchoalveolar lavage fluid  (Louten, et al., 2011). 
A role for IL-33 in infection was first suggested when levels of the soluble 
receptor for IL-33 (sST2) were found to be elevated in patients with sepsis and 
trauma (Brunner et al., 2004). Indeed, IL-33 has been demonstrated to play a 
role in infection in a number of mouse models. In a Pseudomonas aeruginosa 
keratitis mouse model, sub-conjunctival injection with recombinant IL-33 was 
shown to induce decreased severity of inflammation and decreased bacterial 
load as well as a decrease in polymorphonuclear leukocytes infiltration. This was 
accompanied by decreased expression of TNF-α and MIP-2, and increased 
expression of Th2 cytokines (IL-4 and IL-5) (Hazlett et al., 2010). In a mouse 
model of sepsis, where the systemic inflammation was induced by cecal ligation 
and puncture (CLP), intravenous injection of IL-33 was shown to reduce 
mortality rate and this was associated with increased neutrophil influx into the 
peritoneal cavity and increased bacterial clearance (Alves-Filho et al., 2010). 
Furthermore, IL-33 plays a role in protection against fungal pathogens as in an 
acute C. albicans peritoneal infection model. Pre-treatment with IL-33 
(intraperitoneal injection) prior to C. albicans infection (intraperitoneal 
injection) was shown to induce rapid fungal clearance and reduced C. albicans 
associated mortality rate. This was associated with a rapid recruitment of 
neutrophils to the site of infection site in the IL-33 pre-treated mice (Le, et al., 
2012). 
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1.6.8 IL-33 and periodontal diseases 
IL-1 family cytokines have been shown to have important roles in periodontal 
disease (Kinane et al., 1992; Masada et al., 1990; Orozco et al., 2006; Pradeep 
et al., 2009). Since IL-33 is a member of the IL-1 family, a role in periodontal 
disease pathogenesis is anticipated. However, although the role of IL-33 has 
been massively studied in other chronic inflammatory diseases, little is known 
about its role in periodontal disease. 
There is tentative evidence that IL-33 may play a role in periodontal disease. 
Nile and colleagues (2010) have shown that LPS from the periodontal pathogen 
P. gingivalis can induce upregulated IL-33 expression in human monocytes (THP-
1 cell line and primary monocytes). In addition, primary human gingival 
fibroblasts were shown to secrete IL-33 after stimulation with TNF-α (Beklen & 
Tsaous Memet, 2014).  However, reports are varied with regard to the 
association between levels of IL-33 in biological samples and periodontal 
disease. IL-33 was found to be below detection levels in GCF samples of chronic 
periodontitis and healthy subjects when evaluated using a multiplex bead 
immunoassay (Papathanasiou et al., 2014). However, Buduneli and colleagues 
(2012) showed that IL-33 levels in GCF were lower in chronic periodontitis 
patients compared to healthy samples, whilst no difference in IL-33 levels was 
observed in saliva and serum levels between the two groups. 
 
1.7 Background and aims of study  
Chronic periodontitis is a chronic inflammatory disease initiated by periodontal 
pathogens (e.g., P. gingivalis) that exist in dental biofilms (Armitage, 1999). 
Although initiated by pathogens the real damage to periodontal tissues is caused 
by an excessive host immune response to these pathogens (Lindhe, et al., 1999). 
Therefore a greater understanding of the host oral immune response is required 
for us to fully delineate the pathogenesis of periodontal disease. 
Cytokines play an important role in mediating the host immune response. IL-1 
family cytokines such as IL-1α, IL-1β and IL-18 have been shown to have 
important roles in periodontal diseases (Jandinski et al., 1991; Kinane, et al., 
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1992; Masada, et al., 1990; Orozco, et al., 2006). However, the role of IL-33, 
another member of the IL-1 family of cytokines, in periodontal disease has yet to 
be fully investigated. IL-33 has been shown to be expressed in many tissues such 
as skin, gut, lung, brain and spinal cord (Hudson, et al., 2008; Moussion, et al., 
2008; Schmitz, et al., 2005) and expression found to be higher in inflammatory 
conditions (Beltran, et al., 2010; Matsuda, et al., 2009; Matsuyama, et al., 2010; 
Xu, et al., 2008). This pattern of IL-33 expression in tissues exposed to the 
environment indicates that IL-33 may be expressed in the oral epithelium. 
Furthermore, periodontal pathogens such as P. gingivalis have been 
demonstrated to stimulate upregulated expression of IL-33 in human monocytes 
(THP-1 cell line and primary monocytes) (Nile, et al., 2010). Therefore it can be 
hypothesised that similar regulatory events may occur in oral epithelial cells.  
The cytokine IL-17A has received considerable attention since the discovery of 
the Th17 cell subset (Aggarwal, et al., 2003). Th17 cells have been 
demonstrated to be present in the periodontium (Schenkein, et al., 2010), 
however analysis of diseased tissue suggests there is limited association of Th17 
cells with periodontal disease progression (Culshaw et al, unpublished). In fact, 
it is now known that despite IL-17A being described as a T cell-secreted 
cytokine, much of the IL-17A released during an inflammatory response is 
produced by innate immune cells (Cua & Tato, 2010). Indeed, IL-17A has been 
shown to be associated with periodontal disease pathogenesis (Behfarnia, et al., 
2013; Honda, et al., 2008; Ohyama, et al., 2009; Takahashi, et al., 2005). 
However, since the discovery of IL-17A, genomic sequencing efforts have led to 
the discovery of several putative IL-17(A) homologues; IL-17B - IL-17F. To date, 
little research has been conducted investigating the association of these other 
IL-17 family members with periodontal disease. In addition, evidence suggests 
that unlike other IL-17 family members, which have pro-inflammatory functions, 
IL-17E can down regulate localized destructive inflammatory responses in 
conditions including rheumatoid arthritis (Gaffen, 2009a). Therefore, it is 
interesting to speculate that IL-17E plays differing roles to IL-17A in the 
pathogenesis of periodontal disease. However, to date this hypothesis has not 
been investigated. 
Based on these proposed hypotheses the aims of this study therefore were: 
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1. To evaluate levels of IL-10, IL-33 and IL-17 family cytokines in serum, saliva 
and GCF from patients with chronic periodontitis and healthy subjects.  
2. To evaluate the expression of IL-33 and its receptors (ST2L and sST2) in 
periodontal tissue samples from patients with chronic periodontitis and 
healthy subjects. 
3. To evaluate the mRNA expression of IL-10 and IL-17 family cytokines in 
periodontal tissue samples from patients with chronic periodontitis and 
healthy subjects. 
4. To evaluate the expression of IL-33 and its receptors (ST2L and sST2) in oral 
keratinocyte cells using an in vitro live P. gingivalis monospecies biofilm 
model. 
5. To evaluate the effect of IL-33 on the expression of inflammatory mediators 
by oral keratinocyte cells in vitro. 
6. To evaluate the expression of IL-17E and its receptor (IL-17RB) in periodontal 
tissue samples from patients with chronic periodontitis and healthy subjects. 
7. To evaluate the role of IL-17E in modulating the expression of chemokines 
(IL-8 and CXCL5) by oral keratinocytes in response to stimulation with P. 
gingivalis and IL-17A. 
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2.1 Study samples 
Serum, gingival crevicular fluid (GCF) and saliva samples from healthy and 
chronic periodontitis patients were used in this study. Samples were selected 
from independent studies conducted at Glasgow Dental Hospital and School and 
Newcastle School of Dental Sciences and were from subjects that were 
systemically healthy non smokers. The sample collection and ethical approvals 
for the Glasgow sample cohort were as previously described (Lappin et al., 2009; 
Pathiyal et al., 2005). The sample collection and ethical approvals for the 
Newcastle cohort are as previously described (Davies et al., 2011; Jaedicke et 
al., 2012; Preshaw & Heasman, 2002). 
The age range of the subjects in this study was 22 – 55 years. To be included in 
the study subjects had to be systemically healthy with a minimum of 16 teeth 
and at least four molars in different quadrants. Subjects were excluded if they 
previously had surgical periodontal therapy and if they were currently taking or 
had previously taken antibiotics or any other medication during the past six 
months. In addition, all smokers or former smokers and females who were 
pregnant at the time of the study or within the previous year were also 
excluded.  
All subjects had a clinical periodontal examination carried out by a single 
calibrated clinician (Kappa scores for clinical probing depths and clinical 
attachment levels were 0.63 (p < 0.001) and 0.59 (p < 0.001) respectively). The 
following data were obtained: age, gender and clinical parameters for 
periodontal conditions (clinical probing depth (CPD), clinical attachment loss 
(CAL) and bleeding on probing (BOP)). 
Full mouth periodontal chartings were recorded using a University of North 
Carolina PCP 15 manual probe at six sites around every tooth: mesiobuccal, 
distobuccal, mesiolingual, distolingual, midlingual and midbuccal. The gingival 
recession was recorded, which is the distance between the cemento-enamel 
junction and the gingival margin. A negative value was recorded if the gingival 
margin was coronal to the cemento-enamel junction. The probe was gently 
inserted into the gingival crevice or pocket along the long axis of the tooth until 
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resistance was felt. CPD was defined as the distance between the gingival 
margin and the base of the crevice or pocket. The CAL is a combined value of 
gingival recession and CPD. BOP was also recorded 30 seconds after placing the 
probe into the crevice or pocket. 
Subjects were grouped as chronic periodontitis patients if they demonstrated a 
minimum of two sites with a CPD and CAL of ≥ 5 mm. The healthy subjects had 
no history of chronic periodontitis and no sites with a CPD or CAL of ≥ 2 mm.  
 
2.2 Serum, gingival crevicular fluid and saliva samples 
 
2.2.1 Serum samples 
Blood was collected between 0900 and 1100 h (to minimize diurnal variations in 
biochemical parameters) from a peripheral vein in a coagulant tube. After 
clotting the sample was centrifuged (200 x g) and the serum isolated, snap 
frozen in aliquots and stored at –80 oC. 
 
2.2.2 Gingival crevicular fluid samples 
Gingival crevicular fluid (GCF) samples were obtained from the buccal aspects of 
two interproximal sites in single rooted teeth from each individual participating 
in the study. Except for the controls, GCF samples were obtained from sites with 
obvious dental biofilm accumulation and visible signs of inflammation such as 
hyperaemia. GCF samples were collected with filter paper strips (Oraflow Inc, 
New York). Prior to GCF sampling, supragingival biofilm was removed carefully 
by sterile curettes and the surfaces were dried and isolated by cotton rolls. 
Filter paper strips were placed in the gingival sulcus/pocket for 30 seconds. Care 
was taken to avoid mechanical trauma and strips visually contaminated with 
blood were discarded. Two strips from each patient were placed into one 
polypropylene tube before freezing at -80 oC. The strips were eluted prior to 
assay by the following method.  The strips were placed into a microcentrifuge 
tube containing 50 µl of phosphate buffered saline (PBS) containing 0.05 % 
Tween® 20 (PBST) and centrifuged at 13,000 x g for 2 min. The supernatant (50 
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µl) was collected and transferred to a new microcentrifuge tube. The 
centrifugation was repeated three times with new PBST to give a total volume of 
150 µl.  
 
2.2.3 Saliva samples 
Saliva was collected according to a modification of the method described by 
Navazesh and Christensen (1982). Prior to saliva sample collection, the subject 
was instructed to refrain from intake of any food or beverage for 1 h. Smoking, 
chewing gum and intake of coffee were prohibited during this hour. The subject 
was instructed to minimise all facial movements, particularly movements of the 
mouth. To begin saliva collection the subject was asked to void the mouth of 
saliva by swallowing. The subject was then asked to lean slightly forward over 
the tube and funnel. The subject was then instructed to keep his/her mouth 
slightly open and to allow saliva to drain into the funnel. At the end of the 5 min 
collection period, the subject was asked to collect any remaining saliva in 
his/her mouth and expectorate into the funnel. The saliva volume was measured 
using micropipettes (Finnipipette, Lab systems). Saliva samples were aliquoted 
and stored at -80 oC. 
 
2.3 Tissue samples 
Periodontal tissue samples were obtained from 26 subjects: 9 healthy and 17 
chronic periodontitis. Healthy tissue samples were taken from patients 
undergoing non-periodontal disease related procedures such as crown 
lengthening and tooth extraction. Disease tissue samples were taken from 
patients suffering from chronic periodontitis, who required surgical periodontal 
therapy as part of their periodontal treatment regime. Gingival tissues were 
obtained from subjects with written consent, undergoing open flap debridement 
in the Unit of Periodontics at Glasgow Dental Hospital. Ethical review and 
approval was provided by the West of Scotland Research Ethics Committee. 
Patients undergoing open flap debridement had clinical probing depths of ≥ 5.0 
mm with clinical attachment loss of ≥ 5.0 mm, which persisted after non-surgical 
treatment. Subject age ranged from 38 - 64 years with a mean age of 47 years. 
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The tissue samples were immediately submerged in RNAlater (Qiagen, UK) and 
stored at -80 oC. 
 
2.4 Cell culture 
 
2.4.1 OKF6/TERT-2 cells 
OKF6/TERT-2 cells were a kind gift from the Rheinwald laboratory (Brigham and 
Women’s Hospital, Boston). The cells were originated from keratinocyte cells of 
the oral mucosa, which have been immortalized by forced ectopic expression of 
the telomerase catalytic subunit, hTERT (Dickson et al., 2000). The cells 
resemble primary oral keratinocyte cells and are regarded as a valuable and 
reproducible model for normal oral epithelial cell studies (Dongari-Bagtzoglou & 
Kashleva, 2006). 
OKF6/TERT-2 cells were grown in keratinocyte serum-free medium (KSFM) 
(Invitrogen, UK) supplemented with 25 µg/ml bovine pituitary extract 
(Invitrogen, UK), 0.2 ng/ml epidermal growth factor (Invitrogen, UK), 2 mM L-
glutamine (Sigma-Aldrich, UK), 100 IU/ml penicillin (Sigma-Aldrich, UK), 100 
mg/ml streptomycin (Sigma-Aldrich, UK), and 0.4 mM calcium chloride. The 
OKF6/TERT-2 cells were allowed to grow in vented tissue culture flasks (Corning, 
UK) in a humidified atmosphere with 5 % CO2 at 37 oC. The growth media was 
changed at two or three day intervals until the cells reach 70 % confluence at 
which point they were subcultured. 
To subculture, the spent media was removed from the flask and cells were 
washed with pre-warmed PBS (Invitrogen, UK). Appropriate volumes (e.g., 4 ml 
for a 75 cm2 flask) of 0.05 % trypsin/EDTA (ethylenediaminetetraacetic acid) 
(Invitrogen, UK) were then added to the flask and incubated at 37 oC until the 
cells detached (2 to 5 min). The trypsin was then inactivated by adding double 
the volume of dulbecco's modified eagle medium (DMEM) with 10 % (v/v) fetal 
bovine serum (Invitrogen, UK) to the flask. The cell suspension was then 
removed from the flask and placed in a sterile 25 ml centrifuge tube and 
centrifuged at 1000 rpm for 5 min. The supernatant was again removed and cells 
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were resuspended in 4 ml Hank’s solution (Sigma-Aldrich®, UK) and then 
centrifuged at 1000 rpm for 5 min. The cells were finally resuspended in 4 ml 
KSFM, and viable cell counts were performed using a haemocytometer. A 1-2 x 
105 cell suspension was then prepared in KSFM and cells seeded into a vented 75 
cm2 cell culture flask (Corning, UK). The cells were then incubated in a 
humidified atmosphere with 5 % CO2 at 37 oC. 
 
2.4.2 Primary human gingival epithelial cells 
Commercially available primary human gingival epithelial (PHGE) cells were 
bought from CELLnTEC advanced cell systems (Switzerland). This is a pooled 
suspension of primary cells isolated from healthy adult gingival tissues of three 
or more donors. The PHGE cells were grown and subcultured as described for the 
OKF6/TERT-2 cells (Section 2.4.1). Only cells at passage two to five were used 
experimentally.  
 
2.4.3 Cryopreservation of cells 
Cryopreservation of cells (OKF6/TERT-2 cells and PHGE cells) was carried out 
using dimethyl sulfoxide (DMSO) (Sigma-Aldrich, UK) as a freezing medium. DMSO 
(20 %) was prepared by adding 4 ml of DMSO to 16 ml fetal bovine serum 
(Invitrogen, UK) and the solution was filter-sterilized (0.22 µm). For the purpose 
of cryopreservation, the cells were harvested during exponential growth. The 
cells were pelleted and suspended in a KSFM (Invitrogen, UK) at a concentration 
of 2 x 106 cells/ml in a sterile universal tube. In a dropwise manner, an equal 
volume of cold 20 % DMSO was then added to the cell suspension and 1 ml of the 
cell solution was transferred to a labelled cryovial. The cryovial was then chilled 
on ice for 30 min, and then placed in a pre-chilled insulation box to be kept at -
80 oC for 6 to 16 h. The cryovial was finally transferred into liquid nitrogen for 
long term preservation. 
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2.4.4 Thawing of cryopreserved cells 
The cryopreserved cells (OKF6/TERT-2 cells and PHGE cells) were removed from 
liquid nitrogen and quickly thawed at 37 oC. The cryovial outer surface was 
disinfected with 70 % ethanol, and carefully the cells were transferred into a 25 
cm2 cell culture flask (Corning, UK) pre-filled with 9 ml warm KSFM (Invitrogen, 
UK). The cells were then incubated overnight in a humidified atmosphere with 5 
% CO2 at 37 oC. The media were changed the next day. Growth and subculture 
was performed as described previously (Section 2.4.1 and Section 2.4.2). 
 
2.5 Porphyromonas gingivalis monospecies biofilm 
 
2.5.1 Bacterial growth conditions 
The monospecies biofilms were prepared using P. gingivalis ATCC 33277, which 
was obtained from the American Type Culture Collection (ATCC, USA). The 
bacteria were maintained at 37 oC on fastidious anaerobic agar (Oxoid, 
Cambridge, UK) with 5 % defibrinated horse blood (E&O laboratories, UK) in an 
anaerobic chamber (Don Whitley Scientific Limited, UK) for 3 days. The chamber 
was set at 85 % N2, 10 % CO2 and 5 % H2. Prior to biofilm preparations, the 
bacteria were grown at 37 oC in schaedler anaerobe broth (Oxoid, UK) for 2 days. 
After 2 days the broth was centrifuged at 3000 rpm for 5 min to obtain a pellet 
of bacteria, which was then washed three times with PBS (pH 7.4). The bacteria 
were then resuspended in PBS and standardized at 0.2 OD550 in a colorimeter 
(Fisher Scientific, UK) to obtain approximately 1  108 CFU (colony forming 
unit)/ml. Live bacterial counts were confirmed as described in Section 2.5.2. 
 
2.5.2 Standard plate counting method 
The method was adapted from the Miles and Misra method (1938) and was used 
to determine the number of colony forming units (CFU) in a bacterial suspension. 
The bacterial suspension was serially diluted (1:10 dilutions) up to 10-5 with PBS. 
Fastidious anaerobic agar (Oxoid, UK) plates with 5 % defibrinated horse blood (E 
& O laboratories, UK) were prepared in advance. 
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The surfaces of the fastidious anaerobic agar plates were first sufficiently dried 
to allow a 20 µl drop of dilution to be absorbed onto the plate in 15 - 20 min. 
Each plate was then divided into four equal sectors. In each sector, three drops 
of the appropriate dilution were placed onto the surface of the agar and the 
drops were allowed to spread naturally over an area of 1.5 to 2.0 cm. The plates 
were left upright to dry on the bench before inversion and incubation in an 
anaerobic chamber (Don Whitley Scientific Limited, UK) for 24 to 48 h with 
continuous observation. The chamber setting was 85 % N2, 10 % CO2 and 5 % H2. 
Colonies were then counted by eye. The following equation was used to 
calculate the number of CFU per ml from the original sample dilution: CFU/ml = 
Average number of colonies for a dilution x 50 x dilution factor. 
 
2.5.3 Artificial saliva 
Artificial saliva was used to prepare a P. gingivalis monospecies biofilms. The 
use of artificial saliva was to simulate the biofilm growth conditions of the oral 
cavity. Artificial saliva base was prepared by mixing the following substances in 
distilled water: 0.25 % (w/v) porcine stomach mucin (Sigma-Aldrich, UK), 0.35 % 
(w/v) sodium chloride (VWR International, Belgium), 0.02 % (w/v) potassium 
chloride (VWR International, Belgium), 0.02 % (w/v) calcium chloride dihydrate 
(VWR International, Belgium), 0.2 % (w/v) yeast extracts (Sigma-Aldrich, UK), 
0.1 % (w/v) lab lemco powder (Oxoid, UK) and 0.5 % (w/v) proteose peptone 
(Sigma-Aldrich, UK). The artificial saliva base was autoclaved at 121 oC for 15 
min and left to cool. Finally, an autoclaved solution of 0.05 % (v/v) urea (Oxoid, 
UK) was added to the base to produce the final artificial saliva solution which 
was kept at 4 oC prior to use. 
 
2.5.4 Preparation of Porphyromonas gingivalis monospecies 
biofilms 
P. gingivalis cultures (Section 2.5.1) were standardized to 1  107 CFU/ml in 
artificial saliva (Section 2.5.3). Next, 500 l of the standardized P. gingivalis 
solution was cultured onto 13 mm diameter cell culture treated Thermanox® 
plastic coverslips (Nalge Nunc International, UK) placed in 24-well cell culture 
plates (Corning, UK). The cultures were incubated at 37 oC in an anaerobic 
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chamber (Don Whitley Scientific Limited, UK) for 4 days. The chamber setting 
was at 85 % N2, 10 % CO2 and 5 % H2. Daily, the spent artificial saliva was 
replaced with 500 l new artificial saliva. After the final incubation, the 
artificial saliva was removed and the biofilms were kept at -80 oC prior to use for 
cell stimulation experiments. 
 
2.5.5 Validation of the Porphyromonas gingivalis monospecies 
biofilms 
2.5.5.1 Viability test 
The P. gingivalis monospecies biofilms were revived by thawing in 500 µl 
artificial saliva and incubating overnight in an anaerobic chamber. The biofilms 
were removed from the artificial saliva the next day and washed in PBS. The 
excess PBS was removed by wiping the coverslip (biofilm free side) on sterile 
paper. Each biofilm was then placed in 1 ml PBS in a 5 ml universal tube. To re-
suspend the P. gingivalis, the universal tube was subjected to sonication at 35 
kHz for 5 min in an ultrasonic bath (Fisherbrand® FB 11021; Fisher Scientific, 
UK). The CFU of the P. gingivalis suspension was determined using a standard 
plate counting method (Section 2.5.2). 
2.5.5.2 Gram staining 
Gram staining is a bacteriological laboratory technique used to differentiate 
Gram-positive and Gram-negative bacterial species based on the biochemical 
properties of their cell walls. The P. gingivalis monospecies biofilms were 
revived by thawing in 500 µl artificial saliva and incubating overnight in an 
anaerobic chamber. The biofilms (coverslip) were removed from the artificial 
saliva the next day and washed in PBS. The excess PBS was removed by wiping 
the coverslip (biofilm free side) on sterile paper, then the biofilms were left to 
dry. The biofilms were subjected to Gram staining procedure, using a Gram 
staining kit (Pro-Lab Diagnostics Inc., UK) which involved the following steps. 
The primary stain (crystal violet) were added to the coverslip (biofilm) and 
incubated for 1 min. The coverslip was rinsed with a gentle stream of water for 
a maximum of five seconds to remove unbound crystal violet. Then the Gram’s 
iodine (an agent that fixes crystal violet to bacterial cell walls) was added for 1 
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min, followed by a gentle rinse with acetone for about three seconds and a rinse 
with a gentle stream of water. Then safranin, a secondary stain was added to 
the coverslip for 1 min, followed by rinsing with a gentle stream of water for a 
maximum of five seconds. The coverslip was then placed on a glass slide for 
viewing under a microscope. The Gram-positive bacteria will retain the primary 
stain (crystal violet) and not uptake the secondary stain (safranin) causing it to 
look purple under a microscope. While Gram-negative bacteria will lose the 
primary stain and uptake the secondary stain causing it to appear red under a 
microscope. The gram stain process was used to confirm visually the presence of 
an abundant monospecies biofilm of the Gram-negative organism (P. gingivalis) 
had grown on the coverslips.   
 
2.6 Cell stimulation studies 
 
2.6.1 Stimulation of cells with a live Porphyromonas gingivalis 
monospecies biofilm 
A day prior to the stimulation experiments, OKF6/TERT-2 cells (Section 2.4.1) or 
PHGE cells (Section 2.4.2) were seeded in duplicate at 2 x 105 cells/ml in 24-well 
cell culture plates (Corning, UK), and incubated overnight in a humidified 
atmosphere at 37 oC with 5 % CO2. At the same time, the P. gingivalis 
monospecies biofilm (Section 2.5.4) were thawed in 500 µl artificial saliva and 
incubated overnight in an anaerobic chamber. 
After an overnight incubation, the spent media was removed from the cell 
monolayer which was subsequently washed once with pre-warmed PBS 
(Invitrogen, UK). The cells were then placed in 1 ml of defined keratinocyte 
serum-free medium (DKSFM) (Invitrogen, UK).  
The P. gingivalis monospecies biofilms were taken out of artificial saliva and 
washed by dipping three times in PBS. The excess PBS was removed by wiping 
the coverslip (on the biofilm-free side) on sterile paper. Each biofilm was then 
attached to a 24-well Millicell® cell culture insert (Millipore, UK) using sterile 
commercially available Vaseline®. The biofilm was then suspended above the 
cell monolayer in the wells of a 24-well plate as shown in Figure 2-1. 
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Figure 2-1: Diagrammatic representation of the P. gingivalis monospecies 
biofilm model 
A live P. gingivalis monospecies biofilm is cultured on cell culture treated 
Thermanox® plastic coverslips which is then secured to the base of a hanging 
basket with sterile Vaseline® (Sherry et al., 2013). The biofilm is then suspended 
0.5 mm above a monolayer of cultured oral keratinocytes. The 0.5 mm is a 
physiologically relevant space representing the gap between the tooth surface 
and gum tissue. 
 
The experimental protocols used in this thesis are summarised in Table 2-1. The 
co-cultures were incubated for between 3, 6, 9 and 24 h in a humidified 
atmosphere with 5 % CO2 at 37 oC. A duplicate unstimulated control for each 
incubation time point was also performed. After completion of the respective 
incubation period, the culture supernatant was removed and stored at -20 oC for 
analysis by ELISA. The remaining adherent cells were lysed with 350 µl of RLT 
lysis buffer (Qiagen, UK) with 1 % β-Mercaptoethanol. The lysate was stored at -
80 oC for future RNA isolation. 
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Experiment design Stimulation conditions 
Incubation  
Hour (h) 
Evaluation 
Effect of P. gingivalis 
biofilm stimulation on 
OKF6/TERT-2 cells or PHGE 
cells 
(a) Control; and (b) Biofilma 3, 6, 9 & 24 h 
 
 
 
 
 
9 h 
a) IL-8 protein release (ELISA) 
b) mRNA expression and protein release of IL-33 and its 
receptors (real-time PCR and ELISA respectively) 
c) mRNA expression of IL-17 family (real-time PCR; 
OKF6/TERT-2 cells only) 
 
a) IL-8 protein release (ELISA) 
b) IL-33 and ST2 protein expression 
(immunocytochemistry) 
Effect of IL-17E on 
OKF6/TERT-2 cells 
stimulated by a P. 
gingivalis biofilm 
(a) Control; (b) rhIL-17E (50 ng/ml); (c) Biofilma ; 
and (d)Treat with rhIL-17E (50 ng/ml) for 30 min, 
followed by biofilma 
 
4 & 24 h a) mRNA expression and protein release of IL-8 and 
CXCL5 (real-time PCR and ELISA respectively) 
 
 
Effect of IL-17E on 
OKF6/TERT-2 cells 
stimulated by IL-17A 
(a) Control; (b) rhIL-17E (400 ng/ml); (c) rhIL-17A 
(10 ng/ml); (d) Treat with combination of rhIL-17A 
(10 ng/ml) and rhIL-17E (10, 50, 100, 200 or 400 
ng/ml); and (e) Treat with rhIL-17E (10, 50, 100, 
200 or 400 ng/ml) for 30 min, followed rhIL-17A (10 
ng/ml) 
 
24 h a) mRNA expression and protein release of IL-8 (real-
time PCR and ELISA) 
 
Effect of IL-33 on 
OKF6/TERT-2 cells 
(a) Control; (b) PMA (10 ng/ml); and (c) rhIL-33 (10, 
50 or 100 ng/ml) 
4, 24 & 48 h a) mRNA expression of IL-8, IL-1RA, G-CSF, TLR-2 and 
TLR-4 (real-time PCR) 
b) Protein release of IL-8, IL-1RA and G-CSF (ELISA) 
c) Proteome profiler analysis (24 h only) 
 
Table 2-1: Oral keratinocyte stimulation experimental protocols 
See Section 2.5.4 for biofilm preparation (a). Detail descriptions of the materials used are as follow: rhIL-17A = recombinant human IL-
17A (Cell Signalling, USA); rhIL-17E = recombinant human IL-17E (PeproTech, USA); PMA = phorbol 12-myristate 13-acetate (PMA) 
(Sigma-Aldrich®, UK); and rhIL-33 = recombinant human IL-33 (PeproTech®, UK).   
  97
2.6.2 Effect of IL-17E on OKF6/TERT-2 cells stimulated by 
Porphyromonas gingivalis monospecies biofilm 
OKF6/TERT-2 cells were prepared for stimulation experiments as described 
previously (Section 2.4.1). P. gingivalis monospecies biofilms were prepared for 
stimulation experiment as described previously (Section 2.5.4). The 
experimental protocol is summarised in Table 2-1. Briefly, the cells were either 
stimulated with rhIL-17E (50 ng/ml) alone, biofilm alone or 30 min pre-
incubation with rhIL-17E (50 ng/ml) followed by biofilm stimulation. The 
stimulations were carried out in DKSFM (Invitrogen, UK). The cultures were 
incubated for 4 and 24 h in humidified atmosphere at 37 oC and 5 % CO2. 
Duplicate unstimulated controls for each incubation time point was also included 
in the experiment. After completion of the respective incubation period, the 
culture supernatant was removed and stored at -20 oC for analysis by ELISA. The 
remaining adherent cells were lysed with 350 µl of RLT lysis buffer (Qiagen, UK) 
with 1 % β-Mercaptoethanol. The lysate was stored at -80 oC for future RNA 
isolation.  
 
2.6.3 Effect of IL-17E on OKF6/TERT-2 cells stimulated by IL-
17A 
OKF6/TERT-2 cells were prepared for stimulation experiments as described 
previously (Section 2.4.1). The experimental protocol is summarised in Table 2-
1. Briefly, the cells were either incubated with rhIL-17E (400 ng/ml) alone, 
stimulated with rhIL-17A (10 ng/ml) alone, stimulated with combination of rhIL-
17A (10 ng/ml) and rhIL-17E (10, 50, 100, 200 or 400 ng/ml) or 30 min pre-
incubation with rhIL-17E (10, 50, 100, 200 or 400 ng/ml) followed by stimulation 
with rhIL-17A (10 ng/ml). The stimulations were carried out in DKSFM 
(Invitrogen, UK). The cultures were then incubated for 24 h in a humidified 
atmosphere with 5 % CO2 at 37 oC. A duplicate of unstimulated control for each 
incubation time point was also included in the experiment. After completion of 
the respective incubation period, the culture supernatant was removed and 
stored at -20 oC for analysis by ELISA. The remaining adherent cells were lysed 
with 350 µl of RLT lysis buffer (Qiagen, UK) with 1 % β-Mercaptoethanol. The 
lysate was stored at -80 oC for future RNA isolation.  
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2.6.4 Effect of IL-33 on OKF6/TERT-2 cells 
OKF6/TERT-2 cells were prepared for stimulation experiments as described 
previously (Section 2.4.1). The experimental protocol is summarised in Table 2-
1. Briefly, the cells were incubated in duplicate with either PMA (10 ng/ml) 
(Sigma-Aldrich®, UK) as a positive control or rhIL-33 (10, 50 or 100 ng/ml) 
(PeproTech®, UK). The culture was then incubated for 4, 24 and 48 h in a 
humidified atmosphere with 5 % CO2 at 37 oC. A duplicate unstimulated control 
for each incubation time point was also included in the experiment. After 
completion of the respective incubation period, the culture supernatant was 
removed and stored at -20 oC for analysis by ELISA. The remaining adherent cells 
were lysed with 350 µl of RLT lysis buffer (Qiagen, UK) with 1 % β-
Mercaptoethanol. The lysate was stored at -80 oC for future RNA isolation. 
 
2.6.5 Validating the bioactivity of recombinant human IL-33 
Naïve CD4+ T cells isolated from cord blood produced enhanced levels of IL-5 
when cultured with an anti-CD3 antibody and IL-33, compared with anti-CD3 
antibody alone (Kurowska-Stolarska, et al., 2008). Since peripheral blood 
mononuclear cells (PBMCs) were also known to compose naïve CD4+ T cells 
(Pflanz et al., 2002), we used easily accessible PBMCs instead of cord blood cells 
for validation of the bioactivity of rhIL-33 (PeproTech®, UK) prior to the IL-33 
stimulation study (Section 2.6.4). The study was carried out using PBMCs isolated 
from human venous blood. Based on the finding by Kurowska-Stolarska and 
colleagues (2008), the bioactivity of rhIL-33 in this study was evaluated by 
comparing levels of IL-5 produced by PBMCs when cultured with an anti-CD3 
antibody and rhIL-33, and anti-CD3 antibody alone. 
Human venous blood was collected in an EDTA tube (final concentration of 1.5 – 
2.0 mM) and used within 2 h of drawing. PBMCs were isolated from venous whole 
blood using PolymorphprepTM (Axis-Shield, UK) as previously devised by Boyum 
(1968). Briefly, a Pasteur pipette was used to layer 5 ml blood over 5 ml 
PolymorphprepTM in 15 ml centrifuge tubes. The tubes were centrifuged at 500 x 
g for 30 – 35 min at room temperature (20 oC). The rotor was allowed to 
decelerate without the brake. Using a Pasteur pipette, the upper plasma layer 
was then drawn off, leaving the PBMC layer. The PBMC layer was aspirated using 
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a Pasteur pipette, and transferred into a fresh 15 ml centrifuge tube containing 
10 ml RPMI (Roswell Park Memorial Institution) media (Sigma-Aldrich, UK). The 
RPMI was supplemented with 10 % fetal bovine serum (Sigma-Aldrich®, UK), 2 mM 
L-glutamine (Sigma-Aldrich®, UK) and 1 % penicillin/streptomycin solution 
(Sigma-Aldrich®, UK). The tube was then centrifuged at 400 x g to pellet the 
cells. The cells were then washed twice in 10 ml PBS by centrifugation at 400 x g 
for 10 min. Cells were finally resuspended in 5 – 10 ml RPMI and counted. 
For the bioactivity assay, the cells were seeded in 6-well plates at 1 x 106 
cells/ml (3 ml in each well) and stimulated in duplicate with combinations as 
follow: anti-CD3 (3 µg/ml) alone; anti-CD3 (3 µg/ml) and rhIL-33 (50 ng/ml); 
anti-CD3 (3 µg/ml) and rhIL-33 (100 ng/ml). The cells were incubated for 3 days 
in a humidified atmosphere at 37 oC and 5 % CO2. The supernatants were 
collected and centrifuged at 10000 x g for 15 min at 4 oC. The supernatants were 
transferred into a new centrifuge tubes and stored at -20 oC prior to analysis for 
IL-5 by ELISA (PeproTech®, UK). The experiment was repeated with three 
separate donors. 
 
2.7 Protein analyses 
 
2.7.1 Enzyme-linked Immunosorbent Assay  
Cytokine concentrations in biological fluids and cell culture supernatants were 
measured by enzyme-linked immunosorbent assay (ELISA). Although various kits 
from various sources were used in this study (Table 2-2), the general assay 
principal was mainly the same. The general ELISA procedure is described as 
below. 
Nunc-Immuno® MaxiSorp® 96-well Plates (Nalge Nunc International, UK) were 
coated with coating antibody diluted in coating buffer, and incubated overnight 
(12 – 18 h). The plate was washed between 1 and 5 times with wash buffer PBS 
with 0.05 % Tween® 20 (Sigma-Aldrich, UK). The plate was then blocked with 
blocking buffer for 2 h at room temperature. The plate was washed again 
between 1 and 5 times with wash buffer. Subsequently, duplicates of sample or 
pre-prepared standards were added to the wells of the 96-well plate and the 
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plate incubated for 2 h at room temperature. The plate was washed between 1 
and 5 times with wash buffer. After washing, the detection antibody was added 
to each well and the plate incubated for 1 h at room temperature. The plate 
was washed again between 1 and 5 times with wash buffer. The plate was then 
incubated with Streptavidin-HRP for 30 min at room temperature. Finally, 
substrate solution e.g., 3,3,5,5’-tetra-methylbenzidine (TMB) substrate (KPL, 
Gaithersburg, USA) was added to each well and the plate incubated for 5 – 30 
min to allow colour development.  Colour development was then stopped using 1 
M HCl and the absorbance was measured at 450 nm with wavelength correction 
set at 650 nm using a microplate reader (FLUOstar Omega; BMG Labtech, 
Germany). For some assays 2, 2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic 
acid) or ABTS (Sigma-Aldrich, UK) was used as a substitute substrate solution. On 
these occasions colour development was measured directly without addition of a 
stop solution at 405 nm with wavelength correction set at 650 nm. The plate was 
monitored at 5-min intervals for approximately 30 min. Data analysis was 
performed using Labtech data analysis software (BMG Labtech, Germany). In all 
cases, data was analysed using a log-log or 4-parameter curve fit.  
Although the general assay principal was the same; there were some subtle 
differences in assay procedure depending on assay source. These are detailed in 
Table 2-2. For each individual ELISA the assay was optimized and validated prior 
to use. Table 2-3 shows the concentration of each antibody used in each assay. 
In addition, the sensitivity limits of each assay were determined as two mean 
standard deviations higher than the mean baseline from 6 replicates standard 
curves (Table 2-3) (Chaloner-Larsson et al., 1997). 
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Manufacturer 
Coating antibody 
(ab) 
Blocking Detection antibody (ab) Peroxidase Substrate Solutions 
Invitrogen, UK 
 
Dilute in coating 
buffer, incubate 
overnight (4oC) 
 
Use diluent, block 
for 1hr (RT) 
Dilute in diluent, 
incubate with samples for 
2 h (RT) 
 
Streptavidin-HRP 
30 min (RT) 
TMB Coating buffer: 0.1 M NaHCO3 
(pH 8.2) 
Diluent: PBS + 0.5% BSA + 0.1% + 
Tween® 20 (pH 7.4) 
PeproTech, USA Dilute in PBS, 
incubate overnight 
(RT) 
Use diluent, block 
for 1hr (RT) 
Dilute in diluent, 
incubate for 2 hr (RT) 
Streptavidin-HRP 
30 min (RT) 
ABTS Diluent: 0.1% BSA, 0.05% Tween® 
20 in PBS 
R&D System, UK  
(DuoSet®) 
Dilute in PBS, 
incubate overnight 
(RT) 
Use diluent, block 
for 1hr (RT) 
Dilute in diluent, 
incubate for 2hr (RT) 
Streptavidin-HRP 
30 min (RT) 
TMB Diluent: 1% BSA in PBS (0.2 µm 
filtered) 
R&D System, UK 
(Quantikine® ST2) 
Ab-coated plate is 
supplied  
Use diluent, 
incubate with 
sample for 2hr (RT) 
Use as supplied, incubate 
for 2 hr (RT) 
HRP conjugated 
to detection ab 
TMB Diluent & detection Ab: supplied 
by manufacturer 
Life Science, UK 
 
Dilute in PBS, 
incubate overnight 
(4oC) 
Use diluent, block 
for 2hr (RT) 
Dilute in diluent, 
incubate for 1hr (RT) 
Streptavidin-HRP 
30 min (RT) 
TMB Diluent: 2% BSA in PBS (0.2 µm 
filtered) 
Table 2-2: Manufacturer variations in ELISA procedure  
BSA = Bovine serum albumin; TMB = 3, 3, 5, 5’-tetra-methylbenzidine substrate (KPL, Gaithersburg, USA); ABTS = 2, 2'-azino-bis (3-
ethylbenzothiazoline-6-sulphonic acid) (Sigma-Aldrich, UK)); NaHCO3 = sodium hydrogen carbonate; PBS = phosphate-buffered saline; RT 
= room temperature; HRP = horseradish peroxidase; and Ab = antibody. 
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ELISA Suppliers 
Capture 
antibody 
(μg/ml) 
Detection 
antibody 
(μg/ml) 
Sensitivity 
limit 
(pg/ml) 
Range 
(pg/ml) 
 
Human IL-1RA 
 
PeproTech®, USA 
 
0.5 
 
0.5 
 
15.1 
 
7.8 – 1000 
 
Human IL-5 
 
PeproTech®, USA 
 
0.25 
 
0.5 
 
64 
 
31.2 - 2000 
 
Human CXCL5 
 
R&D Systems, UK 
 
2.0 
 
0.10 
 
7.8 
 
7.8 -1000 
 
Human IL-8 
 
Invitrogen, UK 
 
1.0 
 
0.04 
 
12.5 
 
12.5 – 800 
 
Human IL-10 
 
PeproTech®, USA 
 
1.0 
 
0.5 
 
39 
 
7.8 - 1000 
 
Human IL-33 
 
Life Science, UK  
 
5 
 
1 
 
15.5 
 
3.9 - 500 
 
Human ST2 
 
R&D Systems, UK 
 
UN 
 
UN 
 
5.6 
 
3.9 - 1000 
 
Human G-CSF 
 
PeproTech®, USA 
 
1 
 
0.25 
 
16 
 
7.8 - 1000 
 
Human IL-17A 
 
PeproTech®, USA 
 
0.5 
 
0.25 
 
1.9 
 
3.9 – 1000 
 
Human IL-17B 
 
R&D System, UK 
 
2.0 
 
2.00 
 
>7.8 – <15.6 
 
15.6 – 2000 
 
Human IL-17C 
 
R&D Systems, UK 
 
2.0 
 
0.20 
 
>7.8 – <15.6 
 
15.6 – 2000 
 
Human IL-17D 
 
PeproTech®, USA 
 
1.0 
 
0.50 
 
>19.6 – <39 
 
39.1 – 5000 
 
Human IL-17E 
 
PeproTech®, USA 
 
1.0 
 
0.25 
 
>2 – <3.9 
 
3.9 – 1000 
 
Human IL-17F 
 
PeproTech®, USA 
 
1.0 
 
1.00 
 
>2 – <3.9 
 
3.9 – 1000 
 
Human IL-17A/F 
 
R&D Systems, UK 
 
0.8 
 
4.00 
 
>4.9 – <9.8 
 
9.8 – 2500 
Table 2-3: ELISA antibody concentrations and sensitivities 
The sensitivity limits of each assay were determined as two mean standard 
deviations higher than the mean baseline from six replicate standard curves 
(Chaloner-Larsson, et al., 1997). UN = undisclosed concentration (readily 
prepared by manufacturer). 
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2.7.2 Immunocytochemistry  
OKF6/TERT-2 cells (Section 2.4.1) were seeded at 2 x 105 cells/ml on top of glass 
disc (13 mm2) in 24-well cell culture plates (Corning, UK) and incubated 
overnight in a humidified atmosphere at 37 oC and 5 % CO2. After overnight 
incubation, the cells were stimulated with P. gingivalis monospecies biofilm 
(Section 2.5.4) for 9 h. After completion of the incubation period, the culture 
supernatant was removed and IL-8 release analysed by ELISA to confirm cells had 
been stimulated before further analysis was undertaken.  
Immunocytochemical analyses of IL-33 and ST2 expression by OKF6/TERT-2 cells 
were performed using the ImmPRESSTM detection system kit (Vector 
Laboratories, USA). After the cell supernatants were removed, the cells on discs 
were washed twice for 10 min each with Tris-buffered saline (with 0.05 % 
Tween®) (TBST). The cells were then fixed in cold methanol (-20 oC) for 15 min. 
After aspiration of the methanol the discs were air dried for 10 min. The cells 
were then permeabilized for 10 min at room temperature using 0.2 % Triton X-
100 (Sigma-Aldrich, UK) diluted in PBS. The discs were then washed twice for 10 
min each with TBST. To avoid non-specific binding, the discs were blocked for 30 
min at room temperature with 2.5 % normal horse serum. The serum was then 
aspirated and replaced with the appropriate primary antibody, pre-absorbed 
primary antibody or isotype control diluted in 2.5 % horse serum in TBST (Table 
2-4). The discs were then incubated overnight on a shaker at 4 oC. The discs 
were brought up to room temperature the next day and antibody solutions were 
aspirated from the wells prior to washing twice for 10 min each with TBST. The 
discs were then incubated for 30 min at room temperature with the appropriate 
ready to use secondary antibody (ImmPRESSTM kit; Vector, USA) (Table 2-4). 
Then the discs were washed twice for 10 min each with TBST. Finally, the 
peroxidase activity was visualised by addition of ImmPACTTM DAB (3, 3’-
diaminobenzidine) peroxidase substrate (Vector Laboratories, USA). Discs were 
incubated with DAB peroxidase substrate until the desired stain intensity 
developed. The discs were then rinsed with tap water for 5 min. The discs were 
then counter stained with filtered Harris Haematoxylin (Sigma-Aldrich, UK), and 
the excess washed off with running tap water. The discs were mounted on glass 
slides using mounting medium (Dako, UK). Photomicrographs were obtained 
using the Olympus® BX40 microscope system and CellB Olympus® Soft Imaging 
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software. The number of IL-33 and ST2 expressing cells were determined by 
counting the protein immunoreactive cells on photomicrographs obtained from 
at least five random high-power microscopic fields (400 x magnifications) as 
described in Section 2.7.4. 
Pre-absorbing antibody experiments were only carried out on the mouse 
monoclonal anti-IL-33 antibody (Enzo® Life Science, UK). Pre-absorption was 
carried out by adding 5 µg/ml mouse monoclonal anti-IL-33 antibody to a double 
concentration of rhIL-33 (PeproTech®, UK) in 2.5 % horse serum in TBST and 
incubating for 1 h on a shaker at 37 oC. For control purposes, the antibody alone 
was subjected to the same protocol prior to use.   
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Primary antibody Isotype control 
Secondary antibody 
ImmPRESSTM detection system  
(Vector Laboratories, USA) 
IL-33 
 
Mouse monoclonal anti-IL-33 antibody (5 µg/ml) 
(Nessy-1, Enzo® Life Science, UK) 
Mouse monoclonal IgG1 (5 µg/ml) 
(Thermo Scientific, UK) 
 anti-mouse IgG  
 
ST2 
Rabbit anti-IL1RL1 antibody (0.2 µg/ml)  
(Sigma-Aldrich®, UK) 
Rabbit IgG (0.2 µg/ml)  
(Abcam®, UK) 
 anti-rabbit IgG 
 
IL-17E 
Mouse monoclonal anti-IL-17E antibody (1 µg/ml) 
(Abcam®, UK) 
Mouse monoclonal IgG1 (1 µg/ml) 
(Thermo Scientific, UK) 
 anti-mouse IgG 
 
IL-17RB 
Rabbit anti-IL17RB antibody (0.2 µg/ml)  
(Sigma-Aldrich®, UK) 
Rabbit IgG (0.2 µg/ml)  
(Abcam®, UK) 
 anti-rabbit IgG 
 
Table 2-4: Antibodies used for immunocyto- and immunohisto- chemistry    
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2.7.3 Immunohistochemistry  
Diseased tissue samples were taken from patients suffering from chronic 
periodontitis, who required surgical periodontal therapy as part of their 
periodontal treatment regime. Whereas, healthy tissue samples were taken from 
patients undergoing non-periodontal disease related procedures such as crown 
lengthening and tooth extraction (Section 2.3). 
Tissue samples were fixed with 4 % formaldehyde and embedded in paraffin. The 
immunohistochemistry for IL-33, ST2, IL-17E and IL-17RB was performed on 5 µm 
thick paraffin embedded sections from periodontal tissues and from tonsil (used 
as a positive control). The immunohistochemistry was performed using the 
ImmPRESSTM detection system kit (Vector Laboratories, USA).  
Briefly, 5 mm paraffin sections were deparaffinised by heating in an oven at 60 
oC for 35 min, and rehydrated in graded alcohol. The sections were incubated 
with 0.5 % hydrogen peroxidase in methanol to block any endogenous peroxidase 
activity. For antigen retrieval, sections were pre-treated by boiling in 0.1 M 
citrate buffer (pH 6.0) in a microwave (700 W, 5 min). Nonspecific reactions 
were blocked for 30 min at room temperature using ready to use 2.5 % normal 
horse serum. Then, specimens were incubated overnight in a humidified 
chamber at 4 oC with the appropriate concentrations of primary antibodies 
diluted in 2.5 % horse serum in TBST (Table 2-4). Next day, the specimens were 
washed twice for 5 min in TBST and the sections incubated for 30 min at room 
temperature with the appropriate secondary antibody (Table 2-4). After washing 
twice for 5 min in TBST, the peroxidase activity was visualised using ImmPACTTM 
DAB (3, 3’-diaminobenzidine) peroxidase substrate solution (Vector Laboratories, 
USA). The sections were then lightly counterstained with Harris Haematoxylin 
(Sigma-Aldrich®, UK). The sections were mounted on glass slides using glycerol 
mounting medium (Dako, UK). 
Photomicrographs were obtained using the Olympus® BX40 microscope system 
and CellB Olympus® Soft Imaging software. The number of IL-33, ST2 and IL-17RB 
expressing cells were determined by counting the protein immunoreactive cells 
on photomicrographs obtained from at least five random high-power microscopic 
fields (400 x magnifications) as described in Section 2.7.4. 
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2.7.4 Quantification of immunostained cells 
Quantification of immunostained cells in the immunohistochemical or 
immunocytochemical analysis was performed using a manual cell counting grid 
as described by Bologna-Molina and colleagues (2011). This method uses only a 
digital camera adapted to a microscope and a personal computer. Briefly, 
photomicrographs of 400 x magnification were captured using the Olympus® BX40 
microscope system, and stored as jpeg files. At least five random 
photomicrographs were captured for each sample. This equates to between 300 – 
500 cells for immunocytochemical analysis, and a range of 300 – 1000 cells for 
immunohistochemical analysis. Each jpeg file was opened using Microsoft Office 
PowerPointTM (Microsoft Corporation,USA). The 6 x 6 grid (Figure 2-2) was placed 
over the entire image completely. For immunohistochemical analysis, areas not 
containing the tissue of interest were visually excluded. For each image, cell 
counting was started in the top left corner and finished in the top right corner 
(Figure 2-2). The number of both negative and positive stained cells was counted 
manually in each image. This image counting procedure was carried out by three 
independent individuals, and the average percentage of positive stained cells 
calculated by all individuals was used. The percentage of positive stained cells 
was calculated as follows: Percentage of positive cells = (positive cells / total 
cells) x 100. 
 
                 
Figure 2-2: Schematic figure of the grid used 
The counting starts at box 1, and continuous as shown by arrows until box 36. 
Numbers of positive and negative cells were counted for each box.  
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2.7.5 FACETM NF-κB p65 profiler assay 
Fast Activated Cell-based ELISA (FACETM) kits are highly sensitive 96-well assays 
designed for detecting activated protein within mammalian cells without the 
requirement for preparation of cell extracts, electrophoresis or membrane 
blotting. FACETM NFκB p65 profiler kits are designed to quantify levels of 
activated (phosphorylated) forms of NFκB p65 subunits and/or total NFκB p65. 
The antibodies used in this FACETM kit were specific for total (regardless of 
phosphorylation state) NF-κB p65 subunit, Serine 468 phosphorylated NF-κB p65 
subunit and the Serine 536 phosphorylated NF-κB p65 subunit. The kit can be 
used to determine the levels of the different forms of the NF-κB p65 subunit 
relative to cell number or it can also be used to determine NF-κB p65 subunit 
phosphorylation relative to total NF-κB p65 subunit levels found in the cells. 
OKF6/TERT-2 cells were seeded into 96 well plates at a density of 1 x 105 
cells/ml and left to adhere overnight in a humidified atmosphere with 5 % CO2 at 
37 oC. The following day, cells were stimulated for 30 min with either rhIL-17E 
(50 ng/ml) alone, rhIL-17A (10 ng/ml) alone, or 30 min pre-incubation with rhIL-
17E (50 ng/ml) followed by stimulation with rhIL-17A (10 ng/ml). Supernatants 
were then removed and the cells were fixed with 100 μl of 4 % formaldehyde in 
PBS for 20 min. The cells were then washed 3 times with 200 μl wash buffer (0.1 
% Triton X-100 in PBS), followed by a 20 min incubation with 100 μl quenching 
buffer (wash buffer with addition of 1 % hydrogen peroxide and 0.1 % Azide) at 
room temperature. After quenching, cells were again washed twice and 100 μl 
antibody blocking buffer (supplied by the manufacturer) was added to each well 
and the plate incubated for 1 h at room temperature. Cells were then washed 
twice as previous and 40 μl of diluted primary antibody was added to the cells. 
The primary antibodies used in the study were Phospho-NF-κB p65 antibodies 
(Serine 468 and Serine 536) and Total-NF-κB p65 antibody, which were diluted 
1/500 in antibody dilution buffer. Antibody dilution buffer only was used as a 
negative control (All antibodies and antibody dilution buffers were supplied by 
manufacturer).  The plates were then sealed and left overnight at 4 oC. The 
following day, the cells were again washed 3 times and incubated for 1 h with 
100 μl of diluted secondary antibody (horseradish peroxidase (HRP)-conjugated 
anti-rabbit IgG, diluted 1/2000 in antibody dilution buffer). Cells were then 
washed with wash buffer 3 times and 200 μl of PBS twice, followed by the 
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addition of 100 μl of developing solution (supplied by the manufacturer) for 2 - 
20 min. The absorbance of each well was then measured at 450 nm with a 
reference wavelength of 655 nm using a Fluostar Omega® microplate reader 
(BMG Labtech, Germany). Data analysis was done using BMG Analysis Software 
(BMG Labtech, Germany).  
To determine whether any differences observed in activated NF-κB p65 or total 
NF-κB p65 were due to differences in cell number; after the plate was read a 
crystal violet assay was performed. The cells were washed twice with wash 
buffer and then twice with PBS and then 100 μl of crystal violet solution was 
added to each well and the plate incubated for 30 min. After incubation the 
cells were washed again 3 times with PBS and then 100 μl of 1 % sodium dodecyl 
sulphate solution was added to each well and the plate  incubated  for 1 h at 
room temperature. Finally, the absorbance was read again at 595 nm. The 
measured OD450 readings are corrected for cell number by dividing the OD450 for 
a given well by the OD595 reading for that well. Then the percentage of the total 
NF-κB p65 subunit phosphorylated at a certain residue was calculated as follows: 
Percentage of phosphorylation at a specific residue =  
100   x   Phospho-NF-κB p65 subunit levels 
            Total NF-κB p65 subunit levels 
 
 
2.7.6 Proteome profiler array 
A human cytokine array (panel A) (Proteome ProfilerTM Array; R&D Systems, UK) 
was used to quantify the cytokines released by OKF6/TERT-2 cells in response to 
24 h stimulation with 100 ng/ml rhIL-33 (PeproTech®, UK) and 10 ng/ml PMA 
(Sigma-Aldrich®, UK) as described in Section 2.6.4.  
The kit contains a nitrocellulose membrane which has been blotted with 36 
selected capture antibodies (Figure 2-3). Cell culture supernatants are mixed 
with a cocktail of biotinylated detection antibodies and incubated with the 
nitrocellulose membrane. Any cytokine/detection antibody complex present is 
bound by its cognate immobilized capture antibody on the membrane. Following 
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a wash to remove unbound material, the bound cytokine/detection antibody 
complex was labelled with streptavidin-HRP, an enzyme reporter. Then 
chemiluminescent substrate was applied to the membrane. Luminol is oxidized 
in the presence of HRP and hydrogen peroxide to form an exited state product 
that emits light. The light produced at each spot is in proportion to the amount 
of cytokine bound. 
The kit was used in accordance with the manufacturer’s instructions and all 
incubations performed at room temperature (20 oC). All buffers were supplied by 
the manufacturer (formulation undisclosed). Briefly, the membranes were 
blocked in 2 ml array buffer 4 for 1 h on a rocking platform. Supernatants were 
centrifuged at 10000 rpm for 10 min to remove particulates. Then 1 ml of each 
sample was added to 0.5 ml of Array Buffer 4 and 15 µl of detection antibody 
cocktail and incubated for 1 h. After removal of the buffer from the membranes, 
the sample/antibody mixtures were added to the membranes and incubated 
overnight at 4 oC on a rocking platform. The next day, the membranes were 
washed 3 times for 10 min in 20 ml wash buffer. Next, 2 ml of streptavidin-HRP 
(1/2000 dilution) was added to the membranes and incubated for 30 min on a 
rocking platform. This was followed by three 10 min washes in 20 ml wash 
buffer. Finally, 1000 ml chemiluminescent detection reagent, Chemi Reagent 1 
and 2 (R&D Systems, UK) was placed onto the membrane, carefully covering the 
whole surface, and incubated for 1 min. Excess solution was drained off the 
membrane which was then wrapped in cling film and placed in an 
autoradiography film cassette with identification numbers facing up. The 
membranes were exposed to X-ray film (Fujifilm Super RX, UK) for 20 min. The 
films were then developed using the KODAK MIN-R Mammography processor 
(Kodak, UK). Digital images were taken of the developed films using a Gel DocTM 
XR Imaging System (Bio-Rad Laboratories, UK) and Quantity One® Software 
Version 4.6.7 (Bio-Rad Laboratories, UK).  
Cytokine array data on digital images were then quantified using Quantity One® 
Software Version 4.6.7 (Bio-Rad Laboratories, UK). First, digital image data were 
inverted prior to analysis procedure. This has to be done as the original digital 
images has light spots on the dark background (i.e., the signal intensity of the 
background is greater than the signal intensity of the sample spots). Then spot 
intensity (INT/mm2) was measured for all visible spots on cytokine array images. 
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The designated circular area (mm2) for intensity measurement was maintained 
unchanged for each spot measured (6.37 mm2). At every spot, the intensity was 
measured at least three times and the highest intensity value was recorded. The 
background signal (signal from the media only control) was subtracted from each 
spot. The average intensity from duplicate spots was calculated for each 
cytokine or chemokine.  
 
 
Figure 2-3: Cytokine array membrane of proteome profiler system 
A, represents a schematic membrane layout and B, represents example of 
processed membrane. RS = reference spot and NC = negative control. 
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2.8 Molecular biology 
 
2.8.1 RNA extraction and purification from periodontal tissue 
samples 
Extraction and purification of total RNA from periodontal tissues samples was 
carried out using the RNeasy® fibrous tissue kit (Qiagen, UK). In brief, a 
maximum of 30 mg of periodontal tissue was placed in an eppendorf tube 
containing 300 µl of 1 % ß-Mercaptoethanol in Buffer RLT (Qiagen, UK). The 
mixture was then homogenized using a disposable rotor-stator tissue 
homogenizer for 20 – 40 seconds. Then, 590 µl of RNase-free water and 10 µl of 
Proteinase K (Qiagen, UK) were added to the homogenous lysate and the mixture 
was incubated for 10 min at 55 oC in a heat block. The homogenate was then 
centrifuged at 10000 rpm for 3 min at room temperature to remove the tissue 
remnant. Next, the supernatant (700 – 900 µl) was transferred into a 1.5 ml 
microcentrifuge tube, followed by addition of an equal volume of ethanol (96 – 
100 %). The mixture was gently mixed by pipetting up and down before being 
transferred onto an RNeasy spin column (Qiagen, UK) placed in a 2 ml collection 
tube and centrifuged for 15 seconds at 10,000 rpm. The flow through was then 
discarded and the membrane was washed with 350 µl Buffer RW1 (Qiagen, UK) 
and centrifuged for 15 seconds at 10000 rpm. The flow through was again 
discarded and on column DNase (deoxyribonuclease) digestion was performed by 
incubating the membrane for 15 min at room temperature with a mixture of 10 
μl DNase I stock solution (Qiagen, UK) and 70 μl Buffer RDD (Qiagen, UK). 
Afterwards, the column was washed again using Buffer RW1 (Qiagen, UK). Next, 
the column was washed twice with 500 µl Buffer RPE (Qiagen, UK). Finally, 
RNase-free water (30 µl) was used to elute the RNA from the column by 
centrifugation at 10,000 rpm for 1 min. This final procedure was repeated to get 
a final elution volume of 60 µl. A NanoDrop 1000 spectrophotometer (Thermo 
Scientific, UK) was used to assess the quantity and quality of the extracted total 
RNA. 
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2.8.2 RNA extraction and purification from in vitro cultured 
cells 
Total RNA was extracted from cell cultures using the RNeasy kit (Qiagen, UK) 
according to the manufacturer’s instructions. Firstly, cells in a 24-well plate 
were lysed using 350 µl Buffer RLT (Qiagen, UK) containing 1 % ß-
Mercaptoethanol. The lysate was homogenized by passing at least 5 times 
through a blunt 20-gauge needle (0.9 mm diameter) fitted to a RNase-free 
syringe. Then, an equal volume of ethanol (96 – 100 %) was added to the 
homogenised lysate. The mixture was gently mixed by pipetting up and down 
before being transferred onto an RNeasy spin column (Qiagen, UK) placed in a 2 
ml collection tube. The tube was then centrifuged for 15 seconds at 10,000 rpm. 
The flow through was then discarded and the membrane was washed with 350 µl 
Buffer RW1 (Qiagen, UK) and centrifuged for 15 seconds at 10,000 rpm. The flow 
through was again discarded and on column DNase digestion was performed by 
incubating the membrane for 15 min at room temperature with a mixture of 10 
μl DNase I stock solution (Qiagen, UK) and 70 μl Buffer RDD (Qiagen, UK). 
Afterwards, the column was washed again using Buffer RW1 (Qiagen, UK). Next, 
the column was washed twice with 500 µl Buffer RPE (Qiagen, UK). Finally, 
RNase-free water (30 µl) was used to elute the RNA from the column by 
centrifugation at 10,000 rpm for 1 min. This final procedure was repeated to get 
a final elution volume of 60 µl. A NanoDrop 1000 spectrophotometer (Thermo 
Scientific, UK) was used to assess the quantity and quality of the extracted total 
RNA. 
 
2.8.3 Reverse transcription 
High Capacity RNA-to-cDNA Master Mix (Applied Biosystems®, UK) was used to 
reverse transcribe mRNA into cDNA. The master mix contains manufacturer 
optimised concentration of MgCl2, dNTPs (dATP, dCTP, dGTP and dTTP), 
recombinant RNase inhibitor protein, reverse transcriptase, random primers, 
oligo-dT (deoxythymine nucleotides) primer and stabilizers. The 20 µl reverse 
transcription reactions were prepared by mixing total RNA prepared in 16 µl of 
RNase free water (500 – 1000 ng) with 4 µl of master mix. For no-RT (reverse 
transcriptase) control, similar 20 µl reverse transcription reactions were 
prepared but without the enzyme component, reverse transcriptase. The tubes 
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were sealed and air bubbles were eliminated by brief centrifugation. The tubes 
were loaded into a thermal cycler (MyCyclerTM Thermal Cycler; Bio-Rad 
Laboratories, UK), and reverse transcription performed under the following 
conditions: 5 min at 25 oC, 30 min at 42 oC, 5 min at 85 oC and held at 4 oC. The 
cDNA was stored at -20 oC prior to use. 
 
2.8.4 Polymerase chain reaction 
Polymerase chain reaction (PCR) was carried out using the ReddyMixTM PCR 
Master Mix (Thermo Scientific, UK). A ready-to-use master mix comes in 1.1 x 
concentration. The final 1 x concentration of master mix contains: 0.625 units 
ThermoPrime Taq DNA polymerase, 75 mM Tris-HCL (pH 8.8 at 25 oC), 20 mM 
ammonium sulphate ((NH4)2SO4), 1.5 mM MgCl2, 0.01 % (v/v) Tween® 20, 0.2 mM 
each of dATP, dCTP, dGTP and dTTP, and also a precipitant and red dye for 
electrophoresis. Amplification reactions were performed in a 25 µl reaction 
volume which consisted of 22.5 µl master mix, 0.5 µM of each primer (forward 
and reverse), 0.5 – 125 ng of cDNA and PCR grade water. The PCR reactions were 
performed under the following conditions: 95 oC for 2 min, followed by 35 to 45 
cycles of 95 oC for 25 seconds, 48 - 63 oC (depending on primer annealing 
temperature) for 35 seconds and 72 oC for 65 seconds and finally 72 oC for 5 min. 
The primers and annealing temperatures used in this study are listed in Table 2-
5. 
PCR products were analysed using agarose gel electrophoresis. The agarose gel 
was prepared by adding 2 % agarose (w/v) (Invitrogen, UK) and 0.5 µg/ml 
ethidium bromide to 0.5 x Tris-Borate-EDTA buffer (Sigma-Aldrich®, UK) and 
heating gently before pouring into a pre-made cast and allowing to set . The 
ladder loading was prepared by mixing 1 µl of 100 base pair DNA Ladder (New 
England Biolabs, UK) with 1 µl 6 x Blue Loading Dye (New England Biolabs, UK) 
and 4 µl of distilled water. As most reactions were performed using ReddyMixTM 
PCR Master Mix, there was no requirement to add a loading dye. The samples 
and ladder were loaded onto the agarose gel which was then ran at 95 volts for 
45 min. Images of electrophoresis gels were captured under ultraviolet lighting 
using the Gel DocTM XR Imaging System (Bio-Rad Laboratories, UK) and Quantity 
One® Software, version 4.6.7 (Bio-Rad Laboratories, UK). 
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Gene 
 
Primer 
 
Forward (F) and Reverse (R) primer 5’ 3’ 
 
Ta (oC) 
 
bp 
 
     
IL-33 F TGTCAACAGCAGTCTACTGTGG 63 158 
 R GCAAAAGTAATGGATTGATCATTGTATGTGCT    
ST2 (total) F TAGTGTGACGGCGACCAGG 60 151 
 R GCCTTTTCCAAAACAAGCAG   
IL-17A F GGAATCTCCACCGCAATGAG 60 201 
 R ACACCAGTATCTTCTCCAGCC   
IL-17B F CTGGGGCTACAGCATCAACC 60 231 
 R GTGCAGCCCACAGCGATGGT    
IL-17C F CCGTTCAGTGTGACCGCCGA 60 339 
 R GTTGGGAAGAGGCAGCCTGC   
IL-17D F GCCAAAGAGATAGGGACGCA 60 288 
 R TTCATCAGTCAGCCATCGGT   
IL-17E F CCAGGTGGTTGCATTCTTGG 62 78 
 R TGGCTGTAGGTGTGGGTTCC   
IL-17F F TGAAGCTTGACATTGGCATC 60 174 
 R TTCCTTGAGCATTGATGCAG   
IL-17RA F GTCATCCTGCTCATCGTCTG 60 74 
 R TTGGTGTCATCACTGTATTTTTCAC   
IL-17RB F CCATCCCTCCAGATGACAAC 60 168 
 R TGCTCCTTCCTTGCCTCCAAGTTA   
IL-17RC F ACCAGAACCTCTGGCAAGC 60 232 
 R GAGCTGTTCACCTGAACACA   
IL-17RD F AAGTCAGGCCGGTCCCTATAC  60 66 
 R GTCGGGCTCCTCGTCAATAA   
IL-17RE F GCTGGAAGCTGCCCTCTGCC 60 74 
 R CTCGAGCTGTGGCATTCGGG   
Table 2-5: Primers used in basic PCR 
All PCR primers were obtained from Invitrogen, UK. Ta = annealing temperature; 
and bp = base pair. 
 
2.8.5 Taqman® real-time PCR 
Taqman® real-time PCR was carried out using 2 x TaqMan® Gene Expression 
Master Mix (Applied Biosystems®, UK), and most of the primers and fluorescent 
probe assays were obtained from Applied Biosystems®, UK (Table 2-6). The 20 x 
TaqMan® Gene Expression Assay master mix contains 5 µM TaqMan® MGB (minor 
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groove binder) probes and 18 µM of each forward and reverse primer. The 20 µl 
real-time PCR reactions were prepared in a 96-well plate format, and each 
reaction contained 10 µl of master mix, 1 µl of gene expression assay mix, 7 µl of 
RNase-free water and 2 µl of cDNA (1 to 100 ng is recommended for each 20 μl). 
The plate was briefly centrifuged to remove any air bubbles. Gene amplification 
steps were carried out using a MX3000PTM real-time PCR instrument 
(Stratagene®, UK). Running conditions were as follows: 50 oC for 2 min, 95 oC for 
10 min, and 40 cycles of 95 oC for 15 seconds and 60 oC for 1 min. The data was 
analysed using MxPro-Mx3000P software, version 4.10 (Stratagene®, UK). 
Real-time PCR data for the periodontal tissue study was analysed using the 2-CT 
method (Schmittgen & Livak, 2008), whereas real-time PCR data for cell culture 
studies was analysed using the 2-CT method (Livak & Schmittgen, 2001). 
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Gene 
 
Species 
 
Primers and fluorescent probes 
(Assay ID / primer sequence) 
Supplier 
 
 
IL-33 
 
Human 
 
Hs00369211_m1 
 
AB 
 
ST2 (total) 
 
Human 
 
Hs00545033_m1 AB 
 
IL-1RA 
 
Human 
 
Hs00174099_m1 AB 
 
IL-10 
 
Human 
 
Hs00961622_m1 AB 
 
G-CSF 
 
Human 
 
Hs00236884_m1 AB 
 
IL-17A 
 
Human 
 
Hs00174383_m1 AB 
 
IL-17B 
 
Human 
 
Hs00975262_m1 AB 
 
IL-17C 
 
Human 
 
Hs00171163_m1 AB 
 
IL-17D 
 
Human 
 
Hs00370528_m1 AB 
 
IL-17E 
 
Human 
 
Hs00224471_m1 AB 
 
IL-17F 
 
Human 
 
Hs00369400_m1 AB 
 
IL-17RA 
 
Human 
 
Hs01064648_m1 AB 
 
IL-17RB 
 
Human 
 
Hs00218889_m1 AB 
 
POLR2A 
 
Human 
 
Hs00172187_m1 AB 
 
ST2L 
 
Human 
 
Forward: 5’-GCACTTTGTTCACCAGATTCT-3’ 
Reverse:  5’-CCAGGTAGCATATCTCTCCCA-3’ 
 
PD 
sST2  
Human 
 
Forward:  5’-TTGTTTGCTGTCTGATCTTTGTAG-3’ 
Reverse:   5’-ACCAACGATAGGAGGGAGTG-3’ 
 
PD 
Table 2-6: Primer and fluorescent probes used in Taqman® real-time PCR 
POLR2A = RNA polymerase II; AB = Applied Biosystems®, UK; and PD = 
Primerdesign Ltd, UK. 
 
2.8.6 SYBR® Green real-time PCR 
SYBR® Green real-time PCR was carried out using a ready to use 2 x 
concentration of SYBR® GreenERTM PCR master mix (Invitrogen, UK). The master 
mix contains hot-start Taq DNA polymerase, SYBR® GreenERTM fluorescent dye, 
MgCl2, dNTPs (with dUTP instead of dTTP), UDG, and stabilizers. The forward 
and reverse primers were used at final concentration of 200 nM (Table 2-7). The 
25 µl real-time PCR reactions were prepared in a 96-well plate format and each 
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reaction contained 12.5 µl of master mix, 0.5 µl of each forward and reverse 
primer, and up to 5 µl cDNA template (cDNA was generated from up to 1 μg of 
total RNA and used at a maximum of 10 % (v/v) of the real-time PCR reaction 
volume). The RNase free water was used to complete the 25 µl reaction volume. 
The 96-well plate was briefly centrifuged to remove any air bubbles. 
Amplification of target gene sequence was carried out using a MX3000PTM real-
time PCR instrument (Stratagene®, UK). Running conditions were as follows: 50 
oC for 2 min, 95 oC for 10 min, followed by 40 cycles of 95 oC for 15 seconds and 
60 oC for 1 min. For melt curve analysis, all products generated during the PCR 
amplification reaction are melted at 95 oC for 60 seconds and then annealed by 
gradual increases in temperature every 30 seconds from 55 oC to 95 oC. The data 
was analysed using MxPro-Mx3000P software, version 4.10 (Stratagene®, UK). 
Real-time PCR data for the periodontal tissue study was analysed using the 2-CT 
method (Schmittgen & Livak, 2008), whereas real-time PCR data for cell culture 
studies was analysed using the 2-CT method (Livak & Schmittgen, 2001).  
 
Gene Species Primer  (5’ 3’) Supplier 
    
MMP-2 Human Forward: TGATCTTGACCAGAATACCATCGA 
Reverse: GGCTTGCGAGGGAAGAAGTT 
Invitrogen, 
UK 
MMP-9 Human Forward: CCCTGGAGACCTGAGAACCA 
Reverse: CCCGAGTGTAACCATAGCGG 
Invitrogen, 
UK 
CXCL5 Human Forward: CCCTGGGTTCAGAGACCTCCA 
Reverse: CCAGAAAATTTTGGACGGTGGAAACA 
Invitrogen, 
UK 
IL-8 Human Forward: CAGAGACAGGAGAGCACACAA 
Reverse: TTAGCACTCCTTGGCAAAAC 
Invitrogen, 
UK 
TLR-2 Human Forward: TGCTTTCCTGCTGGAGATTT 
Reverse: TGTAACGCAACAGCTTCAGG 
Invitrogen, 
UK 
TLR-4 Human Forward: TTCAAGACCAAGCCTTTCAG 
Reverse: CATAGTCCT TCCATGATAGA  
Invitrogen, 
UK 
GAPDH Human Forward: CAAGGCTGAGAACGGGAAG 
Reverse: GGTGGTGAAGACGCCAGT 
Invitrogen, 
UK 
Table 2-7: Primers used in SYBR® Green real-time PCR 
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2.9 Statistical analysis 
In the case of comparing more than two categorical data (e.g., gender), 
statistical analysis was carried out using the Chi-square test. 
As for numerical data, Q-Q plot analysis was carried out to check normality of 
distribution. In certain circumstances, natural log transformation was used to 
facilitate representation of normally distributed data. On the other hand, for 
proportional data (e.g., %s), the data was first angular transformed prior to 
analysis for normal distribution. 
When comparing two numerical variables, statistical analysis for the normally 
distributed data was carried out using the independent t-test. However, when 
comparing more than two numerical variables, statistical analysis for the 
normally distributed data was analysed using the ANOVA with a Bonferroni 
correction. Whereas, when data were not normally distributed, statistical 
analysis for comparing two numerical variables was carried out using the Mann-
Whitney test; and a Bonferroni correction was carried out if more than two 
variables were compared. 
When measuring correlations between two variables, data were first analysed 
for the bivariate distribution. Natural log transformations of the data were used 
to facilitate representation of linear and normally distributed data. When data 
were linear and normally distributed, the statistical analysis was carried out 
using the Pearson correlation coefficient test. Whenever necessary, adjustment 
for possible confounding factors was carried out using the Partial correlation 
test. 
The significance level for all statistical analyses were set at p = 0.05. All 
statistical analyses were carried out using SPSS (Version 18). 
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Chapter 3: IL-33 and periodontal disease 
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3.1 Introduction 
Depending on the disease model, IL-33 has been shown to have both 
exacerbatory and protective roles. IL-33 is known to aggravate inflammation in 
many chronic inflammatory conditions such as rheumatoid arthritis and allergy 
(Beltran, et al., 2010; Louten, et al., 2011; Xu, et al., 2008). However, in 
conditions such as atherosclerosis and Type 2 diabetes it has been shown to have 
a protective role and can promote the resolution of potentially damaging 
inflammatory responses (Miller, 2011). To date the role of IL-33 in chronic 
periodontitis is not known. IL-33 levels in plasma, GCF and saliva were found not 
to differentiate between healthy and diseased individuals (Buduneli, et al., 
2012). However, there are studies which implicate this cytokine in pathogenesis 
of the disease. LPS derived from the periodontal pathogen (P. gingivalis) has 
been shown to induce increased expression of IL-33 by human monocytes (Nile, 
et al., 2010). In addition, TNF-α induces IL-33 expression in human gingival 
fibroblasts (Beklen & Tsaous Memet, 2014).  
At present, the expression of IL-33 and its regulation has yet to be investigated 
in oral keratinocytes. Oral keratinocytes are known to express an array of TLRs 
and release a variety of inflammatory mediators in response to stimuli, and in 
vivo occupy the space adjacent to the dental biofilm on the tooth surface. Due 
to their proximity, oral keratinocytes will therefore be one of the first cells to 
encounter periodontal pathogens and co-ordinate host defence mechanisms 
accordingly. It is therefore interesting to speculate that oral keratinocytes 
express IL-33 and that expression is upregulated in response to periodontal 
pathogens. Epithelial cells (intestinal, bronchial and corneal) have been shown 
to express IL-33 (Beltran, et al., 2010; Schmitz, et al., 2005). Indeed, signalling 
through TLR-3 and TLR-5 induces increased IL-33 expression in human corneal 
epithelial cells (Zhang, et al., 2011a). Likewise, TLR-4 signalling in bronchial 
epithelial cells and TLR-9 signalling in sinonasal epithelial cells has also been 
found to induce the expression of IL-33 (Reh et al., 2010; Willart et al., 2012).  
Despite studies reporting increased expression of IL-33 by a variety of cells in 
response to bacteria, the mechanisms which promote its extracellular release 
are still a matter of debate. However, a variety of studies have demonstrated 
that epithelial cells express the ST2 receptor and can respond to IL-33 signalling. 
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Indeed, IL-33 has been shown to induce increased release a variety of cytokines 
and chemokines from bronchial epithelial cells, nasal epithelial cells and 
epidermal keratinocytes (Balato, et al., 2012; Fujita, et al., 2012; Kamekura, et 
al., 2012; Meephansan, et al., 2012; Yagami, et al., 2010). However, whether 
oral keratinocytes express the ST2 receptor and can respond to IL-33 signalling is 
to date unknown. 
The aim of this study was to investigate the role of IL-33 in periodontal disease 
pathogenesis in further detail. Firstly, to determine associations between levels 
of IL-33 in biological fluids and clinical parameters of periodontal disease. 
Secondly, using in vitro model systems, to determine the role IL-33 plays in the 
oral epithelial immune response to periodontal pathogens. Based on the previous 
literature it was hypothesised that: 
1. IL-33 levels in serum, GCF and saliva in periodontal tissue cannot be 
correlated with periodontal disease. 
2. IL-33 and its receptors are expressed by periodontal epithelial cells and its 
expression is modulated by the periodontal pathogen; P. gingivalis. 
3. Periodontal epithelial cells express the membrane bound form of the IL-33 
receptor (ST2L) and can respond to IL-33 signalling by initiating the 
expression of inflammatory mediators 
In order to investigate these hypotheses; the specific aims of the study were as 
follows: 
1. To evaluate IL-33 levels in serum, GCF and saliva of chronic periodontitis 
patients and healthy subjects. This was to be achieved using samples 
collected as part of previous studies at Glasgow University Dental School 
(Lappin, et al., 2009; Pathiyal, et al., 2005) and Newcastle University School 
of Dental Sciences (Davies, et al., 2011; Jaedicke, et al., 2012; Preshaw & 
Heasman, 2002) 
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2. To evaluate the expression of IL-33 and its receptors (ST2L and sST2) in 
periodontal tissue samples from chronic periodontitis patients and healthy 
subjects. 
3. To evaluate the expression of IL-33 and its receptors (ST2L and sST2) in 
OKF6/TERT-2 cells and PHGE cells using an in vitro live P. gingivalis 
monospecies biofilm model. 
4. To evaluate the effect of rhIL-33 on the expression of inflammatory 
mediators by OKF6/TERT-2 cells in vitro. 
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3.2 Results 
 
3.2.1 Analysis of IL-33 levels in clinical samples 
3.2.1.1 Clinical and demographic parameters of subject participants 
Serum, GCF and saliva samples from 77 healthy subjects and 97 chronic 
periodontitis patients were used in this study. Samples were selected from 
independent studies conducted at Glasgow Dental Hospital and School and 
Newcastle School of Dental Sciences and were from subjects/patients that were 
systemically healthy non smokers. The sample collection and ethical approvals 
for the Glasgow sample cohort were as previously described (Lappin, et al., 
2009; Pathiyal, et al., 2005). The sample collection and ethical approvals for the 
Newcastle cohort are as previously described (Davies, et al., 2011; Jaedicke, et 
al., 2012; Preshaw & Heasman, 2002) 
Table 3-1 describes comparisons of demographic (gender and age) and clinical 
parameters between the healthy and chronic periodontitis cohort. There was no 
significant difference in the incidence of chronic periodontitis between males 
and females (p > 0.05). However, the median age of the chronic periodontitis 
patients was significantly higher than the healthy subjects (p < 0.001). In 
addition, as expected, all the clinical parameters measured were significantly 
higher in the chronic periodontitis patients in comparison to the healthy subjects 
(p < 0.001). 
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Healthy 
(n = 77) 
CP 
(n = 97) p value 
Gender Male, n (%) 43 (55.84) 39 (40.20) 
0.082a 
 Female, n (%) 34 (44.16) 58 (59.80) 
Age (years)  28 (27.00 – 49.00) 47.00 (42.00 – 53.00) <0.001b 
Clinical parameters    
 CPD (mm) 1.48 (1.21 – 1.69) 2.87 (2.69 – 3.27) <0.001b 
 CAL (mm) 1.40 (1.10 – 1.85) 3.33 (3.03 – 3.94) <0.001b 
 BOP (%) 2.70 (0.00 – 9.00) 36.00 (25.00 – 48.80) <0.001b 
Table 3-1: Patient demographics and clinical periodontal measurements of study 
groups 
The demographic variable of gender was presented as number of subjects (n) 
and percentage (%); and the demographic variable of age and clinical 
parameters were presented as medians (interquartile range). Statistical analyses 
were carried out using the Chi-square test (a) and the Mann-Whitney test with a 
Bonferroni correction (b) (IBM SPSS Statistics, version 19). The significance level 
was set at p = 0.05. CP = chronic periodontitis, n = number of subjects, CPD = 
clinical probing depth, CAL = clinical attachment loss and BOP = bleeding on 
probing. 
 
3.2.1.2 Serum, gingival crevicular fluid and saliva levels of IL-33  
Serum, GCF and saliva levels of IL-33 were measured by a commercially available 
ELISA (Life Science, UK). Table 3-2 shows levels of IL-33 were below the 
detection limit of the assay in serum, GCF and saliva samples of healthy subjects 
and chronic periodontitis patients (Limit of sensitivity = 15.5 pg/ml; determined 
as two mean standard deviations higher than the mean baseline from 6 replicate 
standard curves (Chaloner-Larsson, et al., 1997)). 
 
  
 
Status 
 
 
n 
 
Median  
(pg/ml) 
 
 
IQR 
 
 
Z statistic 
 
 
p value 
Serum IL-33 Healthy 17 1.90 1.30 – 2.25 
-0.466 0.641 
 CP 23 1.40 1.00 – 2.60 
GCF IL-33 Healthy 17 0.00 - 
- - 
 CP 23 0.00 - 
Saliva IL-33 Healthy 7 0.00 - 
- - 
 CP 23 0.00 - 
Table 3-2: Levels of IL-33 in serum, gingival crevicular fluid and saliva  
IL-33 was measured in biological samples using the human IL-33 Elisa Kit (Life 
Science, UK). The table represents median levels of IL-33 in serum, GCF and 
saliva samples of the healthy and chronic periodontitis (CP) cohort. Statistical 
analyses were carried out using the Mann-Whitney test (IBM SPSS Statistics, 
version 19). Significance level was set at p = 0.05. n = number of subjects. 
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3.2.1.3 Expression of IL-33 mRNA in periodontal tissues 
The failure to detect any IL-33 in serum, GCF or saliva was hypothesised to be 
due to the ELISA used in this study. Therefore expression of IL-33 mRNA in 
periodontal tissues was investigated; firstly by basic PCR and then quantitatively 
by real-time PCR. 
Periodontal tissue samples were obtained from 27 subjects. Healthy tissue 
samples were taken from 10 patients undergoing non-periodontitis related 
procedures such as crown lengthening and tooth extraction. Seventeen tissue 
samples were taken from patients suffering from chronic periodontitis, who 
required surgical periodontal therapy as part of their periodontal treatment 
regime. Patients undergoing surgical periodontal therapy had clinical probing 
depths of ≥ 5.0 mm, with clinical attachment loss of ≥ 5.0 mm, which persisted 
after non-surgical treatment.  
Figure 3-1 shows that mRNA for IL-33 was detected in periodontal tissue samples 
from 3 healthy individuals and 3 chronic periodontitis patients. 
 
                                                
Figure 3-1: IL-33 mRNA expression in healthy and diseased periodontal tissue  
Expression of IL-33 mRNA in periodontal tissues was investigated by basic PCR. 
IL-33 mRNA is expressed in healthy (Lanes 1, 2 and 3) and diseased (Lanes 4, 5 
and 6) periodontal tissue samples. No-RT (reverse transcriptase) reactions and 
RNase free water (Lanes 7 and 8 respectively) were used as controls. The 100 
base pair DNA ladder was used as reference. The expected band size for IL-33 
was 158 base pairs (bp).    
 
Real-time PCR was employed to quantitate levels of IL-33 mRNA in healthy and 
diseased periodontal tissue. Figure 3-2 shows that IL-33 mRNA was significantly 
upregulated in diseased periodontal tissue samples when compared to healthy 
control tissues (p < 0.05). 
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Figure 3-2: Real-time PCR analysis of IL-33 mRNA expression in healthy and 
diseased periodontal tissues 
Quantification of IL-33 mRNA expression in periodontal tissues was performed by 
real-time PCR. RNA polymerase II was used as a reference gene. The box-and-
whiskers plot represents the median relative expression (2-CT) of IL-33 mRNA 
from tissues of healthy subjects and chronic periodontitis (CP) patients. 
Statistical analysis was carried out using the Mann-Whitney test (IBM SPSS 
Statistics, version 19). * = p < 0.05. Whiskers were determined by the Tukey 
method.   
 
3.2.1.4 Expression of IL-33 protein in periodontal tissues 
Since IL-33 mRNA was upregulated in diseased periodontal tissue (Figure 3-2), 
levels of IL-33 protein in periodontal tissue samples was evaluated using 
immunohistochemistry.   
IL-33 was found to be expressed in the epithelial layer (Figure 3-3) and 
connective tissue (Figure 3-4) of healthy periodontal tissue and visually 
expression seemed to be elevated in tissue of chronic periodontitis patients. IL-
33 expression in periodontal tissue samples was quantified by calculating the 
number of IL-33 positive cells in the epithelial and connective tissue layers 
(Bologna-Molina, et al., 2011). Elevated expression was confirmed as the 
percentage of IL-33 positive cells was significantly higher in the epithelial and 
connective tissue layers of diseased periodontal tissue in comparison to healthy 
periodontal tissue (Figure 3-5).       
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Figure 3-3: IL-33 expression in the epithelial layer of healthy and diseased periodontal tissue  
Expression of IL-33 in periodontal tissues was determined by immunohistochemical analysis using a mouse monoclonal anti-IL-33 
antibody (Nessy -1, Enzo® Life Science, UK). The panels show representative photomicrographs of 5 μm-thick paraffin-embedded 
sections of periodontal tissue specimens obtained from healthy subjects (A - F) and chronic periodontitis patients (G - L). An isotype 
control antibody was used to estimate non-specific binding. Tonsil tissue specimens were stained for IL-33 as a positive control (M-N). 
Original magnification x 400. 
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Figure 3-4: IL-33 expression in the connective tissue of healthy and diseased periodontal tissue  
Expression of IL-33 in periodontal tissues was determined by immunohistochemical analysis using a mouse monoclonal anti-IL-33 
antibody (Nessy -1, Enzo® Life Science, UK). The panels show representative photomicrographs of 5 μm-thick paraffin-embedded 
sections of periodontal tissue specimens obtained from healthy subjects (A - F) and chronic periodontitis patients (G - L). An isotype 
control antibody was used to estimate non-specific binding. Original magnification x 400.         
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Figure 3-5: Percentage of IL-33 positive cells in the epithelial layer and 
connective tissue of healthy and diseased periodontal tissues 
The % of IL-33 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of IL-33 positive cells in the epithelial layer (epithelium) and 
connective tissue (CT) of healthy and chronic periodontitis (CP) tissue. Data was 
derived from 5 micrographs depicting different fields from 3 different tissue 
samples. Prior to statistical analyses the % data was angular transformed. 
Statistical analysis was carried out using the independent t-test (IBM SPSS 
Statistics, version 19). * = p < 0.05. Error bars indicate the standard error of the 
mean (SEM).   
 
3.2.1.5 Expression of ST2 mRNA in periodontal tissues 
The expression of the IL-33 receptor (ST2) in periodontal tissue was first 
investigated by basic PCR and then quantitatively by real-time PCR. 
Figure 3-6 shows that mRNA for ST2 was detected in periodontal tissue samples 
from 3 healthy subjects and 3 chronic periodontitis patients.  
 
                                           
Figure 3-6: ST2 mRNA expression in healthy and diseased periodontal tissue.  
Expression of ST2 mRNA in periodontal tissues was investigated by basic PCR. ST2 
mRNA is expressed in healthy (Lanes 1, 2 and 3) and diseased (Lanes 4, 5 and 6) 
periodontal tissue samples. No-RT (reverse transcriptase) reactions and RNase 
free water (Lanes 7 and 8 respectively) were used as controls. The 100 base pair 
DNA ladder was used as reference. The expected band size for ST2 was 151 base 
pairs (bp). 
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Real-time PCR was employed to quantitate levels of ST2 mRNA in healthy and 
diseased periodontal tissue. Figure 3-7 shows that there was statistically 
significant increase in ST2 mRNA levels in diseased periodontal tissue samples 
compared to healthy control (p < 0.05). 
 
                  
Figure 3-7: Real-time PCR analysis of ST2 mRNA expression in healthy and 
diseased periodontal tissues 
Quantification of ST2 mRNA expression in periodontal tissues was performed by 
real-time PCR. RNA polymerase II was used as a reference gene. The box-and-
whiskers plot represents the median relative expression (2-CT) of ST2 mRNA from 
tissues of healthy subjects and chronic periodontitis (CP) patients. Statistical 
analyses were carried out using the Mann-Whitney test (IBM SPSS Statistics, 
version 19). * = p < 0.05. Whiskers were determined by the Tukey method and a 
value of 1.5 x IQR (interquartile range) was set as a demarcation line for outliers 
(·) 
 
Although the data showed that ST2 was expressed in periodontal tissues the 
primer/probe sets used in the PCR analysis could not differentiate between 
mRNA encoding the membrane bound IL-33 receptor (ST2L) and the soluble 
decoy receptor (sST2). Therefore, the study was repeated using custom designed 
primer/probe sets for real-time PCR to specifically quantify levels of ST2L and 
sST2 mRNA in healthy and diseased periodontal tissue. Figure 3-8 shows that 
mRNA for sST2, not ST2L was significantly upregulated in diseased periodontal 
tissue samples when compared to healthy control tissues (p < 0.05). 
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Figure 3-8: Real-time PCR analysis of ST2L and sST2 mRNA expression in healthy 
and diseased periodontal tissues 
Quantification of ST2L and sST2 mRNA expression in periodontal tissues was 
performed by real-time PCR. RNA polymerase II was used as a reference gene. 
The box-and-whiskers plot represents the median relative expression (2-CT) of 
ST2L and sST2 mRNA from tissues of healthy subjects and chronic periodontitis 
(CP) patients. Statistical analyses were carried out using the Mann-Whitney test 
with a Bonferroni correction (IBM SPSS Statistics, version 19). * = p < 0.05. 
Whiskers were determined by the Tukey method and a value of 1.5 x IQR 
(interquartile range) was set as a demarcation line for outliers (∙). 
  
3.2.1.6 Expression of ST2 protein in periodontal tissues 
Since ST2 mRNA was upregulated in diseased periodontal tissue (Figure 3-7), 
levels of ST2 protein in periodontal tissue samples were evaluated using 
immunohistochemistry. At present, no antibodies are commercially available 
which can distinguish between the two different ST2 isoforms, therefore analysis 
of only total ST2 protein is reported.  
ST2 was found to be expressed in the epithelial layer (Figure 3-9) and connective 
tissue (Figure 3-10) of healthy periodontal tissue. However no elevated 
expression in diseased periodontal tissue could be observed. In addition, when 
the number of ST2 positive cells in the epithelial layer and connective tissue 
were quantified no significant difference between healthy and diseased 
periodontal tissue was determined (Figure 3-11).      
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Figure 3-9: ST2 expression in the epithelial layer of healthy and diseased periodontal tissue  
Expression of ST2 in periodontal tissues was determined by immunohistochemical analysis using a rabbit anti-IL1RL1 antibody (Sigma-
Aldrich®, UK).  The panels show representative photomicrographs of 5 μm-thick paraffin-embedded sections of periodontal tissue 
specimens obtained from healthy subjects (A - D) and chronic periodontitis patients (E - J). An isotype control antibody was used to 
estimate non-specific binding. Tonsil tissue specimens were stained for ST2 as a positive control (K-L). Original magnification x 400.  
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Figure 3-10: ST2 expression in the connective tissue of healthy and diseased periodontal tissue  
Expression of ST2 in periodontal tissues was determined by immunohistochemical analysis using a rabbit anti-IL1RL1 antibody (Sigma-
Aldrich®, UK).  The panels show representative photomicrographs of 5 μm-thick paraffin-embedded sections of periodontal tissue 
specimens obtained from healthy subjects (A - D) and chronic periodontitis patients (E - J). An isotype control antibody was used to 
estimate non-specific binding. Original magnification x 400.         
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Figure 3-11: Percentage of ST2 positive cells in the epithelial layer and 
connective tissue of healthy and diseased periodontal tissues 
The % of ST2 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of ST2 positive cells in the epithelial layer (epithelium) and 
connective tissue (CT) of healthy and chronic periodontitis (CP) tissue. Data was 
derived from 5 micrographs depicting different fields from 3 different tissue 
samples. Prior to statistical analyses the % data was angular transformed. 
Statistical analysis was carried out using the independent t-test (IBM SPSS 
Statistics, version 19). NS = not significant (p > 0.05). Error bars indicate the 
standard error of the mean (SEM). 
 
3.2.2 Expression of IL-33 by oral epithelial cells in response to 
Porphyromonas gingivalis 
3.2.2.1 Validation of the in vitro live Porphyromonas gingivalis 
monospecies biofilm model 
To investigate whether oral epithelial cells express IL-33 and if expression was 
modulated by the periodontal pathogen (P. gingivalis); a live biofilm model 
system was employed. This model had been previously developed by colleagues 
in our laboratory (Sherry, et al., 2013) and is designed to be more in vivo 
relevant. In this in vitro model, the live P. gingivalis monospecies biofilm is 
separated from the oral keratinocytes by a 0.5 mm space. This space represents 
the distance between dental biofilm and epithelial cells in the gingival sulcus. 
For this model system, a live P. gingivalis monospecies biofilm is cultured on 
ThermanoxTM coverslips (Nunc Nalgene, UK). These biofilms are made in batches 
and can be used immediately or stored at –70 oC long term for later use. 
However, before the biofilms were used in the investigations reported in this 
thesis, it was important to determine whether there was any batch to batch 
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variability in biofilms which may affect the results of further investigations. In 
addition, it was important to ensure that storage at -70 oC had no significant 
effects on biofilm viability.  
Figure 3-12 shows there were no significant differences in viability (CFU/ml) 
between batches of P. gingivalis monospecies biofilms cultured on ThermanoxTM 
coverslips before and after storage at –70 oC for 14 days.  
 
              
Figure 3-12: The effect of freezing on P. gingivalis monospecies biofilms 
Bars show colony forming unit (CFU)/ml of P. gingivalis recovered from 
monospecies biofilms. Initial inoculums = CFU/ml of P. gingivalis used to seed 
onto ThermanoxTM coverslips to prepare biofilms; before freezing = CFU/ml 
recovered from ThermanoxTM coverslips 4 days after seeding; and after freezing 
= CFU/ml recovered from ThermanoxTM coverslips after storage at –70 oC for 14 
days. The data was generated from duplicate wells of three independent 
experiments. Statistical analysis of the data was performed on the natural log 
transformed CFU/ml values using the ANOVA with a Bonferroni correction. * = p 
< 0.05; NS = not significant. Error bars indicate the standard error of the mean 
(SEM). 
 
In addition to determining CFUs, the viability of the biofilms was assessed 
visually using a simple Gram stain. Figure 3-13 shows representative images of 
biofilms from the 3 batches both before and after freezing. Visually, no 
differences in biofilm structure were observed. 
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Figure 3-13: Gram stained P. gingivalis monospecies biofilms before and after 
freezing  
Figure shows images of three batches of Gram stained P. gingivalis monospecies 
biofilms before and after freezing at –70 oC for 14 days. P. gingivalis 
monospecies biofilms appear pink-red in colour after staining. Each panel is a 
representative image from one of three independent experiments carried out in 
triplicate. Original magnification x 400. 
 
These data showed that there was no significant variability between batches of 
live P. gingivalis monospecies biofilms. In addition, there was no significant loss 
of viability when biofilms were frozen for long term storage and revived 24 h 
prior to use in the in vitro model system. 
 
3.2.2.2 IL-33 expression by OKF6/TERT-2 cells in response to 
Porphyromonas gingivalis 
Previously, immunohistochemical analysis revealed that IL-33 was expressed in 
the epithelial layer of periodontal tissues. Therefore we investigated whether 
oral keratinocytes express IL-33 and whether expression was modulated by the 
periodontal pathogen; P. gingivalis.      
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For the initial studies an oral keratinocyte cell line, OKF6/TERT-2, was used. 
OKF6/TERT-2 cells were cultured in vitro and exposed to a live P. gingivalis 
monospecies biofilms for 3, 6, 9 and 24 h as previously described (Section 2.6.1). 
Unstimulated cells acted as controls at each time point. To confirm the cells had 
been stimulated, the release of the chemokine IL-8 (CXCL8) into the bathing 
supernatant was measured by ELISA. Figure 3-14 shows that there was a 
significant increase in IL-8 release from OKF6/TERT-2 cells in response to P. 
gingivalis stimulation at all time points.           
 
       
Figure 3-14: Release of IL-8 (CXCL8) from OKF6/TERT-2 cells in response to a 
live P. gingivalis monospecies biofilm 
IL-8 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of IL-8 in unstimulated (Control) 
and a live P. gingivalis monospecies biofilm (Biofilm) stimulated OKF6/TERT-2 
cells at 3, 6, 9 and 24 h. The data was generated from duplicate wells of three 
independent experiments. Statistical analyses were carried out using the 
independent t-test (IBM SPSS Statistics, version 19) on the natural log 
transformed IL-8 levels (pg/ml). * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
Error bars indicate the standard error of the mean (SEM).  
 
Once stimulation of the cells had been confirmed, the expression of IL-33 mRNA 
was investigated by real-time PCR. Figure 3-15 shows that IL-33 mRNA was 
expressed by OKF6/TERT-2 cells and levels were significantly upregulated in 
response to P. gingivalis. 
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Figure 3-15: The effect of a live P. gingivalis monospecies biofilm on IL-33 
mRNA expression by OKF6/TERT-2 cells 
Quantification of IL-33 mRNA expression in OKF6/TERT-2 cells was performed by 
real-time PCR. The bars represent mean relative expression (2-CT) of IL-33 
mRNA in unstimulated (Control) and a live P. gingivalis monospecies biofilm 
(Biofilm) stimulated OKF6/TERT-2 cells at 3, 6, 9 and 24 h. RNA polymerase II 
was used as a reference gene. The data was generated from duplicate wells of 
three independent experiments. Statistical analyses were carried out using the 
independent t-test (IBM SPSS Statistics, version 19) on the natural log 
transformed IL-33 mRNA relative expression (2-CT) values. * = p < 0.05 and *** = 
p < 0.001. Error bars indicate the standard error of the mean (SEM). 
 
Having established that IL-33 mRNA expression is upregulated in response to 
stimulation with P. gingivalis, we next investigated whether IL-33 protein was 
released from stimulated OKF6/TERT-2 cells. Figure 3-16 shows that using a 
commercially available ELISA kit (Enzo® Life Science, USA) no IL-33 release was 
detected in the bathing supernatants of unstimulated or P. gingivalis 
monospecies biofilm stimulated OKF6/TERT-2 cells.  
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Figure 3-16: Release of IL-33 from OKF6/TERT-2 cells in response to a live P. 
gingivalis monospecies biofilm 
IL-33 release into bathing supernatants was measured by ELISA. No IL-33 was 
detected in any of the bathing supernatants analysed from unstimulated 
(Control) and live P. gingivalis monospecies biofilm (Biofilm) stimulated 
OKF6/TERT-2 cells at 3, 6, 9 and 24 h. The data was generated from duplicate 
wells of three independent experiments. 
 
In monocytes, IL-33 is not released from cells in response to P. gingivalis LPS. 
However, increased protein expression can be observed intracellularly (Nile, et 
al., 2010). To determine if similar responses occurred in OKF6/TERT-2 cells; 
immunocytochemical analysis was employed. OKF6/TERT-2 cells were cultured 
on glass coverslips in the presence and absence of a live P. gingivalis 
monospecies biofilm for 9 h. Prior to immunocytochemistry, stimulation was 
confirmed by measurement of IL-8 release (Figure 3-17).  
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Figure 3-17: Release of IL-8 (CXCL8) from OKF6/TERT-2 cells cultured on glass 
coverslips and stimulated with a live P. gingivalis monospecies biofilm for 9 h 
IL-8 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of IL-8 in unstimulated (Control) 
and a live P. gingivalis monospecies biofilm (Biofilm) stimulated OKF6/TERT-2 
cells at 9 h. The data was generated from duplicate wells of three independent 
experiments. Statistical analyses were carried out using the independent t-test 
(IBM SPSS Statistics, version 19) on the natural log transformed IL-8 levels 
(pg/ml). ** = p < 0.01. Error bars indicate the standard error of the mean (SEM)  
 
Once stimulation had been confirmed, immunohistochemistry analysis of fixed 
cells was conducted using a mouse monoclonal anti-IL-33 antibody (Nessy -1, 
Enzo® Life Science, UK). IL-33 was found to be expressed in OKF6/TERT-2 cells 
and an increase in intracellular expression could be observed after stimulation 
for 9 h with a live P. gingivalis monospecies biofilm (Figure 3-18). To confirm the 
specificity of the antibody, HUVECs (which are known to be positive for IL-33) 
were used as a positive control (Baekkevold, et al., 2003; Moussion, et al., 
2008). In addition, for negative control purposes, stimulated OKF6/TERT-2 cells 
were also exposed to a mouse monoclonal anti-IL-33 antibody (Nessy -1, Enzo® 
Life Science, UK) which had previously been pre-absorbed with an excess of rhIL-
33 (PeproTech®, UK) (Figure 3-18).  
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Figure 3-18: Intracellular IL-33 expression by OKF6/TERT-2 cells cultured on glass coverslips and stimulated with a P. gingivalis 
monospecies biofilm for 9 h 
Intracellular expression of IL-33 was determined using a mouse monoclonal anti-IL-33 antibody (Nessy-1, Enzo® Life Science, UK). The 
panels show representative photomicrographs of methanol fixed OKF6/TERT-2 cells on glass coverslips after 9 h incubation either with 
media only as a control (A, C and E) or a live P. gingivalis monospecies biofilm (B, D and F). An isotype control antibody was used to 
determine non-specific binding (G). Specificity of the IL-33 antibody was confirmed by pre-absorption of the mouse monoclonal anti-IL-
33 antibody with an excess of rhIL-33 (PeproTech®, UK) (H). HUVEC cells were also exposed to a mouse monoclonal anti-IL-33 antibody 
(Nessy-1, Enzo® Life Science, UK) (I) and an isotype control (J) to further confirm antibody specificity. Original magnification x 400.     
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The use of an isotype control, pre-absorption studies and a cell line known to 
express IL-33 confirmed the specificity of the mouse monoclonal anti-IL-33 
antibody (Nessy-1, Enzo® Life Science, UK). Therefore, to quantify increases in 
intracellular IL-33 expression the counting method described by Bologna-Molina 
and colleagues (2011) was employed. Figure 3-19 shows that the % of IL-33 
positive OKF6/TERT-2 cells was significantly higher after stimulation with a live 
P. gingivalis monospecies biofilm for 9 h.  
 
                     
Figure 3-19: Percentage of IL-33 positive OKF6/TERT-2 cells on glass coverslips 
after incubation with media alone or a live P. gingivalis monospecies biofilm for 
9 h 
The % of IL-33 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of IL-33 positive OKF6/TERT-2 cells after 9 h incubation with media 
alone (Control) or with a live P. gingivalis monospecies biofilm (Biofilm). Data 
was derived from 5 micrographs depicting different fields from 3 different 
coverslips. Prior to statistical analyses the % data was angular transformed. 
Statistical analysis was carried out using the independent t-test (IBM SPSS 
Statistics, version 19). * = p < 0.05. Error bars indicate the standard error of the 
mean (SEM).  
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3.2.2.3 ST2 expression by OKF6/TERT-2 cells in response to 
Porphyromonas gingivalis 
Previous data established that IL-33 expression by OKF6/TERT-2 cells is 
modulated by a live P. gingivalis monospecies biofilm. Therefore, the effect of a 
live P. gingivalis monospecies biofilm on expression of both sST2 and ST2L was 
also investigated.    
Real-time PCR analysis showed that levels of sST2 mRNA, but not ST2L mRNA 
were significantly upregulated in P. gingivalis monospecies biofilm stimulated 
OKF6/TERT-2 cells after 6, 9 and 24 h (Figure 3-20).  
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
Figure 3-20: The effect of a live P. gingivalis monospecies biofilm on sST2 and 
ST2L mRNA expression by OKF6/TERT-2 cells 
Quantification of ST2L (A) and sST2 (B) mRNA expression in OKF6/TERT-2 cells 
was performed by real-time PCR. The bars represent mean relative expression 
(2-CT) of ST2L and sST2 mRNA in unstimulated (Control) and a live P. gingivalis 
monospecies biofilm (Biofilm) stimulated OKF6/TERT-2 cells at 3, 6, 9 and 24 h. 
RNA polymerase II was used as a reference gene. The data was generated from 
duplicate wells of three independent experiments. Statistical analyses were 
carried out using the independent t-test (IBM SPSS Statistics, version 19) on the 
natural log transformed sST2 and ST2L mRNA relative expression (2-CT) values. 
** = p < 0.01; *** = p < 0.001.* = p < 0.05 and NS = not significant. Error bars 
indicate the standard error of the mean (SEM). 
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Having established that sST2 mRNA expression is upregulated in response to 
stimulation with P. gingivalis we next investigated whether sST2 protein was also 
released from stimulated OKF6/TERT-2 cells. Figure 3-21 shows that using a 
commercially available ELISA kit (Quantikine® ST2; R&D System, UK), sST2 
protein was detected at low levels in the cell supernatant and there was no 
difference in sST2 levels between P. gingivalis monospecies biofilm stimulated 
OKF6/TERT-2 cells and non stimulated controls at all the time points 
investigated.    
 
Figure 3-21: Release of sST2 from OKF6/TERT-2 cells in response to stimulation 
with a live P. gingivalis monospecies biofilm 
sST2 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of sST2 in unstimulated 
(Control) and a live P. gingivalis monospecies biofilm (Biofilm) stimulated 
OKF6/TERT-2 cells at 3, 9 and 24 h. The data was generated from duplicate 
wells of three independent experiments. Statistical analyses were carried out 
using the independent t-test (IBM SPSS Statistics, version 19) on the natural log 
transformed sST2 levels (pg/ml). NS = not significant (p > 0.05). Error bars 
indicate the standard error of the mean (SEM). 
 
The ELISA analysis revealed there was no significant change in sST2 levels in 
bathing supernatants from P. gingivalis stimulated OKF6/TERT-2 cells. We 
therefore used immunocytochemistry to confirm there was no change in 
intracellular or membrane bound (ST2L) levels under the same conditions. 
OKF6/TERT-2 cells were cultured on glass coverslips in the presence and absence 
of a live P. gingivalis monospecies biofilm for 9 h. Prior to 
immunocytochemistry, stimulation was again confirmed by measurement of IL-8 
release. As investigations were conducted alongside IL-33 immunocytochemistry 
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investigations, the data confirming that all cells cultured on coverslips were in 
fact stimulated by a live P. gingivalis monospecies biofilm is shown Figure 3-17. 
Immunocytochemistry investigations of ST2 expression were performed using a 
rabbit anti-IL1RL1 antibody (Sigma-Aldrich®, UK). This antibody was not specific 
for any of the ST2 isoforms (sST2 or ST2L) and stained only total ST2. Figure 3-22 
shows that ST2 was detected in/on the majority of OKF6/TERT-2 cells exposed 
to fresh media only (control) and a live P. gingivalis monospecies biofilm for 9 h. 
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Figure 3-22: ST2 expression by OKF6/TERT-2 cells cultured on glass coverslips 
and stimulated with a live P. gingivalis monospecies biofilm for 9 h 
Expression of ST2 protein was determined by immunocytochemical analysis using 
a rabbit anti-IL1RL1 antibody (Sigma-Aldrich®, UK). The panels show 
representative photomicrographs of methanol fixed OKF6/TERT-2 cells on glass 
coverslips after 9 h incubation either with media only as a control (A, C and E) 
or a live P. gingivalis monospecies biofilm (B, D and F). An isotype control 
antibody was used to determine non-specific binding (G). Original magnification 
x 400. 
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Despite the abundance of staining, the % of ST2 positive OKF6/TERT-2 cells was 
still quantified by the counting method described by Bologna-Molina and 
colleagues (2011). Figure 3-23 shows that, as expected, there was no significant 
difference in the % of ST2 positive cells after stimulation with a live P. gingivalis 
monospecies biofilm for 9 h.  
 
                       
Figure 3-23: Percentage of ST2 positive OKF6/TERT-2 cells on glass coverslips 
after incubation with media alone or a live P. gingivalis monospecies biofilm for 
9 h 
The % of ST2 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of ST2 positive OKF6/TERT-2 cells after 9 h incubation with media 
alone (Control) or with a live P. gingivalis monospecies biofilm (Biofilm). Data 
was derived from 5 micrographs depicting different fields from 3 different 
coverslips. Prior to statistical analyses the % data was angular transformed. 
Statistical analysis was carried out using the independent t-test (IBM SPSS 
Statistics, version 19). * = p < 0.05. Error bars indicate the standard error of the 
mean (SEM).     
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3.2.2.4 IL-33 expression by primary human gingival epithelial cells in 
response to Porphyromonas gingivalis 
Previously the data demonstrated that IL-33 is expressed by the OKF6/TERT-2 
oral keratinocyte cell line and expression was upregulated in response to a live 
P. gingivalis monospecies biofilm. However, in order to determine the in vivo 
relevance of these findings, the studies were repeated using primary human 
gingival epithelial (PHGE) cells (CELLnTEC advanced cell systems, Switzerland). 
PHGE cells were cultured in vitro and exposed to a live P. gingivalis monospecies 
biofilm for 3, 9 and 24 h as previously described (Section 2.6.1). Unstimulated 
cells acted as controls at each time point. Stimulation was once again confirmed 
by measurement of IL-8 release into bathing supernatants. Figure 3-24 shows 
that there was a significant increase in IL-8 release from PHGE cells in response 
to P. gingivalis stimulation at all time points.  
 
     
Figure 3-24: Release of IL-8 (CXCL8) from primary human gingival epithelial 
cells in response to a live P. gingivalis monospecies biofilm 
IL-8 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of IL-8 in unstimulated (Control) 
and a live P. gingivalis monospecies biofilm (Biofilm) stimulated PHGE cells at 3, 
9 and 24 h. The data was generated from duplicate wells of three independent 
experiments. Statistical analyses were carried out using the independent t-test 
(IBM SPSS Statistics, version 19) on the natural log transformed IL-8 levels 
(pg/ml). * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. Error bars indicate the 
standard error of the mean (SEM). 
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Once stimulation of the PHGE cells had been confirmed, real-time PCR was 
employed to quantitate levels of IL-33 mRNA. Figure 3-25 shows that levels of IL-
33 mRNA were significantly upregulated in P. gingivalis stimulated PHGE cells 
after 9 h stimulation. However, expression returned to basal levels after 24 h 
stimulation. 
 
                  
Figure 3-25: Effect of a live P. gingivalis monospecies biofilm on IL-33 mRNA 
expression by primary human gingival epithelial cells 
Quantification of IL-33 mRNA expression in PHGE cells was performed by real-
time PCR. The bars represent mean relative expression (2-CT) of IL-33 mRNA in 
non stimulated (Control) and a live P. gingivalis monospecies biofilm (Biofilm) 
stimulated PHGE cells at 3, 9 and 24 h. RNA polymerase II was used as a 
reference gene. The data was generated from duplicate wells of three 
independent experiments. Statistical analyses were carried out using the 
independent t-test (IBM SPSS Statistics, version 19) on the natural log 
transformed IL-33 mRNA relative expression (2-CT) values. * = p < 0.05 and Ns= 
not significant. Error bars indicate the standard error of the mean (SEM).  
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Having established that IL-33 mRNA expression is upregulated in PHGE cells in 
response to stimulation with P. gingivalis; we next investigated whether IL-33 
protein was released from stimulated cells. Figure 3-26 shows that using a 
commercially available ELISA kit (Enzo® Life Science, USA) no IL-33 release was 
detected in the bathing supernatants of unstimulated or P. gingivalis 
monospecies biofilm stimulated PHGE cells. 
 
                  
Figure 3-26: Release of IL-33 from primary human gingival epithelial cells in 
response to a live P. gingivalis monospecies biofilm 
IL-33 release into bathing supernatants was measured by ELISA. No IL-33 was 
detected in any of the bathing supernatants analysed in unstimulated (Control) 
and a live P. gingivalis monospecies biofilm (Biofilm) stimulated PHGE cells at 3, 
9 and 24 h. The data was generated from duplicate wells of three independent 
experiments. 
 
The ELISA failed to demonstrate the release of IL-33 from P. gingivalis 
stimulated PHGE cells. Therefore, immunocytochemistry analysis was employed 
to detect intracellular levels of IL-33. PHGE cells were cultured on glass 
coverslips in the presence and absence of a live P. gingivalis monospecies 
biofilm for 9 h. Prior to immunocytochemistry, stimulation was confirmed by 
measurement of IL-8 release (Figure 3-27). 
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Figure 3-27: Release of IL-8 (CXCL8) from primary human gingival epithelial 
cells cultured on glass coverslips and stimulated with a P. gingivalis monospecies 
biofilm for 9 h 
IL-8 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of IL-8 in unstimulated (Control) 
and a live P. gingivalis monospecies biofilm (Biofilm) stimulated at 9 h. The data 
was generated from duplicate wells of three independent experiments. 
Statistical analyses were carried out using the independent t-test (IBM SPSS 
Statistics, version 19) on the natural log transformed IL-8 levels (pg/ml). ** = p < 
0.01. Error bars indicate the standard error of the mean (SEM).  
 
Once stimulation had been confirmed, immunocytochemistry analysis of fixed 
cells was conducted using a mouse monoclonal anti-IL-33 antibody (Nessy-1, 
Enzo® Life Science, UK). The specificity of this antibody had been determined 
previously (Figure 3-18). IL-33 was found to be expressed in PHGE cells and an 
increase in intracellular expression could be observed after stimulation for 9 h 
with a live P. gingivalis monospecies biofilm (Figure 3-28).  
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Figure 3-28: Intracellular IL-33 expression by primary human gingival epithelial 
cells cultured on glass coverslips and stimulated with a live P. gingivalis 
monospecies biofilm for 9 h 
Intracellular expression of IL-33 was determined using a mouse monoclonal anti-
IL-33 antibody (Nessy-1, Enzo® Life Science, UK). The panels show representative 
photomicrographs of methanol fixed PHGE cells on glass coverslips after 9 h 
incubation either with media only as a control (A, C and E) or a live P. gingivalis 
monospecies biofilm (B, D and F). An isotype control antibody was used to 
determine non-specific binding (G). Original magnification x 400. 
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To quantify increases in intracellular IL-33 expression, the counting method 
described by Bologna-Molina et al  (2011) was employed. Figure 3-29 shows that 
the % of IL-33 positive PHGE cells was significantly higher after stimulation with 
a live P. gingivalis monospecies biofilm for 9 h.  
 
 
Figure 3-29: Percentage of IL-33 positive primary human gingival epithelial cells 
on glass coverslips after incubation with media alone or a live P. gingivalis 
monospecies biofilm for 9 h 
The % of IL-33 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of IL-33 positive PHGE cells after 9 h incubation with media alone 
(Control) or with a live P. gingivalis monospecies biofilm (Biofilm). Data was 
derived from 5 micrographs depicting different fields from 3 different coverslips. 
Prior to statistical analyses the % data was angular transformed. Statistical 
analysis was carried out using the independent t-test (IBM SPSS Statistics, version 
19). * = p < 0.05. Error bars indicate the standard error of the mean (SEM).  
 
3.2.2.5 ST2 expression by primary human gingival epithelial cell in 
response to Porphyromonas gingivalis 
Having established that IL-33 is expressed by PHGE cells; and demonstrating that 
its expression is upregulated in response to a live P. gingivalis monospecies 
biofilm; it was logical to also investigate whether there were similar effects on 
ST2 expression.  
Real-time PCR was employed to quantitate levels of ST2L and sST2 mRNA in non 
stimulated and P. gingivalis monospecies biofilm stimulated PHGE cells. Figure 
3-30 shows that neither sST2 nor ST2L mRNA was significantly upregulated by 
PHGE cells after P. gingivalis monospecies biofilm stimulation.  
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Figure 3-30: Effect of a live P. gingivalis monospecies biofilm on sST2 and ST2L 
mRNA expression by primary human gingival epithelial cells 
Quantification of ST2L (A) and sST2 (B) mRNA expression in PHGE cells was 
performed by real-time PCR. The bars represent mean relative expression (2-
CT) of ST2L and sST2 mRNA in non stimulated (Control) and a live P. gingivalis 
monospecies biofilm (Biofilm) stimulated PHGE cells at 3, 9 and 24 h. RNA 
polymerase II was used as a reference gene. The data was generated from 
duplicate wells of three independent experiments. Statistical analyses were 
carried out using the independent t-test (IBM SPSS Statistics, version 19) on the 
natural log transformed sST2 and ST2L mRNA relative expression (2-CT) values. 
NS = not significant (p > 0.05). Error bars indicate the standard error of the 
mean (SEM). 
 
Having established that sST2 mRNA is expressed by PHGE cells but not regulated 
by a live P. gingivalis monospecies biofilm; we next confirmed this finding at the 
protein level by investigating the release of sST2 protein from these cells. Figure 
3-31 shows that using a commercially available ELISA kit (Quantikine® ST2; R&D 
System, UK) sST2 protein was detected at low levels in the cell supernatant and 
there was no difference in sST2 levels between P. gingivalis monospecies biofilm 
stimulated PHGE cells and unstimulated controls. 
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Figure 3-31: Release of sST2 from primary human gingival epithelial cells in 
response to stimulation with a live P. gingivalis monospecies biofilm 
sST2 release into bathing supernatants was measured by ELISA. The bars 
represent the mean supernatant concentrations of sST2 in unstimulated 
(Control) and a live P. gingivalis monospecies biofilm (Biofilm) stimulated PHGE 
cells at 3, 9 and 24 h. The data was generated from duplicate wells of three 
independent experiments. Statistical analyses were carried out using the 
independent t-test (IBM SPSS Statistics, version 19) on the natural log 
transformed sST2 levels (pg/ml). NS = not significant. Error bars indicate the 
standard error of the mean (SEM)  
 
The data shown in Figure 3-31 confirmed at the protein level the findings of the 
mRNA for sST2 shown in Figure 3-30. To confirm the findings of Figure 3-31 at 
the protein level for ST2L however, immunocytochemistry analysis was 
employed. PHGE cells were cultured on glass coverslips in the presence and 
absence of a live P. gingivalis monospecies biofilm for 9 h. Prior to 
immunocytochemistry, stimulation was again confirmed by measurement of IL-8 
release. As investigations were conducted alongside IL-33 immunocytochemistry 
investigations, the data confirming that all cells cultured on coverslips were in 
fact stimulated by a live P. gingivalis monospecies biofilm is shown in Figure 3-
27. 
Once stimulation had been confirmed, immunocytochemistry analysis of fixed 
cells was conducted using a rabbit anti-IL1RL1 (anti-ST2) antibody (Sigma-
Aldrich®, UK). This antibody was not specific for any of the ST2 isoforms (sST2 or 
ST2L) and stained only total ST2. Figure 3-32 shows that protein for ST2 was 
found expressed in unstimulated PHGE cells and no visual increase in surface 
receptor ST2L protein expression was observed in P. gingivalis monospecies 
biofilm stimulated cells.  
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Figure 3-32: ST2 expression by primary human gingival epithelial cells cultured 
on glass coverslips and stimulated with a live P. gingivalis monospecies biofilm 
for 9 h 
Expression of ST2 protein was determined by immunocytochemical analysis using 
a rabbit anti-IL1RL1 antibody (Sigma-Aldrich®, UK). The panels show 
representative photomicrographs of methanol fixed from PHGE cells on glass 
coverslips after 9 h incubation either with media only as a control (A, C and E) 
or a live P. gingivalis monospecies biofilm (B, D and F). An isotype control 
antibody was used to determine non-specific binding (G). Original magnification 
x 400. 
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Despite the abundance of staining, the % of ST2 positive from PHGE cells was 
still quantified by the counting method described by Bologna-Molina and 
colleagues (2011). Figure 3-33 shows that, as expected, there was no significant 
difference in the % of ST2 positive cells after stimulation with a live P. gingivalis 
monospecies biofilm for 9 h.  
 
                     
Figure 3-33: Percentage of ST2 positive primary human gingival epithelial cells 
on glass coverslips after incubation with media alone or a live P. gingivalis 
monospecies biofilm for 9 h 
The % of ST2 positive cells was determined from photomicrographs using the 
methodology described by Bologna-Molina and colleagues (2011). Bars show the 
percentage of ST2 positive PHGE cells after 9 h incubation with media alone 
(Control) or with a live P. gingivalis monospecies biofilm (Biofilm). Data was 
derived from 5 micrographs depicting different fields from 3 different coverslips. 
Prior to statistical analyses the % data was angular transformed. Statistical 
analysis was carried out using the independent t-test (IBM SPSS Statistics, version 
19). * = p < 0.05. Error bars indicate the standard error of the mean (SEM). 
  
3.2.2.6 Effect of IL-33 on OKF6/TERT-2 cells 
The previous data confirmed that oral keratinocytes express the membrane 
bound form of the IL-33 receptor (ST2L). Therefore, it is rational to assume that 
these cells can mediate IL-33 signalling. Therefore, the effect of rhIL-33 on the 
innate immune response of OKF6/TERT-2 cells was investigated in vitro.  
Prior to investigations the bioactivity of the commercially obtained rhIL-33 
(PeproTech®, UK) was confirmed. This was achieved using the methodology of 
Kurowska-Stolarska and colleagues (2008). The authors showed that IL-33 
enhanced production of IL-5 by anti-CD3 antibody activated naïve CD4+ T cells 
isolated from cord blood. As cord blood cells are difficult to obtain; PBMCs, 
  159
which are known to contain naïve CD4+ T cells (Pflanz, et al., 2002), were used 
instead.  
Figure 3-34 shows that recombinant human IL-33 significantly augmented IL-5 
release from anti-CD3 antibody activated PBMCs in a dose dependant manner. 
 
               
Figure 3-34: Effect of recombinant human IL-33 on IL-5 release from anti-CD3 
antibody activated PBMCs  
IL-5 release into bathing supernatants was measured by ELISA. The figure 
represents mean relative levels (relative to control) of IL-5 in bathing 
supernatant of peripheral blood mononuclear cells (PBMCs) after 3 days. The 
data is derived from three independent experiments, carried out in duplicate on 
PBMCs isolated from three separate donors. Statistical analyses were carried out 
using the ANOVA with a Bonferroni correction (IBM SPSS Statistics, version 19) on 
the natural log transformed IL-5 relative levels. * = p < 0.05. Error bars indicate 
the standard error of the mean (SEM).  
 
Once the bioactivity of the rhIL-33 had been confirmed, OKF6/TERT-2 cells were 
stimulated in vitro with 10, 50 and 100 ng/ml rhIL-33 for 4, 24 and 48 h; as 
described in Section 2.6.4. For control purposes, cells were either stimulated 
with 10 ng/ml PMA or left unstimulated.  
Initial investigations were performed to determine the effect of rhIL-33 on the 
release of IL-8 (CXCL8) from OKF6/TERT-2 cells. Figure 3-35 shows that PMA (10 
ng/ml) induced a significant increase in IL-8 release from OKF6/TERT-2 cells at 
all time points when compared to unstimulated cells. However, no effect on IL-8 
release was observed when cells were stimulated with various concentrations of 
rhIL-33 at any of the time points investigated.  
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Figure 3-35: The effect of phorbol 12-myristate 13-acetate and recombinant 
human IL-33 on IL-8 expression by OKF6/TERT-2 cells  
IL-8 released into bathing supernatants was measured by ELISA. The figure 
represents mean supernatant levels of IL-8 in PMA and rhIL-33 stimulated 
OKF6/TERT-2 cells. Unstimulated cells acted as controls. Figure represents three 
independent experiments, carried out in duplicate. Incubation periods were 4, 
24 and 48 h. Statistical analysis was performed on the natural log transformed 
IL-8 levels (pg/ml) using the ANOVA with a Bonferroni correction (IBM SPSS 
Statistics, version 19). ** = p < 0.01. Error bars indicate the standard error of the 
mean (SEM). 
 
The failure of IL-33 to induce IL-8 expression from OKF6/TERT-2 cells was 
confirmed at the mRNA level. Figure 3-36 shows that PMA significantly 
upregulated the expression of IL-8 mRNA in OKF6/TERT-2 cells. However, no 
significant changes in IL-8 mRNA expression were observed in cells stimulated 
with 100 ng/ml rhIL-33.            
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Figure 3- 36: Effect of phorbol 12-myristate 13-acetate and recombinant human 
IL-33 on IL-8 mRNA expression by OKF6/TERT-2 cells 
Quantification of IL-8 mRNA expression in OKF6/TERT-2 cells was performed by 
real-time PCR. The figure represents mean relative expression (2-CT) of IL-8 
mRNA in PMA and rhIL-33 stimulated OKF6/TERT-2 cells. Unstimulated cells 
acted as controls. Incubation periods were 4 and 24 h. GAPDH was used as a 
reference gene. Figure represents three independent experiments carried out in 
duplicate. Statistical analysis was performed on the natural log transformed IL-8 
mRNA relative expression (2-CT) values using the ANOVA with a Bonferroni 
correction (IBM SPSS Statistics, version 19). ** = p < 0.01 and *** = p < 0.001. 
Error bars indicate the standard error of the mean (SEM).  
 
To further investigate whether rhIL-33 had any effect on the innate immune 
responses of OKF6/TERT-2 cells a holistic approach was undertaken. The use of 
the Proteome ProfilerTM Array (R&D Systems, UK) allowed us to rapidly and 
economically detect changes in expression of 36 different cytokines and 
chemokines without performing numerous immunoassays. Therefore the 
supernatants collected from OKF6/TERT-2 cells stimulated with PMA and rhIL-33 
(Section 2.6.4) were exposed to the array (Section 2.7.6).  
Figure 3-37 visually suggested that PMA (10 ng/ml) induced upregulated release 
of CD40L, G-CSF, GM-CSF, CXCL1, IL-1RA, IL-6 and IL-8 from OKF6/TERT-2 cells. 
However, no changes in release of any cytokines and chemokines could be 
observed from OKF6/TERT-2 cells stimulated by rhIL-33. 
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Figure 3-37: Proteome profiler analysis of phorbol 12-myristate 13-acetate and 
recombinant human IL-33 stimulated OKF6/TERT-2 cells 
Cytokines and chemokines released into bathing supernatants were measured 
using the Proteome ProfilerTM Array (R&D Systems, UK). Images show membranes 
incubated with culture media only (A), supernatants from unstimulated cells (B), 
rhIL-33 (100 ng/ml) stimulated cells (C), and PMA (10 ng/ml) stimulated cells 
(D). Panel (E) shows the key for the membranes. For membranes incubated with 
bathing supernatants; these were pooled samples derived from 24 h time points 
of three independent experiments. The X-ray films were exposed for 20 min 
prior to imaging.  
 
The membranes only give a visual indication to changes in cytokine and 
chemokine release from stimulated cells. Therefore, in order to quantify these 
changes the pixel densities on the developed X-ray film were analyzed using a 
Gel DocTM XR Imaging System (Bio-Rad Laboratories, UK) and Quantity One® 
Software Version 4.6.7 (Bio-Rad Laboratories, UK). 
Pixel density analysis (Figure 3-38) showed that PMA (10 ng/ml) induced 
upregulated release of CD40L, G-CSF, GM-CSF, CXCL1, IL-1α, IL-1RA, IL-6, IL-8 
E 
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and RANTES from OKF6/TERT-2 cells. However, no changes in release of any 
cytokines and chemokines could be observed from OKF6/TERT-2 cells stimulated 
by rhIL-33. 
 
           
Figure 3-38: Pixel density analysis to determine changes in cytokine and 
chemokine expression by OKF6/TER-2 cells stimulated by recombinant human IL-
33 and phorbol 12-myristate 13-acetate 
Pixel densities for each cytokine and chemokine were measured on the 
membranes shown in Figure 3-37 using a Gel DocTM XR Imaging System (Bio-Rad 
Laboratories, UK) and Quantity One® Software Version 4.6.7 (Bio-Rad 
Laboratories, UK). Each bar represents the average intensity on membranes 
which were probed with supernatants from unstimulated cells (Control), cells 
stimulated with rhIL-33 (100 ng/ml) and cells stimulated with PMA (10 ng/ml). 
The pixel intensity was corrected for the media control. Error bars indicate the 
standard error of the mean (SEM). 
 
To confirm the findings of the Proteome ProfilerTM Array (R&D Systems, UK), 
expression of selected genes (G-CSF and IL-1RA) was investigated further using 
standard real-time PCR and ELISA technologies. 
Figure 3-39A shows there were significant increase in G-CSF mRNA by 
OKF6/TERT-2 cells after PMA (10 ng/ml) stimulation at 4 h (p < 0.001) and 24 h 
(p < 0.01); when compared to the unstimulated control. However, no change in 
expression of G-CSF mRNA expression could be observed from OKF6/TERT-2 cells 
stimulated by rhIL-33 after either 4 or 24 h. Figure 3-39B shows no changes in IL-
1RA mRNA expression by OKF6/TERT-2 cells after PMA (10 ng/ml) stimulation at 
4 h when compared to unstimulated control (p > 0.05). However, IL-1RA mRNA 
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expression was significantly decreased 24 h after stimulation (p < 0.01). Once 
again, no changes in expression of IL-1RA mRNA could be observed from 
OKF6/TERT-2 cells stimulated by rhIL-33 after either 4 or 24 h. Figure 3-39C 
shows there was significant increase in G-CSF protein levels in supernatants of 
OKF6/TERT-2 cells stimulated by PMA (10 ng/ml) after 24 h stimulation (p < 
0.01); when compared to the unstimulated control. However, there was no 
change in levels of G-CSF after stimulation with rhIL-33 (p > 0.05). Figure 3-39D 
shows no changes in supernatant levels of IL-1RA protein observed from 
OKF6/TERT-2 cells stimulated for 24 h by either PMA (10 ng/ml) or rhIL-33 when 
compared to the unstimulated control (p > 0.05). 
 
 
Figure 3-39: The effect of phorbol 12-myristate 13-acetate and recombinant 
human IL-33 on G-CSF and IL-1RA expression by OKF6/TERT-2 cells  
Quantification of mRNA expression and supernatant protein levels were 
performed by real-time PCR and ELISA respectively. The bars represent mean 
relative mRNA expression (2-CT) of G-CSF and IL-1RA (A and B), as well as mean 
supernatant levels of G-CSF and IL-1RA (C and D) by OKF6/TERT-2 cells 
stimulated by either PMA (10 ng/nl) or rhIL-33 (100 ng/ml). Unstimulated cells 
acted as controls. For real-time PCR analysis, RNA polymerase II was used as a 
reference gene. The data was generated from duplicate wells of three 
independent experiments. Statistical analysis of real-time PCR and ELISA data 
was performed on the natural log transformed values using the ANOVA with a 
Bonferroni correction (IBM SPSS Statistics, version 19). ** = p < 0.01; *** = p < 
0.001 and NS = not significant (p > 0.05). Error bars indicate the standard error 
of the mean (SEM).  
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The data suggested that rhIL-33 had no direct effect on the innate immune 
responses of OKF6/TERT-2 cells. However, IL-33 has been suggested to augment 
bacterially induced innate immune responses by promoting increased expression 
of TLRs (Joshi, et al., 2010). Therefore, changes in expression of TLR-2 and TLR-
4 mRNA in OKF6/TERT-2 cells after stimulation with PMA (10 ng/ml) and rhIL-33 
(100 ng/ml) were investigated by real-time PCR. 
Figure 3-40A shows significant increase in TLR-2 mRNA by OKF6/TERT-2 cells 
after PMA (10 ng/ml) stimulation at 4 h and 24 h (p < 0.01) when compared to 
the unstimulated control. However, no change in expression of TLR-2 mRNA 
expression could be observed from OKF6/TERT-2 cells stimulated with rhIL-33 
(100 ng/ml) at both time points. Figure 3-40B shows significant increase in TLR-4 
mRNA by OKF6/TERT-2 cells after PMA (10 ng/ml) stimulation at 4 h (p < 0.01), 
but not at 24 h (p > 0.05) when compared to the unstimulated control. However, 
no change in expression of TLR-4 mRNA could be observed from OKF6/TERT-2 
cells stimulated by rhIL-33 at both time points. 
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Figure 3-40: The effect of phorbol 12-myristate 13-acetate and recombinant 
human IL-33 on TLR-2 and TLR-4 mRNA expression by OKF6/TERT-2 cells 
Quantification of TLR-2 and TLR-4 mRNA expression by OKF6/TERT-2 cells was 
performed by real-time PCR. The bars represent mean relative expression (2-
CT) of TLR-2 (A) and TLR-4 (B) in unstimulated (Control), PMA (10 ng/ml) and 
rhIL-33 (100 ng/ml) stimulated cells. The data was generated from duplicate 
wells of three independent experiments. RNA polymerase II was used as a 
reference gene. Statistical analysis was performed on the natural log 
transformed 2-CT values using the ANOVA with a Bonferroni correction (IBM SPSS 
Statistics, version 19). ** = p < 0.01; NS = not significant (p > 0.05). Error bars 
indicate the standard error of the mean (SEM). 
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3.3 Discussion 
The data, for the first time, showed that IL-33 (mRNA and protein) was 
expressed in periodontal tissues. Furthermore, expression was significantly 
elevated in tissue of patients with chronic periodontitis. These findings are in 
agreement with previous data. IL-33 has been shown to be expressed in 
numerous epithelial tissues; including bronchial, colonic, nasal, skin and giant 
papillae (Kamekura, et al., 2012; Manetti et al., 2010; Matsuda, et al., 2009; 
Prefontaine, et al., 2009; Seidelin et al., 2010). In addition, in various chronic 
inflammatory disease models, pathogenesis has been associated with elevated 
expression of IL-33 (Miller, 2011). Furthermore, levels of IL-33 have been found 
to be upregulated within the chronically inflamed tissue of patients with 
rheumatoid arthritis, inflammatory bowel diseases, asthma and chronic allergic 
conjunctivitis (Beltran, et al., 2010; Matsuda, et al., 2009; Matsuyama, et al., 
2010; Prefontaine, et al., 2009; Xu, et al., 2008). In agreement with these 
findings, our data demonstrate that elevated epithelial expression of IL-33 is 
associated with periodontal disease. This therefore was suggestive of a role for 
IL-33 in periodontal disease pathogenesis.  
The data presented in this thesis also showed that both the soluble form (sST2) 
and membrane bound form (ST2L) of the IL-33 receptor (ST2 or IL-1RL1) were 
expressed in periodontal tissue. Interestingly, at the mRNA level, expression of 
total ST2 was significantly increased in tissue of patients with chronic 
periodontitis. Furthermore, using primers to distinguish between ST2L and sST2 
mRNA, it was found that expression of sST2, but not ST2L mRNA was elevated in 
tissue from patients with chronic periodontitis. These data are similar to findings 
in other chronic inflammatory diseases. mRNA expression of total ST2 and sST2, 
not ST2L were found to be increased in colonic tissue samples of patients with 
ulcerative colitis as compared to healthy subjects (Beltran, et al., 2010; 
Pastorelli et al., 2010). Similarly, total ST2 mRNA was also found to be increased 
in human nasal mucosa samples of patients with allergic rhinitis when compared 
to healthy subjects (Kamekura, et al., 2012). In addition, no difference in ST2L 
mRNA expression was also reported between synovial tissue samples of 
rheumatoid arthritis and osteoarthritis patients (Talabot-Ayer et al., 2012). 
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Despite these interesting findings at the mRNA level, confirmation at the protein 
level proved problematic in our studies. For IL-33, attempts to quantify levels in 
clinical samples (serum, GCF and saliva) from healthy volunteers and patients 
with periodontal disease proved unsuccessful. The ELISA analyses showed that in 
all samples IL-33 levels were below the detection limits of the ELISA kit used 
(Human IL-33 ELISA; Life Science, UK). The lowest standard for the Human IL-33 
ELISA from Enzo Life sciences was 3.9 pg/ml. However, the actual limits of 
sensitivity in our hands was calculated as 15.5 pg/ml based on the concept of 
determining  two mean standard deviations higher than the mean baseline from 
6 replicate standard curves (Chaloner-Larsson, et al., 1997).  
In our investigations, serum IL-33 levels ranged from between 4.4 - 12.6 pg/ml; 
below the limits of detection. In addition, no IL-33 was detected in any of the 
saliva or GCF samples. This was found to be in contrast to some previous findings 
(Table 3-3). For analysis of levels of IL-33 in saliva and GCF only a few studies 
are reported (Table 3-3). However, these studies highlight the problems faced 
when using commercially available ELISA kits from different sources. Using an IL-
33 ELISA assay from GenWay Biotech (USA), with reported detection limits of 
between 700 – 500000 pg/ml, Nizam et al (2014) and Buduneli et al (2012) 
reported high IL-33 levels in saliva and GCF (>1000 pg/ml) in healthy subjects 
ranging from 1100 – 14000 pg/ml (Table 3-3). Conclusions from these findings 
must however be drawn with care. Indeed, the literature consistently shows that 
the most abundant cytokines and chemokines in  GCF such as IL-1β, IL-6, IL-8, 
CXCL10 are reported to be presented in ranges of between 5 - 400 pg/ml using 
multiplex immunoassays as well as commercially available ELISA kits (Becerik et 
al., 2012; de Lima Oliveira et al., 2012; Shimada et al., 2013). Similarly, the 
most abundant cytokines present in saliva, such as IL-1β, IL-6 and TNF-α, were 
reported to be presented at ranges between 2 -700 pg/ml as measured by 
multiplex immunoassays as well as commercially available ELISA kits. Indeed, 
only levels of IL-8 in saliva have been reported to be higher (1800 – 2400 pg/ml) 
(Gursoy et al., 2009; Teles et al., 2009; Tobon-Arroyave et al., 2008). 
Therefore, it is hard to believe that IL-33 levels in these fluids can be in the 
multiple thousand pg/ml ranges. Indeed, Papathanasiou and colleagues (2014) 
using a multiplex immunoassay (Millipore Corporation, USA) which has a 
sensitivity of between 0.4 – 55.8 pg/ml (company statement) reported that IL-33 
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was below the detection limit in the GCF of healthy subjects and chronic 
periodontitis patients. These were more in agreement with the findings reported 
in this thesis. 
 
 
Biological 
Fluid 
 
 
Disease 
 
Healthy 
IL-33 (pg/ml) 
 
Disease 
IL-33 (pg/ml) 
 
LDL 
 
ELISA 
source 
 
Reference 
Serum RA 42.8 
(±3.0) 
138.6* 
(±16.5) 
23.0 A1 Xiangyang et 
al (2012) 
Serum pSS 24.1 
(13.4-31.6) 
54.5* 
(26.2-169.5) 
23.0 A1 Zhao et al 
(2013) 
Serum AS 146 
(63-167) 
450#* 
(217-730) 
32.0 A2 Han et al 
(2011) 
Serum RA Below 
detection 
392.0* 
(±889.4) 
23.0 A1 Mu et al 
(2010) 
Saliva CP 7700 
(1100-14000) 
13300#* 
(2200-27700) 
700 A3 Nizam et al 
(2014) 
Saliva CP 1100 
(±500) 
1200 
(±600) 
700 A3 Buduneli et al 
(2012) 
GCF CP 3823 
(±1970) 
8300* 
(±4857) 
700 A3 Buduneli et al 
(2012) 
GCF CP Below 
detection 
Below 
detection 
0.4 
 
A4 Papathanasiou 
et al (2014) 
Table 3-3: Comparison of published studies measuring levels of IL-33 by ELISA in 
biological fluids of healthy subjects and patients with chronic inflammatory 
disease 
RA = rheumatoid arthritis, pSS = primary Sjogren’s Syndrome, AS = ankylosing 
spondylitis, CP = chronic periodontitis, A1 = ELISA (R&D System, USA), A2 = ELISA 
(Peprotech®, USA), A3 = ELISA (GenAway Biotech, USA), A4 = Multiplex 
immunoassay (Millipore Corporation, USA), LDL = lower detection limit, # = 
estimation of values from figures, and * = significant difference between health 
and disease (p < 0.05).  
 
Based on our data and the available literature, it seems that evaluation of IL-33 
levels in biological fluids can be variable depending upon the source of the ELISA 
used in the study. Therefore, perhaps a different approach could have been 
taken in our investigations; for example the use of western blot analysis or 
immunoprecipitation analysis to evaluate levels of IL-33 in biological fluids. The 
reasons for the problems encountered in our studies using ELISA are unknown. 
However, it is possible that in biological fluids there may be other mediators 
which bind to IL-33 and mask the epitope on the protein to which the capture 
antibody in the commercially available ELISA binds. Indeed, one such molecule 
may be sST2 which is well known to act as a decoy receptor and bind to IL-33 
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(Hayakawa, et al., 2007; O'Neill, 2008; Schmitz, et al., 2005). In addition, the 
lack of success with this ELISA kit could be due to numerous other factors 
including; sensitivity of the assay, sample preparation and long term storage and 
repeated freeze/thawing of samples. The shortcoming in our study was we did 
not have a suitable positive control sample to assess the efficiency of the ELISA 
kit used. Due to the problems that arose during the investigations into levels of 
IL-33 in biological fluids and sample limitations we therefore did not evaluate 
serum levels of sST2 in these samples.  
Despite the failure to detect IL-33 at the protein level in biological fluids; using 
an immunohistochemical approach IL-33 protein was detected in periodontal 
tissue. Sections of periodontal tissue were stained using a mouse monoclonal 
anti-IL-33 antibody (Nessy-1, Enzo® Life Science, UK). This antibody was used 
extensively throughout this thesis for both the immunohistochemistry and 
immunocytochemistry. Although this antibody had routinely been used by other 
researchers in the field of IL-33 biology (Kamekura, et al., 2012; Manetti, et al., 
2010); it was important that its specificity was determined in our hands before 
any inferences from results could be made. In this thesis we have confirmed 
specificity in a number of ways. Firstly, an appropriate isotype control (mouse 
monoclonal IgG1; Thermo Scientific, UK) was used to exclude non-specific 
binding. Secondly, staining of human tonsil tissue (Figure 3-3) which is known to 
contain IL-33 expressing immune cells (Baekkevold, et al., 2003; Moussion, et 
al., 2008) was performed as a positive control. Thirdly, staining of HUVEC cells, 
which are also known to express IL-33 (Baekkevold, et al., 2003; Hayakawa et 
al., 2009; Savinko, et al., 2012) was also performed (Figure 3-18). Finally, pre-
absorption studies using an excess of rhIL-33 (PeproTech®, UK) (Section 2.7.2) 
were also conducted (Figure 3-18). In isolation, these steps do not confirm 
specificity. However, when the evidence is combined we can be fairly sure that 
the antibody used in our investigations is specific for IL-33. In addition, our 
methodological approach for determining specificity is in agreement with the 
literature which suggests:  (1) the use of appropriate diluent control, isotype 
control and pre-absorbed antibody in replace of primary antibody, (2) the use of 
sections of tissue with cells that are known to express the protein of interest and 
(3) the use of several antibodies that are directed against the same protein 
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(Burry, 2000, 2011). However, due to budget restriction, we only used one type 
of primary antibody in our study. 
A specific and reliable IL-33 antibody was important to our immunohistocehmical 
analysis as it allowed us to quantify expression of IL-33 in tissues using the 
methodology of Bologna-Molina and colleagues (2011). This is a highly 
reproducible cell/nuclei counting technique that can be applied to both 
immunohistochemistry and immunocytochemistry, which uses only a digital 
camera attached to a microscope and a personal computer (Bologna-Molina et 
al., 2008; Bologna-Molina et al., 2009; Gonzalez-Ramirez et al., 2011; Ramirez-
Amador et al., 2009). This quantification technique was employed as it is easy, 
cheap and highly reproducible. As an alternative, quantification can also be 
conducted using an advanced image scanner and image analysis software 
specifically designed for cell counting. However, we did not have access to the 
necessary equipment and in addition this automated method has been associated 
with issues of specificity and reproducibility (Persohn et al., 2007).      
The immunohistochemical analysis of periodontal tissues confirmed the findings 
at the mRNA level, showing that IL-33 protein levels are elevated in the 
epithelial and connective tissue layer of periodontal tissue from patients with 
chronic periodontitis. The tissue for this study was derived from patients 
undergoing surgery for chronic periodontitis and had clinical probing depths of ≥ 
5.0 mm and clinical attachment loss of ≥ 5.0 mm. These data are similar to 
findings in other chronic inflammatory diseases, where upregulation of IL-33 was 
observed in tissues of patients with rheumatoid arthritis, inflammatory bowel 
diseases and chronic allergic conjunctivitis (Beltran, et al., 2010; Matsuda, et 
al., 2009; Xu, et al., 2008). In addition, IL-33 levels were found to be 
upregulated in nasal epithelium of chronic allergic rhinitis patients, bronchial 
epithelium of asthma patients, colonocytes of ulcerative colitis patients, skin of 
systemic sclerosis patients and giant papillae of allergic conjunctivitis patients 
(Kamekura, et al., 2012; Manetti, et al., 2010; Matsuda, et al., 2009; 
Prefontaine, et al., 2009; Seidelin, et al., 2010).  
To confirm the findings for ST2 at the mRNA level a similar approach to that 
undertook for IL-33 was taken. In this instance immunohistochemical analysis of 
tissues was conducted using a rabbit anti-IL1RL1 (ST2) antibody (Sigma-Aldrich®, 
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UK). However, this antibody is only able to detect total ST2 and can not 
distinguish between sST2 and ST2L. In addition, the specificity of this antibody 
was not investigated in as greater detail as the IL-33 antibody. Firstly, an 
appropriate isotype control (rabbit IgG; Abcam®, UK) was used to exclude non-
specific binding. Then, the tonsil tissues, which were known to contain ST2 
expressing cells (Ciccia et al., 2013) were used as a positive control. However, 
due to budget and time restrictions, we were unable to do pre-absorption 
studies. Therefore, in future studies, further steps to determine the specificity 
of this antibody in line with measures reported in the literature (Burry, 2000, 
2011) need to be performed to confirm fully specificity. Therefore, we can only 
conclude that the specificity of this antibody had been partially confirmed. 
Nonetheless, the pattern of ST2 staining in periodontal tissue was comparable 
with ST2 expression in other epithelial tissues such as skin and corneal 
epithelium ("The human protein atlas (ST2)," 2013). The human protein atlas is a 
publicly available database of comprehensive antibody-based protein expression 
profiles of various normal and cancer tissues developed by certified pathologists 
(Uhlen et al., 2005; Uhlen et al., 2010). Interestingly, ST2 staining was abundant 
throughout periodontal tissue in both health and disease. This however made 
quantification by the methodology of Bologna-Molina and colleagues (2011) 
difficult. This abundance in staining may again be due to issues of antibody 
specificity. However, this abundance of ST2 staining has been observed in other 
epithelial tissues. For example, immunohistochemical analysis revealed an 
abundance of ST2 staining in epithelial tissue of skin, oral mucosa and cornea 
(Hueber, et al., 2011; "The human protein atlas (ST2)," 2013; Lin, et al., 2013; 
Meephansan et al., 2013). 
Despite the proposed abundance of ST2 staining in epithelial tissues, there are 
studies that report increased ST2 immunostaining in cells from the skin of 
psoriatic disease and colonic epithelial cells of ulcerative colitis (Manetti, et al., 
2010; Pastorelli, et al., 2010). To our knowledge there are no antibodies 
commercially available to distinguish between the two isoforms of ST2 protein 
(ST2L and sST2). Since many studies, including our own, report that at the mRNA 
level; sST2 and not ST2L is upregulated in diseased tissue samples compared to 
healthy control, the availability of an antibody that can differentiate the two 
ST2 isoforms would benefit immunohistochemical investigations. 
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Our analysis of gingival tissue samples confirmed that IL-33 levels are 
upregulated in tissues of patients with chronic periodontitis.  In addition, our 
mRNA data suggests that tissue levels of sST2, but not ST2L are upregulated in 
periodontal disease. IL-33 is well known to promote cellular immune responses 
by signalling through its membrane receptor ST2L. Formation of the IL-33/ST2L 
complex induces a conformational change in the extracellular domain of the 
ST2L that facilitates recruitment of IL-1RAcP (Schmitz, et al., 2005). Together; 
IL-33, ST2 and IL-1RAcP form an active receptor complex and the TIR 
(toll/interleukin-1 receptor) domain of the receptor rapidly assembles the 
adaptor and kinase signaling proteins such as myeloid differentiation primary‑
response protein 88 (myD88), IL‑1R‑associated kinase 1 (IRAK1), IRAK4 and (TNF 
receptor-associated factor 6) (TRAF6) (Ali, et al., 2007; Chackerian, et al., 2007; 
Palmer, et al., 2008). Studies have shown that IL-33 induced protein-kinase 
cascades can activate NF-κB, ERK1/2, p38 and JNK1 (Funakoshi-Tago, et al., 
2008; Iikura et al., 2007; Kurowska-Stolarska, et al., 2008; Pushparaj et al., 
2009; Schmitz, et al., 2005) and eventually lead to the induction of expression 
of numerous inflammatory mediators. This IL-33 signalling was shown to be 
inhibited by the decoy receptor sST2 that competes with ST2L for IL-33 binding. 
In vitro, soluble ST2 directly bound to IL-33 and suppressed activation of NF-κB 
in a thymoma cell line stably expressing ST2L, suggesting that the complex of 
soluble ST2 and IL-33 fails to bind to ST2L (Hayakawa, et al., 2007). In vivo, 
mice administered an intra-articular irritant (bovine serum albumin) exhibited 
dose dependent hypernociception, which was found to be IL-33 mediated. The 
response was inhibited by administration of sST2 (Verri et al., 2008). 
Additionally, in a murine model of asthma, pre-treatment with sST2 reduced the 
expression of IL-4, IL-5, and IL-13 from IL-33-stimulated splenocytes (Hayakawa, 
et al., 2007). These studies demonstrate the inhibitory effect of sST2 on IL-33 
signalling. Hence, dysregulation of IL-33 and sST2 expression could contribute to 
pathogenesis of chronic inflammatory diseases. Indeed, IL-33 and sST2 were 
shown to be involved in the pathogenesis of chronic inflammatory diseases such 
as asthma, rheumatoid arthritis and inflammatory bowel diseases (Kakkar & Lee, 
2008; Miller, 2011). 
Since IL-33 and sST2 were suggested to be upregulated in the gingival tissue of 
chronic periodontitis patients, we needed to further explore the cell types 
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within the periodontium that contribute to their expression. In addition, we 
aimed to determine if initiating factors of periodontal disease, such as the 
periodontal pathogen P. gingivalis, could regulate expression of this cytokine 
and its receptors. The immunohistochemical analysis suggested that both IL-33 
and ST2 (total) were expressed in the epithelial layer of the periodontium 
(Figure 3-3 and Figure 3-9). Epithelial cells, particularly within the 
sulcular/pocket epithelium, are located adjacent to the tooth surface which 
harbours the dental biofilm and represent the first line of defence against 
periodontal pathogens. It was therefore interesting to investigate whether these 
cells express IL-33 and ST2, and whether expression was modulated by the 
periodontal pathogen; P. gingivalis.  
In this study we originally chose to use the OKF6/TERT-2 cell line. OKF6/TERT-2 
cells were a kind gift from the Rheinwald laboratory (Brigham and Women’s 
Hospital, Boston). The cells were originated from keratinocyte cells of the oral 
mucosa, which have been immortalized by forced ectopic expression of the 
telomerase catalytic subunit, hTERT (Dickson, et al., 2000). The cells resemble 
primary oral keratinocyte cells and are regarded as a valuable and reproducible 
model for normal oral epithelial cell studies (Dongari-Bagtzoglou & Kashleva, 
2006). We chose to use a cell line in the first instance due to the fact that the 
OKF6/TERT-2 cells were readily available at the time. In addition, these cells 
are easy to maintain in vitro and are well characterised. The fact that these 
cells were immortal was advantageous as it provided a constant supply of cells 
which was required for method optimisation at the beginning of the study. 
However, after initial studies using a cell line we confirmed our findings using 
commercially available primary human gingival epithelial cells (PHGE) (CELLnTEC 
advanced cell systems, Switzerland). These cells were isolated from healthy 
gingiva and are pooled from at least 3 healthy donors.  
For stimulation studies we used the periodontal pathogen P. gingivalis (ATTCC 
33277 strain). P. gingivalis was chosen as this species was shown to highly 
associate with periodontal diseases (Bostanci & Belibasakis, 2012). In addition, 
P. gingivalis is also known for one of the most studied periodontal pathogens 
(Wang et al., 2013). The ATTCC 33277 strain was used in this study as it has 
been widely used by other laboratories and associates with periodontal diseases 
(Guyodo et al., 2012; Naito et al., 2008). P. gingivalis has been used extensively 
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for in vitro cell stimulation studies. However, researchers use a variety of 
different strains, live or dead forms, planktonic or biofilm cultured forms and a 
plethora of specific antigens such as LPS, fimbriae and bacterial DNA. Research 
has shown that these variables can have differential effects on cell responses in 
vitro. Indeed, human and mouse macrophages stimulated with different forms of 
P. gingivalis including the live organism, LPS or fimbriae were found to exhibit 
differential patterns of gene expression (Yu et al., 2010; Zhou & Amar, 2006; 
Zhou, et al., 2005). The findings indicate host immune cells sense live P. 
gingivalis and its components differently, which translate into the expression of 
different inflammatory cytokine profiles. In vitro, P. gingivalis exists in a biofilm 
containing both live and dead bacteria as well as a plethora of specific antigens 
(LPS, fimbriae and bacteria DNA). Therefore, to model the in vivo situation in 
vitro, culturing organisms as a biofilm for stimulation studies may be more 
appropriate. Indeed, in chronic inflammatory conditions such as chronic wound 
infection, dermatitis and periodontal disease the majority of organisms are 
found present in biofilm form (Bjarnsholt et al., 2008; Pihlstrom, et al., 2005; 
Vlassova et al., 2011). Furthermore, gene expression profile analysis has showed 
difference in the gene expression profiles of bacteria grown planktonically and 
bacteria grown as a biofilm; including genes encoding antigens known to activate 
immune responses (Southey-Pillig et al., 2005; Waite et al., 2005). In addition, 
studies on the acellular filtrate of planktonic verses biofilm cultured 
Staphylococcus aureus showed that the acellular filtrate from the biofilm 
cultured organisms had stronger cytokine stimulatory activity on leukocytes than 
that from planktonic cultured organisms (Sadowska et al., 2013). Monospecies 
biofilms of F. nucleatum, P. gingivalis and Actinomyces naeslundii also induced 
distinct patterns of cytokine expression in oral keratinocytes when compared to 
their respective planktonic bacteria species (Peyyala et al., 2012). Therefore it 
was decided in our studies that in order to mimic the in vivo situation more 
accurately a live P. gingivalis monospecies biofilm was to be used in stimulation 
studies. In addition, to further mimic the in vivo situation we used a live P. 
gingivalis monospecies biofilm model in which  oral epithelial cells were 
stimulated with the biofilm attached to a cell culture insert suspended 0.5 mm 
above the cells (Sherry, et al., 2013). This mimics the relationship between the 
dental biofilm and epithelium of the gingival crevice/pocket which is separated 
by GCF. In this model, some of the bacteria were observed to detach and fall 
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from the biofilm to directly contact the oral epithelial cells, which further 
resembles the events in the gingival sulcus/pocket epithelium in vivo. 
The data presented in this manuscript shows for the first time that IL-33 is 
expressed by oral epithelial cells at both the mRNA and protein level. This is in 
line with literature that shows IL-33 is expressed by various other epithelial cells 
of the body, including bronchial, colon, nasal, skin and giant papillae 
(Kamekura, et al., 2012; Manetti, et al., 2010; Matsuda, et al., 2009; 
Prefontaine, et al., 2009; Seidelin, et al., 2010). In addition, the data 
demonstrates for the first time significant upregulation of IL-33 mRNA expression 
by oral epithelial cells in response to the periodontal pathogen; P. gingivalis. 
This is in agreement with literature that shows stimulation of TLRs such as TLR-
2, TLR-3, TLR-4 and TLR-5 by their respective agonist increases expression of IL-
33 in corneal epithelial cells, bronchial epithelial cells and sinunasal epithelial 
cells, as well as monocytes (Reh, et al., 2010; Willart, et al., 2012; Zhang, et 
al., 2011a). In addition, it has specifically been shown that LPS of P. gingivalis 
can induce upregulated IL-33 expression in human monocytes (Nile, et al., 
2010). 
Although P. gingivalis induced increased expression of IL-33 mRNA in oral 
epithelial cells we found that IL-33 was not released into bathing supernatants 
using the in vitro model system. As the same ELISA kit was used in this 
investigation as was used for analysis of clinical samples this finding could be 
explained by the inability of the commercial kit to accurately measure IL-33 
levels as discussed previously. However, a similar phenomenon has been 
reported in the literature. In monocytes, P. gingivalis induced elevated 
intracellular expression of IL-33, however the protein was not released from 
cells unless subjected to necrosis (Nile, et al., 2010). In addition, cells isolated 
from rheumatoid arthritis patients, including fibroblast-like synoviocytes and 
PBMCs were found not to release IL-33 after stimulation with combinations of IL-
1β, TNF-α, and anti-CD3/CD28 respectively (Matsuyama, et al., 2010). Likewise, 
TNF-α stimulated intestinal epithelial cells showed increased intracellular IL-33 
expression but no extracellular release was detected (Pastorelli, et al., 2010). In 
contrast to these findings, however, in vitro studies using rat cardiac fibroblasts, 
mixed glial cell and astrocyte-enriched cultures and human macrophages have 
been shown to secrete IL-33 upon stimulation with combinations of LPS and PMA, 
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PMA only, ATP, and combinations of LPS and aluminium hydroxide adjuvant 
(alum) (Hudson, et al., 2008; Li, et al., 2008; Sanada, et al., 2007; Talabot-
Ayer, et al., 2009). Literature also shows that IL-33 is released by cells into the 
extracellular environment when physically injured or subjected to mechanical 
stress (Cayrol & Girard, 2009; Kakkar et al., 2012). In addition, IL-33 release was 
found to be ATP dependant in bronchial epithelial cells and corneal epithelial 
cells (Kakkar, et al., 2012; Kouzaki et al., 2011; Zhang, et al., 2011a). Based on 
these findings, therefore, a limitation of our study was that potential 
mechanisms of IL-33 release from oral epithelial cells were not investigated 
further.  
To determine if IL-33 protein mirrored mRNA and was upregulated intracellularly 
by stimulated oral epithelial cells; an immunocytochemical approach was 
undertaken. This once again employed the specific mouse monoclonal anti-IL-33 
antibody (Nessy-1, Enzo® Life Science, UK) and the quantitative approach of 
Bologna-Molina and colleagues (2011). This analysis confirmed the findings at the 
mRNA level and showed that elevated IL-33 protein expression occurs 
intracellularly in oral epithelial cells stimulated with P. gingivalis. This finding 
casts doubts on the hypothesis that IL-33 is released from epithelial cells in 
response simply to stimulation with whole pathogens or associated antigens. 
However, further research investigating IL-33 release mechansisms by oral 
epithelial cells is required to confirm this. 
In addition to IL-33, expression of ST2 by oral epithelial cells was also 
investigated in vitro. Oral epithelial cells were found to express mRNA encoding 
both ST2L and sST2. This is unsurprising given the fact that numerous other 
epithelial cells of the colonic mucosa, cornea and lung (Beltran, et al., 2010; 
Lin, et al., 2013; Yagami, et al., 2010) as well as keratinocytes of skin (Hueber, 
et al., 2011) have all been demonstrated to express these receptors. These 
studies also demonstrate that expression of sST2 and not ST2L mRNA is 
upregulated in OKF6/TERT-2 cells that come into contact with the periodontal 
pathogen; P. gingivalis. Indeed, in other cell types expression of sST2 has been 
found to be inducible whilst ST2L is found to be constitutively expressed. In 
murine alveolar macrophages, stimulation with LPS or pro-inflammatory 
cytokines (IL-1β, IL-6 and TNF-α) has been shown to induce increased expression 
of sST2 mRNA but not ST2L mRNA (Oshikawa et al., 2002). In addition, 
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stimulation of alveolar epithelial cells with a combination of IL-1β, TNF-α and IL-
4 and stimulation of intestinal epithelial cells with TNF-α upregulated sST2 
protein release with no effect on ST2L  (Pastorelli, et al., 2010; Tajima et al., 
2007). 
Although we showed increased expression of sST2 mRNA in oral keratinocytes in 
response to P. gingivalis, we found that P. gingivalis does not induce increased 
release of sST2 into bathing supernatant as measured by ELISA. Interestingly, 
Mildner and colleagues (2010) showed LPS did not induce increased expression of 
sST2 by PBMCs. This was despite the fact that in response to LPS, PBMCs 
expressed pro-inflammatory cytokines including IL-1α, IL-1β, IL-6 and TNF-α 
which were expected to act in an autocrine manner and subsequently induce 
sST2 expression. It is therefore possible that P. gingivalis does not induce 
increased release of sST2 by oral keratinocytes. Again, this would be despite the 
fact that P. gingivalis can induce release of IL-1α, IL-1β and TNF-α from oral 
keratinocytes (Eskan et al., 2008a; Kraus et al., 2012; Peyyala et al., 2013). 
However, at present the reason for these sST2 ELISA results in our study are not 
known. sST2 was measured in bathing supernatants at levels of between 10 – 80 
pg/ml; which is above the lowest detection limit (5.6 pg/ml) of the ELISA. This is 
in line with previous finding that show spontaneous sST2 secretion occurs in lung 
epithelial cells (Mildner, et al., 2010). However, no upregulation of sST2 protein 
release was measured in samples stimulated by P. gingivalis despite the findings 
at the mRNA level. There is also possibility that sST2 is bound to IL-33, hence 
masking the sST2 epitopes and hindering ELISA analysis of bathing supernatants 
as  previous for the analysis of biological samples. The shortcoming in our study 
was that we did not use suitable positive control samples to assess the efficiency 
of the ELISA kit used. Hence, if given time and budget our plan was to confirm 
the findings by evaluating the efficiency of ELISA further or by measuring sST2 
levels in bathing supernatants by alternative means such as western blot. 
Instead, we investigated expression of ST2 (total) in oral keratinocytes by 
immunohistochemical analysis. This revealed no observable differences in total 
ST2 expression between unstimulated and P. gingivalis stimulated OKF6/TERT-2 
cells and PHGE cells.  
Interestingly, although levels of sST2 mRNA were upregulated by OKF6/TERT-2 
cells in response to P. gingivalis, a similar phenomenon was not observed in 
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PHGE cells. In addition, in contrast to OKF6/TERT-2 cells, IL-33 mRNA levels did 
not remain significantly upregulated after 24 h stimulation with P. gingivalis in 
PHGE cells. The difference in expression pattern may relate to differences 
between the use of a cell line and primary cells. Indeed, studies have shown 
there is both a qualitative and quantitative expression profile differences 
between cell lines and primary cells (Pan et al., 2009). In addition, the basal 
layer of the oral epithelium is known to consist of a heterogeneous mixture of 
primary cells with varying proliferation capacity (Jones & Klein, 2013). This in 
vitro phenotypic-distinct subpopulation of primary cells was also observed in 
retina pigment epithelium (Chaloner-Larsson, et al., 1997). Therefore, there 
could be phenotypical differences between the epithelial cell population from 
which OKF6/TERT-2 cells are derived and the population of epithelial cells that 
predominate the PHGE cells (CELLnTEC advanced cell systems, Switzerland). 
This therefore may explain the differences in regulation of IL-33 expression. 
Evidence from our in vitro studies thus far suggested that oral keratinocytes 
express the transmembrane form of the IL-33 receptor (ST2L) and therefore can 
respond to IL-33 signalling. Therefore, this was investigated further in vitro 
using rhIL-33 (PeproTech®, UK). However, in our investigations rhIL-33 did not 
induce OKF6/TERT-2 cells to upregulate the expression of a panel of cytokines 
and chemokines as well as TLR-2 and TLR-4. This was in contrast to literature 
describing studies performed on other epithelial cells as well as macrophages 
(Table 3-4).  
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Cells 
 
Stimulation 
(Concentration) 
 
Stimulation 
time 
 
 
Increased 
expression 
 
References 
NHBE IL-33  
(10 & 50ng/ml) 
24h IL-8 Yagami et al (2010) 
NHBE 
BEAS-2A 
IL-33 
(100ng/ml) 
12, 24 & 48h IL-17F Fujita et al (2012) 
HNEC 
 
IL-33 
(100ng/ml) 
6h IL-8 & GM-CSF Kamekura et al 
(2012) 
NHEK 
 
IL-33 
(100ng/ml) 
48h IL-8 Meephanson et al 
(2012) 
HaCaT 
 
IL-33 (100ng/ml) &  
TNF-α (20ng/ml) 
24h IL-6, VEGF, 
MCP-1 & IL-20 
Balato et al (2012) 
HaCaT IL-33 (100ng/ml) &  
IL-17A (10ng/ml) 
24h IL-20 & VEGF Balato et al (2012) 
HMVEC IL-33 
10 & 50ng/ml 
24h IL-6, IL-8 & 
MCP-1 
Yagami et al (2010) 
HMC-1 IL-33 
(100ng/ml) 
24h VEGF & MCP-1 Balato et al (2012) 
Macrophages 
 
IL-33 (50ng/ml) 6, 8 & 10h MD-2 & TLR-4  Espinassous et al 
(2009) 
Macrophages IL-33 (20ng/ml) &
IL-13 (10ng/ml) 
48h CCL17 & CCL24 Kurowska-Stolarska 
et al (2009) 
Table 3-4: Effect of IL-33 on cells 
NHBE = normal human bronchial epithelial, BEAS-2A = bronchial epithelial cell 
line, HNEC = human nasal epithelial cells, NHEK = normal human epidermal 
keratinocytes, HaCaT = immortal human keratinocyte cell line, HMVEC = human 
microvascular endothelial cells, TNF-α = tumour necrosis factors-α, GM-CSF = 
granulocyte-macrophage colony-stimulating factor, VEGF = vascular endothelial 
growth factor, MCP-1 = monocyte chemoattractant protein-1, MD-2 = myeloid 
differentiation protein 2, and TLR-4 = toll-like receptor 4. 
 
One explanation for the findings in this thesis may have been the concentration 
of rhIL-33 used in our studies. The rhIL-33 (PeproTech®, UK) exhibited bioactivity 
at 50 and 100 ng/ml in a T cell stimulation assay; where IL-5 was measured as an 
output. However, we observed no response of OKF6/TERT-2 cells to 10, 50 and 
100 ng/ml rhIL-33, despite the fact that studies showed the membrane bound 
receptor (ST2L) is expressed by these cells. Studies have shown that expression 
of ST2L is most prevalent in hematopoietic cells, such as T cells and mast cell, 
compared to other cell types such as epithelial cells and fibroblasts (Bergers, et 
al., 1994; Gachter et al., 1996). Therefore, although 100 ng/ml is an effective 
concentration for activating T-cells, it may not be sufficient to elicit a response 
in cells where active membrane associated ST2L is less abundant such as 
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OKF6/TERT-2 cells. Therefore, it may be pertinent to repeat these experiments 
using a higher concentration of rhIL-33. The literature shows that in vitro studies 
with IL-33 have utilised a variety of concentrations and stimulation times to 
induce expression of mediators in a variety of cell types (Table 3-4). This 
variation could be due to the cell type and culture conditions, the source of 
rhIL-33 and the sample preparation for analysis of phenotypic changes. In our 
studies we explored a limited number of concentrations of rhIL-33 and 
stimulation times. Therefore, it may be pertinent to repeat these experiments 
using different concentrations and sources of rhIL-33 as well as variations in 
simulation time and culture conditions. Indeed, the proteome profiler analysis 
was only performed on the 24h stimulated samples (100 ng/ml only), which 
means earlier events may have been missed. Furthermore, although the profiler 
analyses a variety of mediators, it is possible that the right panel of cytokines 
and chemokines were not investigated in our studies. Finally, the recruitment of 
the IL-1RAcP to the IL-33/ST2L is important for mediation of IL-133 signalling 
(Ali, et al., 2007; Chackerian, et al., 2007; Palmer, et al., 2008; Schmitz, et al., 
2005). Although, IL-1RAcP was found to be constitutively expressed in epithelial 
cells such as the A549 cell line and primary bronchial epithelial cells (Coulter et 
al., 1999) there is no evidence to confirm its expression in oral keratinocytes. 
Therefore we should have investigated IL-1RAcP expression in oral keratinocytes 
as this may explain why in our in vitro system we saw no genotypic or 
phenotypic changes in oral keratinocytes stimulated with rhIL-33. 
In conclusion, the data in this chapter support a role for IL-33 in the 
pathogenesis of periodontal disease. In addition, it shows that oral keratinocytes 
express IL-33 and that the periodontal pathogen, P. gingivalis, can induce 
increased intracellular expression of this cytokine. Furthermore, oral 
keratinocytes also express the receptor for IL-33 suggesting that mechanisms of 
autocrine and paracrine IL-33 signalling occur within the periodontium. 
However, at present the exact means by which IL-33 is released from cells, its 
intracellular role in oral keratinocytes and its overall contribution to the early 
oral mucosal immune responses to periodontal pathogens remain to be 
elucidated.  
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Chapter 4: IL-17 family cytokines and periodontal 
disease 
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4.1 Introduction 
The IL-17 family cytokines consists of six members (IL-17A - IL-17F) (Gaffen, 
2009b). IL-17A is the founding member and has been associated with periodontal 
disease pathogenesis (Buduneli, et al., 2009; Correa, et al., 2012; Duarte, et al., 
2010; Gumus, et al., 2013; Honda, et al., 2008; Kadkhodazadeh, et al., 2013; 
Lester et al., 2007; Ozcaka, et al., 2013; Ozcaka et al., 2011; Saraiva et al., 
2013; Schenkein, et al., 2010; Silva et al., 2012; Vernal, et al., 2005). In vivo 
models have suggested that IL-17A plays a protective role in periodontal disease. 
Indeed, IL-17RA deficient mice show exacerbated bone loss in a P. gingivalis 
induced model of periodontal disease (Yu, et al., 2007). However, an excessive 
IL-17A response promotes inflammatory alveolar bone loss in an ageing mouse 
model of periodontal disease (Eskan, et al., 2012). Indeed, IL-17A signalling 
activates NF-κB which in turn induces expression of a variety of pro-
inflammatory mediators (Koenders et al., 2005). Furthermore, IL-17A can act in 
synergy with TNF-α and IL-1β and augment the expression of pro-inflammatory 
mediators from keratinocytes and fibroblasts (Iyoda et al., 2010; Koenders et 
al., 2011). In addition, IL-17A can modulate bone remodelling through induction 
of RANKL both in vivo and in vitro (Kotake et al., 1999; Kotake et al., 2012). 
Like IL-17A, IL-17F can be secreted as a homodimer. However a heterodimeric 
species consisting of a disulphide linked IL-17A and IL-17F molecule can also be 
formed (Wright, et al., 2007). Similarly to IL-17A, both the IL-17F homodimer 
and IL-17A/F heterodimer have pro-inflammatory properties (Fujie et al., 2012; 
Liang, et al., 2006). Indeed, elevated levels of IL-17F and IL-17A/F have been 
associated with chronic inflammatory diseases such as rheumatoid arthritis 
(Kotake, et al., 1999). However, the role of IL-17F and IL-17A/F in the 
pathogenesis of periodontal disease is currently unknown. 
In contrast to IL-17A and IL-17F, the biology of IL-17B, IL-17C and IL-17D are 
poorly understood at present and their cellular sources have still to be fully 
elucidated. Levels of IL-17B, IL-17C and IL-17D are elevated in inflammation 
driven pathologies such as rheumatoid arthritis; and in vivo IL-17B, IL-17C and 
IL-17D can induce pro-inflammatory cytokine release from a variety of epithelial 
and myeloid cells (Pappu et al., 2010). In relation to the periodontium, IL-17C 
has been demonstrated to be expressed by oral epithelial cells and is known to 
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upregulate expression of a number of pro-inflammatory mediators (Ramirez-
Carrozzi, et al., 2011). However, little is known about the expression and 
functions of IL-17B, and IL-17D. Indeed, in terms of periodontal disease 
pathogenesis the roles of IL-17B, IL-17C and IL-17D remain to be elucidated. 
IL-17E has been described as a ‘double edged sword’ and has been shown to 
down-regulate localised destructive inflammation and promote Th2 driven 
pathologies (Monteleone et al., 2010). Indeed, IL-17E plays a major role in the 
clearance of parasitic infections (Fallon et al., 2006) and the pathogenesis of 
allergic disease (Angkasekwinai, et al., 2007; Ballantyne et al., 2007). IL-17E 
induces activation and differentiation of Th2 cells and regulates their 
recruitment to sites of inflammation (Tamachi et al., 2006; Wang, et al., 
2007b). IL-17E also regulates Th9 cells (Angkasekwinai, et al., 2010) and 
activates multi-potent progenitor type 2 cells (MPPtype2) (Saenz, et al., 2010b), 
innate type 2 helper cells (Ih2) (Price, et al., 2010), natural helper cells (NHCs) 
(Moro, et al., 2010) and neuocytes (Neill, et al., 2010). In contrast, IL-17E down-
regulates Th1/Th17 and IL-17A responses (Emamaullee et al., 2009; Kleinschek, 
et al., 2007; Owyang, et al., 2006) and can directly inhibit toll-like receptor 
ligand driven expression of pro-inflammatory cytokines via p38 MAP kinase-
driven SOCS3 activation in human blood monocytes and intestinal CD14+ cells 
(Caruso, et al., 2009a; Caruso, et al., 2009b). However, despite extensive 
literature on the immunological functions of IL-17E, to date very little research 
has been undertaken to determine whether it plays a role in the pathogenesis of 
periodontal disease. 
IL-10 is a prototypic anti-inflammatory cytokine. In periodontal disease IL-10 was 
shown to play an anti-inflammatory role as evidenced by the data from in vitro, 
in vivo and clinical studies (Al-Rasheed, et al., 2003; Sasaki, et al., 2004). In 
other chronic inflammatory diseases such as rheumatoid arthritis and 
inflammatory bowel disease the role of IL-10 as an anti-inflammatory cytokine 
has been confirmed (Finnegan, et al., 2003; Kuhn, et al., 1993; Murai, et al., 
2009; Tanaka, et al., 1996). As IL-10 is a well characterised anti-inflammatory 
cytokine, the relationship between fluid levels of IL-17A and IL-10 was 
investigated and similarities between the IL-17A and IL-17E relationship 
determined to provide more evidence for an anti-inflammatory role of IL-17E in 
periodontitis pathogenesis. 
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The specific aims of this study were to: 
1. Determine levels of IL-17 family cytokines and IL-10 in clinical samples and 
correlate levels with both clinical and demographic parameters. 
2. Determine levels of IL-17 family cytokines and IL-10 mRNA expression in 
gingival tissue of patients with chronic periodontitis and healthy volunteer 
control.  
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4.2 Results 
 
4.2.1 Clinical and demographic parameters of subject 
participants 
Serum, gingival crevicular fluid (GCF) and saliva samples from 77 healthy 
subjects and 97 chronic periodontitis patients were used in this study. The 
clinical and demographic parameters of the subjects/patients cohort are 
described in Section 3.2.1.1. 
 
4.2.2 Serum levels of IL-17 family cytokines 
Serum levels of IL-17 family cytokines were measured by ELISA. Table 4-1 shows 
serum levels of IL-17A and IL-17A/F were significantly increased (p < 0.001) in 
the patients with chronic periodontitis (47.5 and 31.4 pg/ml respectively), 
compared to healthy subjects (15.5 and 8.0 pg/ml respectively). In contrast, the 
serum level of IL-17E was significantly decreased (p = 0.007) in the chronic 
periodontitis patients (17.2 pg/ml) compared to healthy subjects (35.3 pg/ml). 
Serum levels of the other members of IL-17 family cytokines: IL-17B, IL-17C, IL-
17D and IL-17F were not significantly different between the two groups. The 
serum IL-17A:IL-17E ratio was also significantly increased (P < 0.001) in patients 
with chronic periodontitis compared to healthy subjects. 
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Status 
 
n 
Median 
(pg/ml) 
 
IQR 
 
Z 
statistic 
 
p value 
IL-17A Healthy 77 15.5 5.3 – 30.1 
-7.568 < 0.001* 
 CP 97 47.5 38.7 – 98.0 
IL-17B Healthy 40 38.8 30.8 – 48.1 
-0.257  0.798 
 CP 55 33.8 18.2 – 59.3 
IL-17C Healthy 40 40.9 2.9 – 49.8 
-1.581   0.114 
 CP 55 31.6 12.0 – 51.7 
IL-17D Healthy 38 22.1 20.1 – 30.6 
-0.785   0.432 
 CP 41 23.8 21.0 – 28.8 
IL-17E Healthy 77 35.3 23.1 – 44.0 
-2.676   0.007* 
 CP 97 17.2 15.9 – 50.3 
IL-17F Healthy 77 14.3 4.0 – 32.2 
-0.106   0.916 
 CP 97 14.2 7.2 – 20.0 
IL-17A/F Healthy 77 8.0 0.0 – 26.0 
-6.950 < 0.001* 
 CP 97 31.4 24.8 – 53.7 
IL-17A: IL-17E Healthy 77 0.5# 0.1 – 1.0 
-6.867 < 0.001* 
 CP 97 2.6# 0.8 – 4.5 
Table 4-1: Levels of IL-17 family cytokines and the IL-17A:IL-17E ratio in serum 
IL-17 family cytokines were measured in serum samples using the appropriate 
ELISA kit (Table 2-3). The table represents median levels of IL-17 family 
cytokines and the IL-17A:IL-17E ratio in serum of the healthy subjects and 
chronic periodontitis (CP) patients. Statistical analyses were carried out using 
the Mann-Whitney test with a Bonferroni correction (IBM SPSS Statistics, version 
19). Significance = p<0.05 (*). n = number of subjects; IQR = interquartile range; 
IL-17A:IL-17E = the serum ratio of IL-17A to IL-17E and # = ratio (no units).  
 
4.2.3 Correlations between serum levels of IL-17 family 
cytokines and clinical parameters 
The serum IL-17 family data was seen to approximate a normal distribution 
following natural log transformations. Therefore, correlations were carried out 
using bivariate analysis using the Pearson correlation coefficient test (IBM SPSS 
Statistics, version 19). 
Table 4-2 shows the serum level of IL-17A significantly positively correlated with 
all clinical parameters measured: CPD (r = +0.429, p < 0.001), CAL (r = +0.464, p 
< 0.001) and BOP (r = +0.331, p < 0.001). Serum level of IL-17A/F also 
significantly positively correlated with all clinical parameters measured: CPD (r = 
+0.544, p < 0.001), CAL (r = +0.436, p < 0.001) and BOP (r = +0.375, p < 0.001). 
In contrast, the serum level of IL-17E was found to significantly negatively 
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correlate with CPD (r = -0.265, p < 0.001) and CAL (r = -0.291, p < 0.001). Serum 
levels of the other members of the IL-17 family (IL-17B, IL-17C, IL-17D and IL-
17F) were found not to significantly correlate with any of the clinical 
parameters. As expected, all the clinical parameters measured significantly 
positively correlated to each other (r > +0.700, p < 0.001).      
 
  
 
CPD 
 
CAL 
 
BOP 
IL-17A n 174 174 174 
 r  +0.429 +0.464 +0.331 
 p <0.001* <0.001* <0.001* 
IL-17B n 97 97 97 
 r -0.005 -0.048 -0.002 
 p 0.958 0.641 0.986 
IL-17C n 97 97 97 
 r -0.024 -0.054 +0.135 
 p 0.817 0.598 0.237 
IL-17D n 79 79 79 
 r  +0.135 +0.117 +0.168 
 p 0.237 0.307 0.139 
IL-17E n 174 174 174 
 r  -0.265 -0.291 -0.060 
 p <0.001* <0.001* 0.433 
IL-17F n 169 169 169 
 r  -0.025 -0.002 +0.024 
 p 0.746 0.978 0.753 
IL-17A/F n 169 169 169 
 r  +0.544 +0.436 +0.375 
 p <0.001* <0.001* <0.001* 
BOP n 203 203  
 r +0.796 +0.743  
 p <0.001* <0.001*  
CAL n 203   
 r  +0.876   
 p <0.001*   
Table 4-2: Correlation between serum levels of IL-17 family cytokines and 
clinical parameters 
The table represents the correlations between serum levels of IL-17 family 
cytokines and clinical parameters for periodontal disease (CPD, CAL and BOP). 
The serum level values were subjected to a natural log transformation. The 
correlations were analysed using the Pearson correlation coefficient test (IBM 
SPSS Statistics, version 19). Significance = p<0.05 (*). n = number of subjects; r = 
the Pearson correlation coefficient; CPD = clinical probing depth; CAL = clinical 
attachment loss and BOP = bleeding on probing. 
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4.2.4 Correlations between serum levels of IL-17 cytokine 
family members 
In addition to associations between circulating levels of IL-17 family cytokines 
and clinical parameters; associations between IL-17 family members were also 
determined. Once again these associations were determined using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). 
Table 4-3 shows that serum level of IL-17A positively correlated with serum level 
of IL-17A/F (r = +0.600, p < 0.001). The serum level of IL-17A was also found to 
positively correlate with the serum level of IL-17F (r = +0.172, p = 0.026) 
although this correlation was weak. The serum level of IL-17C was positively 
correlated with the serum levels of IL-17A (r = +0.201, p = 0.048) and IL-17F (r = 
+0.326, p = 0.001). In addition, a weak but significant positive correlation was 
also found between serum levels of IL-17A/F and IL-17B (r = +0.201, p = 0.049). 
Interestingly, the serum level of IL-17A significantly negatively correlated with 
the serum level of IL-17E (r = -0.227, p = 0.003). There was no correlation 
between serum levels of IL-17F and IL-17A/F. 
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IL-17A/F 
 
IL-17F 
 
IL-17E 
 
IL-17D 
 
IL-17C 
 
IL-17B 
IL-17A n 168 168 173 79 97 97 
 r  +0.600 +0.172 -0.227 +0.092 +0.201 +0.152 
 p <0.001* 0.026* 0.003* 0.419 0.048* 0.128 
IL-17B n 96 96 97 79 97  
 r  +0.201 +0.089 -0.031 +0.012 +0.167  
 p 0.049* 0.387 0.767 0.912 0.107  
IL-17C n 96 96 97 79   
 r +0.008 +0.326 +0.036 -0.050   
 p 0.936 0.001* 0.725 0.660   
IL-17D n 79 79 79    
 r +0.031 +0.138 +0.045    
 p 0.789 0.226 0.693    
IL-17E n 169 169     
 r  +0.131 -0.062     
 p 0.090 0.420     
IL-17F n 169      
 r  +0.057      
 p 0.464      
Table 4-3: Correlations between serum levels of IL-17 family cytokines  
The table represents correlations between serum levels of each IL-17 family 
cytokine. The serum level values were subjected to a natural log transformation. 
The correlations were analysed using the Pearson correlation coefficient test 
(IBM SPSS Statistics, version 19). Significance = p<0.05 (*). n = number of 
subjects and r = the Pearson correlation coefficient. 
 
4.2.5 Correlations between serum IL-17A:IL-17E ratio and 
clinical parameters 
The literature suggests that IL-17A and IL-17E have opposing roles in the 
inflammatory response. The serum analysis demonstrated a significant negative 
correlation between circulating levels of IL-17A and IL-17E in peridontitis (table 
4-3). Therefore it was hypothesised that the circulating ratio of IL-17A:IL-17E 
could be a determinant of periodontal disease. Therefore, associations between 
individuals serum IL-17A:IL-17E ratio and clinical parameters were determined. 
Associations were determined using the Pearson correlation coefficient test (IBM 
SPSS Statistics, version 19). Serum IL-17A:IL-17E ratios were subjected to natural 
log transformations to facilitate graphical representation.  
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Figure 4-1 shows that the serum IL-17A:IL-17E ratio has a weak but significant 
positive correlation with CPD (r = +0.335, p < 0.001) and BOP (r = +0.286, p < 
0.001). In addition, the serum IL-17A:IL-17E ratio has a significant moderate 
positive correlation with CAL (r = +0.480, p < 0.001).  
                          
Figure 4-1: Correlations between the serum IL-17A:IL17E ratio and clinical 
parameters 
The serum IL-17A:IL-17E ratio of all subjects (regardless of disease state) was 
calculated. To facilitate graphical representation the IL-17A:IL-17E ratio’s were 
subjected to a natural log transformation (Ln). Correlation analysis against CPD 
(A), CAL (B) and BOP (C) was then performed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Significance = p<0.05. r = the 
Pearson correlation coefficient. 
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4.2.6 Correlations between serum levels of IL-17 family 
cytokines and age 
Immunosenescence is a term that refers to the gradual deterioration of 
the immune system due to increase in age. Development and maintenance of 
peripheral immune responses are postulated to be affected by aging (Miller, 
1991). Evidence also shows that immunosenescence could play a role in the 
pathogenesis of periodontal disease (Rajendran et al., 2013).   
Since there was a large spread of subjects in terms of age enrolled in our study 
(22 – 55 years) we determined the association between serum levels of IL-17 
family cytokines and age. Once again, correlations were determined using the 
Pearson correlation coefficient test (IBM SPSS Statistics, version 19). 
Table 4-4 shows serum levels of IL-17A and IL-17A/F positively correlated with 
age (r = +0.338, p < 0.001; and r = +0.598, p < 0.001 respectively) regardless of 
disease state. Interestingly, although the serum IL-17A:IL-17E ratio was also 
found to significantly positively correlate with age (r = +0.259, p = 0.001), the 
correlations are found not significant after correction for disease (clinical 
probing depth). 
 
   
IL-17A 
 
IL-17B 
 
IL-17C 
 
IL-17D 
 
IL-17E 
 
IL-17F 
 
IL-17A/F 
 
IL-17A: 
IL-17E 
          
Age n 174 97 97 79 174 169 169 172 
          
 r  +0.338 +0.157 -0.092 +0.107 +0.031 -0.080 +0.598 +0.259 
 p <0.001*   0.124   0.372   0.347   0.684   0.303 <0.001*   0.001* 
          
 rpartial  +0.160 +0.173 +0.179 -0.142 +0.001 +0.109 +0.381 +0.142 
 p   0.036*   0.092   0.081   0.217   0.994   0.085 <0.001*   0.064 
Table 4-4: Correlations between serum levels of IL-17 family cytokines and age 
The table represents correlations between levels of IL-17 family cytokines and 
age. The values were subjected to a natural log transformation. The correlations 
were analysed using the Pearson correlation coefficient test (IBM SPSS Statistics, 
version 19). Adjustment for disease severity was carried out using the Partial 
correlation test controlling for clinical probing depth (CPD) (IBM SPSS Statistics, 
version 19). Significance = p<0.05 (*). n = number of subjects; r = the Pearson 
correlation coefficient; rpartial = the Partial correlation and IL-17A:IL-17E = the 
serum ratio of IL-17A to IL-17E. 
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4.2.7 Relationship between serum levels of IL-17 family 
cytokines and gender 
Incidence of humoral and cell mediated autoimmune diseases such as multiple 
sclerosis, rheumatoid arthritis and systemic erythematosus were found to be 
higher in females compared to males (Beeson, 1994; Whitacre et al., 1999), 
indicating possible differences in immune regulation between genders. However, 
epidemiological studies have demonstrated a higher prevalence and severity of 
periodontal disease in men than women (Shiau & Reynolds, 2010). 
Since our study involved both male and female subjects, we compared the serum 
levels of IL-17 family cytokines between genders. Our Q-Q plot analysis showed 
the data was not normally distributed, and hence statistical analysis was carried 
out using the Mann-Whitney test with a Bonferroni correction (IBM SPSS 
Statistics, version 19).  
Table 4-5 shows analysis demonstrating that serum levels of IL-17 family 
cytokines were found not to be significantly different between males and 
females. 
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Gender 
 
n 
Median 
(pg/ml) 
 
IQR 
 
Z statistic 
 
p value 
IL-17A Male 72 42.20 13.40 – 50.30 
-2.354 0.133 
Female 102 37.65 14.53 – 47.15 
IL-17B Male 42 39.70 25.00 – 57.10 
-2.141 0.224 
Female 55 31.00 16.83 – 42.93 
IL-17C Male 42 31.70 9.80 – 50.90 
-0.284 1.000 
Female 55 39.05 16.20 – 50.75 
IL-17D Male 35 24.30 20.40 – 31.10 
-1.032 1.000 
Female 44 23.05 20.55 – 25.15 
IL-17E Male 73 16.90 15.90 – 21.10 
-0.994 1.000 
Female 101 17.00 16.00 – 34.43 
IL-17F Male 69 14.80 13.20 – 20.10 
-0.383 1.000 
Female 100 15.60 13.75 – 26.70 
IL-17A/F Male 69 23.10 0.00 – 26.50 
-0.210 1.000 
Female 100 23.00 8.00 – 25.50 
Table 4-5: Comparison of serum levels of IL-17 family cytokines between males 
and females 
The table represents median levels of IL-17 family cytokines in the serum of 
male and female subjects. Statistical analyses were carried out using the Mann-
Whitney test with a Bonferroni correction (IBM SPSS Statistics, version 19). 
Significance = p<0.05 (*). n = number of subjects; and IQR = interquartile range.  
 
4.2.8 Gingival crevicular fluid levels of IL-17A, IL-17E, IL-17F 
and IL-17A/F 
GCF levels of IL-17 family cytokines were measured by ELISA. Due to sample 
limitations, only GCF levels of IL-17A, IL-17E, IL-17F and IL-17A/F were 
measured. Table 4-6 shows GCF levels of IL-17A, IL-17F and IL-17A/F were 
significantly increased in the patients with chronic periodontitis (94.9 pg/ml, 6.4 
pg/ml and 19.0 pg/ml respectively) as compared to healthy subjects (44.4 
pg/ml, 3.9 pg/ml and 5.5 pg/ml respectively). GCF levels of IL-17E were not 
significantly different between the two groups. The GCF IL-17A:IL-17E ratio was 
also not significantly different between the two groups. 
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Status 
 
n 
Median 
(pg/ml) 
 
IQR 
 
Z statistic 
 
p value 
IL-17A Healthy 37 44.4 5.0 – 117.2 
-3.585 <0.001* 
 CP 41 94.9 76.6 – 119.6 
IL-17E Healthy 37 86.6 2.0 – 127.0 
-0.996 0.319 
 CP 41 70.6 40.6 – 145.3 
IL-17F Healthy 21 3.9 1.9 – 7.8 
-2.138 0.023* 
 CP 13 6.4 5.8 – 12.5 
IL-17A/F Healthy 21 5.5 4.9 – 15.0 
-4.235 <0.001* 
 CP 13 19.0 15.0 – 35.0 
IL-17A: IL-
17E 
Healthy 37 0.5# 0.2 – 2.4 
-0.980 0.320 
 CP 41 0.6# 0.2 – 1.5 
Table 4-6: Levels of IL-17A, IL-17E, IL-17F, IL-17A/F and the IL-17A:IL-17E ratio 
in gingival crevicular fluid 
The table represents median levels of IL-17A, IL-17E, IL-17F, IL-17A/F and IL-
17:IL-17E ratio in GCF of the healthy subjects and chronic periodontitis (CP) 
patients. Statistical analyses were carried out using the Mann-Whitney test with 
a Bonferroni correction (IBM SPSS Statistics, version 19). Significance = p<0.05 
(*). n = number of subjects; IQR = interquartile range; IL-17A:IL-17E = the serum 
ratio of IL-17A to IL-17E and # = ratio value (no units).  
 
4.2.9 Correlations between gingival crevicular fluid levels of 
IL-17A, IL-17E, IL-17F, IL-17A/F and clinical parameters 
To determine any associations between GCF levels of IL-17 family cytokines and 
clinical parameters, as the data was not normally distributed natural log 
transformation were performed prior to analysis. The correlations were carried 
out using the Pearson correlation coefficient test (IBM SPSS Statistics, version 
19).  
Table 4-7 shows the GCF level of IL-17A positively correlated with all clinical 
parameters measured: CPD (r = +0.611, p < 0.001), CAL (r = +0.543, p < 0.001) 
and BOP (r = +0.273, p = 0.016). As did GCF levels of IL-17E: CPD (r = +0.415, p = 
0.001), CAL (r = +0.463, p < 0.001) and BOP (r = +0.355, p = 0.002). In addition, 
the GCF level of IL-17F positively correlated with CPD (r = +0.481, p = 0.008), 
CAL (r = +0.449, p = 0.005) and BOP (r = +0.349, p = 0.043). Furthermore, the 
GCF level of IL-17A/F positively correlated with CPD (r = +0.435, p = 0.010), CAL 
(r = +0.444, p = 0.008) and BOP (r = +0.368, p = 0.032). 
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CPD 
 
CAL 
 
BOP 
IL-17A n 77 77 77 
 r +0.611 +0.543 +0.273 
 p <0.001* <0.001* 0.016* 
IL-17E n 77 77 77 
 r +0.415 +0.463 +0.355 
 p 0.001* <0.001* 0.002* 
IL-17F n 34 34 34 
 r  +0.481 +0.449 +0.349 
 p 0.008* 0.005* 0.043* 
IL-17A/F n 34 34 34 
 r +0.435 +0.444 +0.368 
 p  0.010*  0.008*  0.032* 
Table 4-7: Correlation between gingival crevicular fluid levels of IL-17A, IL-17E, 
IL-17F, IL-17A/F and clinical parameters 
The table represents the correlations between GCF levels of IL-17A, IL-17E, IL-
17F, IL-17A/F and clinical parameters for periodontal disease (CPD, CAL and 
BOP). The serum level values were subjected to a natural log transformation. 
The correlations were analysed using the Pearson correlation coefficient test 
(IBM SPSS Statistics, version 19). Significance= p<0.05 (*). n = number of 
subjects; r = the Pearson correlation coefficient; CPD = clinical probing depth; 
CAL = clinical attachment loss and BOP = bleeding on probing. 
 
4.2.10 Correlations between gingival crevicular fluid levels of 
IL-17A, IL-17E, IL-17F and IL-17A/F 
In addition to associations between GCF levels of IL-17 family cytokines and 
clinical parameters; associations between each IL-17 family member were also 
determined. Once again these associations were determined using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). 
Table 4-8 shows that the GCF level of IL-17A positively correlated with the GCF 
level of IL-17E (r = +0.384, p = 0.001), IL-17F (r = +0.638, p < 0.001) and IL-
17A/F (r = +0.867, p < 0.001). In addition, the GCF level of IL-17E positively 
correlated with the GCF levels of IL-17F (r = +0.422, p = 0.013) and IL-17A/F (r = 
+0.684, p < 0.001). Furthermore, the GCF level of IL-17F positively correlated 
with the GCF level of IL-17A/F (r = +0.677, p < 0.001).     
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IL-17A/F 
 
IL-17F 
 
IL-17E 
IL-17A n 34 34 78 
 r  +0.867 +0.638 +0.384 
 p <0.001* <0.001* 0.001* 
IL-17E n 34 34  
 r  +0.684 +0.422  
 p <0.001* 0.013*  
IL-17F n 34   
 r +0.677   
 p <0.001*   
Table 4-8: Correlations between gingival crevicular fluid levels of IL-17A, IL-17E, 
IL-17F and IL-17A/F  
The table represents correlations between levels of each IL-17A, IL-17E, IL-17F 
and IL-17A/F. The serum level values were subjected to a natural log 
transformation. The correlations were analysed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Significance = p<0.05 (*). n = 
number of subjects and r = the Pearson correlation coefficient. 
 
4.2.11 Correlations between gingival crevicular fluid levels of 
IL-17A:IL-17E ratio and clinical parameters 
As was performed for serum (Section 4.2.5), the associations between individuals 
GCF IL-17A:IL-17E ratio and clinical parameters were determined. Associations 
were determined using the Pearson correlation coefficient test (IBM SPSS 
Statistics, version 19). GCF IL-17A:IL-17E ratios were subjected to natural log 
transformations to facilitate graphical representation.  
Figure 4-2 shows that the GCF IL-17A:IL-17E ratio showed a weak but significant 
positive correlation with CPD (r = +0.344, p = 0.002) and CAL (r = +0.250, p = 
0.029), but no significant correlation with BOP (r = +0.116, p = 0.318).  
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Figure 4-2: Correlations between the GCF IL-17A:IL17E ratio and clinical 
parameters 
The GCF IL-17A:IL-17E ratio of all subjects (regardless of disease state) was 
calculated. To facilitate graphical representation the IL-17A:IL-17E ratio’s were 
subjected to a natural log transformation (Ln). Correlation analysis against CPD 
(A), CAL (B) and BOP (C) was then performed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Significance = p<0.05. r = the 
Pearson correlation coefficient. 
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4.2.12 Correlations between gingival crevicular fluid levels of 
IL-17A, IL-17E, IL-17F, IL-17A/F and age 
Correlations between GCF levels of IL-17 family cytokines and age were 
determined using the Pearson correlation coefficient test (IBM SPSS Statistics, 
version 19). 
Table 4-9 shows GCF levels of IL-17A, IL-17E, IL-17F and IL-17A/F positively 
correlated with age (r = +0.498, p < 0.001; r = +0.357, p = 0.001; r = +0.481, p = 
0.004; and r = +0.531, p = 0.001 respectively). However, only GCF levels of IL-
17A, IL-17E and IL-17F show significant positive correlation after corrected for 
disease severity parameter (clinical probing depth). In addition, no correlation 
was determined between the GCF IL-17A:IL-17E ratio and age after correction 
for disease state (CPD). 
 
  
 
IL-17A 
 
IL-17E 
 
IL-17F 
 
IL-17A/F 
 
IL-17A: IL-17E 
       
Age n 78 78 34 34 77 
       
 r  +0.498 +0.357 +0.481 +0.531 +0.202 
 p <0.001* 0.001* 0.004* 0.001* 0.078 
       
 rpartial  +0.474 +0.303 +0.405 +0.236 +0.144 
 p <0.001* 0.008* 0.019* 0.186 0.218 
Table 4-9: Correlations between gingival crevicular fluid levels of IL-17A, IL-17E, 
IL-17F, IL-17A/F, IL-17A:IL-17E ratio and age 
The table represents correlations between levels of IL-17A, IL-17E, IL-17F, IL-
17A/F, IL-17A:IL-17E ratio and age. The GCF level values were subjected to a 
natural log transformation. The correlations were analysed using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). Adjustment for 
disease severity was carried out using the Partial correlation test controlling for 
clinical probing depth (CPD) (IBM SPSS Statistics, version 19). Significance = 
p<0.05 (*). n = number of subjects; r = the Pearson correlation coefficient; rpartial 
= the Partial correlation and IL-17A:IL-17E = the serum ratio of IL-17A to IL-17E. 
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4.2.13 Relationship between gingival crevicular fluid levels of 
IL-17A, IL-17E, IL-17F, IL-17A/F and gender 
Statistical comparisons of GCF levels of IL-17 family cytokines between male and 
female subjects were carried out using the Mann-Whitney test with a Bonferroni 
correction (IBM SPSS Statistics, version 19). 
Table 4-10 shows the GCF levels of IL-17 family cytokines were not significantly 
different between males and females. 
 
  
Gender 
 
n 
 
Median 
 
IQR 
 
Z statistic 
 
p value 
IL-17A Male 35 89.70 69.07 – 118.90 
-2.365 0.072 
Female 42 69.83 5.00 – 119.83 
IL-17E Male 35 89.20 54.50 – 161.77 
-2.144 0.128 
Female 42 56.70 5.38 – 126.20 
IL-17F Male 13 7.20 6.10 – 11.38 
-2.116 0.136 
Female 21 3.90 1.90 – 7.20 
IL-17A/F Male 13 13.56 9.45 – 29.05 
-2.428 0.060 
Female 21 6.48 3.56 – 13.71 
Table 4-10: Comparison of gingival crevicular fluid levels of IL-17A, IL-17E, IL-
17F and IL-17A/F between males and females 
The table represents median levels of IL-17A, IL-17E, IL-17F and IL-17A/F in the 
GCF of male and female subjects. Statistical analyses were carried out using the 
Mann-Whitney test with a Bonferroni correction (IBM SPSS Statistics, version 19). 
Significance = p<0.05 (*). n = number of subjects; and IQR = interquartile range. 
 
4.2.14 Saliva levels of IL-17A, IL-17E, IL-17F and IL-17A/F 
Saliva levels of IL-17 family cytokines were measured by ELISA. Due to sample 
limitation, only saliva levels of IL-17A, IL-17E, IL-17F and IL-17A/F were 
measured. Table 4-11 shows saliva levels of IL-17A, IL-17E and IL-17F were 
significantly increased in patients with chronic periodontitis (21.8 pg/ml, 56.3 
pg/ml and 30.7 pg/ml respectively) as compared to healthy subjects (12.7 
pg/ml, 22.4 pg/ml and 9.6 pg/ml respectively). The saliva levels of IL-17A/F 
were not significantly different between the two groups. Also, the saliva IL-
17A:IL-17E ratio was not significantly different between the two groups. 
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Status 
 
n 
Median 
(pg/ml) 
 
IQR 
 
Z statistic 
 
p value 
IL-17A Healthy 37 12.73 8.13 – 21.16 
-3.337 0.001* 
 CP 65 21.84 13.14 – 51.37 
IL-17E Healthy 37 22.40 4.00 – 60.60 
-3.655 <0.001* 
 CP 65 56.63 27.56 – 112.55 
IL-17F Healthy 37 9.60 8.00 – 19.02 
-6.219 <0.001* 
 CP 65 30.70 19.91 – 55.37 
IL-17A/F Healthy 37 9.40 1.90 – 17.60 
-1.438 0.151 
 CP 65 11.02 7.46 – 37.17 
IL-17A: IL-17E Healthy 37 0.8# 0.3 – 1.28 -0.867 0.386 
 CP 65 0.8# 0.5 – 1.1 
Table 4-11: Levels of IL-17A, IL-17E, IL-17F, IL-17A/F and the IL-17A:IL-17E ratio 
in saliva 
The table represents median levels of IL-17A, IL-17E, IL-17F, IL-17A/F and the IL-
17A:IL-17E ratio in saliva of the healthy subjects and chronic periodontitis (CP) 
patients. Statistical analyses were carried out using the Mann-Whitney test with 
a Bonferroni correction (IBM SPSS Statistics, version 19). Significance = p<0.05 
(*). n = number of subjects; IQR = interquartile range; IL-17A:IL-17E = the serum 
ratio of IL-17A to IL-17E and # = ratio value (no unit).  
 
4.2.15 Correlations between saliva levels of IL-17A, IL-17E, IL-
17F, IL-17A/F and clinical parameters 
To determine any associations between saliva levels of IL-17 family cytokines 
and clinical parameters, as the data was not normally distributed natural log 
transformation were performed prior to analysis. Once again, the correlations 
were carried out using the Pearson correlation coefficient test (IBM SPSS 
Statistics, version 19).  
Table 4-12 shows the saliva level of IL-17A positively correlated with CPD (r = 
+0.585, p = 0.001) and CAL (r = +0.520, p = 0.002). The saliva level of IL-17E 
positively correlated with all clinical parameters measured: CPD (r = +0.673, p < 
0.001), CAL (r = +0.761, p < 0.001) and BOP (r = +0.480, p = 0.004). The Saliva 
level of IL-17F also positively correlated with CPD (r = +0.462, p < 0.001) and 
CAL (r = +0.404, p = 0.020). The Saliva level of IL-17A/F did not correlate with 
any of the clinical parameters. 
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CPD 
 
CAL 
 
BOP 
IL-17A n 102 102 102 
 r +0.585 +0.520 +0.275 
 p 0.001* 0.002* 0.115 
IL-17E n 102 102 102 
 r  +0.673 +0.761 +0.480 
 p <0.001* <0.001* 0.004* 
IL-17F n 102 102 102 
 r  +0.462 +0.404 +0.254 
 p <0.001*  0.020*  0.167 
IL-17A/F n 102 102 102 
 r +0.199 +0.212 +0.050 
 p 0.555 0.457 0.856 
Table 4-12: Correlations between saliva levels of IL-17A, IL-17E, IL-17F, IL-
17A/F and clinical parameters 
The table represents the correlations between saliva levels of IL-17 family 
cytokines and clinical parameters for periodontal disease (CPD, CAL and BOP). 
The serum level values were subjected to a natural log transformation. The 
correlations were analysed using the Pearson correlation coefficient test (IBM 
SPSS Statistics, version 19). Significance = p<0.05 (*). n = number of subjects; r = 
the Pearson correlation coefficient; CPD = clinical probing depth; CAL = clinical 
attachment loss and BOP = bleeding on probing. 
 
4.2.16 Correlations between saliva levels of IL-17A, IL-17E, IL-
17F and IL-17A/F 
In addition to associations between saliva levels of IL-17 family cytokines and 
clinical parameters; associations between each IL-17 family member were also 
determined. Once again these associations were determined using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). 
Table 4-13 shows that the saliva level of IL-17A positively correlated with the 
saliva levels of IL-17E (r = +0.267, p = 0.001), IL-17F (r = +0.408, p < 0.001) and 
IL-17A/F (r = +0.442, p < 0.001). The saliva level of IL-17E positively correlated 
with the saliva levels of IL-17F (r = +0.411, p < 0.001) and IL-17A/F (r = +0.360, p 
< 0.001). The Saliva level of IL-17F positively correlated with the saliva level of 
IL-17A/F (r = +0.338, p = 0.001). 
  203
  
 
IL-17A/F 
 
IL-17F 
 
IL-17E 
IL-17A n 102 102 102 
 r  +0.442 +0.408 +0.267 
 p <0.001* <0.001* 0.001* 
IL-17E n 102 102  
 r  +0.360 +0.411  
 p <0.001* <0.001*  
IL-17F n 102   
 r  +0.338   
 p 0.001*   
Table 4-13: Correlations between saliva levels of IL-17A, IL-17E, IL-17F and IL-
17A/F  
IL-17A, IL-17E, IL-17F and IL-17A/F were measured in saliva samples using the 
appropriate ELISA kit (Table 2-3). The table represents correlations between 
levels of each IL-17 family cytokine. The serum level values were subjected to a 
natural log transformation. The correlations were analysed using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). Significance = 
p<0.05 (*). n = number of subjects and r = the Pearson correlation coefficient. 
 
4.2.17 Correlations between saliva levels of IL-17A:IL-17E ratio 
and clinical parameters 
As was performed for serum and GCF (4.2.5 and 4.2.11), the associations 
between individuals saliva IL-17A:IL-17E ratio and clinical parameters were 
determined. Associations were determined using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Saliva IL-17A:IL-17E ratios were 
subjected to natural log transformations to facilitate graphical representation.  
Figure 4-3 shows that the saliva IL-17A:IL-17E ratio did not to significantly 
correlate with any of the clinical parameters. 
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Figure 4-3: Correlations between the saliva IL-17A:IL17E ratio and clinical 
parameters 
The saliva IL-17A:IL-17E ratio of all subjects (regardless of disease state) was 
calculated. To facilitate graphical representation the IL-17A:IL-17E ratio’s were 
subjected to a natural log transformation (Ln). Correlation analysis against CPD 
(A), CAL (B) and BOP (C) was then performed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Significance = p<0.05. r = the 
Pearson correlation coefficient. 
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4.2.18 Correlations between saliva levels of IL-17A, IL-17E, IL-
17F, IL-17A/F and age 
Correlations between saliva levels of IL-17 family cytokines and age were 
determined using the Pearson correlation coefficient test (IBM SPSS Statistics, 
version 19). 
Table 4-14 shows saliva levels of IL-17E, IL-17F and IL-17A/F positively 
correlated with age (r = +0.495, p < 0.001; r = +0.525, p < 0.001; and r = +0.356, 
p < 0.001 respectively), regardless of disease state. Although saliva levels of IL-
17A also show significant positive correlation with age (r = +0.235, p = 0.017), 
this correlation is found not to significant after correction for disease severity 
(clinical probing depth). In addition, the saliva IL-17A:IL-17E ratio did not 
significantly correlate with age after correction for disease state.  
 
  
 
IL-17A 
 
IL-17E 
 
IL-17F 
 
IL-17A/F 
 
IL-17A: IL-17E 
       
Age n 102 102 102 102 102 
       
 r  +0.235 +0.495 +0.525 +0.356 -0.117 
 p 0.017* <0.001* <0.001* <0.001* 0.243 
       
 rpartial +0.168 +0.389 +0.415 +0.343 -0.120 
 p 0.092 <0.001* <0.001* <0.001* 0.032 
Table 4-14: Correlations between saliva levels of IL-17A, IL-17E, IL-17F, IL-
17A/F, IL-17A:IL-17E ratio and age 
The table represents correlations between levels of IL-17 family cytokines and 
age. The saliva level values were subjected to a natural log transformation. The 
correlations were analysed using the Pearson correlation coefficient test (IBM 
SPSS Statistics, version 19). Adjustment for disease severity was carried out using 
the Partial correlation test controlling for clinical probing depth (CPD) (IBM SPSS 
Statistics, version 19). Significance = p<0.05 (*). n = number of subjects; r = the 
Pearson correlation coefficient; rpartial = the Partial correlation and IL-17A:IL-17E 
= the serum ratio of IL-17A to IL-17E. 
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4.2.19 Relationship between saliva levels of IL-17A, IL-17E, IL-
17F, IL-17A/F and gender 
Statistical comparisons of saliva levels of IL-17 family cytokines between male 
and female participants were carried out using the Mann-Whitney test with a 
Bonferroni correction (IBM SPSS Statistics, version 19). 
Table 4-15 shows saliva levels of IL-17 family cytokines were not significantly 
different between males and females. 
 
  
Gender 
 
n 
 
Median 
 
IQR 
 
Z statistic 
 
p value 
IL-17A Male 48 21.72 11.32 – 51.00 
-1.552 0.484 
Female 54 15.01 9.60 – 34.08 
IL-17E Male 48 52.22 25.39 – 108.77 
-2.371 0.072 
Female 54 32.39 5.33 – 75.30 
IL-17F Male 48 24.12 17.57 – 36.18 
-0.727 1.000 
Female 54 23.50 9.70 – 41.08 
IL-17A/F Male 48 9.45 5.51 – 32.59 
-0.443 1.000 
Female 54 11.03 7.18 – 21.07 
Table 4-15: Comparison of saliva levels of IL-17A, IL-17E, IL-17F and IL-17A/F 
between males and females 
The table represents median levels of IL-17A, IL-17E, IL-17F and IL-17A/F in the 
saliva of male and female subjects. Statistical analyses were carried out using 
the Mann-Whitney test with a Bonferroni correction (IBM SPSS Statistics, version 
19). Significance = p<0.05 (*). n = number of subjects; and IQR = interquartile 
range. 
 
4.2.20 mRNA expression of IL-17 family cytokines in periodontal 
tissues 
Analyses of IL-17 family cytokine expression in clinical samples (serum, GCF and 
saliva) indicated a possible association between IL-17A, IL-17E, IL-17F, IL-17A/F 
and chronic periodontitis. To further confirm this finding, quantitative real-time 
PCR was used to investigate expression of these cytokines at the mRNA level in 
periodontal tissue samples from chronic periodontitis patients and healthy 
subjects undergoing non-periodontal related surgery.  
Figure 4-4 shows that mRNA for IL-17 family cytokines (IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E and IL-17F) were all expressed in periodontal tissue samples. In 
addition, apart from IL-17B, mRNA species for the remaining IL-17 family 
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cytokines were significantly upregulated in tissue from patients with chronic 
periodontitis compared to healthy subjects (all p < 0.05). 
 
      
Figure 4-4: Real-time PCR analysis of IL-17 family cytokines mRNA expression in 
healthy and diseased periodontal tissues 
Quantification of IL-17 family cytokine mRNA expression in periodontal tissues 
was performed by real-time PCR. Box-and-whiskers plot represent the median 
relative expression (2-CT) IL-17 family mRNA levels in tissues from healthy 
subjects and chronic periodontitis (CP) patients. RNA polymerase II was used as a 
reference gene. Statistical analyses were carried out using the Mann-Whitney 
test with a Bonferroni correction (IBM SPSS Statistics, version 19). * = p < 0.05, ** 
= p < 0.01, and NS = p > 0.05. Whiskers were determined by the Tukey method. 
Outliers were determined as 1.5 x IQR (interquartile range) above or below the 
median value and shown as black circles. 
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4.2.21 Serum levels of IL-10 
The opposing associations between the clinical parameters of periodontal 
disease and serum levels of IL-17E suggested that IL-17E may play a role as a 
negative regulator of periodontal immunity. Therefore, we investigated whether 
the relationship between biological levels of IL-17E and clinical parameters was 
similar to that of the archetypical anti-inflammatory cytokine IL-10. 
The serum level of IL-10 was measured by ELISA. Table 4-16 shows that the 
serum level of IL-10 was significantly decreased in patients with chronic 
periodontitis (69.6 pg/ml) compared to healthy subjects (107.8 pg/ml). 
 
 
 
Status 
 
n 
Median 
(pg/ml) 
 
IQR 
 
Z statistic 
 
p value 
IL-10 Healthy 45 107.80 30.50 – 200.40 
-2.209 0.027* 
 CP 57 69.60 52.15 – 90.40 
Table 4-16: Levels of IL-10 in serum 
IL-10 were measured in serum samples using the appropriate ELISA kit (Table 2-
3). The table represents median levels of IL-10 in serum of the healthy and 
chronic periodontitis (CP) patients. Statistical analyses were carried out using 
the Mann-Whitney test (IBM SPSS Statistics, version 19). Significance = p<0.05 (*). 
n = number of subjects and IQR = interquartile range. 
 
4.2.22 Correlations between serum levels of IL-10 and clinical 
parameters 
To determine any associations between the serum level of IL-10 and clinical 
parameters, as the data was not normally distributed natural log transformation 
were performed prior to analysis. The correlations were carried out using the 
Pearson correlation coefficient test (IBM SPSS Statistics, version 19).  
Table 4-17 shows that the serum level of IL-10 negatively correlated with all 
clinical parameters but only statistically significantly with CPD (r = -0.208, p = 
0.036) and BOP (r = -0.204, p < 0.040). 
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CPD 
 
CAL 
 
BOP 
IL-10 n 102 102 102 
 r  -0.208 -0.141 -0.204 
 p 0.036* 0.157 0.040* 
Table 4-17: Correlation between serum levels of IL-10 and clinical parameters 
The table represents the correlations between IL-10 and clinical parameters for 
periodontal disease (CPD, CAL and BOP). The serum level value was subjected to 
a natural log transformation. The correlations were analysed using the Pearson 
correlation coefficient test (IBM SPSS Statistics, version 19). Significance = 
p<0.05 (*). n = number of subjects; r = the Pearson correlation coefficient; CPD = 
clinical probing depth; CAL = clinical attachment loss and BOP = bleeding on 
probing. 
 
4.2.23 Correlations between serum levels of IL-10 and IL-17 
family cytokines 
The association between circulating levels of IL-10 and IL-17 family cytokines 
was determined using the Pearson correlation coefficient test (IBM SPSS 
Statistics, version 19). 
Table 4-18 shows that the serum level of IL-10 positively correlated with the 
serum levels of IL-17C (r = +0.240, p = 0.025), IL-17E (r = +0.212, p = 0.033) and 
IL-17F (r = +0.250, p = 0.011). There is no correlation between IL-10 and other 
members of the IL-17 family cytokines (IL-17A, IL-17B, IL-17D and IL-17A/F). 
 
  
 
IL-17A 
 
IL-17B 
 
IL-17C 
 
IL-17D 
 
IL-17E 
 
IL-17F 
 
IL-17A/F 
IL-10 n 102 88 87 74 102 102 102 
 r -0.187 -0.140 +0.240 -0.120 +0.212 +0.250 -0.149 
 p 0.060 0.194 0.025* 0.310 0.033* 0.011* 0.134 
Table 4-18: Correlations between serum levels of IL-10 and IL-17 family 
cytokines  
The table represents correlations between levels of each cytokine. The serum 
level values were subjected to a natural log transformation. The correlations 
were analysed using the Pearson correlation coefficient test (IBM SPSS Statistics, 
version 19). Significance = p<0.05 (*). n = number of subjects and r = the Pearson 
correlation coefficient. 
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4.2.24 Correlations between serum IL-17A:IL-10 ratio and 
clinical parameters 
The literature suggests that IL-17A and IL-10 have opposing roles in the 
inflammatory response. Therefore, as was previously performed for IL-17E, the 
circulating IL-17A:IL-10 ratio for each individual subject was calculated. 
Associations between the IL-17A:IL-10 ratio and clinical parameters were then 
determined using the Pearson correlation coefficient test (IBM SPSS Statistics, 
version 19). 
Figure 4-5 shows that the serum IL-17A:IL-10 had strong significant positive 
correlations with all clinical parameters measured: CPD (r = +0.559, p < 0.001), 
CAL (r = +0.536, p < 0.001) and BOP (r = +0.455, p < 0.001). 
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Figure 4-5: Correlations between the serum IL-17A:IL10 ratio and clinical 
parameters 
The serum IL-17A:IL-17E ratio of all subjects (regardless of disease state) was 
calculated. To facilitate graphical representation the IL-17A:IL-10 ratio’s were 
subjected to a natural log transformation (Ln). Correlation analysis against CPD 
(A), CAL (B) and BOP (C) was then performed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Significance = p<0.05. r = the 
Pearson correlation coefficient. 
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4.2.25 Correlations between serum levels of IL-10 and age 
Correlations between the serum level of IL-10 and age were determined using 
the Pearson correlation coefficient test (IBM SPSS Statistics, version 19). 
Table 4-19 shows serum levels of IL-10 was found not to significantly correlate 
with age regardless of disease state. Although, the serum IL-17A:IL-10 ratio was 
found to significantly positively correlate with age (r = +0.402, p < 0.001), the 
correlations are found not significant after correction for the disease severity 
(clinical probing depth). 
 
  
 
IL-10 
 
IL-17A:IL-10 
    
Age n 102 102 
    
 r -0.167 +0.402 
 p 0.093 <0.001* 
    
 rpartial -0.153 0.154 
 p 0.106 0.125 
Table 4-19: Correlations between serum levels of IL-10, IL-17A:IL-10 ratio and 
age 
The table represents correlations between serum levels of IL-10 and IL-17A:IL-10 
ratio and age. The serum level values were subjected to a natural log 
transformation. The correlations were analysed using the Pearson correlation 
coefficient test (IBM SPSS Statistics, version 19). Adjustment for disease severity 
was carried out using the Partial correlation test controlling for clinical probing 
depth (CPD) (IBM SPSS Statistics, version 19). Significance = p<0.05 (*). n = 
number of subjects; r = the Pearson correlation coefficient; rpartial = the Partial 
correlation and IL-17A:IL-10 = the serum ratio of IL-17A to IL-10. 
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4.2.26 Relationship between serum levels of IL-10 and gender 
Statistical comparisons of the serum IL-10 level between male and female 
subjects were carried out using the Mann-Whitney test (IBM SPSS Statistics, 
version 19). 
Table 4-20 shows the serum level of IL-10 was not significantly different 
between males and females.   
  
Gender 
 
n 
 
Median 
 
IQR 
 
Z statistic 
 
p value 
IL-10 Male 42 69.60 31.75 – 106.00 
-1.823 0.068 
Female 60 83.85 57.15 – 164.68 
Table 4-20: Comparison of serum levels of IL-10 between males and females 
The table represents median levels IL-10 in serum of male and female subjects. 
Statistical analyses were carried out using the Mann-Whitney test (IBM SPSS 
Statistics, version 19). Significance = p<0.05 (*). n = number of subjects; and IQR 
= interquartile range. 
 
4.2.27 mRNA expression of IL-10 cytokine in periodontal tissues 
Previous data has shown that IL-10 levels are significantly elevated in 
periodontal tissue of patients with periodontal disease (Napimoga, et al., 2011). 
To confirm this finding quantitative real-time PCR method was used to evaluate 
expression of IL-10 mRNA in periodontal tissue samples from chronic 
periodontitis patients and healthy subjects undergoing non-periodontal related 
surgery.  
Figure 4-6 shows that mRNA for IL-10 was found expressed in healthy periodontal 
tissue samples and expression was significantly upregulated in tissue isolated 
from chronic periodontitis patients (p < 0.05). 
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Figure 4-6: Real-time PCR analysis of IL-10 mRNA expression in healthy and 
diseased periodontal tissues 
Quantification of IL-10 mRNA expression in periodontal tissues was performed by 
real-time PCR. Box-and-whiskers plot represent the median relative expression 
(2-CT) of IL-10 mRNA in tissue from healthy subjects and chronic periodontitis 
(CP) patients. RNA polymerase II was used as a reference gene. Statistical 
analyses were carried out using the Mann-Whitney test (IBM SPSS Statistics, 
version 19). * = p < 0.05. Whiskers were determined by the Tukey method. 
Outliers were determined as 1.5 x IQR (interquartile range) above or below the 
median and shown as black circles. 
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4.3 Discussion 
In agreement with previous studies these findings confirm that serum, GCF, and 
saliva levels of IL-17A are elevated in chronic periodontitis patients and 
correlate with clinical parameters (Buduneli, et al., 2009; Duarte, et al., 2010; 
Ozcaka, et al., 2011; Schenkein, et al., 2010; Vernal, et al., 2005). Our real-
time PCR analysis also confirmed that the IL-17A mRNA levels are upregulated in 
the gingival tissue of chronic periodontitis patients compared to healthy subjects 
(Behfarnia, et al., 2013; Honda, et al., 2008; Ohyama, et al., 2009). 
In addition to confirming previous findings; this study further advances our 
understanding of the associations between IL-17F and the IL-17A/F heterodimer 
and chronic periodontitis. This study demonstrated significant increased serum 
levels of the IL-17A/F heterodimer in chronic periodontitis patients that 
correlated with clinical parameters (Table 4-1 and 4-2). However, serum levels 
of IL-17F were not significantly different between the 2 groups and did not 
correlate with clinical parameters (Table 4-1 and 4-2). The serum levels of IL-
17A, IL-17F and IL-17A/F did positively correlate to one another (Table 4-3). 
Additionally, significant increases in GCF levels of IL-17F and the IL-17A/F 
heterodimer were demonstrated in chronic periodontitis patients and these 
correlated with clinical parameters (Table 4-6 and 4-7). In saliva, significant 
differences in IL-17F levels were observed between chronic periodontitis 
patients and healthy subjects; which correlated with clinical parameters (Table 
4-11 and 4-12). In contrast, saliva levels of IL-17A/F were found not to 
significantly differ and did not correlate with any clinical parameters (Table 4-11 
and 4-12). The GCF and saliva levels of IL-17A, IL-17F and IL-17A/F are found to 
positively correlate to one and other. 
Associations between serum levels of IL-17A and IL-17A/F and chronic 
inflammatory diseases has been observed previously. Serum levels of IL-17A and 
IL-17A/F were elevated in patients with rheumatoid arthritis, 
lymphoproliferation syndrome (autoimmune syndrome), systemic sclerosis, 
systemic lupus erythematous and polycystic ovarian syndrome (Boggio et al., 
2014; Nakashima et al., 2012; Ozcaka, et al., 2013; Shimamoto et al., 2013; 
Tanasescu et al., 2010). However, serum levels of IL-17F were also found to be 
elevated in chronic inflammatory disease such as rheumatoid arthritis and 
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systemic lupus erythematous (Shimamoto, et al., 2013; Tanasescu, et al., 2010). 
This is in contrast to our findings which showed no difference in serum IL-17F 
levels (Table 4-1). However, the literature on IL-17F is contradictory with some 
studies on systemic sclerosis and rheumatoid arthritis reporting no differences in 
serum IL-17F levels between health and disease (Gumus, et al., 2013; 
Nakashima, et al., 2012). In fact, serum levels of IL-17F were reported to be 
lower in patients with chronic hepatitis C virus infection as well as severe 
helminthic infection (Echinococcus multilocularis) compared to healthy subjects 
(Lechner et al., 2012; Sousa et al., 2012). These data suggest that the role of IL-
17F in pathogenesis is disease specific. 
Apart from investigating IL-17A, few studies have evaluated the levels of other 
IL-17 family members in GCF. In line with our findings (Table 4-6), Gumus and 
colleagues (2013) showed increased GCF levels of IL-17A and IL-17F in chronic 
periodontitis patients with rheumatoid arthritis compared to chronic 
periodontitis patients who are systemically healthy. In addition, GCF levels of 
17A, IL-17F and IL-17A/F were positively correlated to one and other (Table 4-
7). In contrast to our findings (Table 4-6), however, Gumus and colleagues 
(2013) showed no difference in the GCF levels of IL-17A/F between both groups. 
Also in line with our data, Ozcaka and colleagues (2013) showed that GCF levels 
of IL-17A and IL-17F were increased in gingivitis patients who suffered polycystic 
ovarian syndrome compared to healthy subjects. However, they found that GCF 
levels of IL-17A and IL-17F were not correlated with any clinical parameters for 
periodontal disease (CPD and BOP). 
Similar to GCF, there are not many studies that evaluated the levels of IL-17 
family cytokines in saliva, with the exception of IL-17A. In line with our findings 
(Table 4-11), Ozcaka and colleagues (2013) showed increased saliva levels of IL-
17A and IL-17F in gingivitis patients who suffered polycystic ovarian syndrome 
compared to healthy subjects. In addition, saliva levels of IL-17A positively 
correlated with clinical parameters such as CPD and CAL (Table 4-12). However, 
saliva levels of IL-17A/F did not correlate with any clinical parameters and no 
difference in saliva levels of IL-17A/F was determined between the two groups 
(Table 4-11 and 4-12).  
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Real-time PCR analyses revealed for the first time that mRNA expression of IL-
17F is elevated in gingival tissue samples of chronic periodontitis patients 
compared to healthy subjects (Figure 4-4). This is in line with studies on other 
inflammatory diseases such ulcerative colitis, psoriasis and lichen planus which 
also demonstrated elevated IL-17F mRNA levels in diseased mucosa/epithelia 
(Fujino, et al., 2003; Im et al., 2012; Johansen et al., 2009; Johnston et al., 
2013; Piccinni et al., 2014; Seiderer, et al., 2008). 
This study is first to investigate associations between serum levels of IL-17B, IL-
17C and IL-17D and chronic periodontitis. However, no significant differences 
between serum levels of these family members were observed between chronic 
periodontitis patients and healthy subjects (Table 4-1). Furthermore, serum 
levels of IL-17B, IL-17C and IL-17D did not significantly correlate with clinical 
parameters (Table 4-2). Due to sample limitation, levels of IL-17B, IL-17C and IL-
17D were not evaluated in GCF and saliva. The Literature revealed a limited 
number of studies evaluating associations between serum levels of IL-17B, IL-17C 
and IL-17D with disease. Serum levels of IL-17B were shown to be elevated in 
patients with severe helminthic infection (Echinococcus multilocularis) and 
systemic lupus erythematous (Lechner, et al., 2012; Robak et al., 2013). Serum 
levels of IL-17C did not differ between healthy subjects and patients with 
hepatitis B (He et al., 2013). In addition, serum levels of IL-17B, IL-17C and IL-
17D were actually shown to be lower in patients with acute exacerbated chronic 
pulmonary heart disease compared to healthy subjects (Chen et al., 2012). 
Therefore, although research is at an early stage, the roles of IL-17B, IL-17C and 
IL-17D in pathogenesis may also be disease specific. 
Real-time PCR analyses demonstrated for the first time increased mRNA 
expression of IL-17C and IL-17D in the gingival tissue samples of chronic 
periodontitis patients compared to healthy subjects (Figure 4-4). However, no 
difference in IL-17B mRNA expression was observed. In line with literature, IL-
17C mRNA levels were also shown to be increased in psoriatic skin as well as in 
the colonic mucosa of ulcerative colitis patients (Im, et al., 2012; Johansen, et 
al., 2009; Johnston, et al., 2013). In contrast, Im and colleagues (2012) showed 
no difference in the mRNA expression of IL-17B and IL-17D in colonic mucosal 
tissue of ulcerative colitis patients and IL-17B and IL-17D mRNA levels were also 
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found to be decreased in the skin of psoriasis patients (Johansen, et al., 2009; 
Johnston, et al., 2013). 
The major novel finding of interest in this study is the association between IL-
17E and chronic periodontitis. Chronic periodontitis patients presented with 
decreased serum levels of IL-17E, which negatively correlated with CPD and CAL 
(Table 4-1 and 4-2). Serum levels of IL-17E also negatively correlated with IL-17A 
(Table 4-3). In GCF and saliva, however, the findings were slightly different. GCF 
levels of IL-17E were not significantly different between chronic periodontitis 
patients and healthy subjects; however levels did positively correlate with all 
clinical parameters (Table 4-6 and 4-7). Furthermore, saliva levels of IL-17E 
were significantly higher in chronic periodontitis patients and levels again 
correlated with all clinical parameters (Table 4-11 and 4-12). The decreased 
serum level of IL-17E in chronic periodontitis patients has been suggested 
previously as serum levels of IL-17E were shown to be lower in patients with a 
combination of gingivitis and polycystic ovarian syndrome (Ozcaka, et al., 2013). 
In addition, in patients with inflammatory bowel diseases, serum levels of IL-17E 
are also lower compared to their respective healthy subjects (Ozcaka, et al., 
2013; Su et al., 2013). In contrast, studies of IL-17E levels in GCF and saliva are 
limited for comparison. In line with our findings Gumus and colleagues (2013) 
showed no difference in GCF levels of IL-17E in chronic periodontitis patients 
who suffered rheumatoid arthritis compared to chronic periodontitis patients 
who are systemically healthy. In addition, Ozcaka and colleagues (2013) also 
showed that GCF levels of IL-17E in gingivitis patients who suffered polycystic 
ovarian syndrome were no different to healthy subjects. Additionally, Ozcaka 
and colleagues (2013) showed that GCF levels of IL-17E positively correlated 
with CPD and BOP. GCF levels of IL-17E were also shown to have positive 
correlations with IL-17A, IL-17F and IL-17A/F (Gumus, et al., 2013). In addition, 
in line with our data, saliva levels of IL-17E were found to be increased in 
gingivitis patients who suffered polycystic ovarian syndrome compared to 
healthy subjects, and these were found to positively correlate with clinical 
parameters (Ozcaka, et al., 2013). At the tissue level, real-time PCR analyses 
demonstrated increased mRNA expression of IL-17E in gingival tissue samples of 
chronic periodontitis patients compared to healthy subjects (Figure 4-4). In line 
with our findings, IL-17E mRNA expression was shown to be increased in sinus 
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mucosal tissue samples of chronic rhinosinusitis patients (Lam et al., 2013). In 
addition, IL-17E mRNA levels were also found to be increased in the sputum of 
patients with chronic rhinitis and asthma (Kwon et al., 2012; Seys et al., 2013). 
Furthermore, in a mouse model, IL-17E mRNA expression was elevated in lung 
tissues of ovalbumin induced lung inflammation (Kawashima et al., 2013) as well 
as in the skin of formaldehyde induced atopic dermatitis (Kim et al., 2013b). 
Chronic periodontitis patients presented with decreased serum levels of IL-17E, 
which negatively correlate with CPD and CAL, and serum levels of IL-17E are also 
negatively correlated with IL-17A (Table 4-1, 4-2 and 4-3). These findings 
suggest that the circulating IL-17A:IL-17E ratio may be a predictive marker of 
disease. Indeed, our data show serum IL-17A:IL-17E ratios are significantly higher 
in chronic periodontitis patients compared to healthy subjects (Table 4-1) and 
the serum IL-17A:IL-17E ratios have positive moderate correlations with both 
CAL and CPD (Figure 4-1). In contrast to the serum analysis, however, the GCF 
and saliva IL-17A:IL-17E ratio are not significantly increased in chronic 
periodontitis patients (Table 4-6 and 4-11); possibly because GCF and saliva 
levels of IL-17E tended to be greater. However, the GCF IL-17A:IL-17E ratio had 
a weak but positive correlation with CPD and CAL (Figure 4-2). No correlations 
were observed between the saliva IL-17A:IL-17E ratio and clinical parameters 
(Figure 4-3). Differences in levels of IL-17 family cytokines in serum, saliva and 
GCF could possibly be explained by the anatomical location from which these 
biological fluids are derived (Buduneli & Kinane, 2011). However, this is a matter 
of conjecture until we have a complete picture of IL-17 family cytokine biology. 
In line with these findings, serum levels of IL-17A and IL-17E were shown to be 
negatively correlated in patients with gingivitis and polycystic ovarian syndrome 
(Ozcaka, et al., 2013). Furthermore the serum IL-17A:IL-17E ratio was shown to 
be higher in patients with rheumatoid arthritis than healthy subjects (Gumus, et 
al., 2013). There were few studies that describe the associations between serum 
levels of IL-17A and IL-17E and chronic inflammatory disease. The GCF IL-17A:IL-
17E ratio was compared in chronic periodontitis patients who suffered from 
rheumatoid arthritis to chronic periodontitis patients who were systemically 
healthy and no significant differences found (Gumus, et al., 2013).  
Interestingly, our data show that serum levels of IL-17A and IL-17A/F have 
significant positive correlations with age regardless of disease state (Table 4-4). 
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However, although serum ratio of IL-17A:IL-17E and IL-17A:IL10 also have 
significant positive correlations with age, the correlations are found not 
significant after correction for disease severity (clinical probing depth) (Table 4-
4 and Table 4-19). In addition GCF levels of IL-17A, IL-17E, IL-17F and IL-17A/F 
have significant positive correlations with age, however only GCF levels of IL-
17A, IL-17E and IL-17F shows significant positive correlation after correction for 
disease severity (clinical probing depth) (Table 4-9). Additionally, saliva levels of 
IL-17E, IL-17F and IL-17A/F have significant positive correlation with age 
regardless of disease severity (Table 4-14). Although saliva levels of IL-17A also 
show significant positive correlation with age, this correlation is found not 
significant after correction for disease severity (clinical probing depth) (Table 4-
14).  
Studies show gradual deterioration of immune system occurs with aging 
(immunosenescence). For instance, although peripheral neutrophils numbers 
were found to increase with age, the migration ability of the aged neutrophils 
upon GM-CSF stimulation in vitro was found to be defective (Butcher et al., 
2000). In addition, age related products such as advanced glycation end products 
(AGE), were shown to induce increased expression of pro-inflammatory cytokines 
by phagocytic cells such as monocytes and macrophages (Thornalley, 1998). The 
population of T lymphocytes are also found to be altered by age, with age being 
associated with a decreased population of naïve T cells in healthy adults due to 
increase in apoptotic activity (Chakravarti & Abraham, 1999; Herndon et al., 
1997). These studies show aging can alter the balance of the immune system, 
which can lead to disturbances in tissue homeostasis as well as responses to 
infection. Clinical data has demonstrated that aging patients have a reduced 
capacity for fighting infection compared to young patients (Schneider, 1983). In 
periodontal disease, age has also been shown to associate with disease severity 
(Brown et al., 1996; Haas et al., 2014; Loe et al., 1992). In addition, 
autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and 
Weagner’s granulomatosis have been shown to have some features of 
immunosenescence (Peters et al., 2009). 
In line with our data, serum levels of IL-17A from chronic periodontitis patients 
have been found to associate with age (Schenkein, et al., 2010). However, 
serum levels of IL-17A were found not to correlate with age of patients with 
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psoriasis and rheumatoid arthritis (Arican et al., 2005; Metawi et al., 2011; Oh 
et al., 2011). In addition, serum levels of IL-10 did not correlate with age in 
patients with hepatitis C virus infection and Plasmodium falciparum infection 
(malaria) (Lyke et al., 2004; Reiser et al., 1997). Serum levels of IL-17A and IL-
10 in healthy subjects were also found not to correlate with age (Kim et al., 
2011; Sivro et al., 2013).  
In this study, we show that serum levels of all members of IL-17 family cytokines 
as well as IL-10 are not significantly different between males and females (Table 
4-5). In addition, GCF and saliva levels of IL-17A, IL-17E, IL-17F and IL-17A/F are 
also not significantly different between males and females (Table 4-10 and 4-
15). Epidemiological studies showed the prevalence of chronic periodontitis is 
greater in males than females (Shiau & Reynolds, 2010). However, this finding is 
probably due to differences in lifestyle choices between males and females; for 
example alcohol consumption, smoking, oral hygiene practices and frequency of 
dental visit (Burt, 2005). Although, gender-specific biological factors cannot be 
ruled out. Indeed, IL-17RA deficient male mice were found to be much more 
susceptible to periodontal disease than male mice (Yu et al., 2008). However, in 
agreement with our findings, serum levels of IL-17A were found not to differ 
between genders in systemically healthy subjects (Gourh et al., 2009). In 
addition, although serum levels of IL-17A were found to positively associate with 
chronic diseases such as psoriasis, systemic lupus erythematous and chronic liver 
disease, no difference between males and females was observed (Arican, et al., 
2005; Kakumu et al., 1997; Vincent et al., 2013). Similarly, although serum 
levels of IL-10 were found to be increased in chronic liver disease and traumatic 
injury, the serum levels in these subjects were not different between males and 
females (Kakumu, et al., 1997; Sperry et al., 2008). 
IL-17A, IL-17F and IL-17A/F have been implicated to play roles in various chronic 
inflammatory disease including rheumatoid arthritis, multiple sclerosis, psoriasis 
and inflammatory bowel diseases (Chabaud, et al., 1999) (Fujino, et al., 2003; 
Ishigame, et al., 2009; Malakouti et al., 2014; Pappu et al., 2011; Seiderer, et 
al., 2008). Structurally, the IL-17A, IL-17F and IL-17A/F heterodimer are closely 
related. The IL-17A and IL-17F monomers have a high degree of homology (40 %) 
(Starnes, et al., 2001), and they both present with a conserved structure of four 
cysteines that form a knot motif in their tertiary structure (Fossiez, et al., 1996; 
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Hymowitz, et al., 2001). In addition, IL-17A and IL-17F monomers can be linked 
at the cysteine knot motif to form the IL-17A/IL-17F heterodimer (Wright, et al., 
2007). IL-17A, IL-17F and IL-17A/F are known to require similar receptors to 
mediate cellular responses; IL-17RA and IL-17RC (Kuestner, et al., 2007; Wright, 
et al., 2007). The similarities in structure and function between these 3 family 
members may explain why they have similar roles in the pathogenesis of chronic 
inflammatory diseases.  
IL-17A is a known pro-inflammatory cytokine involved in the pathogenesis of 
periodontal disease (Behfarnia, et al., 2013; Buduneli, et al., 2009; Liang, et 
al., 2010; Takahashi, et al., 2005). However, studies on the roles of IL-17F and 
IL-17A/F in periodontal disease are limited. In this study we confirmed the 
association of IL-17A in the pathogenesis of periodontal disease. In addition, we 
show elevated levels of IL-17F and IL-17A/F protein in clinical samples (serum, 
GCF and saliva) as well as elevated levels of mRNA expression in diseased 
periodontal tissue. These data indicate that IL-17F and IL-17A/F may have a role 
in pathogenesis of periodontal disease. Since IL-17F and IL-17A/F are known to 
be produced by Th17 cells (Wright, et al., 2007) and Th17 cells are known to be 
present in the tissue of periodontal disease (Adibrad, et al., 2012; Cardoso, et 
al., 2009) the findings in our study are perhaps unsurprising. However, we 
cannot be sure of the cellular source of these cytokines within the oral cavity at 
present. Studies have shown that epithelial cells derived from the bronchus and 
lung activated by IL-17A, IL-17F and IL-17A/F increase expression of GRO-α, IL-8 
and CXCL1 (Kawaguchi, et al., 2006; Liang, et al., 2007; Wright, et al., 2007). 
Hence, similar to other types of tissue, IL-17F and IL-17A/F probably play an 
important role as part of cytokine network in regulating immune responses in 
periodontal tissues. However, more studies are required to confirm the role of 
IL-17A, IL-17F and IL-17A/F in the pathogenesis of periodontal disease. 
IL-17E is described as an anti-inflammatory cytokine with functions opposing to 
those of IL-17A (Monteleone, et al., 2010; Tosello Boari et al., 2012). IL-17E 
inhibits Th17 cell proliferation via IL-4 and IL-13 (Cooney, et al., 2011; 
Kleinschek, et al., 2007). IL-17E induces expression of IL-4 and IL-13 by many 
cell types including; Th2 cells, mast cells and macrophages (Angkasekwinai, et 
al., 2010; Angkasekwinai, et al., 2007; Ikeda, et al., 2003; Kang, et al., 2005; 
Wang, et al., 2007b). In vitro, IL-17E was shown to inhibit IL-17A release from 
  223
CD4+ T cells isolated from the colon of patients with inflammatory bowel 
diseases (Su, et al., 2013). In addition, the ability of IL-17E to supress the 
Th17/IL-17A inflammatory response in EAE was also shown in vivo (Kleinschek, et 
al., 2007). Since IL-17A and IL-17E have opposing functions, it is interesting to 
speculate that the ratio between these family members could become an 
important determinant for chronic periodontitis. However, further studies into 
the biology of these cytokines in relation to periodontal disease are required 
before this can be confirmed.  
To determine whether the relationship between IL-17A and IL-17E was similar to 
that of a prototypic anti-inflammatory cytokine; levels of IL-10 in biological 
samples were also investigated. Th17 cells express the receptor for IL-10 (IL-
10R1) and stimulation with IL-10 directly inhibits Th17 cell proliferation and 
secretion of IL-17A (Heo et al., 2010; Huber et al., 2011). IL-10 is also known to 
indirectly down regulate Th17 driven responses (through IL-17A, TNF- α and IL-6) 
via inhibition of IL-23  (Stetsko & Sauder, 2008). In addition, IL-10 was shown to 
suppress the proliferation of Th17 cells in mice with established colitis (Huber, 
et al., 2011). These studies suggest that IL-10 may play an important role in IL-
17A biology. In addition, IL-17E was also shown to inhibit CD4+ T cells isolated 
from colon of inflammatory bowel diseases patients in an IL-10 dependent 
manner (Su, et al., 2013), suggesting a further complexity in the relationship 
between IL-17A and IL-17E. This study (Table 4-16 and 4-17) suggests a similar 
complexity occurs in patients with chronic periodontitis as serum levels of IL-10 
were significantly elevated and that this increase correlated with clinical 
parameters (Andrukhov et al., 2011; Enwonwu et al., 2005; Havemose-Poulsen 
et al., 2005). This study also shows week positive correlations between serum 
levels of IL-10 and IL-17C, IL-17E and IL-17F, and quite interestingly IL-10 also 
showed a negative correlation with serum IL-17A (Table 4-18). However, this 
correlation did not quite reach significance (r = -0.187, p = 0.060). However, the 
serum IL-17A:IL-10 ratio did have a positive moderate correlation with CPD, CAL 
and BOP (Figure 4-5). 
Real-time PCR analysis (Figure 4-6) confirmed previous findings demonstrating 
elevated levels of IL-10 mRNA expression from tissues from chronic periodontitis 
patients compared to healthy subjects (Garlet et al., 2004; Napimoga, et al., 
2011). This is in line with the findings in the other chronic inflammatory diseases 
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such as rheumatoid arthritis, ulcerative colitis and atopic dermatitis that show 
increased IL-10 expression in diseased compared to healthy control tissue 
(Furuzawa-Carballeda & Alcocer-Varela, 1999; Gambichler et al., 2008; Olsen et 
al., 2007). 
In chronically inflamed periodontal tissue, inflammatory mediators including 
cytokines and chemokines are produced by innate and adaptive immune cells. 
Some of these chemical mediators leave the tissue and enter the circulatory 
system and have endocrine-like effects (Engleberg et al., 2012). In addition, 
these mediators accumulate in the GCF found in the gingival sulcus/pockets and 
can also enter the oral cavity to become part of mixed saliva (whole saliva) 
(Kaufman & Lamster, 2002). Although the mediators in serum, GCF and saliva 
are derived from the same source, in different biological mediums they are 
subjected to diluting processes and protein degradation. Thus, it is not surprising 
that quantification of these mediators in the clinical samples is varied. Hence, 
differences in levels of IL-17 family cytokines in serum, GCF and saliva in our 
study could possibly be explained by the anatomical location from which these 
biological fluids are derived (Buduneli & Kinane, 2011).  
GCF collection can be performed in three ways: absorbent paper strips or paper 
points; capillary tubes and gingival crevicular washes. The use of a capillary tube 
is necessary when large amounts of GCF are required (Skaleric et al., 1987). 
However, this method can cause irritation to the gingival sulcus. Gingival 
crevicular washes are beneficial for collection of cellular components of GCF 
(Adonogianaki et al., 1993).  However, this method requires a trained and 
experienced investigator. In our study, we used the paper strip collection 
method as this is probably the most commonly used methodology (Adonogianaki 
et al., 1994; Guentsch et al., 2011; Ozkavaf et al., 2001). The GCF volume from 
a paper strip can be quantify using a Periotron® (Tozum et al., 2004). However, 
the measurement is only accurate over a limited volume range (Griffiths, 2003). 
This can be problematic as minimal inaccuracies in GCF volume measurement 
can have profound effects on calculated concentrations of protein mediators.  
Therefore, in our study we presented data as total amounts in GCF and did not 
correct for volume. 
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For isolation of serum, the method used is well established. However, variations 
in the sample collection process could have an impact on the analytical 
outcome. These variations may include: types of additive used in the collection 
tube; sample processing time and temperature; sample storage conditions; 
hemolysis of the sample; and the number of freeze-thaw cycles prior to analysis 
(Tuck et al., 2009). It is difficult, if not impossible, to make sure all studies 
carried out in exactly similar conditions. Hence variation in findings could occur 
in serum sample analysis between studies.  
Whole saliva is actually a mixture of oral fluids; including major and minor 
salivary gland secretions, as well as other additional components derived from 
GCF, expectorated bronchial secretions, serum and blood cells from oral wounds 
(Kaufman & Lamster, 2000). The use of whole saliva for evaluating markers for 
soft tissue inflammation and hard tissue destruction in periodontal disease has 
been the subject of considerable research activity (Giannobile et al., 2009). 
Since inflammatory mediators in GCF can make their way into saliva, the use of 
saliva as a diagnostic marker has advantages over serum and GCF as collection is 
non-invasive and only requires minimal training. In our study, we used whole 
unstimulated saliva collected by the method of Navazesh and Christensen 
(1982). The use of unstimulated saliva in investigating cytokine levels has been 
previously reported (Javed et al., 2013; Liu et al., 2014). However, there are 
draw backs in the use of saliva to evaluate levels of protein markers. Bacteria 
derived from dental biofilm, including anaerobic species, can survive in the 
saliva medium (Bowden, 1997; de Jong et al., 1984; De Jong et al., 1986). These 
bacteria can then produce proteolytic enzymes that in combination with 
proteolytic enzymes derived from the host which are also present can break 
down proteinacious markers which will effect analysis  (Chauncey, 1961). In our 
study, the serum, GCF and saliva samples were collected as part of previous 
studies (Davies, et al., 2011; Jaedicke, et al., 2012; Pathiyal, et al., 2005; 
Preshaw & Heasman, 2002). The samples had been subjected to long term 
storage and had possibly undergone multiple freeze-thaw episodes. Therefore, it 
is impossible to discount the fact that these factors may have affected the 
results of our protein analysis. 
Our findings indicate that IL-10 and IL-17 family cytokines; especially IL-17A, IL-
17E, IL-17F and IL-17A/F could have a potential role in the pathogenesis of 
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periodontal disease. Of greatest interest was the relationship between IL-17A 
and IL-17E, which may play opposing roles. The negative correlations between 
IL-17A and IL-17E were similar to that of the prototypic anti-inflammatory 
cytokine; IL-10. Indeed, the serum ratio of IL-17A:IL-17E and IL-17A:IL-10 both 
negatively associated with clinical parameters of periodontal disease. However, 
the biological significance of these relationships require further investigation. 
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Chapter 5: IL-17E and periodontal disease 
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5.1 Introduction 
Although our understanding of the IL-17E biology is increasing, how IL-17E 
expression is regulated and its target cell populations are still poorly 
understood. The evidence to date however suggests that even though IL-17E and 
IL-17A are characterised as being members of the same cytokine family, they 
play vastly opposing roles in the pathogenesis of inflammatory diseases. This 
therefore makes dissemination of the role IL-17E plays in the pathogenesis of 
periodontal disease an exciting target for further investigation.  
IL-17E has been detected in GCF and serum of periodontal patients and levels 
negatively correlated with periodontal clinical probing depth (CPD) (Ozcaka, et 
al., 2013). In the previous chapter, the data confirmed that IL-17E can be 
detected in serum and GCF of patients with chronic periodontitis. In addition, IL-
17E can also be detected in saliva. Interestingly, serum levels of IL-17E 
negatively correlated with CAL and CPD. However, levels in GCF were actually 
elevated in chronic periodontitis patients and furthermore at the mRNA level IL-
17E expression was elevated in tissue of chronic periodontitis patients. The 
biological significance of these findings are at present unknown; but may be 
related to the functional role IL-17E plays in the pathogenesis of periodontal 
disease. Therefore, in this chapter the expression of IL-17E in periodontal tissues 
was investigated further and its potential role in pathogenesis of periodontal 
disease evaluated using in vitro model systems. 
Based on the previous literature and the findings in Chapter 4, IL-17E was 
hypothesised to act as an anti-inflammatory cytokine down regulating 
potentially damaging localised pro-inflammatory responses in the periodontium; 
including those driven by IL-17A 
In order to investigate this hypothesis; the specific aims of this chapter were as 
follows: 
1. To further evaluate the expression of IL-17E and its receptors in periodontal 
tissue samples from patients with chronic periodontitis patients and healthy 
subjects. 
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2. To evaluate the role of IL-17E in modulating the expression of cytokine 
expression by oral keratinocytes in response to stimulation with P. gingivalis 
and IL-17A. 
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5.2 Results 
 
5.2.1 Analysis of IL-17E expression in periodontal tissues 
5.2.1.1 Expression of IL-17E in periodontal tissues 
Previously, the expression of IL-17E mRNA in periodontal tissues was confirmed. 
In addition, expression levels were found to be elevated in chronic periodontitis 
patients (Figure 4-4). However, the cell types responsible for IL-17E expression 
had not been determined. Therefore, immunohistochemical analysis using a 
mouse monoclonal anti-IL-17E antibody (Abcam® UK) was employed to 
investigate further.  
Figure 5-1 shows IL-17E expression associated with blood vessels as well as 
invading leukocytes in tissues derived from chronic periodontitis patients. There 
was no evidence of IL-17E staining in the epithelium or connective tissue layers. 
This suggested that IL-17E is not expressed by oral keratinocytes or fibroblasts.  
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Figure 5-1: IL-17E expression associated with blood vessels and inflammatory 
cell infiltrates in diseased periodontal tissues  
Expression of IL-17E was determined by immunohistochemical analysis using a 
mouse monoclonal anti-IL-17E antibody (Abcam® UK). The panels show 
representative photomicrographs of 5-μm-thick paraffin-embedded sections of 
periodontal tissue specimens obtained from chronic periodontitis patients. 
Positive staining was associated with blood vessels in tissue derived from 3 
individual donors (white arrows) (A – C), as well as in invading leukocytes (black 
arrows) (D) (a representative image of findings observed in all 3 diseased tissue 
samples). An isotype control antibody was used to estimate non-specific binding 
(E and F). Original magnification x 100.  
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5.2.1.2 Expression of IL-17RB in periodontal tissues 
Figure 5-1 showed that IL-17E was expressed in diseased periodontal tissues. 
Therefore to determine its target cell populations; the expression of its known 
receptor, IL-17RB, was also investigated. Again, immunohistochemical analysis a 
using a rabbit anti-IL-17RB antibody (Sigma-Aldrich®, UK) was employed.  
Faint expression of IL-17RB was found in the epithelial layer of diseased 
periodontal tissue (Figure 5-2). In addition, strong IL-17RB staining was 
associated with immune cells found in diseased periodontal tissue (Figure 5-3).  
 
                         
Figure 5-2: IL-17RB expression in the epithelial layer of diseased periodontal 
tissues  
Expression of IL-17RB in periodontal tissues was determined by 
immunohistochemical analysis using a rabbit anti-IL-17RB antibody (Sigma-
Aldrich®, UK). The panels show representative photomicrographs of 5 μm-thick 
paraffin-embedded sections of periodontal tissue specimens obtained from 
chronic periodontitis patients. Positive staining was associated with epithelial 
cells (A, C and E). An isotype control antibody was used to estimate non-specific 
binding (B, D and F). Original magnification x 400. 
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Figure 5-3: IL-17RB expression associated with immune cells in diseased 
periodontal tissues  
Expression of IL-17RB in periodontal tissues was determined by 
immunohistochemical analysis using a rabbit anti-IL-17RB antibody (Sigma-
Aldrich®, UK). Panels show representative photomicrographs of 5 μm-thick 
paraffin-embedded sections of periodontal tissue specimens obtained from 
chronic periodontitis patients. Positive staining was associated with invading 
leukocytes (A, C and E). An isotype control antibody was used to estimate non-
specific binding (B, D and F). Original magnification x 400. 
 
5.2.2 Analysis of IL-17 family cytokines in oral keratinocytes 
5.2.2.1 Expression of IL-17 family cytokines mRNA in oral keratinocytes 
The proposed expression of IL-17RB in the epithelial cell layer was indicative of 
oral keratinocytes being a target cell population for this cytokine. Therefore the 
role of oral keratinocytes in IL-17 family cytokine biology was investigated 
further. Basic PCR analysis investigating the expression of IL-17 family cytokine 
receptors in OKF6-TERT-2 cells (an oral keratinocyte cell line) revealed that all 
known IL-17 family receptors; including those purported to mediate IL-17E 
signalling; IL-17RB are expressed (Figure 5-4A). Interestingly, basic PCR analysis 
also indicated that oral keratinocytes may express IL-17B, C and D but do not 
express IL-17A, IL-17E and IL-17F (Figure 5-4B). 
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Figure 5-4: Expression of mRNA for IL-17 family cytokines and their receptors in 
OKF6/TERT-2 cells  
Expression of IL-17 family cytokines and their receptors mRNA in OKF6/TERT-2 
cells was investigated by basic PCR. The figures represent mRNA expression of 
IL-17 cytokine receptor family (A) and mRNA expression of IL-17 family cytokines 
(B). The 100 base pair DNA ladder was used as reference. All bands ran at 
reported sizes for genes of interest (Table 2-5). M = lane containing 100 base 
pair DNA ladder; + = PCR samples with cDNA; - = PCR samples with water in 
place of cDNA; and N = PCR with samples from no-RT (reverse transcriptase) 
controls. 
 
Figure 5-4B showed that IL-17E mRNA was not expressed by OKF6/TERT-2 oral 
keratinocytes. However, these cells were unstimulated. Therefore to determine 
whether bacterial challenge with a known periodontal pathogen would induce 
expression of IL-17E and other IL-17 family cytokines the in vitro model of P. 
gingivalis infection described previously was employed.  
Figure 5-5 shows that IL-17A, IL-17E and IL-17F mRNA are not expressed by 
OKF6/TERT-2 oral keratinocytes; even after stimulation with a live P. gingivalis 
monospecies biofilm. In addition, the real-time analysis confirmed that IL-17B, 
IL-17C and IL-17D are expressed by OKF6/TERT-2 oral keratinocytes. However, 
expression of none of these cytokines was upregulated in response to stimulation 
by a live P. gingivalis monospecies biofilm. 
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Figure 5-5: The effect of a live P. gingivalis monospecies biofilm on IL-17 family 
cytokine mRNA expression by OKF6/TERT-2 cells 
Quantification of IL-17 family cytokines mRNA expression (A – F) in OKF6/TERT-2 
cells was performed by real-time PCR. The bars represent mean relative 
expression (2-CT) of IL-17 family cytokine mRNA in unstimulated (Control) and a 
live P. gingivalis monospecies biofilm (Biofilm) stimulated OKF6/TERT-2 cells at 
3 and 24 h. RNA polymerase II was used as a reference gene. The data was 
generated from duplicate wells of three independent experiments.  Statistical 
analyses were carried out using the independent t-test (IBM SPSS Statistics, 
version 19) on the natural log transformed IL-17 family cytokines mRNA relative 
expression (2-CT) values. NS = not significant (p > 0.05). Error bars indicate the 
standard error of the mean (SEM).  
 
As the basic PCR analysis suggested that oral keratinocytes express both IL-17RA 
and IL-17RB (reported to be required for IL-17E signalling) we also investigated if 
P. gingivalis induced elevated expression of these receptors. Figure 5-6 shows 
that OKF6/TERT-2 cells constitutively express both IL-17RA and IL-17RB mRNA 
and P. gingivalis does not induce changes in mRNA expression.  
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Figure 5-6: The effect of a live P. gingivalis monospecies biofilm on IL-17RA and 
IL-17RB mRNA expression by OKF6/TERT-2 cells 
Quantification of IL-17RA and IL-17B mRNA expression in OKF6/TERT-2 cells was 
performed by real-time PCR. The bars represent mean relative expression (2-
CT) of IL-17RA (A) and IL-17RB (B) mRNAs in unstimulated (Control) and a live P. 
gingivalis monospecies biofilm (Biofilm) stimulated OKF6/TERT-2 cells at 3 and 
24 h. RNA polymerase II was used as a reference gene. The data was generated 
from duplicate wells of three independent experiments. Statistical analyses 
were carried out using the independent t-test (IBM SPSS Statistics, version 19) on 
the natural log transformed IL-17 family cytokines mRNA relative expression (2-
CT) values. NS = not significant (p > 0.05). Error bars indicate the standard 
error of the mean (SEM). 
 
5.2.2.2 IL-17E negatively regulates P. gingivalis induced chemokine 
expression by oral keratinocytes 
The fact that oral keratinocytes express IL-17RA and IL-17RB indicated that 
these cells were a target for IL-17E signalling. Literature suggests that IL-17E can 
act as a negative regulator of bacterially induced inflammatory mediator 
expression by numerous cell types including CD4+ T cells and macrophages 
(Stolfi, et al., 2011; Zaph, et al., 2008). Therefore, the effect of IL-17E on P. 
gingivalis induced expression of chemokines by oral keratinocytes was 
investigated in vitro.  
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Figure 5-7 showed that rhIL-17E alone had no effect on OKF6/TERT-2 cells 
expression of IL-8 and CXCL5. In contrast, stimulation with a live P. gingivalis 
monospecies biofilm induced increased expression of both chemokines at the 
mRNA and protein level. Interestingly, however, exposure of OKF6/TERT-2 cells 
to rhIL-17E 30 min prior to stimulation with a live P. gingivalis monospecies 
biofilm led to a significant decrease in the P. gingivalis induced expression of 
both chemokines. 
 
     
Figure 5-7: Effect of IL-17E on P. gingivalis induced expression of CXCL8 (IL-8) 
and CXCL5 by OKF6/TERT-2 cells 
Quantification of IL-8 and CXCL5 mRNA expression and supernatant protein 
levels were performed by real-time PCR and ELISA respectively. The bars 
represent mean relative mRNA expression (2-CT) of IL-8 (A) and CXCL5 (C), and 
mean supernatant level of IL-8 (B) and CXCL5 (D) in three stimulation conditions 
of OKF6/TERT-2 cells at 4 and 24 h: rhIL-17E (50 ng/ml), biofilm, or combination 
of rhIL-17E (50 ng/ml) and biofilm. Unstimulated wells acted as a control. For 
real-time PCR analysis GAPDH was used as a reference gene. The data was 
generated from duplicate wells of three independent experiments. Statistical 
analysis of ELISA and real- time PCR data were performed on the natural log 
transformed values using the ANOVA with a Bonferroni correction (IBM SPSS 
Statistics, version 19). * = compare to control (p < 0.05); # = compare to biofilm 
only (p < 0.05); and NS = not significant. Error bars indicate the standard error of 
the mean (SEM). 
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5.2.2.3 IL-17E negatively regulates IL-17A induced IL-8 expression by oral 
keratinocytes 
Previous studies from our laboratory have demonstrated that IL-17A induces a 
pro-inflammatory expression profile in OKF6/TERT-2 cells; including promotion 
of IL-8 and CXCL5 expression (Culshaw et al, unpublished). The negative 
correlations between levels of IL-17A and IL-17E and clinical parameters of 
periodontal disease described previously along with the findings in Figure 5-7 led 
to the hypothesis that IL-17E may also negatively regulate the IL-17A induced 
expression of chemokines by oral keratinocytes. This was therefore investigated 
in vitro.  
In the first instance OKF6/TERT-2 cells were stimulated concurrently with rhIL-
17A and rhIL-17E. Figure 5-8A shows stimulation of OKF6/TERT-2 cells with rhIL-
17A alone for 24 h induced significant release of IL-8 (p < 0.01). In contrast, 
stimulation with rhIL-17E alone had no significant effect on IL-8 release.  A 
linear analysis showed there was a dose-dependent decrease in rhIL-17A-induced 
IL-8 release from OKF6/TERT-2 cells when stimulated concomitantly with varying 
concentrations of rhIL-17E. However, post-test analysis revealed a significant 
inhibitory effect only with 400 ng/ml rhIL-17E (p < 0.01).  
In the second instance OKF6-TERT-2 cells were stimulated with varying 
concentrations of rhIL-17E for 30 min prior to stimulation with rhIL-17A.  Figure 
5-8B shows stimulation with rhIL-17A alone for 24 h induced significant release 
of IL-8 (p < 0.01). The ANOVA analysis showed there was a dose-dependent 
decrease in rhIL-17A-induced IL-8 release from OKF6/TERT-2 cells when 
stimulated with varying concentrations of rhIL-17E 30 min prior to rhIL-17A (p < 
0.01). On this occasion, a significant inhibition of rhIL-17A induced IL-8 release 
was observed with all concentrations of rhIL-17E. Real-time PCR analysis was 
employed to determine whether the inhibitory effect of IL-17E was mediated at 
the transcriptional level. Figure 5-8C shows that stimulation of OKF6/TERT-2 
cells with rhIL-17A alone induced a significant increase in IL-8 mRNA expression 
in comparison to control unstimulated cells. Furthermore, 30 min pre-
stimulation with 10 and 50 ng/ml rhIL-17E reduced the rhIL-17A induced 
upregulation of IL-8 mRNA expression. However, this reduction was only 
significant when cells were pre-stimulated for 30 min with 50 ng/ml rhIL-17E.
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Figure 5-8: Effect of IL-17E on IL-17A induced expression of CXCL8 (IL-8) by 
OKF6/TERT-2 cells 
Quantification of IL-8 mRNA expression and IL-8 bathing supernatant protein 
levels were performed by real-time PCR and ELISA respectively. (A) The bars 
represent mean supernatant level of IL-8 release from OKF6/TERT-2 cells 
stimulated concomitantly with combination of rhIL-17A and rhIL-17E (see x axis 
for concentration). (B) The bars represent mean supernatant level of IL-8 release 
from OKF6/TERT-2 cells pre-incubated with rhIL-17E for 30 min prior to 
stimulation with rhIL-17A (see x axis for concentrations). (C) The bars represent 
mean relative mRNA expression (2-CT) of IL-8 from OKF6/TERT-2 cells pre-
incubated with rhIL-17E for 30 min prior to stimulation with rhIL-17A (see x axis 
for concentrations). Unstimulated wells acted as a control. The data was 
generated from duplicate wells of three independent experiments. For real-time 
PCR analysis GAPDH was used as a reference gene. Statistical analysis of ELISA 
and real-time PCR data were performed on the natural log transformed values 
using the ANOVA with a Bonferroni correction (IBM SPSS Statistics, version 19). * 
= compare to control (* = p < 0.05, ** = p < 0.01); and # = compare to IL-17A (10 
ng/ml) only (# = p < 0.05, ##= p < 0.01). Error bars indicate the standard error of 
the mean (SEM).  
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5.2.2.4 IL-17E negatively regulates the IL-17A induced response of oral 
keratinocytes through NF-κB mediated pathways 
Previous research has demonstrated that IL-17E negatively regulates expression 
of cytokines (i.e., IL-1β, IL-6, IL-12 and TNF-α) by LPS and peptidoglycan 
stimulated CD4+ T cells. This inhibition of expression occurs through induction of 
SOCS3 (Suppressor of cytokine signalling 3) via p38 MAP kinase activation 
(Caruso, et al., 2009b). Evidence suggests that SOCS3 expression limits the 
activation of NF-κB in granulocytes (Chhabra et al., 2014). We therefore 
investigated the effect of IL-17A/IL-17E on intracellular levels of two 
phosphorylated forms of the NF-κB p65 subunit implicated in the process of 
nuclear translocation, and therefore NF-κB p65 subunit activation, using the 
FACETM NF-κB p65 Profiler (Active Motif, UK).  
Figure 5-9A shows stimulation of OKF6/TERT-2 cells with 10 ng/ml rhIL-17A 
caused significantly elevated phosphorylation of the NF-κB p65 subunit at serine 
468 (p < 0.05). Furthermore, there was a significant decrease in rhIL-17A 
induced NF-κB P65 serine 468 subunit phosphorylation when 50 ng/ml rhIL-17E 
was added to the cultures 30 min prior (p < 0.05). Likewise, stimulation of 
OKF6/TERT-2 cells with 10 ng/ml rhIL-17A caused significantly elevated 
phosphorylation of the NF-κB p65 subunit at serine 536 (p < 0.05) (Figure 5-9B). 
In addition, there was a significant decrease in rhIL-17A induced NF-κB P65 
serine 536 subunit phosphorylation when 50 ng/ml rhIL-17E was added to the 
cultures 30 min prior (p < 0.05) (Figure 5-9B).  
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Figure 5-9: Effect of IL-17E on IL-17A induced phosphorylation of the NF-κB p65 
subunit at serine 468 and serine 536 by OKF6/TERT-2 cells 
Quantification of NF-κB p65 subunit phosphorylation was carried out using the 
FACETM NF-κB p65 Profiler (Active Motif, UK). (A) The bars represent the mean 
angular transformed % of NF-κB p65 subunit phosphorylated at serine 468 pre-
incubated with IL-17E for 30 min prior to stimulation with IL-17A (see x axis for 
concentrations). (B) The bar represent mean angular transformed % of NF-κB p65 
subunit phosphorylated at serine 536 pre-incubated with IL-17E for 30 min prior 
to stimulation with IL-17A (see x axis for concentrations). Unstimulated wells 
acted as a control. The data was generated from duplicate wells of three 
independent experiments. Statistical analysis was performed on angular 
transformed data using the ANOVA with a Bonferroni correction (IBM SPSS 
Statistics, version 19). * = compare to control (* = p < 0.05); and # = compare to 
IL-17A (10 ng/ml) only (# = p < 0.05). Error bars indicate the standard error of 
the mean (SEM). 
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5.3 Discussion 
Immunohistochemical analysis revealed for the first time expression of IL-17E 
and IL-17RB in gingival tissue samples of chronic periodontitis patients (Figure 5-
1 and 5-2). These IL-17E positive stained cells were found to associate with 
blood vessels as well as invading leukocytes, but not epithelial cells. In contrast, 
IL-17RB was observed to be expressed by invading leukocytes in gingival tissue 
samples of chronic periodontitis patients and at lower levels in epithelial cells. 
The expression of IL-17E in the periodontium was confirmed at the mRNA level in 
gingival tissue samples (Figure 4-4). In addition, both real-time and basic PCR 
analysis, using different primer sets, demonstrated a lack of IL-17E mRNA 
expression by oral keratinocytes (Figure 5-4 and 5-5), which was in agreement 
with the immunohistochemical findings (Figure 5-1). In contrast, both real-time 
and basic PCR analysis, again using different primer sets, showed that IL-17RB 
mRNA was expressed by oral keratinocytes (Figure 5-4 and 5-6); which was in 
agreement with the immunohistochemical findings (Figure 5-2).  The findings 
presented in this thesis are in line with previous findings that showed 
immunochemical staining of IL-17E in endothelial cells and invading 
inflammatory cells in chronic inflammatory disease tissue samples from the 
cerebrum of multiple sclerosis patients, bronchus of asthma patients, coronary 
artery of atherosclerosis patients, skin of atopic dermatitis patients and colon of 
ulcerative colitis patients   (Corrigan et al., 2011; de Boer et al., 2010; Hvid et 
al., 2011; Letuve, et al., 2006; Sonobe, et al., 2009). However, in contrast to 
our findings, immunohistochemical staining of IL-17E was observed in epithelial 
cells of atopic dermatitis patients and colon of ulcerative colitis patients 
(Caruso, et al., 2009b; Hvid, et al., 2011). Immunohistochemical staining of IL-
17RB has also been observed in endothelial cells,  inflammatory cells and 
epithelial cells in tissue from the artery of atherosclerosis patients, skin of 
atopic dermatitis patients and skin of psoriasis patients (Corrigan, et al., 2011; 
de Boer, et al., 2010; Hvid, et al., 2011; Kim et al., 2013a). 
In this study IL-17E and IL-17RB protein was detected immunohistochemically 
using a mouse monoclonal anti-IL-17E antibody (Abcam®, UK) and a rabbit anti-
IL17RB antibody (Sigma-Aldrich®, UK), respectively. Use of the mouse 
monoclonal anti-IL-17E antibody (Abcam®, UK) has not been previously reported 
in the literature. In contrast, use of the rabbit anti-IL17RB antibody (Sigma-
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Aldrich®, UK) has been reported in a previous immunohistochemical study (de 
Boer, et al., 2010). Due to the limited number of publications using these 
antibodies, a limitation of this study is that specificity was not investigated in as 
greater detail as the IL-33 antibody (Section 3.3). An appropriate isotype control 
for each antibody was used to exclude the non-specific binding. However, we did 
not have appropriate tissue samples to use as a positive control in this study. In 
addition, due to budget and time restrictions, we were also unable to undertake 
pre-absorption studies. Therefore, the specificity of these antibodies has only 
been partially confirmed. Further studies using a suitable positive control, pre-
absorption with recombinant protein and use of several antibodies against IL-17E 
are required to confirm fully specificity (Burry, 2000, 2011). Nonetheless, the 
pattern of IL-17E staining in periodontal tissue samples is comparable with IL-17E 
staining in other diseased tissue samples (Corrigan, et al., 2011; de Boer, et al., 
2010; Letuve, et al., 2006). In addition, the pattern of IL-17RB cell staining in 
epithelium and connective tissue layer of periodontal tissue samples is 
comparable with the archived staining in normal oral mucosa catalogued in the 
human protein atlas ("The human protein atlas (IL17RB)," 2013). The human 
protein atlas is a publicly available database of comprehensive antibody-based 
protein expression profiles in normal and cancer tissues certified by pathologists 
(Uhlen, et al., 2005; Uhlen, et al., 2010). In this study, we observed IL-17E 
staining in invading leukocytes (determined morphologically). At present, the 
subset(s) of lymphocytes which express IL-17E in diseased periodontal tissue 
remain undetermined. Future studies are required to delineate in detail the 
lymphocyte populations that express IL-17E using double staining with known 
markers of lymphocyte subsets; e.g., CD3 (T cell marker) and CD20 (B cell 
marker) (Batran et al., 2013). 
Our data show increased mRNA expression of IL-17 family cytokines (except IL-
17B) in tissue derived from patients with chronic periodontitis (Section 4.2.2). 
For many of these cytokines the cell types responsible for expression have yet to 
be delineated. As oral keratinocytes are one of the first cell types within the 
periodontium to encounter periodontal pathogens, expression of these cytokines 
by these cells was investigated further. Our basic PCR analysis shows the pattern 
of mRNA expression of IL-17 family receptors and cytokines by unstimulated 
OKF6/TERT-2 cells. mRNA encoding all IL-17 family receptors were found to be 
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expressed by unstimulated OKF6/TERT-2 cells. However only mRNA encoding IL-
17B, IL-17C and IL-17D was expressed by unstimulated OKF6/TERT-2 cells. These 
findings were confirmed by real-time PCR analysis. However, expression of IL-
17B, IL-17C, IL-17D, IL-17RA and IL-17RB mRNA was not upregulated in response 
to P. gingivalis stimulation. In line with our findings, IL-17A mRNA was found not 
to be expressed by human oral keratinocytes (Al-Samadi et al., 2014). However, 
IL-17A, IL-17E and IL-17F were found to be expressed in other epithelial cells, 
including corneal epithelial cells, lung epithelial cells and intestinal/colonic 
epithelial cells (Angkasekwinai, et al., 2007; Arranz-Valsero et al., 2013; 
Ishigame, et al., 2009; Suzuki, et al., 2007; Zaph, et al., 2008). In agreement 
with our findings, IL-17B and IL-17C are also expressed in other epithelial cells, 
including mammary epithelial cells and intestinal epithelial cells (Huang et al., 
2013; Song et al., 2014). However, no studies have previously reported 
expression of IL-17D in any epithelial cell type. As for the IL-17 receptor family, 
our findings are in line with literature that showed expression of IL-17RA, IL-
17RB, IL-17RC and IL-17E in various types of epithelial cells, including gingival 
epithelial cells, oral keratinocytes, mammary epithelial cells, corneal epithelial 
cells, and intestinal epithelial cells (Al-Samadi, et al., 2014; Arranz-Valsero, et 
al., 2013; Huang, et al., 2013; Song, et al., 2014; Takahashi et al., 2011). In 
contrast, no specific reference was found on the expression of IL-17RD on 
epithelial cells.  
Our study shows IL-17E is present in gingival tissue samples of chronic 
periodontitis patients. Although oral keratinocytes were found not to express IL-
17E, they do express IL-17RA and IL-17RB, the receptors required for IL-17E 
signalling (Ely, et al., 2009; Hymowitz, et al., 2001; Lee, et al., 2001; Shi, et 
al., 2000). This indicates that oral keratinocytes are a target for IL-17E 
signalling. Therefore, the role of IL-17E in oral keratinocyte mediated innate 
immune responses was investigated in vitro. Previous literature had 
demonstrated that IL-17E could regulate the innate immune response of 
bacterial LPS stimulated myeloid cells (Caruso, et al., 2009b). Therefore, similar 
in vitro studies were replicated using the OKF6/TERT-2 cell line.  In our 
investigations P. gingivalis upregulated the expression of IL-8 and CXCL5 in 
accordance with previous studies (Barksby et al., 2009; Huang et al., 1998). In 
contrast, IL-17E alone had no effect on IL-8 expression. However, IL-17E 
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inhibited the P. gingivalis induced expression of both these chemokines and this 
inhibition was evident at the transcriptional level (Figure 5-7). In addition, IL-
17E also inhibited IL-17A-induced expression of IL-8 by oral keratinocytes, which 
was again mediated at the transcriptional level (Figure 5-8). This therefore 
implies that IL-17E can directly negatively regulate the pro-inflammatory 
functions of IL-17A. 
IL-17A promotes recruitment of neutrophils and monocytes by inducing 
chemokine expression from a variety of epithelial cells (Shahrara et al., 2009). 
Commensurate with these findings IL-17A induced oral keratinocytes to express 
IL-8. However, the notable inhibition of IL-17A and P gingivalis induced 
expression of IL-8 by IL-17E suggests that IL-17E can regulate neutrophil 
responses in early inflammation. It is known that effective neutrophil responses 
are important for periodontal health (Kinane et al., 2011). Although the 
principle role of neutrophils is protection, these cells can also release a variety 
of factors that can cause tissue damage, including reactive oxygen species, 
collagenases and other proteases (Nathan, 2006; Scott & Krauss, 2012). Chronic 
and persistent activation of neutrophils by a microbial biofilm in the 
periodontium can therefore lead to gingival tissue damage and periodontal 
disease (Nussbaum & Shapira, 2011). Therefore it is important the neutrophil 
migration and activation are tightly controlled. The literature shows increased 
activities of neutrophils are associated with periodontal disease (Kinane, et al., 
2011; Liu et al., 2001). It is known that IL-8 is important chemoattractant for 
neutrophils and IL-8 expression by host cells, such as oral keratinocytes and 
fibroblasts is induced by IL-17A and P. gingivalis (Luo, et al., 2012; Macpherson 
et al., 2014; Mahanonda et al., 2008; Wang & Ohura, 2002). Since our data 
shows IL-17E could negatively regulate the expression of IL-8 by oral 
keratinocytes in response to stimulation with IL-17A and P. gingivalis, the 
presence of IL-17E in periodontal tissue may be important in regulating 
neutrophil migration and therefore be an important immunoregulatory control 
mechanism during early inflammation.   
In our studies we further investigated the potential mechanism by which IL-17E 
can inhibit IL-17A induced expression of IL-8 by oral keratinocytes. IL-17A was 
shown to promote IL-8 expression via intracellular signalling pathways leading to 
the phosphorylation of the NF-κB p65 subunit at serine 536 and serine 468 
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(Figure 5-9). Phosphorylation of serine 536 of the NF-κB p65 subunit has been 
demonstrated to be important in transcription of the IL-8 gene (Buss et al., 
2004), while phosphorylation at serine 468 has been shown to have an important 
role for NF-κB ubiquitination and degradation (Geng et al., 2009). However, 
despite their opposing functions, phosphorylation at serine 536 and 468 occurs 
simultaneously (Mattioli et al., 2004). 
NF-κB is a complex of proteins responsible for cytokine production and cell 
survival through control over DNA transcription (Memet, 2006). The NF-κB family 
of proteins has 5 members including; p50, p52, RelA (p65), c-Rel and RelB 
(Hoffmann et al., 2006; Moynagh, 2005). These proteins exist in homo- or 
hetero-dimeric forms and remain inactive in the cell cytoplasm by binding to 
IκBs. IκBs are inhibitory molecules that prevent translocation of NF-κB into the 
nucleus (Memet, 2006). Activation of either the classical or alternative pathway 
leads to ubiquitination and degradation of IκBs through phosphorylation events 
that free NF-κB for nuclear translocation (Lawrence, 2009; Memet, 2006). It is 
known that the classical pathway is stimulated by microorganisms and cytokines 
(including IL-17A) which results in activation of the NF-κB p65 subunit (RelA) 
complex (Karin & Ben-Neriah, 2000; Olsson Akefeldt et al., 2013; Xie et al., 
2010). In contrast, proteins such as CD40 ligand, RANKL and BAFF (B-cell 
activating factor) are known to stimulate the alternative pathway which results 
in activation of the NF-κB RelB complex (Lawrence, 2009). 
In line with literature, our study shows increased phosphorylation of the NF-κB 
p65 subunit at serine 536 and serine 468 by oral keratinocytes occurs upon 
stimulation with IL-17A (Figure 5-9). Interestingly, the data shows that when oral 
keratinocytes are primed with IL-17E prior to IL-17A stimulation, the 
phosphorylation of the NF-κB p65 subunit at serine 536 and serine 468 is 
decreased. There is no evidence in the literature demonstrating that IL-17E can 
directly inhibit NF-κB phosphorylation. The mechanism by which IL-17E promotes 
this inhibitory effect is currently unknown. It could be due to the result of 
competing for the same receptor as both IL-17A and IL-17E require IL-17RA for 
intracellular signalling (Ely, et al., 2009; Hymowitz, et al., 2001; Toy, et al., 
2006). However, this remains a matter of conjecture and further study is 
required to understand in detail the pathway(s) involved. 
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Based on the findings in this study, and the current literature, it could be argued 
that increased expression of IL-17E in periodontal tissue occurs as an attempt to 
down-regulate the damaging localised periodontal inflammatory response. 
Th17/IL-17A responses have been shown to be associated with inflammatory 
tissue damage in chronic inflammatory diseases, including periodontal disease, 
rheumatoid arthritis and inflammatory bowel diseases (Adibrad, et al., 2012; 
Feng et al., 2011; Leipe et al., 2010). Since in vitro data show that IL-17E is 
capable of inhibiting Th17 responses via IL-4 and IL-13 (Angkasekwinai, et al., 
2007; Cooney, et al., 2011; Harrington, et al., 2005; Kleinschek, et al., 2007; 
Park, et al., 2005; Wang, et al., 2007b), it is possible that one role of IL-17E in 
inflammatory disease pathogenesis is to inhibit Th17/IL-17A pro-inflammatory 
responses. In addition, in vivo studies using a collagen-induced arthritis model 
showed that increased expression of IL-17A occurs during early stage disease, 
whereas increased expression of IL-17E occurs during the later stages and is 
associated with enhanced production of IL-4 (Kaiwen et al., 2012). Additionally, 
in vivo, using a Chlamydia muridarum lung infection mouse model, elevated IL-
17E expression in the lung was shown to occur during the latter stages of 
infection, whilst IL-17A expression occurred during the early stages (Mosolygo et 
al., 2013). These studies add weight to the hypothesis that IL-17E expression 
occurs as a mechanism to regulate Th17/IL-17A responses.  
In summary, our data show expression of IL-17E and it receptors (IL-17RA and IL-
17RB) in periodontal tissues. This indicates possible involvement of IL-17E in 
pathogenesis of periodontal disease. In vitro analysis shows that IL-17E is 
capable of negatively regulating the IL-17A and P. gingivalis induced expression 
of chemokines (i.e., IL-8 and CXCL5) by oral keratinocytes. In addition, this 
negative regulation occurs at the transcriptional level and is mediated by 
inhibition of phosphorylation and therefore activation of the NF-κB p65 subunit. 
The finding that IL-17E acts as an anti-inflammatory cytokine in periodontal 
tissues may be of major importance for studies into IL-17A/Th17 induced 
pathologies. However, further studies are required to look in detail at the 
mechanisms by which IL-17E perpetrates its anti-inflammatory effects.  
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Chapter 6: General discussion 
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The major findings of this study are as follows: 
1. IL-33 and its receptors (ST2L and sST2) are expressed in gingival tissue 
samples and the expression of IL-33 (mRNA and protein), as well as sST2 
(mRNA) is up-regulated in gingival tissue samples of chronic periodontitis 
patients.  
2. IL-33 and its receptors (ST2L and sST2) are expressed in oral 
keratinocytes. In addition, the periodontal pathogen, P. gingivalis, is 
capable of inducing oral keratinocytes to upregulate the expression of IL-
33.  
3. There are associations between serum, GCF and saliva levels of IL-17 
family cytokines and IL-10 with clinical outcomes of chronic periodontitis. 
4. The clinical association studies suggest that IL-17A, IL-17F and the IL-
17A/F heterodimer may have pro-inflammatory functions, whilst IL-17E 
may have anti-inflammatory functions in pathogenesis of chronic 
periodontitis. 
5. IL-17E is capable of negatively regulating the IL-17A and P. gingivalis 
induced expression of chemokines (i.e., IL-8 and CXCL5) by oral 
keratinocytes. 
6. IL-17E mediates its anti-inflammatory function at the transcriptional level 
by inhibiting activation and therefore nuclear translocation of the NF-κB 
p65 subunit in oral keratinocytes. 
Cytokines are known to play an important role in maintaining tissue homeostasis. 
They are also shown to play roles in defence against pathogens by co-ordinating 
both innate and adaptive immune mechanisms. For examples, cytokines can 
induce increased expression of pattern recognition receptors (e.g., TLR’s); 
promote chemotaxis of phagocytes (polymorphonuclear leukocytes and 
macrophages) and also promote activation and proliferation of T cell populations 
and antibody producing B lymphocytes (Espinassous, et al., 2009; Modi, et al., 
1990; Takatsu, 1997; Taub, et al., 1993). In addition, cytokines also play 
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important roles in regulating tissue repair. Indeed, cytokines can co-ordinate 
tissue re-modelling by mechanisms such as inducing extracellular matrix 
production by fibroblasts (Appleton, 1994).  
Despite the important role cytokines play in tissue homeostasis and protection 
against pathogens, it is important that their activity occurs in a controlled 
‘balanced’ manner. Cytokines are known to interact and function in networks 
(Balkwill & Burke, 1989; Nathan & Sporn, 1991). In simplistic terms, cytokines 
can be grouped into two classes: pro-inflammatory and anti-inflammatory. The 
biological activity of these two classes plays an important role in regulating 
cytokine networks and ensuring a ‘balanced’ response. The balanced activities 
between the two groups of cytokines are important in initiating the appropriate 
immune response against pathogenic threats whilst also maintaining the integrity 
of host tissues. However, numerous chronic inflammatory pathologies such as 
periodontal disease and rheumatoid arthritis are characterised by an excessive 
inflammatory responses. This dysregulated chronic inflammation is characterised 
by an unbalanced cytokine response (Graves, 2008; Kinane, et al., 2011; McInnes 
& Liew, 2005; McInnes & Schett, 2007). In periodontal tissue, pro-inflammatory 
cytokines such as IL-1 and TNF-α have been shown to drive soft tissue 
destruction via promotion of MMP expression and activation by host cells 
(Birkedal-Hansen, 1993; Reynolds, et al., 1994). In addition, cytokines such as 
IL-1, IL-6, IL-17A and TNF-α have also been shown to drive destruction of hard 
tissues by promoting excessive production of RANKL and inhibiting production of 
OPG, and thus promoting osteoclastogenesis (Quinn & Saleh, 2009). Therefore, 
long standing uncontrolled activity of pro-inflammatory cytokines leads to the 
excessive tissue destruction that manifests clinically in periodontal disease. 
Therefore, a dysregulated cytokine response plays an important role in the 
pathogenesis of periodontal disease.  
The pathogenesis of periodontal disease is characterised by an excessive 
inflammatory response to pathogenic bacteria within dental plaque. This 
inflammation is coordinated by cytokines and chemokines. Indeed, dysregulated 
expression of cytokines is associated with inflammation of periodontal tissue. 
Periodontal pathogens such as P. gingivalis induce expression of numerous 
cytokines and chemokines by cells of the periodontium (Kinane, et al., 2011). 
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The presence of P. gingivalis in dental plaque has been demonstrated to induce 
increased expression of IL-1α, IL-1β, IL-8, IL-17A and TNF-α by various cell types 
such as epithelial cells and macrophages (Bostanci, et al., 2007; Hirschfeld, et 
al., 2001; Kocgozlu, et al., 2009; Luo, et al., 2012; Milward, et al., 2013; Zhou, 
et al., 2005). Furthermore, elevated levels of IL-1α, IL-1β, IL-6, IL-8, IL-17A and 
TNF-α are associated with periodontal disease (Graves, 2008). Hence excessive 
levels of pro-inflammatory cytokines and chemokines are associated with disease 
outcome. However, the biological role of many of these mediators in the 
pathogenesis of periodontal disease remains unclear. Furthermore, it is now 
known that anti-inflammatory cytokines can act to regulate the inflammatory 
response within tissues and therefore it is now hypothesised that cytokines and 
chemokines act in ‘networks’ to ensure an appropriate and coordinated immune 
response. In terms of periodontal tissue we do not fully understand the 
complexity of these networks, how they are regulated in health and the factors 
that lead to a dysregulated response as observed in periodontal disease (Figure 
6-1). Therefore, key cytokine networks still remain to be studied which will aid 
our understanding of the pathogenesis of periodontal diseases. 
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Figure 6-1: Proposed cytokine networks involved in co-ordinating the innate and 
adaptive arms of the periodontal immune response and their role in transition 
from periodontal health to disease 
The presence of periodontal pathogens in the subgingiva activates innate and 
adaptive immune responses. These immune responses are regulated by networks 
of cytokines and chemokines and are tightly regulated. In certain individuals 
however, these networks are pushed toward pro-inflammatory pathways that are 
over-excessive for the perceived threat. Therefore, periodontal tissue 
destruction and bone resorption occur. The figure is taken from the Journal of 
Clinical Periodontology (Kinane, et al., 2011). Permission to reproduce this 
figure has been granted by John Wiley & Sons, Inc.  
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As mentioned previously, the role of numerous individual cytokines in the 
pathogenesis of periodontal disease is still a matter of debate. Since IL-33 was 
shown to play a role in pathogenesis of chronic inflammatory diseases such as 
rheumatoid arthritis, inflammatory bowel disease and atopic dermatitis (Miller, 
2011), we anticipated that IL-33 would play a role in periodontal disease 
pathogenesis. In our study, we found that IL-33 and its receptors (ST2L and sST2) 
are expressed in periodontal tissue. In addition, the expression of IL-33 (mRNA 
and protein) and sST2 (mRNA) are increased in diseased tissue. Furthermore, in 
vitro we showed that oral keratinocytes express IL-33, ST2L and sST2; and 
expression of IL-33 (protein and mRNA) is increased in these cells after 
stimulation with a live P. gingivalis monospecies biofilm. These findings 
suggested that IL-33 may have a pro-inflammatory role in periodontal disease. 
Indeed, previous studies have demonstrated that IL-33 can mediate tissue 
destruction and bone loss. For example, IL-33 was shown to promote bone 
resorption in a collagen induced arthritis mouse model (Palmer, et al., 2009). In 
addition, serum levels of IL-33 and MMP-3 were positively correlated in 
rheumatoid arthritis patients, and the serum levels of IL-33 was found to 
associate with arthritic bone resorption (Xiangyang, et al., 2012). However, 
whether IL-33 plays a similar role in destruction of periodontal tissues and 
alveolar bone remains to be elucidated. Indeed, despite evidence suggesting IL-
33 mediates tissue destruction and bone loss in rheumatoid arthritis (Beltran, et 
al., 2010; Louten, et al., 2011; Xu, et al., 2008), studies have also demonstrated 
that IL-33 may actually play a protective anti-inflammatory role in 
atherosclerosis, hepatitis, obesity and type 2 diabetes (Miller, 2011; Miller et 
al., 2010; Miller et al., 2008; Sanada, et al., 2007; Volarevic et al., 2012). The 
differences in the role of IL-33 in varying pathologies are currently unknown. 
However, it could be due to differential regulation in tissues. Furthermore, as 
cytokines operate in ‘networks’ the function of IL-33 may not also be dependent 
on the tissue in which it is expressed but also its interactions with other 
cytokines and chemokines. Therefore, an understanding of the role of a cytokine 
in a ‘network’ may be more important than understanding their roles in 
isolation. 
The importance of investigating the relationship between networks of cytokines 
and disease was emphasised by our IL-17 family cytokine study. This study 
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showed that levels of IL-17A, IL-17F and IL-17A/F heterodimer are found 
increased in clinical samples (i.e., serum, GCF and saliva) of chronic 
periodontitis patients compared to healthy subjects, and levels of these 
cytokines were positively associated with clinical parameters for periodontal 
disease (CPD, CAL and BOP). In addition, levels of these cytokines positively 
correlated to each other. These findings suggested that IL-17A, IL-17F and the 
IL-17A/F heterodimer play a pro-inflammatory role in periodontal disease 
pathogenesis as has been demonstrated for other chronic inflammatory diseases 
(Iwakura, et al., 2011; Kolls & Linden, 2004). For example, IL-17A and IL-17F 
were shown to induce increased expression of MMPs (e.g., MMP-1, MMP-3, MMP-8 
and MMP-13) by chondrocytes and synovial cells (Tanigawa et al., 2011; Toh et 
al., 2010). MMPs are known to associate with destruction of soft tissue and 
cartilage in inflammatory conditions. Ex vivo, IL-17A was shown to induce 
released of MMP-1 and increased collagenase activity by synovium explant of 
rheumatoid arthritis (Chabaud et al., 2000). In addition, injection of murine IL-
17A into mouse knee joint was shown to degrade the joint cartilage (Chabaud et 
al., 2001). IL-17A, via RANKL was also shown to stimulate osteoclastogenesis and 
bone erosion in arthritis mouse model (Lubberts et al., 2003). 
Interestingly, the study shows serum levels of IL-17E and IL-10 are decreased in 
patients with chronic periodontitis, and serum levels negatively correlate with 
clinical parameters (CPD, CAL and BOP). Furthermore, the study shows serum 
levels of IL-17E and IL-10 are negatively correlated with serum levels of IL-17A. 
Indeed, the serum IL-17A:IL-17E and IL-17A:IL-10 ratio both negatively 
correlated with all clinical parameters (CPD, CAL and BOP). These findings 
indicate that IL-17E and IL-10 play opposing roles to IL-17A in periodontal 
immunity. Indeed, it could be hypothesised that IL-17E and IL-10 act as anti-
inflammatory cytokines as suggested by the literature (Caruso et al., 2011; 
Moore, et al., 2001; Sabat, et al., 2010). Therefore, as IL-17A is a pro-
inflammatory cytokine, it could be said that periodontal disease is characterised 
by increased levels of pro-inflammatory cytokines in conjunction with decreased 
levels of anti-inflammatory cytokines. The role of IL-10 as an anti-inflammatory 
cytokine in periodontal disease is well established (Al-Rasheed, et al., 2003; 
Sasaki, et al., 2004). The literature on IL-17E and periodontal disease is however 
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in its infancy. However, studies in other disease models have suggested an anti-
inflammatory role for IL-17E (Caruso, et al., 2011).  
Studies investigating clinical associations between levels of mediators in 
biological fluids and disease state are useful for determining a role in disease 
pathogenesis. However, in order to fully understand the biological significance 
of such findings more detailed studies are required (i.e., in vitro and in vivo). 
Among the interesting findings in our clinical association study was the positive 
correlation between the serum IL-17A:IL-17E ratio and clinical parameters (CPD, 
CAL and BOP). Further investigations began to delineate the biological 
significance of this finding and in vitro it was shown that IL-17E negatively 
regulates NF-κB p65 mediated increased expression of IL-8 by oral keratinocytes 
stimulated with IL-17A. Furthermore, IL-17E also negatively regulated the P. 
gingivalis induced expression of IL-8 by oral keratinocytes. These findings 
indicate that IL-17A and IL-17E are true pro- and anti-inflammatory cytokines 
respectively. Previous studies similarly demonstrated that IL-17A induces 
increased release of IL-8 via activation of the NF-κB transcription factor in 
fibroblast-like synoviocytes (Hwang et al., 2004). However, how IL-17E 
negatively regulates NF-κB p65 activation is not known. It is possible that IL-17E 
may have an indirect effect on NF-κB p65 activation as IL-17A and IL-17E share 
the same receptor (IL-17RA). Therefore, inhibition of activation could be simply 
due to the fact that IL-17E competes with IL-17A for the same receptor. 
However, further studies are required to delineate the mechanisms involved in 
more detail. Indeed, competition for receptors suggests that there is even more 
complex interplay between IL-17 family cytokines which we are yet to discover. 
Studies suggest that although IL-17A, IL-17F and IL-17A/F all have pro-
inflammatory cytokine activity (Hu et al., 2011), their ability to activate an 
innate immune response varies subtly due to differential affinities for IL-17RA 
(Kuestner, et al., 2007; Liang, et al., 2007; Wright, et al., 2007). Hence, 
competition for the same receptor and differential binding affinities may be a 
further mechanism by which activity of IL-17 family cytokines are regulated. 
However, there is still a lot more to understand about individual members of the 
IL-17 family of cytokines and their receptors before we can begin to speculate 
how this family operates in a network to co-ordinate immune responses. 
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Recently a link between IL-33 and IL-17E has been discovered. Both IL-17E and 
IL-33 are known to induce a Th2 immune response (Eiwegger & Akdis, 2011). In 
addition, it was shown that elevated expression of IL-33 in the lung tissues of 
house dust mite allergy is IL-17E dependent (Gregory et al., 2013). IL-17E and/or 
IL-33 are known to be capable of activating innate immune cells including 
natural helper cells (NHCs), multi-potent progenitor type 2 (MPPtype2) cells, 
nuocytes, and innate type 2 helper (Ih2) cells, and also promote a Th2 response 
by stimulating the release of IL-4, IL-5 and IL-13 (Saenz et al., 2010a; Saenz, et 
al., 2010b; Salimi et al., 2013). Since IL-4 and IL-13 are known to inhibit Th17 
cells response (Cooney, et al., 2011; Harrington, et al., 2005; Park, et al., 
2005), there is also a possibility that IL-33 and IL-17E can also inhibit the Th17 
response. These findings suggest that the association between IL-17A, IL-17E and 
IL-33 in periodontal disease pathogenesis is an exciting area for further study. 
Indeed, in vivo studies using a mouse model of periodontal disease would be 
beneficial in determining the role of these cytokines individually and collectively 
in the pathogenesis of periodontal disease.  
The Immune system is in dynamic equilibrium, regulated by networks of 
cytokines. Under normal physiologic conditions, the activities of these cytokine 
networks are balanced between activities of pro- and anti-inflammatory 
cytokines. However in chronic inflammatory diseases such as chronic 
periodontitis and rheumatoid arthritis, the balance of these cytokine network 
activities are found to tip towards pro-inflammatory (Preshaw & Taylor, 2011; Xu 
et al., 2013). A complete understanding of this un-balanced cytokine network 
activity in periodontal disease is important if immune modulation therapy is to 
be considered for treatment of the disease. Immune modulation therapy could 
be used to potentially restore the balance between the pro- and anti-
inflammatory network activities. Usually, immune modulators in the form of 
either recombinant, synthetic or natural preparations of protein mediator are 
used. There are already many immune modulators that are licenced for human 
use, for example: anakinra, recombinant IL-1RA (Kineret, Amgen Inc., CA) and 
infliximab, a chimeric monoclonal antibody against TNF-α (Remicade, Centocor, 
Inc., Malvem, PA). Immune modulation therapy has been used in the treatment 
of a variety of chronic inflammatory diseases. For example immune modulation 
targeting pro-inflammatory cytokines has been used in treating rheumatoid 
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arthritis. Anakinra (Kineret, Amgen Inc., CA) which is recombinant IL-1RA blocks 
the activity of IL-1 cytokines. In clinical trials Anakinra has been successful in 
treating rheumatoid arthritis and acute gout (Fleischmann et al., 2006; So et al., 
2007). In addition, the TNFRp75-Fc fusion protein (Enbrel®, Enbrel, Immunex, 
Seattle), which is a fusion of soluble TNFRp75 (TNF receptor p75) and Fc portion 
of IgG1, and targets TNF-α has been developed. In clinical trial, subcutaneous 
injection of TNFRp75-Fc was shown to significantly reduce the severity of 
rheumatoid arthritis (Moreland et al., 1997). However, using immune modulators 
to treat periodontal disease has not been as successful as other chronic 
inflammatory disease. In terms of periodontal disease studies looking at patients 
with both arthritis and periodontal disease seemed to show potential for 
immunomodulation therapies. Indeed, for rheumatoid arthritis patients who also 
had chronic periodontitis, intravenous infusion treatment with infliximab (anti-
TNF-α) (Remicade, Centocor, Inc., Malvem, PA) reduced GCF levels of TNF-α and 
improved periodontal status (CPD, CAL and BOP) (Mayer et al., 2009). Similarly, 
Kobayashi and colleagues (2014) showed tocilizumab (a monoclonal anti-IL-6 
receptor antibody) treatment of patients with a combination of rheumatoid 
arthritis and chronic periodontitis also showed an improvement in periodontal 
disease status (CPD, CAL and BOP). However, it could be argued that these were 
indirect effects due to treatment of rheumatoid arthritis and not direct 
therapeutic effects on periodontal disease. 
Treatment of periodontal disease in isolation using immunomodulation therapies 
has been a subject of investigation. In animal studies, anti-cytokine modulators 
were investigated using the Macaca fascicularis primate model of experimental 
periodontitis. Functional-blocking soluble receptors for IL-1 and TNF were 
injected to sites of periodontal destruction and revealed that injection of these 
anti-cytokine modulators reduced periodontitis related alveolar bone loss by 50 – 
60 % (Assuma et al., 1998; Delima et al., 2001). In another studies, OPG (a 
soluble decoy receptor for RANKL) was used as an anti-cytokine modulator. A 
preparation of OPG-Fc fusion protein was intraperitoneally injected to the A. 
actinomycetemcomitans induced (oral inoculation) periodontitis mouse model. 
These studies showed treatment with OPG significantly inhibit the RANKL 
associated alveolar bone loss (Mahamed et al., 2005; Teng, et al., 2000). A study 
was also performed using a C-C motif chemokine receptor 2 (CCR2) antagonist to 
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treat periodontitis using a P. gingivalis-induced periodontitis mouse model. The 
study found that mice treated with CCR2 antagonist exhibited reduced alveolar 
bone loss compared to control mice (Barros et al., 2011). 
Despite successful studies investigating immune modulation therapies for 
periodontal disease in animal model, very few have advanced to human clinical 
trials. Doxycycline, a synthetic non-specific MMP inhibitor, has been investigated 
in human cohorts. Emingil and colleagues (2004) showed 6-month treatment with 
a sub-antimicrobial dose of doxycycline (SDD) (20 mg, twice a day) plus scaling 
and root planing resulted in significant improvement in clinical outcomes and 
this was associated with a reduction of MMP-8 levels in GCF. Similarly, Caton and 
colleagues (2000) showed significant improvement in clinical outcomes (CPD and 
CAL) of chronic periodontitis in patients treated for 9 months with SDD (20 mg, 
twice a day) plus scaling and root planing compared to a parallel placebo group. 
In addition to SDD, therapies targeting arachidonic acid metabolites (e.g., 
thromboxane, prostacyclins and prostaglandins) for treatment of periodontal 
disease have been investigated in human cohorts. Arachidonic acid metabolites  
are pro-inflammatory mediators known to associate with bone resorptive activity 
in periodontal disease (Williams et al., 1989). Non-steroidal anti-inflammatory 
drugs (NSAIDs) such as ibuprofen and aspirin are cyclooxygenase inhibitors that 
block the formation of arachidonic acid metabolites. Chronic periodontitis 
patients treated for 6 months with flurbiprofen (NSAID) (50 mg, twice a day) plus 
dental prophylaxis (teeth cleaning) every three months presented with 
significant less alveolar bone loss compared to the parallel placebo group 
(Jeffcoat et al., 1995). However the use of NSAIDs is associated with increased 
bleeding time, incidence of peptic ulcers and gastrointestinal bleeding (Lanza et 
al., 2009). Hence, the use of these drugs to treat periodontitis has to be 
approached with care. 
Immune modulation therapies may offer therapeutic strategies for treatment of 
periodontal diseases. However, at present our understanding of the role of 
cytokines in periodontal immunity and disease pathogenesis is still lacking 
compared to other diseases. Therefore, before anti-cytokine therapies can begin 
to be considered, studies, such as described in this thesis, are required to 
advance our basic knowledge of periodontal cytokine biology and provide a 
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platform for further research to identify rational targets for therapeutic 
interventions.  
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